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2ABSTRACT
Health care economic evaluations assess the costs and consequences of competing
interventions, programmes or services. Such assessments use a decision model, with
parameters informed by available evidence. Evidence, however, is rarely derived
from a single source, in which case researchers are expected to combine information
on multiple sources. This thesis contributes to the methodological debate on the use
of evidence, particularly, the use of individual level data (IPD), for cost effectiveness
analysis.
This thesis defines a taxonomy which summarises the methodological and analytical
issues in the use and synthesis of evidence for cost effectiveness modelling. For
alternative parameter types (e.g. relative effectiveness, costs) the taxonomy offers
guidance on appropriate synthesis methodologies to use and identifies areas where
further methodological contributions are needed. The thesis also explores methods of
synthesis of IPD and develops novel frameworks which allow both IPD and AD to
be jointly modelled, specifically in estimating relative effectiveness. The use of IPD
from studies is found desirable, particularly when the estimation of subgroup effects
is of interest.
An applied decision model of the cost effectiveness of smoke alarm equipment in
households with pre-school children is developed within this thesis. This application
offers a means to evaluate the impact of using IPD on the cost effectiveness
outcomes, compared to the use of AD. The thesis examines the advantages of having
access to IPD when quantifying decision uncertainty. Additionally, it discusses the
use of IPD in estimating the value of further research. Specifically, a framework is
used which allows considering population subgroups. It is argued that the use of IPD
allows a more suitable characterisation of decision uncertainty, appropriately
allowing for subgroup value of information analysis.
3LIST OF CONTENTS
Abstract ........................................................................................................................ 2
List of Contents ............................................................................................................ 3
List of Tables................................................................................................................ 7
List of Figures ............................................................................................................ 11
Acknowledgements .................................................................................................... 14
Publications ................................................................................................................ 15
Author’s declaration................................................................................................... 15
1. Introduction ............................................................................................................ 16
1.1 Background ............................................................................................................ 16
1.2 Thesis aims and objectives..................................................................................... 22
1.2.1 Objective 1: Exploring the use of evidence for cost effectiveness analysis – enhancing
the use of individual level data .................................................................................................... 22
1.2.2 Objective 2: Assess the added value of having access to and using individual patient
level data for cost effectiveness decision making ........................................................................ 22
1.3 Case study .............................................................................................................. 23
1.4 Structure of the thesis............................................................................................. 25
2. Deriving Input Parameters for Cost effectiveness Modelling: Taxonomy of Data
Types and Approaches to their Statistical Synthesis.................................................. 28
2.1 Introduction............................................................................................................ 28
2.2 A taxonomy for the use of evidence in cost effectiveness models: application to
clinical effectiveness evidence........................................................................................... 31
2.2.1 Single source of evidence ............................................................................................... 34
2.2.2 Multiple sources of evidence .......................................................................................... 36
2.3 Use of evidence for other model input parameters ................................................ 46
2.3.1 Disease natural progression data .................................................................................. 47
2.3.2 Cost / resource use data ................................................................................................. 49
2.3.3 Health-state utility data.................................................................................................. 50
2.4 Discussion .............................................................................................................. 53
3. Synthesizing Evidence using Aggregate- and Individual-participant Level Data . 57
3.1 Introduction............................................................................................................ 57
43.2 Motivating example: The effectiveness of home safety education and the provision
of safety equipment for the prevention of accidents in pre-school children and the impact
of socioeconomic characteristics ....................................................................................... 60
3.3 Methods for estimating a pooled treatment effect – direct comparisons ............... 63
3.3.1 Synthesizing aggregate data only................................................................................... 63
3.3.2 Synthesizing individual participant-level data only ....................................................... 64
3.3.3 Synthesizing individual and aggregate level data .......................................................... 65
3.3.4 Meta-regression models: the inclusion of covariates ..................................................... 68
3.3.5 Application ..................................................................................................................... 73
3.4 Methods for estimating a pooled treatment effect – indirect and mixed treatment
comparisons ....................................................................................................................... 82
3.4.1 Synthesizing aggregate data only................................................................................... 84
3.4.2 Synthesizing individual participant-level data only ....................................................... 85
3.4.3 Synthesizing individual and aggregate level data .......................................................... 85
3.4.4 Mixed treatment comparisons models: including covariates ......................................... 88
3.4.5 Application ..................................................................................................................... 92
3.5 Challenges for the synthesis of (little) evidence of different formats: extending
developed synthesis models ............................................................................................. 100
3.5.1 Extensions to mixed treatment comparisons models including covariate(s): the synthesis
of aggregate and individual level data ...................................................................................... 101
3.5.2 Application ................................................................................................................... 104
3.6 Discussion ............................................................................................................ 108
4. Economic Evaluation of Smoke Alarm Programs for Preventing Fire-related
Injuries of Pre-school Children in the Home ........................................................... 112
4.1 Defining the context: Economic Evaluation of Public Health interventions ....... 112
4.2 Review of the existing economic evidence in accident prevention ..................... 115
4.3 Methods................................................................................................................ 117
4.3.1 The decision problem ................................................................................................... 117
4.3.2 Decision model structure.............................................................................................. 117
4.3.3 Decision analytic model assumptions/simplifications .................................................. 121
4.3.4 Model implementation.................................................................................................. 122
4.3.5 Identifying, combining and analysing existing relevant evidence ................................ 122
4.3.6 Base case and scenario analysis .................................................................................. 138
4.4 Cost effectiveness results ..................................................................................... 141
4.4.1 Overall population results (no covariates)................................................................... 141
4.4.2 Subgroup cost effectiveness analysis results ................................................................ 145
54.4.3 Results of analysis under alternative scenarios............................................................ 148
4.5 Discussion ............................................................................................................ 149
5. Using Aggregate- and Individual-participant Level Data for Cost Effectiveness
Modelling ................................................................................................................. 154
5.1 Background .......................................................................................................... 154
5.2 Framework of analyses ........................................................................................ 155
5.3 Results in the absence of subgroups .................................................................... 158
5.3.1 Effectiveness ................................................................................................................. 158
5.3.2 Cost effectiveness ......................................................................................................... 159
5.4 Results in the presence of mutually exclusive subgroups.................................... 161
5.4.1 Subgroup analyses: number of parents in the household (two vs single)..................... 161
5.4.2 Subgroup analyses: household employment status (employed vs at least one parent
unemployed) .............................................................................................................................. 165
5.4.3 Subgroup analyses: number of parents in the household and their employment status 168
5.5 Discussion ............................................................................................................ 172
6. The Value of Further Research: the Added Value of Individual-participant Level
Data .......................................................................................................................... 175
6.1 Introduction.......................................................................................................... 175
6.1.1 Background .................................................................................................................. 175
6.1.2 Aims and objectives ...................................................................................................... 178
6.2 Value of additional research in the absence of subgroups ................................... 181
6.2.1 Definitions and methods............................................................................................... 181
6.2.2 Available evidence and the value of further research .................................................. 182
6.2.3 Application: value of additional research in the context of having access to individual
participant level data................................................................................................................. 187
6.3 Value of additional research in the presence of mutually exclusive subgroups... 191
6.3.1 Definitions and methods............................................................................................... 191
6.3.2 Available evidence and the value of further research in the presence of subgroups.... 194
6.3.3 Application: value of additional research in the presence of subgroups and in the
context of having access to individual participant level data.................................................... 199
6.4 Discussion ............................................................................................................ 205
7. Discussion ............................................................................................................ 210
7.1 Summary of the main thesis findings................................................................... 210
7.2 What could have been done differently?.............................................................. 215
7.3 Recommendations for accessing and analysing individual-level evidence ......... 216
67.4 Recommendations for future research ................................................................. 217
7.5 Conclusions.......................................................................................................... 219
Appendices............................................................................................................... 220
Appendix 1....................................................................................................................... 220
Appendix 2....................................................................................................................... 224
Appendix 3....................................................................................................................... 228
Appendix 4....................................................................................................................... 233
Appendix 5....................................................................................................................... 234
Appendix 6....................................................................................................................... 252
Appendix 7....................................................................................................................... 256
Appendix 8....................................................................................................................... 263
List of abbreviations (in alphabetic order) ............................................................... 266
References ................................................................................................................ 270
7LIST OF TABLES
Table 2.1 – A gallery of scenarios arising when using clinical evidence in cost effectiveness
models .................................................................................................................................... 33
Table 2.2 – Scenarios and corresponding current methods literature for when using clinical
evidence to inform cost effectiveness modelling. .................................................................. 45
Table 3.1 – Available evidence on interventions seeking to increase the ownership of
functioning smoke alarm safety equipment to prevent fire injuries in children..................... 62
Table 3.2 - Parameter estimates from fitting the pair-wise meta-analytic model to AD
without covariates to the functioning smoke alarm outcome................................................. 74
Table 3.3 - Parameter estimates from fitting the pair-wise meta-analytic models to IPD and
to AD and IPD without covariates to the functioning smoke alarm outcome........................ 76
Table 3.4 - Parameter estimates from fitting the pair-wise meta-regression model to AD with
a binary covariate (single parent status) to the functioning smoke alarm outcome. .............. 78
Table 3.5 - Parameter estimates from fitting pair-wise meta-regression models to IPD and to
AD plus IPD with covariate ‘single parent status’ to the functioning smoke alarm outcome
data considering exchangeable treatment interactions and modelling separately within and
between study associations. ................................................................................................... 79
Table 3.6 - Parameter estimates from fitting the pair-wise model to IPD and to AD plus IPD
with information on the covariate ‘single parent status’ to the binary functioning smoke
alarm outcome data considering exchangeable and independent treatment interactions, not
separating between- and within-study interactions. ............................................................... 81
Table 3.7 - Parameter estimates from fitting different MTC synthesis models without
including covariates to the functioning smoke alarm outcome data ...................................... 95
Table 3.8 - Parameter estimates from fitting a MTC model of AD and IPD with covariate
‘single parent status’ to the functioning smoke alarm outcome data, considering
exchangeable treatment interactions and modelling separately within and between
associations. ........................................................................................................................... 97
Table 3.9 - Parameter estimates from fitting the MTC model of AD, IPD only and AD and
IPD with covariate ‘single parent status’ to the functioning smoke alarm outcome data;
8considering exchangeable treatment interactions, estimating subgroup baseline effects and
imputing missing covariate values....................................................................................... 107
Table 4.1 – ORs and absolute probabilities of success estimates for each intervention result
of fitting MTC model for AD without including covariates to the functioning smoke alarm
outcome data. ....................................................................................................................... 127
Table 4.2 - Relative intervention effect estimates and absolute probabilities of success
estimates for each intervention, result of fitting MTC models for AD including: (a) a
covariate relating to the number of parents (i.e. 1P vs. 2P) in the household; and (b) a
covariate parents’ employment status (i.e. 2U vs. 1U), to the functioning smoke alarm
outcome data. ....................................................................................................................... 129
Table 4.3 – Absolute probabilities of success estimates for each intervention result of fitting
MTC model for AD including covariates ‘single parent status’ and ‘parents’ employment
status’ to the functioning smoke alarm outcome data.......................................................... 130
Table 4.4 - List of model input parameters used within part 1 (intervention) of the decision
model for functioning smoke alarms. Parameter descriptions and sources of evidence used to
inform the parameter are shown........................................................................................... 131
Table 4.5 - All cause mortality. ........................................................................................... 134
Table 4.6 – List of model input parameters used within part 2 (5 year Markov structure) of
the decision model for functioning smoke alarms. Parameter descriptions and sources of
evidence used to inform the parameter are shown. .............................................................. 136
Table 4.7 – List of model input parameters used within the decision model for functioning
smoke alarms. Sources of evidence used to inform the parameter and parametric assumption
used to model parameter uncertainty is also shown............................................................. 138
Table 4.8 - Summary of the base case................................................................................. 139
Table 4.9 – List of scenarios considered in current analysis (each one assessed as a specific
scenario, includes base case) showing how these are interconnected and their inherent
hierarchical structure............................................................................................................ 140
Table 4.10 – Results of the base case scenario for all interventions (for when effectiveness
AD were synthesised and used to populate the decision model) ......................................... 142
Table 4.11 - ICERs and probabilistic sensitivity analysis results for each intervention for the
base case scenario and for the subgroup of (a) 2Us and of (b) 1Us..................................... 146
9Table 4.12 - Cost effectiveness results for the functioning smoke alarms decision model for
four subgroups (a) two employed parent household (2EP); (b) employed single parent
household (1EP); (c) two parent household with at least one unemployed (2UP); and (d)
unemployed single parent household (1UP). ....................................................................... 147
Table 4.13 – Cost effectiveness results of the 4 scenarios for all interventions and all
participant households and for when AD on effectiveness was synthesised and used to
populate the decision model, all the rest remaining constant............................................... 148
Table 5.1 - Absolute probabilities of ‘success’ estimates (i.e. uptake of ‘functioning’ safety
equipment in the household) for each intervention result of fitting different MTC models
(AD and AD plus IPD) without including covariates, to the functioning smoke alarm
outcome data. ....................................................................................................................... 159
Table 5.2 – Cost effectiveness results for all interventions and for when AD and AD plus
IPD on effectiveness was synthesised and used to populate the decision model. Both
analyses use base case characteristics and, in both, evidence informing all other economic
model parameters remained the same. ................................................................................. 160
Table 5.3 - Cost effectiveness results for all interventions, for the 2P and 1P subgroups and
for when AD and AD plus IPD effectiveness evidence was synthesised and used to populate
the decision model. .............................................................................................................. 164
Table 5.4 – Absolute probabilities of ‘success’ estimates (i.e. uptake of ‘functioning’ safety
equipment in the household) from fitting the MTC model for AD and for AD plus IPD
including covariate ‘single parent status’ to the functioning smoke alarm outcome data. .. 165
Table 5.5 – Cost effectiveness results for all interventions, for the 2U and 1P subgroups and
for when AD and AD plus IPD effectiveness evidence was used. ...................................... 167
Table 5.6 - Absolute probabilities of ‘success’ estimates (i.e. uptake of ‘functioning’ safety
equipment in the household) from fitting the MTC model for AD and for AD plus IPD
including covariates ‘single parent status’ and ‘parents’ employment status’ to the
functioning smoke alarm outcome data. .............................................................................. 169
Table 5.7 – Cost effectiveness results for all interventions, for 4 subgroups of families: (a) 2
employed (2EP); (b) employed single (1EP); (c) 2 with at least one unemployed (2UP); and
(d) unemployed single parents (1UP). Results are shown for when using AD and AD plus
IPD to populate the decision model. .................................................................................... 171
10
Table 6.1 – Expected cost effectiveness of functioning smoke alarms interventions per
participant for when using AD plus IPD effectiveness evidence to inform the economic
model. .................................................................................................................................. 189
Table 6.2 – Population EVPI at a threshold value of £20,000 per QALY (2009 values)
derived from the cost effectiveness decision model for functioning smoke alarms. Results are
shown for the use of AD and AD plus IPD for when decisions are made for: 1 subgroup (the
entire targeted population); 2 subgroups – single parent status specification; 2 subgroups –
parent’s employment status specification; and 4 subgroups. ............................................... 203
11
LIST OF FIGURES
Figure 3.1 – Diagrams of evidence structures: (a) indirect comparison of intervention A and
B given studies on the comparisons of CA and CB, and (b) network of studies reflecting
MTCs of CA, CB, AB and AD trials. .................................................................................... 83
Figure 3.2 - Network diagram for the functioning smoke alarm outcome with information on
the number and format of evidence available for each treatment comparison (continuous
line) and on the number and format of evidence available for single parent status (dashed
line). ....................................................................................................................................... 93
Figure 3.3 - Parameter estimates from fitting the MTC of AD and the MTC of AD plus IPD
models with information on covariate ‘single parent status’ to the functioning smoke alarm
outcome data, considering exchangeable and independent treatment interactions, not
separating between- and within-study interactions. ............................................................... 99
Figure 4.1 - Decision analytical model structure, part 1: model for households receiving
interventions; part 2: Markov state transition model for pre-school children aged 1 to 5; and
part 3: Markov state transition model for rest of life (5 years onwards).............................. 120
Figure 4.2 – (a) Cost effectiveness plane and (b) acceptability curves for the functioning
smoke alarms decision model. ............................................................................................. 143
Figure 4.3 – Cost effectiveness acceptability frontier for the functioning smoke alarms
decision model. .................................................................................................................... 144
Figure 5.1 – Absolute probabilities of ‘success’ estimates (i.e. uptake of ‘functioning’ safety
equipment in the household) for two parent families (2P) and single parent families (1P)
from fitting the MTC model for AD (i.e. MTC AD RE) and for AD plus IPD (i.e. MTC
AD+IPD RE)........................................................................................................................ 162
Figure 6.1 - Representation of (a) an increase in estimates precision when IPD is considered;
and (b) the possible consequences over the EVPI when using AD and IPD in these
circumstances (scenario 1.1). ............................................................................................... 185
Figure 6.2 - Representation of (a) a decrease (removal) of bias in obtained estimates when
IPD is considered; and (b) the possible consequences over the EVPI when using AD and IPD
in these circumstances (scenario 1.2)................................................................................... 186
12
Figure 6.3 - Representation of (a) an increase in precision and a decrease (removal) of bias
in obtained estimates when IPD is considered; and (b) the possible consequences over the
EVPI when using AD and IPD in these circumstances (scenario 1.3)................................. 187
Figure 6.4 – Cost effectiveness results for the smoke alarms decision model: NMBs
estimates at £30,000 threshold ratio versus the probability of the intervention(s) being cost
effective. Results shown are for when AD only was used to inform the effectiveness decision
model parameters and when no subgroups are considered. ................................................. 188
Figure 6.5 – Population expected NMBs at a threshold value of £20,000 per QALY (2009
values) derived from the cost effectiveness decision model for functioning smoke alarms.
Results are shown for the use of AD and AD plus IPD effectiveness evidence. ................. 190
Figure 6.6 – Two forms of VoH: (i) the static value (represented by gain A and representing
the NMB obtained with existing information for the average population, equivalent to the
gains obtained when considering 2 subgroups); and (ii) the dynamic value (represented by
the vertical distance B, where EVPIB1 > EVPIA). The x-axis reflects the number of subgroups
and the y-axis the NMBs. Reproduced from Espinoza et al. (2011) and Claxton (2011), with
permission from the authors................................................................................................. 194
Figure 6.7 – Representation of (a) considering existing heterogeneity in the identification of
2 subgroups and possible impact in the distribution of subgroup effects when IPD is
considered and the inability of performing this analysis when using AD; and (b) the possible
consequences over the EVPI when using AD and IPD in these circumstances (scenario 2.1).
............................................................................................................................................. 196
Figure 6.8 - Representation of (a) considering existing heterogeneity in the identification of
4 subgroups and possible impact in the distribution of subgroup effects when IPD is
considered and the inability of performing this analysis when using AD, although possible
for 2 subgroups; and (b) the possible consequences over the EVPI when using AD and IPD
in these circumstances (scenario 2.2)................................................................................... 197
Figure 6.9 – Representation of (a) considering existing heterogeneity in the identification of
4 subgroups and possible impact in the distribution of subgroup effects when AD and IPD
are considered; and (b) the possible consequences over the EVPI when using AD and IPD in
these circumstances (scenario 2.3)....................................................................................... 198
Figure 6.10 - Population expected NMBs at a threshold value of £20,000 per QALY (2009
values) derived from the cost effectiveness decision model for functioning smoke alarms.
13
Results are shown for the use of AD and AD plus IPD for when decisions are made for (a)
the average population (repeated from above for completeness); (b) 2 subgroups,
specification 1 – single parent status specification; (c) 2 subgroups, specification 2 – parent’s
employment status specification; and (d) 4 subgroups. ....................................................... 201
Figure 6.11 – Expected (individual level) NMBs with perfect information (for £20,000
threshold values and 2009 values) for the cost effectiveness decision model for functioning
smoke alarms. Results are shown for the use of AD and AD plus IPD effectiveness evidence
to inform the decision model when heterogeneity is considered. That is, no subgroups,
weighted average for 2 subgroups (2 specifications – number of parents in the family and
their employment status) and the weighted average for the 4 subgroups are considered. ... 204
14
ACKNOWLEDGEMENTS
The completion of this thesis was made possible by the financial support of the
Medical Research Council and the Fundação para a Ciência e Tecnologia (Portugal).
I would like to thank them for this assistance.
I am eternally grateful to a number of people for their help and support throughout
my studies. In particular, my supervisors Dr Andrea Manca and Professor Alex
Sutton, for their time, expertise, constant support, encouragement and guidance.
Members of the Thesis Advisory Group (TAG), Professor Mark Sculpher and Dr
Cynthia Iglesias also provided useful input, for which I am thankful. Special thanks
goes to Professor Karl Claxton, a precious late addition to the TAG, and Professor
Nicola Cooper, who provided me with helpful guidance during the initial stages of
the thesis.
Members of the academic community within the Centre for Health Economics are
also acknowledged, especially all members of the Team for Economic Evaluation
and Health Technology Assessment for welcoming me into their group. In particular,
my friend, office colleague and fellow PhD student Manuel Espinoza who provided
me with continued support throughout the PhD program.
An immense thank you is due to my beautiful and gifted partner Marta Soares for her
constant colossal support and for making my existence so joyful. My last word of
thanks goes to my father, mother, sister and my departed grandmother for their love
and support.
15
PUBLICATIONS
I have made efforts to disseminate the research presented in this thesis. The
following papers have been submitted to peer-review journals and were accepted for
publication:
Saramago P., Manca A., Sutton A. J., Deriving input parameters for cost-
effectiveness modelling: taxonomy of data types and approaches to their statistical
synthesis. Value in Health, 2012, 15 (5), 639-649, July 2012,
DOI:10.1016/j.jval.2012.02.009.
Saramago P., Sutton A. J., Cooper N. J., Manca A., Mixed treatment comparisons
using aggregate- and individual-participant level data. Statistics in Medicine, 2012,
31 (28), DOI: 10.1002/sim.5442.
AUTHOR’S DECLARATION
I declare that this thesis is my original work and that none of the material contained
in this thesis has previously been submitted for a degree in this, or any other,
awarding institution. The contents and views expressed reflect the best of my own
knowledge, investigation, and belief.
Pedro Saramago, 2012
16
CHAPTER 1
1. INTRODUCTION
1.1 Background
The rising costs of health and demand pressures associated with demographic
alterations, together with rising consumer expectations, have led to an escalating
burden on health care systems. To guide health care policy decisions in the efficient
allocation of available health resources, an increasing emphasis on the use of
economic evidence has been observed in recent years. This emphasis on economic
evidence goes hand in hand with a move towards evidence-based health care, which
has raised health service researchers’ awareness concerning a number of
methodological issues. This thesis contributes to some of the recent methodological
debates, aiming to explore and structure how evidence of different disaggregation
levels, and in particular, evidence at the individual level can be used to best inform
economic evaluations of health care technologies.
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Economic evaluation in health care
Economic evaluation is defined as the “…comparative analysis of alternative courses
of action in terms of both their costs and consequences.” (Drummond et al., 2005).
Its main purpose is to assess the economic and health consequences of health care
interventions, programmes or services with the aim of informing policy decisions
regarding resource provision within health care systems operating under a fixed
budget. Economic evaluation provides a way of systematically analysing the relevant
alternatives, without which it would be impossible to explicitly identify the
interventions that should be made available to maximize benefits from the available
budget. This involves making difficult judgements regarding the value for money of
alternative health interventions (e.g. drugs, medical devices and surgical techniques).
The use of economic evaluation in health care decision making appears to have
increased over the last couple of decades. This tool is seen by many health systems
as a helpful instrument in controlling costs and improving efficiency in an evidence-
based decision-making environment1.
In the United Kingdom (UK), the National Institute for Health and Clinical
Excellence (NICE) was set up to take the lead in the provision of clinical and cost
effectiveness evidence - issues considered central to its mission (Government,
2005)2. The NICE is seen as an independent organisation responsible for providing
1 In Australia [Department of Health and Ageing’s Health Technology Assessment (DoHA - HTA)],
Canada [Canadian Agency for Drugs and Technologies in Health (CADTH)], and other European
countries such as Finland [Finnish Office for Health Technology Assessment (FINOHTA)], the
Netherlands [Medicines Evaluation Board (CBG-MEB)], Portugal [National Authority of Medicines
and Health Products (INFARMED)] and Sweden [Swedish Council on Health Technology
Assessment (SBU) and the Medical Products Agency (MPA)] have introduced economic evaluation
guidelines at the end of the 90’s and beginning of 2000’s. The United States of America (USA) – a
country of, in many ways, different health care system – also considered the need to guarantee an
efficient use of collective health care resources, making some Health Maintenance Organisations
(HMOs) use formal economic criteria in performing decisions about which interventions to subsidize.
2 The National Health System (NHS) Research & Dissemination Health Technology Assessment
programme was setup in 1996 to evaluate health care technologies. Its main objective was to
guarantee that information on costs, effectiveness and, more generally, the broader impact of health
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national guidance on promoting good health and preventing and treating ill health.
The NICE publishes guidelines on how it selects interventions for review and on the
methods and types of analysis performed to assess them3. These guidelines are
comprised of a set of documents that describe the processes and methods the NICE
uses to undertake technology appraisals, providing guidance for the organisations
invited to contribute to these appraisals.
Cost effectiveness analysis (CEA) is the type of economic evaluation that, by
adhering to the principles of resource allocation, is promoted in the above mentioned
guidance and has been widely used in health care. In CEA, effectiveness is
commonly measured in terms of Quality Adjusted Life Years (QALYs), a composite
measure combining mortality and morbidity (Williams, 1985). The theoretical and
methodological strengths and weaknesses of the QALY approach have been
discussed elsewhere (Weinstein et al., 2009, Drummond et al., 2005) and will be
revisited later in this thesis. The main application of CEA is to support
reimbursement decisions made by health care providers regarding health
technologies. This tool evaluates technologies to find the one minimizing the cost of
generating a given level of health, or maximizing the level of health within a
specified budget (Garber & Phelps, 1997). Intrinsically, CEA is a comparative tool,
requiring the contrast of costs and consequences of at least two alternative options.
When making the choice between alternatives, the potential health outcomes gained
technologies, was provided by quality research. Moreover, this information was to be produced in an
efficient way, aimed at those who use, manage and work in the NHS (Burns, 1998). In 1999, the
NICE was established in an attempt to resolve the so-called ‘postcode lottery’ of health care in
England and Wales, where treatments that were available depended upon the NHS primary care trust
area in which the patient happened to live. In 2005 it was amalgamated with the Health Development
Agency to become the new National Institute for Health and Clinical Excellence.
3 In 2001, the NICE published a first set of technical guidance for manufacturers’ and sponsors’
submissions. The aim was to harmonize submissions for technology appraisal and maintain a
transparency format in policy decisions. In 2004, an updated guidance was issued (NICE, 2004) which
attempted to establish a clear role for economic evaluation within the NICE appraisal process and
incorporate a range of methodological developments, which, by then, were raised in the cost
effectiveness literature. An updated version of 2004 guidance was released in 2008 (NICE, 2008) and
a new updated version is being prepared with the help of technical reports produced by the Decision
Support Unit (DSU).
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must be compared to those lost from interventions displaced by reallocating
resources to fund this new technology. In CEA, the summary measures of interest to
the decision maker are the expected values of both costs and effectiveness outcomes
for each treatment strategy. These are commonly aggregated in a distinctive cost
effectiveness outcome measure, as the incremental cost effectiveness ratio (ICER)
=ΔC / ΔE (where ΔC are the mean differential costs, and ΔE the mean differential 
effects), or its reformulation, the net benefit4 (NB) measure. When a trade-off
situation is raised, decision rules should be applied (Drummond & McGuire, 2001).
If the ICER is used, it is interesting to assess the probability of its estimates being
smaller than predefined fixed threshold values5, ICER < λ (with ΔE > 0). In these 
circumstances, the intervention is cost effective in relation to the comparator (NICE,
2008). Cost effectiveness analysis has been undertaken in the literature using either
individual participant level data (IPD) collected alongside primary studies, such as
randomised controlled clinical trials (RCTs), or using decision analytic models. The
latter, as discussed below, are mathematical models used to combine information
from various sources (Sculpher, M. J. et al., 2006).
Decision analytic modelling for economic evaluation
In the presence of multiple sources of information, mathematical relationships need
to be established to synthesise or gather data on both costs and effectiveness
components of interest (Drummond et al., 2005, Gold, 1996). Cost effectiveness
analysis combining information sources is denominated decision analytic modelling
4 The Net Health Benefit (NHB) of an intervention, as defined by Stinnett and Mullahy (1998), is
interpreted as “... the net benefit (measured in units of health) of investing resources in intervention
T1, compared with T0, rather than investing those resources in a marginally cost effective program.”.
Within the NB framework, the new technology is accepted if: NHB = ΔE – ΔC / λ > 0, or 
equivalently, NMB = λ • ΔE − ΔC > 0 (net monetary benefit (NMB)), where λ is the predefined 
threshold value.
5 Current guidance (NICE, 2008) considers the existence of a cost effectiveness threshold in the form
of a range of empirically plausible values (i.e. between £20,000 and £30,000/QALY). Issues
surrounding the existence or not of a cost effectiveness threshold as well as its (approximate) value
have received extensive debate in recent literature (Raftery, 2009, Towse, 2009, McCabe et al., 2008,
Appleby et al., 2007, Culyer et al., 2007, Birch & Gafni, 2006).
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(Briggs, A. H. et al., 2006). Decision analysis provides a systematic approach to
decision making under uncertainty (Briggs, A. H. et al., 2006), by allowing: (i) a
clear definition of the decision problem; (ii) the choice of an appropriate time
horizon for the analysis; (iii) consistency in costs and benefits perspective; (iv)
comparison of the new technology judged against all relevant comparators and
consideration of all relevant evidence; and (v) an appropriate understanding of
existing uncertainty and assessment of the value of acquiring additional research
(Claxton, K. et al., 2007, Sculpher, M. J. et al., 2006). The majority of these items are
briefly discussed in Appendix 1.
Use of evidence in cost effectiveness analysis
The current state of the art of the use of evidence in the economic assessment of
health care interventions is reflected in the methods guidance for technology
appraisal from the NICE (NICE, 2008). As with the 2001 and 2004 versions, more
recent guidance acknowledges the need to assemble an analytical framework to
synthesise available evidence for the estimation of clinical and cost effectiveness
results, central to the clinical decision making context. These guidelines advise the
identification, assessment and use of ‘relevant’ available evidence. The usefulness of
the results obtained from decision models directly depends on the source and quality
of the estimates informing the model (Cooper, N. J. et al., 2007, Cooper, N. et al.,
2005, Briggs, A., 2000).
Currently, decision model parameter estimates are mainly obtained from diverse
sources of evidence ranging from more reliable sources as RCTs to less robust ones
as the estimates obtained from eliciting expert opinion. The range of relevant study
designs depends on the nature of the parameter to be informed. For instance, RCT
data is likely to be the preferred to inform estimates of treatment efficacy, while for
costs and health related quality of life associated to an intervention, administrative
sources or observational studies may be more appropriate. Techniques for systematic
reviews are often used to identify the range of evidence sources available and their
quality. These techniques are known for their transparency and replicable
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characteristics. The formal synthesis of (effectiveness) evidence tends to be limited
to RCT data and usually applied using standard meta-analytic techniques. Pair-wise
and network meta-analyses, together with indirect treatment comparisons, are now
commonly used to summarize evidence on clinical effectiveness in the NICE
technology appraisals, and the estimates of effect they generate are frequently used to
inform the economic analyses.
As discussed by Cooper et al. (2007, 2005), there are a number of methodological
issues relating to the use of evidence in the economic assessment of heath care
technologies. Problems that threaten the validity of study findings, may, for instance,
be related to: (i) the suitability of methods to analyse/synthesise evidence –
irrespective of its level of disaggregation; (ii) failure to consider all relevant evidence
– through discarding or reducing evidence; (iii) failure to adequately model/adjust for
effect modifiers; (iv) failure to appropriately reduce/eliminate existing confounding
effects and/or bias; (v) failure to correctly reflect existing decision uncertainty.
Ultimately, all these potential issues may undermine decisions to approve/reject
particular options and to undertake further research. These and other methodological
issues are explored throughout this thesis.
In relation to point (ii) above, and although no inclination is shown to exist in the
NICE methods guidance (NICE, 2008), the use/synthesis of IPD is usually preferred
by analysts/modellers because it offers several advantages over using/synthesizing
published aggregated data (Simmonds et al., 2005). The idea behind this preference
is that IPD better informs model input parameter estimates and correctly reveal their
uncertainty by illustrating consequences on the cost effectiveness outputs of interest,
helping the decision making process (Drummond & McGuire, 2001) – and
responding to issues (iii) and (iv) above. These arguments are the starting points of
this thesis.
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1.2 Thesis aims and objectives
The overall aim of this thesis is to develop the methods on the use and synthesis of
evidence for CEA for health care decision making. To achieve this, two main
objectives are defined.
1.2.1 Objective 1: Exploring the use of evidence for cost effectiveness analysis
– enhancing the use of individual level data
The first objective is to explore how evidence, and, in particular, how aggregate data
(AD) and IPD are used to populate decision model input parameters. The use and
relevance of a particular source of data varies depending on its characteristics, the
type of model parameter it seeks to inform and the number of parameters it may
inform, among other issues.
Two specific research targets have been set. The first target is to review the literature
on the use of evidence for economic modelling of heath care interventions. This
review aims to further the reader’s appreciation of: (i) the diversity of (evidence
type) scenarios that the analyst/modeller may face when wanting to inform a decision
model and consequently answer a particular research question; (ii) the variety of
modelling options available in the current literature to synthesise evidence; (iii) the
gaps in the methods literature; and (iv) to provide key references where such methods
have been used in practice. The second target, and linked to aim (iii) above, is to
develop novel methodology to address identified gaps and fully substantiate the
advantages of these with the support of a case study (see section 1.3).
1.2.2 Objective 2: Assess the added value of having access to and using
individual patient level data for cost effectiveness decision making
The second objective of this thesis is to investigate the use of evidence at the
individual level, compared to aggregate level, when: (a) assessing the cost
effectiveness of alternative options (thus informing the suitability of the provision of
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health care, given available information); (b) judging the feasibility of funding
supplementary research (thus diminishing existing decision uncertainty); and (c)
understanding heterogeneity by undertaking subgroup analysis (and therefore
checking for whom (a) and (b) is true/successful). Again, to work towards this
second objective of the thesis, two immediate research goals have been set.
Firstly, the thesis aims to use a case study that provides the grounds for a comparison
of performances between alternative, new and existing methods of synthesis.
Additionally, the case study will be a vehicle for the investigation of the impact on
the estimation of CEA outcomes and decision uncertainty across a set of scenarios.
Among other issues, these scenarios will evaluate decisions for the overall
population and for subgroups of the population.
Secondly, as decisions based on available information are inherently uncertain, it is
important to evaluate the opportunity costs of getting them wrong, conditional to the
format of evidence used. Therefore, quantification of the upper boundary of the value
of conducting further research is required and will be estimated. Additionally, it is
crucial to have an understanding of heterogeneity in order to guide decisions about
further research for different population strata. Thus, the final aim of this thesis is to
evaluate the value of further research and the added value of individual level
evidence in the presence and in the absence of population subgroups.
1.3 Case study
Throughout this thesis, a case study is used to illustrate the methodological issues
being considered. This case study is based on a Public Health (PH) accident
prevention scheme, focusing on the evaluation of interventions that promote the
provision of functioning smoke alarm safety devices for the prevention of accidents in
the home in pre-school children.
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In 2008-9, local authority fire services attended over 700,000 fires of false alarms in
the UK, almost 50,000 of which were domestic fires. In 2008-9 in the UK, 335
fatalities were estimated to have happened as a result of fires in the home, and
approximately 10,000 people suffered non-fatal injuries (Government, 2009). The
majority of childhood injuries are found to occur in the home (Unicef, 2001) and
within the range of possible causes, fire-related injuries are considered one of the most
relevant in terms of resultant disabilities, deaths and costs incurred (Government,
2009, 2004a). For several years, the UK government has conducted publicity
campaigns in order to increase the number of households which have smoke alarms
fitted and fully operational. Fires detected by smoke alarms tend to be discovered
more rapidly and are associated with a reduced risk of death and less property damage
(DiGuiseppi & Higgins, 2001). Although some parents of children aged 0-4 have
smoke alarms installed, fewer take other safety measures inside the home. Generally,
there is higher incidence of safety measures being adopted inside the home when
children reach one year and older (Government, 2004b).
Despite several interventions being available to improve the uptake of security
measures in this context, few attempts have been made to systematically review and
subsequently synthesise evidence in this area (DiGuiseppi & Higgins, 2001,
DiGuiseppi & Roberts, 2000, Elkan et al., 2000). These have found that interventions
which were based in counselling and education did not have a significant impact on
the increased ownership of smoke alarms. Nonetheless, interventions delivered with
counselling as part of primary care child health surveillance have revealed an effect on
smoke alarm ownership (DiGuiseppi & Higgins, 2001).
A systematic review (Kendrick et al., 2007) and its update (Wynn et al., 2010) were
found to play a key role in the identification of evidence and in performing an initial
synthesis of findings from a variety of sources. The primary intention of these
systematic reviews was to obtain IPD from all relevant studies and to subsequently
synthesise these in a meta-analysis. Unfortunately, the investigators were only
successful in obtaining IPD for a proportion of the studies. The reviews included non-
randomised and RCTs, as well as controlled before-and-after studies. While the initial
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Cochrane review (Kendrick et al., 2007) identified much of the relevant literature
base, comparative studies that did not have usual care as a comparator (e.g. studies
comparing ‘smoke alarms education’ vs. ‘smoke alarms education plus low-cost/free
fitted smoke alarm’, etc) were not considered. Therefore, a supplementary systematic
review of existing reviews was conducted (Kendrick et al., 2010) to identify further
relevant “head-to-head” primary studies that could be included in a network analysis.
The exploration of participant-level socioeconomic characteristics was of primary
interest for both reviews because there were concerns that the effectiveness of such
interventions was dependent on socioeconomic characteristics.
The evidence base used for this thesis was identified by both these review studies.
Details on the included trials will be provided later in this thesis but it also can be
found in the systematic reviews by Kendrick et al. (2007) and Wynn et al. (2010), and
also in Sutton et al. (2008) and Cooper et al. (2012).
1.4 Structure of the thesis
This thesis is structured as follows.
Chapter 2 develops a taxonomy based on possible scenarios typically faced by the
analyst when dealing with the evidence base. This provides guidance to modellers on
the appropriateness of certain methodologies which may enable the use/synthesis of
available data to inform a given model parameter. Although its main focus is on
effectiveness type parameters, this chapter also briefly considers available methods
for the use of evidence in other key economic model parameters. Advantages and
disadvantages of using evidence at the individual level, compared to aggregate level,
are discussed throughout and gaps in the methods literature identified.
Chapter 3 begins by revising available methodologies for the estimation of
combined statistics when direct head-to-head comparisons are at stake. Revised
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methods consider the synthesis of study summary estimates, of evidence available at
individual level and of the mixture of AD and IPD – all in a binary outcome setting.
It illustrates how to incorporate treatment-effect modifiers in all the above mentioned
modelling scenarios. These are extended to the indirect and mixed treatment
comparisons (MTCs) framework, with the development of novel synthesis
methodologies. All model implementation, including that for novel models, is
supported by the above mentioned motivating example.
Chapter 4 focuses mainly on the case study decision problem relating to the
assessment of ‘functioning’ smoke alarm programs for the prevention of fire-related
injuries of pre-school children in the home. A decision analytic model that addresses
the decision problem is described and cost effectiveness results are discussed.
Summary evidence is the source used to populate the effectiveness model input
parameters. Different viewpoints of the analysis are evaluated and subgroup cost
effectiveness analysis is implemented in order to evaluate whether suboptimal
intervention decisions are being made for different subgroups of patients.
Chapter 5 evaluates the impact of using different effectiveness model inputs (from
alternative synthesis models for AD and/or IPD) over the cost effectiveness
outcomes. Chapter 4 and Chapter 5 are interrelated in the sense that both follow from
Chapter 3 by using the results from the relevant (novel and existing) synthesis
models, and both make use of the same (case study) decision analytic model.
Chapter 6 deals with the issue of whether and for whom it is worthwhile funding
additional research. For the whole population of interest or for subsets thereof, this
chapter highlights the advantages of having access to IPD, compared to having
summary data only, when quantifying decision uncertainty and estimating the
expected cost of uncertainty.
Finally, Chapter 7 brings together the conclusions of the thesis, focusing on its
contributions to the methods in evidence synthesis and CEA. This chapter concludes
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with a discussion of future research topics that emerges from the work that has been
produced.
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CHAPTER 2
2. DERIVING INPUT PARAMETERS FOR COST EFFECTIVENESS
MODELLING: TAXONOMY OF DATA TYPES AND
APPROACHES TO THEIR STATISTICAL SYNTHESIS
2.1 Introduction
Economic evaluations assess the costs and health consequences of competing health
care interventions, programme or services. Their aim is to inform policy decisions
regarding resource provision within health care systems operating under a limited or
fixed budget.
The information required to carry out an economic evaluation rarely comes from a
single study (Sculpher, M. J. et al., 2006). More commonly, the evidence base
informing the model parameters is represented by one or more data sources,
including individual patient level datasets (e.g. RCTs and observational studies),
expert opinions, and secondary data analyses (e.g. meta-analysis). Decision analytic
models represent an ideal vehicle to structure the decision problem, combine all
available data and characterise the various sources of uncertainty associated with the
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decision problem (Sculpher, M. & Claxton, 2005). As with any modelling
framework, the results of the analysis depend on the suitability of the model
structure, the quality of the data inputs and the methods used to derive these (Cooper,
N. J. et al., 2007).
The NICE (or the Institute) for England and Wales is one of the many national
agencies worldwide that recognise the value of decision models to inform the
assessment of whether or not technologies represent value for money. The Institute’s
guideline for methods of technology appraisal (NICE, 2008) recommends that after
defining ‘…explicit criteria by which studies are included and excluded…’(page 14)
‘…all relevant evidence...’ should be ‘…identified, quality assessed and, when
appropriate, pooled using explicit criteria...’ by means of ‘...justifiable and
reproducible methods (page 27)’.
One issue typically faced by health economics modellers is how to proceed when
multiple sources of evidence are available to inform the same model input (e.g.
relative effectiveness). In the last decade, at least for effectiveness parameters, there
has been a shift towards recognising the need for a more systematic identification
and utilisation of statistical evidence synthesis in decision models (Cooper, N. J. et
al., 2007), with approaches such as meta-analysis or MTCs increasingly being used
in CEA (Ades, A. E. et al., 2006b).
Parameters used in decision analytic models, for instance, are increasingly being
estimated from AD available from published literature. There are, however, several
examples where the model parameters have been derived almost exclusively from a
single individual patient level trial dataset (Epstein, D. M. et al., 2008, Henriksson et
al., 2008, Briggs, A. et al., 2007, Mihaylova et al., 2006, 2005). Advantages of the
latter approach, compared to using AD only, include more accurate modelling of the
disease’s natural history and the possibility of exploring heterogeneity in baseline
risk (and/or relative treatment effect) across patient groups. In this case, the
challenge is how to integrate IPD with any other component of the evidence-base
that may be available in aggregate or summary measures format. Methods for
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combining multiple individual level (Higgins et al., 2001), or IPD and AD, are
rapidly developing (Riley, Richard D. & Steyerberg, 2010, Riley, Richard D. et al.,
2008, Riley, R. D. et al., 2008, Sutton, A. J. et al., 2008, Riley, R. D. et al., 2007),
although many applied health economics modellers are currently unaware of these.
This chapter develops a taxonomy based on possible scenarios typically faced by the
analyst when dealing with the evidence base. Since most of the methods
development took place in the area of statistical synthesis of clinical effectiveness
measures from RCTs, the proposed taxonomy is structured around examples
concerning such parameters (section 2.2). Statistical approaches available to
synthesise the evidence base under different scenarios are briefly reported and
discussed together with key references to full explanations of the methodologies and
examples of where such methods have been used in practice. This chapter makes no
claim to be exhaustive with respect to reviewing the various applications, as this is
not its objective. Instead, the aim is to use these examples to illustrate and to provide
recommendations regarding which techniques are most appropriate in order to use
synthesise available information depending on its format, number of data sources
and number of parameters to be derived.
In addition to applying this taxonomy to clinical effectiveness parameters, its
application is considered in relation to other key economic model input parameters
(in section 2.3) of an economic model including disease natural history, resource use
/ costs, and preferences, with a view to discussing issues with the application of the
taxonomy to these other parameters. In doing so, it is hoped to encourage a fuller
application of this taxonomy to non-effectiveness parameters in future modelling.
Finally, section 2.4 summarises the main points of the manuscript and includes
suggestions for future research.
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2.2 A taxonomy for the use of evidence in cost effectiveness models:
application to clinical effectiveness evidence
Good practice in health economic evaluation suggests that decision models should be
structured in a way that appropriately reflects the decision problem at hand
(Weinstein et al., 2003). The evidence used to inform the model inputs often comes
from different sources, with potentially heterogeneous designs (e.g. RCTs,
observational and expert panels). International HTA standards in systematic
reviews and meta-analysis (Higgins & Green, 2008) indicate that good quality RCT
evidence is the preferred data source for estimating the main clinical effect(s) of
interest.6 Country-specific HTA guidance documents provide more heterogeneous
indications as to whether or not it is acceptable to use non-randomised evidence to
inform the main clinical effectiveness part of the model in the absence of evidence
from good quality randomised studies (McGhan et al., 2009). In the case of the
NICE for instance, its methods guidance states that any limitations of the methods
used, potential biases in obtained parameter estimates, caveats about the
interpretation of results and appropriate reflection of parameter uncertainty should be
extensively reported in the analyses submitted for consideration of the Institute
(NICE, 2008). For simplicity, this chapter deals with situations in which the main
body of evidence for effectiveness comes from randomised studies7.
It is argued here that the selection of an appropriate method for the analysis and
synthesis of clinical effectiveness data for use in a decision model does depend on
three dimensions of the evidence base (listed below), the combination of which gives
rise to a taxonomy of possible scenarios the analyst may face, as illustrated in Table
6 There are of course many features of the evidence base (e.g. characteristics of target population, use
of intermediate outcomes rather than final ones) that may complicate its use for informing a particular
economic analysis. However these are not specific to randomised data alone.
7 The added level of complication deriving from the inclusion of non-randomised data is discussed
when relevant to the argument.
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2.1. These are briefly introduced here and discussed more fully in the following
sections.
Number of available sources of evidence Depending on the research question, there
may be multiple sources of evidence from RCTs from which to derive an estimate of
clinical effectiveness, although there are examples where a single RCT provides the
only evidence available.
Formats in which data are available The above evidence may be available in (a)
aggregate form only (sometimes referred to as summary data), (b) at the individual
level or, when multiple sources of data are available, (c) a combination of AD and
IPD8.
Number of (effectiveness) parameters to be derived It is important to distinguish
between the need to synthesise the evidence to inform a single parameter versus the
need to estimate multiple parameters for use in the decision model9.
8 Care must be taken when classifying these data formats, since in some contexts IPD may not
contain any extra information beyond what is conveyed by available summary statistics. For example,
basic IPD can be reconstructed from a summary 2 x 2 table recording numbers of individuals at risk
and those who experienced a binary outcome in a 2-arm trial. Either approach will give the same
estimate of the odds ratio (OR) of effect (Lambert et al., 2002). In this case, the OR is a sufficient
statistic, in the sense that “...no other statistic which can be calculated from the same sample provides
any additional information as to the value of the parameter” (Fisher, 1922).
9 One example may be the synthesis of the sensitivity and specificity of a diagnostic test, another one
may be the need to synthesise (one or more) clinical outcome(s) reported at different time-points -
most often these requiring different analytical and evidence synthesis strategies.
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Table 2.1 – A gallery of scenarios arising when using clinical evidence in cost effectiveness models
Single source of evidence Multiple sources of evidence
Parameter Parameter
Single Multiple Single Multiple
Fo
rm
at
of
da
ta
av
ai
la
bl
e
Aggregate level data Scenario A1 Scenario B1 Scenario A2 Scenario B2
Individual level data Scenario C1 Scenario D1 Scenario C2 Scenario D2
Mixture of
aggregate and
individual level data
--- --- Scenario E2 Scenario F2
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2.2.1 Single source of evidence
Let’s start with the simplest scenario of all, that is, where there is only one single
source of evidence from which to derive the parameter(s) of interest. In this case the
problem is not how to synthesise the available evidence but how to make the best of
this single source to inform parameter estimate(s) for use in the economic model.
2.2.1.1 Aggregate data to inform the estimation of a single parameter (A1)
If all the available evidence is in the form of published (summary) results of a single
study, the simplest option is to use these data in the model ‘as they are’ to inform the
derivation of the relevant parameter estimate in the decision model. For a
probabilistic representation of these parameters the analyst will need to have access
to multiple statistics from the source of evidence (e.g. mean and standard error).
Also, plausibility and sample characteristics (e.g. skewness) may be used to define an
appropriate distribution.
Clearly, exploration of any statistical heterogeneity10 relating to a parameter in this
circumstance is unfeasible and usually no further appraisals of the evidence are
possible, other than a simple sensitivity or threshold analysis. At this stage and in
the absence of other source of evidence, the analyst may want to explore whether
attempting to acquire further evidence, through other techniques (e.g. expert
elicitation) is worth the effort.
2.2.1.2 Aggregate data to inform the estimation of multiple parameters (B1)
It is possible for a single published study to provide several inputs that may be used
to derive model parameters. For instance, a single (three-arm) trial may provide
effectiveness data for a decision model evaluating the same three alternative
10 Statistical heterogeneity refers to variability between effect sizes from studies than would be
expected from chance only.
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treatments. Since the resulting measures of relative effectiveness (such as ORs or
log-ORs) between these three arms are inherently correlated, it has been
recommended that correlation between parameters should be explicitly modelled
where possible. Failure to do so would produce not just an incorrect assessment of
the uncertainty11 in the model but also result in an incorrect estimation of each
treatment’s expected costs and benefits (Epstein, D. & Sutton, 2011, Ades, A. E. et
al., 2006a, Ades, A. E. & Lu, 2003). Methods such as indirect or MTC models can
be successfully used to address the above problem (see section 2.2.2 and references
therein) (NICE, 2008).
Another situation where it is possible to derive multiple parameters from a single
study occurs when the interest of the modeller lies in estimating multiple
outcomes/multiple time points on the same treatment comparison. The range of
possible analytical options here may be limited by the lack of information on the
correlation between outcomes. In some cases, approximate or ad hoc methods may
be available to take into account the correlated nature of the outcomes (e.g. the phi
coefficient, Yule’s Q or Yule’s Y – see Epstein and Sutton (2011) for further details),
and this will usually be preferable to assuming the outcomes are independent (but
less desirable than obtaining the IPD and estimating the correlations directly).
2.2.1.3 Individual patient data to inform the estimation of a single parameter (C1)
Access to IPD, especially when there is only one relevant study forming the evidence
base, is particularly advantageous since it allows re-analysis of the data (e.g.
inclusion of further explanatory covariates, conduct of more in-depth analyses than is
possible from summary evidence extracted from published reports (Stewart &
Clarke, 1995)) aimed to derive appropriate model input parameters. Indeed,
compared to the use of AD, the analysis of IPD may be considered the most flexible
11 In such instances, propagation of correlations is automatic if parameter estimation is conducted in
the same program as the decision model (sometimes called one-step comprehensive decision
modelling (Cooper, N. J. et al., 2004)), or can be achieved by specifying the full multivariate
distributions for the correlated parameters (Ades, A. E. & Lu, 2003).
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way to explore and answer clinical and economic research questions. In this case,
data can be analysed using the range of statistical models developed to analyse trial
data to estimate the decision model parameter of interest (Glick, 2007, Bland, 2000).
Given that appropriate methods in this context are extensively documented
elsewhere, this section is kept brief.
2.2.1.4 Individual patient data to inform the estimation of multiple parameters (D1)
The availability of IPD often enables the estimation of multiple model parameters.
The economic model constructed around the third Randomised Intervention Trial of
unstable Angina (RITA 3) (Henriksson et al., 2008) is an example where the trial
data were used to derive estimate rates of cardiovascular death and myocardial
infarction (as well as costs and health-related quality of life) through regression
models applied to a single individual patient-level dataset. As noted in section
2.2.1.2, the possibility to estimate correlations between correlated input model
parameters based on summary measures is often limited by the data being reported.
This is no longer an issue when one has access to the original study IPD. Another
important area where access to IPD facilitates estimation of multiple parameters
relates to the analysis of time-to-event data. Since trials’ follow up are short in
duration (Sculpher, M. J. et al., 2006) to produce long term estimates of cost
effectiveness, most models need to extrapolate the observed trial results (e.g. fatal
and non-fatal events) beyond the trial follow up. This can be achieved employing
parametric distributions to model the outcome of interest, which are typically
governed by a combination of two or more correlated ancillary parameters. Popular
examples of parametric distributions include the Weibull, the Log-Logistic and the
Generalised Gamma (Collett, 2003) for the analysis of time-to-event outcomes.
2.2.2 Multiple sources of evidence
There are situations where the evidence base is represented by multiple studies.
Depending on the format in which they are available and the number of parameters
needed to estimate, these give rise to six possible scenarios (Table 2.1).
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2.2.2.1 Multiple aggregate data to inform the estimation of a single parameter (A2)
A typical case occurs when there are several studies reporting results on the same
parameter of interest, and the researcher needs to combine these into a single
quantitative estimate. The statistical methods most commonly used to achieve such a
synthesis fall within the meta-analytic family (Whitehead, 2002). In standard meta-
analysis of clinical trials, the parameter of interest is usually some measure of
comparative effectiveness between treatment arms.
A fixed effect12 (FE) meta-analysis is carried out under the assumption that a single
common (or 'fixed') effect underlies every study in the meta-analysis (Higgins &
Green, 2008). It is common, though, to observe between-study variation in treatment
effect estimates (heterogeneous treatment effects). In such a case, it is customary to
use a random effects13 (RE) model. For an up to date comprehensive review of
recent developments in meta-analysis, the reader can refer to the paper by Sutton and
Higgins (2008).
Some authors have argued that one of the prime weaknesses of meta-analysis is a
possible failure to control for sources of bias, and that a good meta-analysis of badly
designed studies will still result in a biased combined statistic. In addition to the
inclusion of evidence of sub-optimal quality, publication and other related biases
may be present (Sutton, A. J. et al., 2000b).
Study level features, such as participants’ characteristics, which may lead to
between-study heterogeneity, can be investigated by adopting a meta-regression
approach in which study-level covariates are included in the analysis. Some
12 In the FEs approach, if, for instance, a meta-analysis of odds ratios is being done, it is assumed that
every study is estimating the same odds ratio. Therefore, only within-study variation is taken to
influence the uncertainty in the results.
13 Random effects meta-analysis makes the assumption that while individual studies are estimating
different treatment effects, these come from a common distribution with some measure of central
tendency and some measure of dispersion (Higgins & Green, 2008).
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researchers would prefer to include ‘weaker’/’low quality’ studies in the meta-
analysis, and add a study-level covariate reflecting the methodological quality of the
trials in order to assess the impact of trial quality on the effect size. Unfortunately,
meta-regression methods also have a number of weaknesses (Thompson & Higgins,
2002). The analyst should be aware of the fact that the use of such mean study-level
covariate values has low power (over IPD methods) and, more importantly, carries
the risk of ‘ecological fallacy’14 (Piantadosi et al., 1988) if these average patient level
characteristics are considered (Berlin et al., 2002, Lambert et al., 2002). In this
sense, as it shall be seen in section 2.2.2.3, access to IPD can be used to disentangle
the relationship between the parameter of interest and baseline covariates
(Wakefield, 2008). Ades et al. (2005) provide an extensive discussion of how
between-study heterogeneity can be incorporated into the parameters of a decision
analytic model15.
In CEA, the use of estimates of relative treatment effects derived from a meta-
analysis is common (Gold, 1996). An example of its use within an economic model
is the prevention and treatment of influenza A and B (Turner, D. et al., 2003), where
a separate meta-analysis was conducted to evaluate time to symptoms alleviated and
time to return to normal activities for different baseline risk groups. In another
study, McKenna et al. (2010) recently carried out a systematic review and economic
evaluation of the clinical effectiveness and cost effectiveness of aldosterone
antagonists for post-myocardial infarction heart failure. The authors estimated the
effectiveness parameter to inform their cost effectiveness model using a Bayesian
meta-regression model.
14 Ecological fallacy refers to situations in which relationships observed at the aggregate variable
level are incorrectly inferred to exist also at the individual level.
15 Notice that if the heterogeneity parameter is used to derive parameters for a decision analytic
model – technically the analysis is estimating multiple parameters (i.e. a RE estimate of the treatment
effect, its variability and a measure of heterogeneity) and thus belongs to the B2 category.
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2.2.2.2 Multiple aggregate data to inform the estimation of multiple parameters (B2)
Meta-analysis can also be used to achieve more complex forms of evidence
synthesis, to address issues related to multiple (indirect and mixed treatment)
comparisons and combinations of evidence on multiple or surrogate/intermediate
endpoints (Baker, 2006). Much of the published work on these complex methods of
synthesis has been undertaken within a Bayesian framework, mainly for
computational reasons but also because of its coherent link to decision making
(Ades, A. E. et al., 2006b). The term ‘multi-parameter evidence synthesis’ (MPES)
adapted from Hasselblad and McCrory (1995) has been coined to designate these
extended methods of synthesis.
When multiple outcomes are of interest, a multivariate meta-analysis model
facilitates the joint estimation of these endpoints, thus estimating possible correlation
between them. Often the advantage of a multivariate REs meta-analysis lies in its
ability to use the within-study and between-study correlation of the multiple
endpoints of interest. For example, Reitsma et al. (2005) have suggested applying a
bivariate REs meta-analysis to jointly synthesise logit-sensitivity and logit-specificity
values from diagnostic accuracy studies.
More generally, a common feature of the evidence base used to inform health care
funding decisions is the absence of head-to-head trials comparing all relevant
treatment strategies. When more than two treatments are to be compared and the
evidence base contains different randomised pair-wise or multi-arm comparisons, the
appropriate techniques to use in the decision making context are indirect treatment
comparisons and network meta-analysis (or MTCs), which are simple extensions of
the pair-wise meta-analysis method (Lu, G. & Ades, 2004, Lumley, 2002). MTCs
can be recognized as an example of MPES, in which parameters are related to one
another by a definable structure (Ades, A. E., 2003).
In a MTC the modeller may choose between a FEs and a REs analysis, depending on
the assumptions made about any between-trial heterogeneity, as discussed in A2
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(Ades, A. E., 2003, Higgins & Whitehead, 1996). MTC relies on exactly the same
assumptions as standard pair-wise meta-analysis (i.e. choice and quality of the
studies), although now these are applicable to the full set of interlinked trials.
Therefore, the similarity between trials included in the network will also be a
determinant of the internal validity of the analyses, at the risk of having high
confounding bias (Dias et al., 2010a). In the instances where direct and indirect
evidence are combined for a particular comparison, it is also vital that there are no
disagreements between the direct and indirect comparisons16 (Dias et al., 2010b,
Salanti, Georgia et al., 2008, Lu, G. B. & Ades, 2006). As for standard meta-
analysis, in network meta-analysis it is important to allow for between-study
heterogeneity (Cooper, Nicola J. et al., 2009). An extension of this family of
techniques, allowing for the incorporation of study-level covariates to explain
between-study heterogeneity and reduce synthesis model inconsistency, is also
available (Salanti, G. et al., 2010, Cooper, Nicola J. et al., 2009, Salanti, G. et al.,
2009). Additional details on the use of indirect and mixed treatment comparisons
can be found elsewhere (Sutton, A. et al., 2008).
A good example illustrating the use of the MTC framework when multiple follow-up
times are available is the paper by Lu et al. (2007). For an application of the MPES
approach, the reader is referred to the recent work by Welton et al. (2008), which
was originally developed using data from the earlier economic appraisal of antiviral
treatment by Turner et al. (2003) referred to in A2. Another example where MTC
was used in an economic analysis can be found in Woolacott et al. (2006). The
authors synthesised clinical effectiveness data from several published trials in
epilepsy to estimate the transition probabilities needed to populate a state-transition
model developed to assess the cost effectiveness of alternative medications for
epilepsy.
16 For instance, in a MTC model comparing three treatments (e.g. A, B, C) consistency is achieved
when, for each pair-wise comparison, no discrepancies can be found between the direct and indirect
estimates of the parameter of interest (e.g. OR) derived from the model. The issue here is in defining
how big a difference is considered a discrepancy – although this is arbitrary to define, there are
statistical tests (potentially with reduced power) for discrepancies found (Dias et al., 2010b).
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2.2.2.3 Multiple individual patient datasets to inform the estimation of a single
parameter (C2)
Meta-analysis of IPD or ‘mega-analysis’, where raw data from each study is obtained
and synthesised to inform the estimation of a single parameter of interest, is
considered the ‘gold-standard’ in evidence synthesis (Higgins et al., 2001, Sutton, A.
J. et al., 2000a). This approach has a series of advantages, which are summarised by
Stewart and Parmar (1993), Stewart and Tierney (2002) and Simmonds et al. (2005).
Access to multiple individual level datasets avoids the risk of bias associated with
published AD; it allows one to obtain information possibly not available from
published reports (or not available in the format required for the meta-analysis and
cost effectiveness model); and it facilitates consistent inclusion/exclusion criteria to
be used across studies (Jeng et al., 1995, 1993). An increase in statistical power to
detect true patient-treatment relationships is gained when compared to meta-
regression of AD (Smith, C. T. et al., 2005, Lambert et al., 2002), which only
assesses treatment in relation to group-level summary data (Cooper, N. J. et al.,
2007). It should be highlighted that, however, in most situations, access to IPD may
be difficult due to issues such as confidentiality, sponsors’ or investigators’ rigidity
in releasing this data.
Surprisingly, there is a paucity of published literature concerning methodologies for
meta-analysis of IPD. Simmonds et al. (2005) recently published a review of meta-
analysis using trial-based IPD suggesting that most methods used in practice are
straightforward. The review shows that the majority of applications use a ‘two-
stage’ process where initially each dataset is analysed separately, AD is drawn for
each study (stage one) and subsequently combined using a ‘standard’ meta-analytic
model for aggregate evidence (stage two). This approach may be considered a
simplification of the techniques discussed in scenario A2. Alternative and more
robust approaches for dealing with binary (Turner, R. M. et al., 2000), ordinal
(Whitehead et al., 2001), continuous (Higgins et al., 2001, Goldstein et al., 2000) and
longitudinal outcomes (Jones et al., 2009, Farlow et al., 2005) based on REs
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generalised hierarchical models exist. Unfortunately, these approaches appear to be
rarely used in practice.
It should be noted that if the outcome of interest is binary and the analyst does not
need to control for covariates, the information from the AD will report the sufficient
statistics, that is, no additional benefit is obtained from access to IPD (as in scenario
A2).
2.2.2.4 Multiple individual patient data to inform the estimation of multiple parameters
(D2)
As outlined in section 2.2.2.2, there are clear theoretical and practical benefits
(besides an obvious policy rationale) that justify why it would be desirable to carry
out an MTC (and MPES models in general) when deriving parameters for use in
CEA. Many of these benefits will also apply when the purpose is to analyse multiple
datasets from which to derive multiple parameters for use in decision modelling.
Nevertheless, some authors believe that this need is exacerbated by the fact that an
MTC is essentially an observational study comparing several treatment strategies.
For instance, Salanti et al. (2009) point out that while each individual trial may have
high internal validity, studies included in an MTC will almost inevitably display
between-study variability in study-level characteristics that can affect the relative
effectiveness of the strategies being compared. One example of this is the definition
of ‘Placebo’ or ‘Standard Care’ in many MTCs (Salanti, G. et al., 2009) and cost
effectiveness models (Hawkins & Scott, 2010), which has been found to vary
enormously between studies. Another example is the work by Nixon et al. (2007)
and subsequent two cost effectiveness models (Wailoo et al., 2008, Brennan et al.,
2007), in which the authors conducted a covariate adjusted AD MTC of trial
evidence in drugs for rheumatoid arthritis. While this approach is better than an
unadjusted MTC, it still suffers the same limitations as standard meta-regression,
making it essential to carry out a series of tests to assess the consistency of the
evidence in the evidence base network.
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2.2.2.5 Mixture of individual and aggregate level data to inform a single parameter (E2)
When the analyst opts for trying to acquire IPD from each relevant study forming the
evidence-base, the most frequent scenario s/he encounters is that these data will be
made available only for a subset of the evidence base. In such situations, analysts
have traditionally taken two alternative routes: (a) include only the studies for which
IPD was available; or (b) for the studies where IPD was available, collapse these to
summary evidence and use only the latter. Neither solution makes optimal use of the
available data. The first option throws away important information and the second
ignores all the advantages that IPD may bring towards an improved estimation of the
effect size. A better approach would be to jointly model the IPD and AD (Riley, R.
D. et al., 2007). As yet, this issue has not received attention in the health economics
literature; although a series of meta-analysis models have been recently developed
(Riley, Richard D. & Steyerberg, 2010, Jackson et al., 2008, Riley, Richard D. et al.,
2008, Riley, R. D. et al., 2008, Sutton, A. J. et al., 2008, Jackson et al., 2006) in the
statistical literature specifically for this purpose. These models are valuable in
reducing between study heterogeneity, or in identifying patient subgroups with
differential treatment effects.
2.2.2.6 Mixture of individual and aggregate level data to inform multiple parameters
(F2)
Access to IPD (alongside existing AD) is particularly important when the objective
of the evidence synthesis model is the estimation of multiple input parameters to
populate a cost effectiveness model. This is clearly the most technically challenging
scenario the analyst may face as the existence of such models have not been
encountered, despite the scenario discussed in this section being quite common. In
this sense further methodological research aimed to develop models appropriate to
deal with these situations are welcome.
An interesting application does exist for diagnostic test evaluation (Riley, Richard D.
et al., 2008), with a bivariate meta-analysis model being used to model outcomes of
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diagnostic studies, although this was not used to inform a cost effectiveness model.
By reconstructing IPD from available AD, the authors manage to take into account
the mixture of IPD and AD which allows for all evidence set to be simultaneously
considered in estimating the parameters of interest (i.e. sensitivity and specificity of
the test). Both IPD and AD studies contribute to the estimation of the impact of
study-level covariates and the across-study effects.
For guidance, a summary of the scenarios with corresponding recommend methods
and related methodological and applied literature is shown in Table 2.2.
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Table 2.2 – Scenarios and corresponding current methods literature for when using clinical evidence to inform cost effectiveness modelling.
Scenario Source ofevidence
Format
of data Parameter Methods * Relevant references
A1 Single AD Single Direct inclusion of reported estimate (or transformation
of it) in the model. ----
B1 Single AD Multiple Direct inclusion of estimates or transformations of them
in the model - correlation should be included if reported.
(Epstein, D. & Sutton, 2011, Rodgers et al., 2011, Ades, A. E. et
al., 2006a, Ades, A. E. & Lu, 2003)
C1 Single IPD Single Using standard analysis procedures relevant for the
primary study. (Glick, 2007, Stewart & Clarke, 1995)
D1 Single IPD Multiple Using standard multivariate estimation procedures -
including correlations. (Henriksson et al., 2008, Stewart & Tierney, 2002)
A2 Multiple AD Single Meta-analysis
(Sutton, A. J. & Higgins, 2008, Ades, A. E. et al., 2005, Turner,
D. et al., 2003, Berlin et al., 2002, Lambert et al., 2002,
Thompson & Higgins, 2002, Whitehead, 2002, Sutton, A. J. et
al., 2000b, Stewart & Parmar, 1993)Meta-regression
B2 Multiple AD Multiple
Multivariate meta-analysis (e.g. Bivariate random-effects
meta-analysis)
(Dias et al., 2010b, Salanti, G. et al., 2010, Cooper, Nicola J. et
al., 2009, Salanti, G. et al., 2009, Salanti, Georgia et al., 2008,
Sutton, A. et al., 2008, Welton et al., 2008, Lu, G. et al., 2007,
Lu, G. B. & Ades, 2006, Woolacott et al., 2006, Reitsma et al.,
2005, Lu, G. & Ades, 2004, Ades, A. E., 2003, Lumley, 2002,
Hasselblad & McCrory, 1995)
Mixed treatment comparison
C2 Multiple IPD Single 'Mega-analysis' (meta-analysis using IPD)
(Jones et al., 2009, Farlow et al., 2005, Simmonds et al., 2005,
Smith, C. T. et al., 2005, Whitehead et al., 2001, Turner, R. M.
et al., 2000)
D2 Multiple IPD Multiple Multivariate meta-analysis using IPD (e.g. Bivariate
random effects meta-analysis) (Nixon, R. M. et al., 2007)
E2 Multiple Mixture Single
Two-stage - reduce IPD to AD or reconstruct IPD from
AD (Riley, Richard D. & Steyerberg, 2010, Jackson et al., 2008,
Riley, Richard D. et al., 2008, Riley, R. D. et al., 2008, Sutton,
A. J. et al., 2008, Riley, R. D. et al., 2007, Jackson et al., 2006)One-stage - hierarchical modelling (e.g. meta-analysis
using AD and IPD)
F2 Multiple Mixture Multiple
Extensions of previous synthesis models to the
hierarchical framework (e.g. Bivariate random-effects
meta-analysis of IPD)
(Riley, Richard D. et al., 2008)
* Where there is the need to define uncertain parameters for inclusion in a decision model and evidence is available as in scenarios A1 and B1, it may be necessary that multiple statistics are reported. Also, it
may be of interest to have some information on the characteristics of the distribution best representing the parameter. All subsequent scenarios allow for expressions of uncertainty.
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2.3 Use of evidence for other model input parameters
While quantitative evidence synthesis methods typically focus on clinical
effectiveness (including adverse events), cost effectiveness models require
information on many other input parameters, the most important being disease
natural progression, cost/resource use, and (health state) utility data. There are some
examples in the literature where evidence synthesis techniques have been applied to
estimate these parameters. In this section the specific characteristics of these
parameters are described and the implications for methods of synthesis highlighted –
aiming to illustrate taxonomy’s applicability.
While clinical effectiveness data used to populate the model typically come from
RCTs, the evidence base used to estimate disease natural progression, resource
use/cost and utility data parameters is often derived from observational evidence (e.g.
registries, administrative claim data) (Briggs, A. H. et al., 2006). There are various
reasons for this, beyond the fact that RCT evidence may not be available to populate
these model parameters.
First, due to their intrinsic design, randomised data on resource use/cost are often
considered to have low external validity. This may be due to the fact that the trial
evidence does not reflect true clinical practice (Drummond et al., 2005), or the
evidence may not be relevant to the decision-maker for whom the model is being
developed (Urdahl et al., 2006). In this case, observational evidence may provide an
opportunity to calibrate the model parameters and assess the extent to which trial
evidence reflects real-world situations. Methods developed in the generalised
evidence synthesis framework, which facilitate the synthesis of both randomised and
non-randomised data while accounting for the different study designs (Spiegelhalter,
David J. & Best, 2003, Prevost et al., 2000) and methods developed for cross-design
synthesis (Ades, A. E. & Sutton, 2006) may be useful here. Applications of these
methods outside the analysis of clinical effectiveness have not been encountered, and
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further research in this direction, focussing on parameters such as disease natural
history, could be of great interest. Second, resource use / cost (and to some extent
utility) data are country specific (Manca & Willan, 2006), and, in many cases, it is
almost impossible to find jurisdiction-specific RCT evidence on these parameters
(Augustovski et al., 2009, Schulman et al., 1998). Third, most RCTs have a short
follow up duration. To model disease natural history as well as long term costs and
utilities, (large) long term, observational studies are often the only solution. Other
specific issues for each type of parameter will be discussed in turn in the next
subsections.
2.3.1 Disease natural progression data
One of the initial and most important phases in building any decision model is to
explicitly define its structure. This entails, among other things, giving an appropriate
representation of the key health states that the population of interest may experience
over time, and reflecting what is known about the natural history of the particular
health condition being modelled as well as the impact of alternative treatment
options on the disease process. These procedures should be performed in
collaboration with both clinical and non-clinical experts from the field(s) of interest.
Evidence about the natural history of a disease is crucial for a good understanding of
possible clinically-defined states and, in view of the complexity of the task, long-
term IPD are ideal for this.17 Furthermore, given the concerns about the external
validity of trial-based data evidence, a favoured source for baseline risk data is often
case series or high-quality individual level administrative or epidemiological datasets
(Cooper, N. et al., 2005). Despite relaxing the evidence base inclusion criteria to
model disease natural history, IPD are still very often unavailable, leaving published
summary evidence as the only feasible option to inform the model parameters.
17 Detailed individual level natural history data are particularly important for modelling the impact
that baseline characteristics may have on parameters in the model that capture the occurrence of
clinical events beyond follow up, and associated resource use and health-related quality of life.
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With respect to the synthesis of data informing the baseline history part of the model,
it is worth highlighting the publication of a recent useful document from the NICE
DSU (Dias et al., 2011c). This report reviews evidence synthesis issues which may
arise when dealing with baseline natural history modelling. A discussion of the
source of evidence to use for baseline outcomes, the simultaneous versus separate
modelling of baseline and treatment effects and the inclusion of covariates in
baseline models is provided by the authors.
Although not presented within an evidence synthesis framework, Isaman and
colleagues (Ye et al., Isaman, D. J. M. et al., 2009, Isaman, D. J. et al., 2006)
proposed an approach that allows the use of published regression data to populate a
multi-state model describing disease natural history, even when the published study
may have ignored intermediary states in the multi-state model (taxonomy section
B1). The authors applied their proposed methodology to model several chronic
conditions, including heart disease and diabetes. Welton and Ades (2005), however,
use evidence synthesis methods applied to AD to estimate transition probabilities
from transition rates, with the objective of using these to model disease progression.
The authors illustrate how to statistically combine data from multiple sources,
including partially observed data at several follow-up times, to inform an
epidemiologically realistic model (taxonomy section B2). Chao and Chen (2009)
recently used a similar approach and developed a multi-state Markov model to
predict the progression of age-related hearing loss, by synthesising partially observed
AD from four studies from which they derived progression rates (taxonomy section
B2).
Modelling disease natural history becomes a lot easier when the analyst has access to
IPD, and there are many examples in the literature that show how one can proceed in
this case. Marshall and Jones (1995), for instance, developed a multi-state model to
describe disease progression in diabetic patients with retinopathy, and used patient-
level covariates in the model to capture the natural course of the disease and identify
the factors associated with progression and regression between disease stages
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(taxonomy section D1). Applications in the medical field, which, in the presence of
multiple patient-level data, carried out the synthesis of these for the purpose of
modelling the natural history of a disease have not been encountered.
2.3.2 Cost / resource use data
The quantification of the cost of each alternative strategy being compared is essential
for any economic assessment. The best study design for quantifying health care
resource utilisation includes prospective data collection within a long term
naturalistic trial setting. In the absence of these, retrospective analysis of existing
data sets, complemented with examination of administrative databases, can be an
alternative solution. In fact, it is not uncommon for model parameters associated
with health care resource use to be estimated by reviewing routine data (e.g. hospital
records) (Cookson et al., 2005, Tumeh et al., 2005). Elicitation of expert opinion
(Connock et al., 2006, Wu et al., 2006) may also play a role in informing the
estimates of some resource use model parameters, although this source of evidence is
considered the least preferred, as it usually carries considerable levels of subjectivity.
An article by Bower et al. (2003) is one of the few examples in which meta-analytic
techniques were employed to synthesise cost data. Using data on costs from trials of
counselling in primary care, the authors attempted to overcome sample size
limitations in their economic analysis by pooling short and long term resource use
data from four different studies using a FEs meta-analysis (taxonomy sections A2
and B2). This approach has a number of limitations, as the authors pointed out (e.g.
the significant variation between trials in standard deviations of costs and the
difficulty in identifying comparable data and consequently of standardising cost
means), reinforcing the fact that under no circumstances will the performed analysis
approach the precision of primary data collection.
Further to these conclusions it is argued here that while it is possible to carry out
quantitative evidence synthesis of health care resource use data, there are some real
concerns that limit its validity, over and above the issues mentioned in the
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introductory part of section 2.3. The first one is a technical issue. Since resource
use and costs are non-normally distributed, their statistical synthesis is particularly
challenging from the analytical point of view, a problem that is exacerbated when the
information is only available at aggregate study level. Second, there is typically a
large methodological heterogeneity that affects costing studies, which is often
impossible to characterise statistically. Some of the study-level features that may be
responsible for it are differences in data collection strategies, methods for measuring
resource use and costs, follow up duration, methods of analysis and reporting. A
third issue relates to time. Technological innovation, relative price changes and
many other factors that may affect resource use and costs are difficult to capture in a
synthesis of secondary data.
2.3.3 Health-state utility data
Quality-adjusted life years are used extensively as a measure of health benefits in
CEA for policy decisions (Kind et al., 2009). Their advantage stems from the fact
that QALYs combine morbidity and mortality into a single numeraire. Morbidity,
for the purpose of QALY calculation, is measured in terms of its impact on a
preference-based generic measure of health related quality of life. Instruments that
can be used to estimate preference-based generic health-related quality of life
include, the EuroQol five-dimensional (or EQ-5D) (Brooks, 1996), the Health Utility
Index (HUI) (Feeny et al., 2004), the Quality of Well-Being (QWB) (Kaplan et al.,
1998) and the Short Form six-dimentional (SF-6D) (Brazier et al., 2002). Several
country-specific preference weights exist for the EQ-5D and SF6D. The abundance
of alternative instruments means that researchers and policy makers are often unclear
as to which of these should be used and accepted in a given country or jurisdiction.
Differences in the descriptive systems used by each of these instruments generate a
comparability problem (Wee et al., 2007, Conner-Spady & Suarez-Almazor, 2003),
which is compounded when the analyst intends to synthesise the available evidence
to produce one parameter estimate of utility for use in the model. In addition,
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disagreement in the literature as to whose preferences should be used to value health
states (Gandjour, 2010) makes the synthesis even more complex.
Despite this ongoing debate, the EQ-5D has become the most widely used
preference-based generic measure of health-related quality of life in recent years. In
the UK, the third edition of the NICE methods guidance for technology assessment
(NICE, 2008) recommend the use of the EQ 5D for the reference case analyses.
Since then, there has been an increasing interest in this instrument.
Publicly available repositories of health state utility values for a variety of health
conditions are potentially a very useful data source. Tengs and Wallace (2000) were
the first to publish a national repository of one thousand utility values gathered from
154 published reports. More recently, Sullivan and Ghushchyan (2006) and
Sullivan et al. (2009) used Medical Expenditure Panel Survey data to develop a
prediction tool for preference-based EQ-5D index scores for chronic conditions in
the USA and the UK, respectively, based on responders ICD-9 codes. These
repositories are particularly useful in the absence of (primary or secondary)
preference-based generic health-related quality of life data. When these are available
and depending on the data’s format and number of parameters to inform, one of the
scenarios described in Table 2.1 is considered.
To date, little work has been undertaken on the methods for statistical synthesis of
preference-based health related quality of life data. This may be due to the fact that
its synthesis is not stated as a requirement by national bodies such as the NICE
(NICE, 2008). Recently, the NICE DSU released a technical support document
giving guidance on the identification, review and synthesis of health state utility
values (Papaioannou et al., 2011). Among a series of recommendations, this
document emphasises the importance of selecting a main set of relevant utility
values, or, in the presence of multiple relevant values, the pooling of these is
suggested in order to improve precision of both mean and variance estimates. Meta-
regression is one of the synthesis methods proposed to account for variability and to
provide support to the choice of values used.
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Perhaps one of the first manuscripts to apply evidence synthesis methods to health
related quality of life data was published by Kinney et al. (1996), who conducted a
meta-analysis of 84 studies reporting summary quality of life data in a cardiac patient
population (taxonomy section A2). Tengs and Lin (2003, 2002) published meta-
regressions in two different clinical areas (i.e. HIV/AIDS and cardiovascular) with
the objective of estimating utility values associated with specific health states while
controlling for specific study- and instrument- related features (taxonomy section
A2). Using the same methodology Sturza (2010) recently published a meta-
regression of utility values in lung cancer, finding a great deal of heterogeneity in the
data even after applying strict inclusion criteria, and concluded that analysts should
avoid direct comparisons of lung cancer utility values elicited with dissimilar
methods (taxonomy section A2). Donnan et al. (2009) and Cheng and Niparko
(1999) found similar problems with respect to combining utility values from a
variety of assessment methods. For Cheng and Niparko (1999) it was found to be
problematic to do so and “…to some extent, this heterogeneity limits the
meaningfulness of statistical pooling…” (page 1217). Other examples of quantitative
evidence synthesis of utility estimates can be found in the literature (Peasgood et al.,
2010, Peasgood et al., 2009, McLernon et al., 2008, Bremner et al., 2007, Post et al.,
2001, Dijkers, 1997) (all examples lay within categories A2 and B2 of the
taxonomy).
These findings suggest that quantitative synthesis of aggregate preference-based
values is limited by: (i) the between-study heterogeneity in the instruments used; (ii)
the value set used to quantify utilities; (iii) the models used to approximate scores for
health states; and over and above (iv) the typical issues related to standard meta-
regression of summary binary outcome data. It has therefore been argued that,
particularly in this context, the use of IPD would be essential (Ara & Brazier, 2010).
Further work is required in this area, both with regard to methods of quantitative
synthesis of heterogeneous preference-based outcomes when these are available at
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aggregate study level, and the need to control for between-study heterogeneity
induced by the use of different preference-based instruments.
2.4 Discussion
The information required to carry out economic evaluation studies for policy
decisions often comes from several different data sources, which often provide
multiple estimates of the parameter(s) of interest. Statistical evidence synthesis
techniques and decision analytic models represent an ideal vehicle to structure the
decision problem, combine all available data and characterise the various sources of
uncertainty associated with the decision problem. Using the synthesis of clinical
effectiveness data as a conceptual framework, a taxonomy of possible scenarios that
the analyst may face was developed (and appropriate methodologies to use
discussed) based on a combination of three factors: (a) the number of data sources;
(b) their format(s); and, (c) whether the analyst wishes to derive single or multiple
parameters from the synthesis. Recommendations concerning appropriate methods
to use under different scenarios were provided throughout. This chapter also
reviewed the way in which evidence has been used to inform decision model
parameters related to the disease natural history, costs and utilities. Areas where
further methodological research may be needed are also identified.
The proposed taxonomy is designed to be used by health economics modellers as an
instrument to support the development of their analysis plan, help them to fulfil
methodological requirements and adequately address the research question at hand.
The three dimensions on which the taxonomy is based provide a simple method of
characterising and categorising the evidence base available (i.e. in terms of its
quantity and format) linking this to the (type and number of) decision model
parameter(s) to be derived. Following this ‘checklist’, the analyst can easily identify
within the relevant taxonomy cell (or cells) methods that are available and those that
are recommended. This list of approaches and methods has been (wherever
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possible) supported by references to key methods literature and case studies where
these have been put into practice. The references can then be consulted by analysts in
search of further methodological and/or practical details of the subject. In this
sense, the taxonomy helps to ensure consistency and completeness when carrying out
the task of using evidence to inform decision models, standardising approaches and
the adequate use of methods to analyse/synthesise evidence. Additionally, it provides
a useful reference on the more recent methodological developments in the context of
evidence synthesis for health care CEA.
The current taxonomy foundations are not, however, without limitations. First, the
evidence synthesis methodologies and applied studies described throughout the
chapter are not the result of a comprehensive systematic review (i.e. not exhaustive).
It is believed, however, that these are representative of the methodologies found in
the methods and applied literature in this area of research. Second, despite the efforts
to make this taxonomy easy to generalise, the three dimensions (number and format
of data sources and number of parameters to inform) may still not capture all
possible scenarios. For instance, the taxonomy could be extended to include extra
dimensions – e.g. extrapolation of model estimates – or detailed to cover other
aspects – e.g. role of covariates within each taxonomy section. It was felt, however,
that such an extension would unnecessarily increase its complexity without adding
substantial benefits. Finally, the taxonomy is applied to clinical effectiveness but not
to other key economic model parameters (i.e. disease natural history, resource use /
costs, and preferences). Nonetheless, issues relating to the application of the
taxonomy to these other parameters are discussed and its fuller application
encouraged in future research. Methodological and applied literature is scarce
regarding the quantitative synthesis of evidence to inform these – it is believed that
further research is required despite recent relevant contributions in this area (Dias et
al., 2011c, Papaioannou et al., 2011). Moreover, the specific characteristics of these
parameters and of the evidence used to inform them may pose further challenges.
Some of these evidence characteristics are highlighted and discussed next.
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In practice, studies included in a certain synthesis may vary in their degree of rigour
and possibly in their relevance towards the research question. This is particularly
important when ‘relevant’ available evidence comes from observational data. Flaws
in the design or conduct of a study can result in bias, and in some cases this can have
as much influence on observed effects as that of treatments. Important intervention
effects, or lack thereof, can be obscured by bias. Assessment of study quality gives
an indication of the strength of evidence provided by the pooled result and,
ultimately, quality assessment helps to answer the question of whether included
studies are sufficiently robust to guide treatment, prevention, diagnostic or policy
decisions. Most of the bias adjustment proposals published so far are reweighting
schemes, usually attributing lower weight to evidence with a high risk of bias. More
information on this topic can be found in Spiegelhalter et al. (2003), Turner et al.
(2009) and Welton et al. (2009).
Common to all evidence identified, to potentially inform decision model parameters,
is the case of partial reporting of information. If, for instance, mean differences
without a measure of variance are reported, difficulties may arise when attempting to
parameterize data for probabilistic modelling and strong assumptions may have to be
imposed. A variety of methods for imputing variances have been proposed – see
Abrams et al. (2005), Wiebe et al. (2006) and Furukawa et al. (2006) for further
details. Another example occurs when different studies report different (multiple)
outcome measures, at different time points and possibly on different scales. All these
issues raise important obstacles for the synthesis of evidence.
A number of authors have recently published papers relating to the synthesis of cost
effectiveness model outputs (Anderson, 2010, Sculpher, M. J. & Drummond, 2006,
Pignone et al., 2005, Sculpher, M. J. et al., 2004, Welte et al., 2004, Birch & Gafni,
2003, Nixon, J. et al., 2001). One of the key questions here is whether or not it is
appropriate to do so. I argue that there is no apparent rationale for assuming that the
costs of a particular health care intervention (or their health-utilities) estimated in
different studies carried out in different countries and health care settings, probably
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using different measurement and assessment instruments, should converge towards a
common value to be estimated using evidence synthesis techniques (Pignone et al.,
2005).
In conclusion, this chapter brings recent developments in quantitative evidence
synthesis to the attention of the health economics modelling community, encouraging
a broader and more explicit consideration of these methods in the future. Several of
the techniques presented here fall in the spheres of epidemiology, statistics and
operational research, which in some cases are not directly accessible (due to lack of
exposure and increased complexity of methods) to health economics modellers.
The taxonomy should be viewed by readers/analysts as a supplement to the
guidelines on methods for technology assessment published by the NICE (NICE,
2008), and increase the users’ confidence surrounding the validity of decision model
inputs and subsequent outputs.
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CHAPTER 3
3. SYNTHESIZING EVIDENCE USING AGGREGATE- AND
INDIVIDUAL-PARTICIPANT LEVEL DATA
3.1 Introduction
As a consequence of the move towards evidence-based health care, with its
underlying principle that evidence synthesis must be seen as the key to more
coherent and efficient research (Sutton, Alexander J. et al., 2009), it is necessary to
systematically identify and consider evidence from all the relevant studies (Higgins
& Green, 2008). The lack of clear guidelines on what data can be used and how to
effectively synthesise it led to the development of a taxonomy in Chapter 2. This
taxonomy is based on possible scenarios faced by the analyst when dealing with all
relevant available evidence. It aims to help analysts to identify the most appropriate
method(s) to use when synthesizing the available data for a given model parameter,
working towards the standardisation of approaches. Moreover, Chapter 2 pushes
forward the methodological agenda in the synthesis field by highlighting several
existing gaps in the methods literature. The current chapter aims to fill in some of
these gaps.
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It has been noted that in many cases the synthesis of evidence is conducted using
pair-wise meta-analysis (Sutton, A. J. et al., 2000a, Hasselblad & McCrory, 1995).
This method is described extensively in the literature (Sutton, A. J. et al., 2000a). It
was also acknowledged that meta-regression techniques can be used to explore any
apparent between-study heterogeneity, with the aim of estimating treatment x
covariate interactions (Simmonds & Higgins, 2007, Berlin et al., 2002). When these
methods rely only on patient-level covariates at aggregate level, they have been
shown to have low statistical power (Lambert et al., 2002) and to be highly
susceptible to ecological fallacy biases (Berlin et al., 2002). This thesis also
acknowledges that another way of obtaining combined statistics is to perform meta-
analyses over IPD (Stewart & Clarke, 1995). Individual participant data may,
however, be available for only a (small) proportion of all relevant studies. Recent
extensions to this modelling framework have been developed, which allow IPD and
AD to be used jointly to estimate the effects of a treatment (Sutton, A. J. et al., 2008,
Kendrick et al., 2007).
In most medical conditions, however, multiple interventions are available, and
clinicians and policy makers need to decide on the optimal strategy among all
relevant alternatives. It was discussed in Chapter 2 that MTCs (Lumley, 2002, Tudur
et al., 2001) may be used to combine evidence on multiple alternative interventions,
informing treatment comparisons that may not have been trialled head-to-head and
without breaking randomization. Nonetheless, several assumptions are imposed by
the MTC approach, such as: (i) such methods can only be applied to connected
networks of studies; (ii) the treatment effects are thought to be generalisable across
patients from trials included in the network; and (iii) in the presence of evidence
loops, consistency across the evidence base must exist (Dias et al., 2011b, Dias et al.,
2010b, Cooper, Nicola J. et al., 2009, Lu, G. & Ades, 2009, Song et al., 2009). As
with any meta-analysis, in the case of MTCs it is desirable to account for
heterogeneity/inconsistency, otherwise results may be biased (Cooper, Nicola J. et
al., 2009). Also, the identification of factors contributing to these two factors may be
valuable clinically, as the optimal treatment strategy may vary across different
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patient groups. Thus, if treatment recommendations are made for subgroups of
patients, this will lead to efficiency gains when compared to the suboptimal
framework of decisions based on overall (mean) effectiveness. Despite the
advantages of IPD for exploring heterogeneity/inconsistency, IPD has rarely been
used in the context of MTCs.
This chapter considers synthesis models for binary outcomes where AD and IPD are
available (although direct simplifications of the models allow the analysis of just AD
or just IPD), and where patient and/or study level information on covariates may be of
interest. Models are fitted to a motivating dataset on uptake of smoke alarms to
prevent accidents in pre-school children.
After describing the motivating example dataset in section 3.2, existing and novel
models for the synthesis of AD, IPD, and AD and IPD simultaneously are outlined in
sections 3.3 and 3.4, considering direct and indirect comparisons, respectively. In both
sections, models which estimate mean intervention effects, ignoring the influence of
covariates, are considered first. These are followed by models which incorporate AD
and IPD data, allowing for both individual and aggregate study level covariate
information to be included, enabling discussions over estimates of treatment x
covariate interactions and their assumptions. Results of applying the described
methods to the motivating datasets are subsequently discussed. These sections are
followed by a modelling extension to consider all available evidence in section 3.5 and
some discussion topics and concluding remarks in section 3.6.
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3.2 Motivating example: The effectiveness of home safety education
and the provision of safety equipment for the prevention of
accidents in pre-school children and the impact of
socioeconomic characteristics
The motivating example comes from an evaluation of the effectiveness of home safety
education and the provision of functioning smoke alarm safety devices for the
prevention of accidents in pre-school children. Studies were identified as part of a
more general and updated Cochrane systematic review of safety equipment (Wynn et
al., 2010, Kendrick et al., 2007) – see Chapter 1 for further detail.
As a case study for this chapter, the outcome measure assessed is the provision of
functioning smoke alarms (binary – Yes/No) given different interventions designed to
increase their prevalence in households with children. The following relevant evidence
is used for the smoke alarm outcome: 9 studies available in IPD format (Bulzacchelli
et al., 2009, Phelan et al., 2009, Gielen et al., 2007, Hendrickson, 2005, Watson et al.,
2005, Sznajder et al., 2003, DiGuiseppi et al., 2002, Kendrick et al., 1999, Clamp &
Kendrick, 1998) and 11 available in AD format (Sangvai et al., 2007, Harvey et al.,
2004, Mock et al., 2003, Gielen et al., 2002, Gielen et al., 2001, King et al., 2001,
Johnston et al., 2000, Schwarz, D. F. et al., 1993, Barone, 1988, Matthews, 1988,
Miller et al., 1982), summing up to approximately 11,500 participants. Seven out of 9
available studies in IPD format and 7 out of 11 in AD format are RCTs. Also, 2 of the
IPD studies and 6 of the AD studies are cluster-allocated trials18, but in none of these
had the cluster design been accounted for in the original analysis. In all subsequent
analyses, the effect of the clustering is modelled for the IPD. For the summary study
estimates, an approximate adjustment is made through the inflation of treatment effect
variances prior to all modelling described below (Note, Sutton et al. (2008) made
18 The allocation level for clustered RCTs varied across studies and ranged from paediatricians to
general practices and electoral wards. The allocation level for the clustered non-RCTs included one
study allocated at the GP practice level and one where allocation was based on time periods. The
allocation level for the clustered CBA was the child health clinic.
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cluster adjustments to the AD within the modelling, this has the advantage of
allowing for the uncertainty in the estimation of the Intra Class Correlation Coefficient
(ICC) and could be pursued within a MTC framework if desired. See also Kendrick et
al. (2007) for further details). Information for these studies is provided in Table 3.1.
Note that values are here presented in summary form, but where IPD is available it is
used as such in the analysis – exceptions are made for the models where AD is
synthesised by reducing available IPD to AD.
Seven implementation strategies are defined across the available evidence base,
namely:
1) usual care (UC);
2) education (E);
3) education plus low cost/free safety equipment (E + FE);
4) education plus low cost/free safety equipment plus home inspection (E + FE +
HI);
5) education plus low cost/free safety equipment plus fitting (E + FE + F);
6) education plus home inspection (E + HI);
7) education plus low cost/free safety equipment plus fitting plus home inspection (E
+ FE + F + HI).
The exploration of (binary) participant-level socioeconomic characteristics is of
interest for this chapter. Thus, in the last column of Table 3.1 information on the
binary covariate relating to the number of parents in the family (i.e. single vs. two
parents households) can be found.
The following section will focus on obtaining a combined statistic of the intervention
effect in a pair-wise framework.
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Table 3.1 – Available evidence on interventions seeking to increase the ownership of
functioning smoke alarm safety equipment to prevent fire injuries in children.
(1) UC (2) E (3) E + FE (4) E + FE +
HI
(5) E +
FE + F
(6) E + HI (7) E + FE +
F + HI
Single-
parent
household
(by
treatment
arm) - %
Matthews,
1988 NRT IA AD 6/12 6/12 NA
Schwarz et al. ,
1993 CBA IA AD 816/1060 866/902 NA
King et al. ,
2001 RCT IA AD 394/469 406/482 NA
Sangvai et al. ,
2007 RCT IA AD 5/10 16/17 NA
Gielen et al. ,
2001 RCT CA AD
54/56
(52.02/53.95)
77/80
(74.18/77.07)
0.848 (0.830;
0.860)
Miller et al. ,
1982 NRT CA AD
46/105
(9.34/21.31)
61/108
(12.38/21.92)
NA
Barone, 1988 RCT CA AD
34/38
(20.08/22.45)
39/41
(23.04/24.22)
NA
Johnston et al. ,
2000 RCT CA AD
211/211
(20.05/21.15)
136/143
(31.07/31.14)
0.573 (0.486;
0.638)
Gielen et al. ,
2002 RCT CA AD
47/56
(44.2/52.66)
47/58
(44.2/54.54) NA
Mock et al. ,
2003 CBA CA AD
10/297
(2.33/69.18)
18/308
(3.03/71.74)
NA
Harvey et al. ,
2004 RCT CA AD
997/1545
(781.6/1211.2)
1421/1583
(1114.0/1241.0)
NA
Clamp et al. ,
1998 RCT IA IPD 71/82 81/83
0.103 (0.122;
0.084)
Hendrickson,
2002 RCT IA IPD 26/40 37/38
0.244 (0.132;
0.350)
Sznajder et al. ,
2003 RCT IA IPD 6/50 27/47
0.135 (0.120;
0.152)
Watson et al. ,
2005 RCT IA IPD 619/737 692/764
0.264 (0.255;
0.273)
Gielen et al. ,
2007 RCT IA IPD 325/375 345/384
0.695 (0.720;
0.669)
Bulzacchelli et
al. , 2009 NRT IA IPD 55/71 109/139
0.719 (0.761;
0.698)
Phelan et al. ,
2010 RCT IA IPD 112/138 130/140 NA
Kendrick et
al. , 1999 NRT CA IPD
305/339
(233.4/259.4)
341/385
(260.9/294.6)
0.108 (0.104;
0.112)
DiGuiseppi et
al. , 2002 RCT CA IPD 5/30 (5/30)
8/44
(8/44)
NA
4) AD - aggregate data; IPD - individually participant data.
Data
available
4)
Allocation
type3)
Study
design
2)
Study lead
author, year
Strategies1) [number of participants with functioning smoke alarms / total number of participants
(numbers adjusting for clustering in parentheses)]
Notes:
1) UC - usual care; E - education; E + FE - education plus low cost / free equipment; E + FE + HI - education plus low cost / free equipment plus home inspection; E + FE + F -
education plus low cost / free equipment plus fitting; E + HI - education plus home inspection; E + FE + F + HI - education plus low cost / free equipment plus fitting + home
inspection.
2) NRT - non-randomised trial; CBA - controlled before and after trial; RCT - randomised controlled trial.
3) IA - participants are individually allocated; CA - participants are cluster allocated.
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3.3 Methods for estimating a pooled treatment effect – direct
comparisons
This section is divided in two subsections. Initially, a description of existing RE
meta-analytic models for binary outcomes is given for the synthesis of AD, of IPD
only and for the simultaneous synthesis of both AD and IPD. Extensions to the
inclusion of information on covariates are also discussed. In a second part, results of
the application to the motivating example are shown and thoroughly discussed. It is
important to note that distinctions between control and intervention groups, as
outlined in Table 3.1, are ignored in this section with all trials combined in a single
‘pair-wise’ comparison.
3.3.1 Synthesizing aggregate data only
A REs meta-analysis assumes that the true effects in each two-arm trial are not equal,
but are random observations drawn from a common distribution. The Bayesian REs
model for binary outcomes can then be written as (Smith, T. C. et al., 1995):
 AjAjAj npBinr ,~  BjBjBj npBinr ,~
  jAjp logit   jjBjp  logit
 610,0~ Nj  2,~  dNj  
610,0~ Nd  10,0~ Unif
(3.1)
Where
Ajn and Bjn denote the total number of individuals in the two arms A and B
of the jth study,
Ajr and Bjr denote the number of events in these two arms, with the
underlying probabilities of an event represented by
Ajp and Bjp , respectively. The
estimated unconstrained log-odds of an event in group A in the jth trial is denoted by
j , and requires a prior distribution. The true treatment effect (on a log-odds scale)
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in trial j is represented by
j , allowed to be different from each other and assumed to
be sampled from a Normal distribution with mean d and variance 2 . Prior
distributions are required for these parameters. The parameter 2 indicates how
much variability there is between estimates from the different studies. For the
parameters requiring a prior distribution, these were specified above (model (3.1)),
and are intended to be vague.
If one wanted to describe a FEs model, the above could be modified so that the
j ’s
are fixed across studies and a (vague) prior distribution assigned to this overall
treatment effect.
3.3.2 Synthesizing individual participant-level data only
The Bayesian REs model for binary outcomes using IPD data, while controlling for
participant allocation, can be written as (notice that the model structure is similar to
that described by Sutton et al. (2008) and Turner et al. (2000)):
 ijij pBernoulliY ~
  ijjjij treatp  logit
 610,0~ Nj  2,~  dNj  610,0~ Nd  10,0~ Unif
(3.2)
The binary response of the ith participant in the jth study, Yij (i.e. 1 = event, 0 = no
event), is assumed Bernoulli distributed, with probability of the event of interest
described by pij. A standard logistic regression is fitted to each of the j trials and the
linear predictor considers an independent term, j , which estimates the log-odds of
an event in the control group, and a term for the treatment difference, j , multiplied
by a treatment group indicator, treatij (i.e. 0 if in control group, and 1 if in
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intervention group). As in (3.1), all estimated parameters require specification of
prior distributions which are intended to be vague.
3.3.3 Synthesizing individual and aggregate level data
One practical limitation of carrying out an IPD only meta-analysis, is that it relies on
the availability of data sets for all studies. Therefore, one may be faced with the
difficulty of having to statistically synthesise evidence in two different formats (i.e.
IPD and AD). The model described here follows the approach used by Sutton et al.
(2008) which, in addition to IPD and AD, allows also for the additional level of
complexity introduced by different randomisation procedures (i.e. cluster- and
individual-allocation). This model is described in five interrelated parts and can be
viewed as an integration of the previous two models, (3.1) and (3.2), with all notation
conventions remaining the same. The Bayesian REs model for the pair-wise
combination of IPD and AD for a binary outcome can be written as:
(3.3) Part I - Model for individually allocated IPD studies
 ijij pBernoulliY ~
  ijjIPDjij treatp  logit
 610,0~ NIPDj
(3.3.1)
For: i = 1, 2, ... , number of participants in the jth individually allocated IPD study; and j = 1, 2, . . . ,
number of individually allocated IPD studies.
Part II - Model for cluster allocated IPD studies
 imjimj pBernoulliY ~
  imjjIPDcmjimj treatp   .logit (3.3.2)
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 2. .,~ jjIPDcmj cN   610,0~ Nj  610,0~. Nc j
For: i = 1, 2, ... , number of participants in the mth cluster of the jth cluster allocated IPD study; m =
1, 2, . . . , number of clusters in the jth study; and j = (number of individually allocated IPD studies +
1),…,(number of individually allocated IPD studies + number of cluster allocated IPD studies)
While equation (3.3.1) is used for individually allocated IPD studies, equation (3.3.2)
allows for clustering effects within studies. A separate unconstrained control group
odds for each cluster is estimated on the logit scale within each study, IPDcmj. ,
assuming that these are exchangeable19 within each study. Cluster effects between
studies are assumed independent.
Part III - Model for individually allocated AD studies
 AjAjAj npBinr ,~  BjBjBj npBinr ,~
  ADjAjp logit   jADjBjp  logit
 610,0~ NADj
(3.3.3)
For: j = (number of individually allocated IPD studies + number of cluster allocated IPD studies +
1), . . . , (number of individually allocated IPD studies + number of cluster-allocated IPD studies +
number of individually allocated AD studies)
Part IV - Model for cluster allocated AD studies
design.effectj = 1 + (ave.c.sizej - 1) · ICCj (3.3.4)
19 As described in Higgins et al. (2009): “exchangeability represents a judgement that the treatment
effects may be non-identical but their magnitudes cannot be differentiated a priori”, that is,
“exchangeability describes the a priori position of expecting underlying effects to be similar, yet non-
identical” and it “reflects a degree of prior ignorance in that the magnitudes of the effects cannot be
differentiated”.
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σ.adj2j = σ
2
j · design.effectj
 2adj.,~ jjj NT  ICCj ~ as described in the text
For: j = (number of individually allocated IPD studies + number of cluster-allocated IPD studies +
number of individually allocated AD studies + 1), . . . , (total number of studies)
Equation (3.3.4) combines cluster-allocated studies in AD format over the
assumption that the original analysis ignored the clustering effect. If this effect is
ignored, cluster allocated studies will benefit from being allocated more weight than
they should. Therefore, adjustments were made to inflate the treatment effect
variances to take this fact into account. These were inflated based on the design
effect, function of the average cluster size in the jth study and the ICC in the jth
study20 (Donner & Klar, 2002). Further details on how ICCs are calculated can be
found in Kendrick et al. (2007) and Sutton et al. (2008).
Part V: Combining estimates of the effect of the intervention from the 4 data sources
 2,~  dNj  610,0~ Nd  10,0~ Unif (3.3.5)
For: j = 1 . . . , total number of studies
Equation (3.3.5) specifies a RE to be placed across all treatment effect estimates
from the IPD and AD, j ’s, imposing the exchangeability property. In this way
20 It is unlikely that the ICCs will be reported in published studies. For the studies which do not
provide this information it is necessary to estimate them from other sources. Estimates of ICC may be
derived, for instance, from the IPD used in part 3.3.2 of the model or based on external evidence. If
distributions are specified for the unknown ICCs then these should represent the uncertainty in its
value.
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synthesis across both types of data is achieved, since equations (3.3.1) and (3.3.2)
“share” parameters. As before, specified prior distributions are intended to be vague.
It is noted that for an analysis such as this, which does not consider patient level
covariates, no loss of information is to be expected when collapsing IPD to AD and
thus the model presented here might seem over-elaborate in this specific
circumstance, though this is not the case if covariates are considered, as is outlined in
the next section.
3.3.4 Meta-regression models: the inclusion of covariates
Random-effects models take into consideration the possible heterogeneity between
studies, although they do not explain the reasons study results vary. While
associations of treatment effect with patient characteristics may be explored using
AD and average study level covariates, as outlined in this chapter’s introduction, this
approach is problematic since possible associations can occur purely by chance, or
due to the presence of confounding factors, and are susceptible to low power and
aggregation/ecological bias (Berlin et al., 2002). Use of IPD is recommended to
explore patient characteristics, and avoids the bias introduced by group-level
analyses.
Covariates can be included in a Bayesian meta-analysis model in a straightforward
way. For example, in the previously described Bayesian REs meta-analytic model of
AD for binary outcomes on a log- OR scale (section 3.3.1), the model can be simply
extended to include a covariate, X, measured at trial level as means in the two arms:
 AjAjAj npBinr ,~  BjBjBj npBinr ,~
  jAjp logit   jjjBj Xβδμp logit
 610,0~ Nj  2,~  dNj  
610,0~ Nd
(3.4)
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 10,0~Unif  610,0~ N
The estimated odds (on the log-scale), denoted by j , can be interpreted as the
model intercept (i.e. the effect where the covariate takes the value 0), and  , an
unconstrained model coefficient which estimates the effect of the covariate on the
treatment effect, and requires a prior distribution – model (3.4). Extension to multiple
regression coefficients is straightforward. The IPD model without covariates (3.2)
can be extended in the same manner, although it is important to note that in such an
analysis the covariate data is at the patient, not the study, level (not shown but
demonstrated below).
Riley and Steyerberg (Riley, Richard D. & Steyerberg, 2010) have shown that IPD
allows for the modelling of treatment x covariate interactions using both within and
between-study variability, and such variability can be partitioned to produce a meta-
regression and a “pure” IPD estimate of the interaction of interest. These estimates
can subsequently be merged into an overall interaction estimate if deemed
appropriate. The following model is described in (interrelated) parts and extends
model (3.3) for the combination of IPD and AD. It is an adaptation of the model
described in Sutton et al. (2008), now including binary covariates and considering
the partitioning of the variability regarding the interactions (extending the framework
used by Riley (2010)). Alternative assumptions could be accommodated with
relatively straightforward modifications to the model specification.
(3.5) Part I – Model for individually allocated IPD studies including covariates
 ijij pBernoulliY ~ (3.5.1)
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 
 
logit 0
ijjij
W
ijj
B
ijjijj
IPD
jij
treatxxtreatx
xtreatp




 610,0~ NIPDj  
6
0 10,0~ Nj
For: i = 1, 2, ... , number of participants in the individually allocated jth IPD study; and j = 1, 2, . . . ,
number of individually allocated IPD studies
Part II - Model for cluster allocated IPD studies including covariates
 imjimj pBernoulliY ~
 
 
logit 0
.
imjjimj
W
imjj
B
imjjimjj
IPDc
mjimj
treatxxtreatx
xtreatp




 2. .,~ jjIPDcmj cN   610,0~ Nj  10,0~. Unifc j
 60 10,0~ Nj
(3.5.2)
For: i = 1, 2, ... , number of participants in the mth cluster of the jth cluster allocated IPD study; m =
1, 2, . . . , number of clusters in the jth study; and j = (number of individually allocated IPD studies +
1),…,(number of individually allocated IPD studies + number of cluster allocated IPD studies)
Compared to model (3.3), the changes applied are the addition of three extra terms:
(i) a study-specific individual level covariate regression term,
ijj x0 (or imjj x0
for cluster-allocated studies), where j0 is the main covariate effect and xij (ximj)
refers to the value for the binary covariate in the ith participant (in the mth cluster) of
the jth study; (ii) an interaction term to account for the within-study association,
  ijjijW treatxx  (or   imjjimjW treatxx  for cluster-allocated studies),
where within-study relationship is modelled by centring xij (ximj) about the mean
covariate value,
jx , in each study and
W is assumed the same throughout all IPD
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studies; and (iii) an interaction term to model the between-study relationship,
ijj
B treatx  (or imjj
B treatx  for cluster-allocated studies), by interacting
with the mean covariate value, where, like W , B is assumed the same throughout
all IPD studies, but also equivalent to the estimated slope for the covariate in model
equations (3.5.3) and (3.5.4) below, the B in j
B aggx. (where x.aggj represents
the proportion of participants with the characteristic of interest in the meta-regression
of aggregate results).
Part III - Model for individually allocated AD studies including covariates
 AjAjAj npBinr ,~  BjBjBj npBinr ,~
  ADjAjp logit   jBjADjBj aggxp .logit  
 610,0~ NADj
(3.5.3)
For: j = (number of individually allocated IPD studies + number of cluster-allocated IPD studies +
1), . . . , (number of individually allocated IPD studies + number of cluster-allocated IPD studies +
number of individually allocated AD studies)
Part IV - Model for cluster allocated AD studies including covariates
design.effectj = 1 + (ave.c.sizej - 1) · ICCj
σ.adj2j = σ
2
j · design.effectj jjj aggx.
*  
 2* adj.,~ jjj NT  ICCj ~ as described in the text
(3.5.4)
For: j = (number of individually allocated IPD studies + number of cluster-allocated IPD studies +
number of individually allocated AD studies + 1), . . . , (total number of studies)
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Both individually- and cluster-allocated IPD studies are contributing to the
estimation of the regression coefficient representing the within-study associations,
W .Vague prior distributions are attributed to the participant-level regression
parameters, j0 . In equation (3.5.5) below the specification of vague priors for
W
and B is required.
V - Combining estimates of the effect of the intervention from the 4 data sources
including covariates
 2,~  dNj  610,0~ Nd  10,0~ Unif
 610,0~ NB  610,0~ NW
(3.5.5)
For j = 1 . . . , total number of studies
In this model, it is necessary that the aggregate covariate (i.e. proportion of people in
the study with the characteristic of interest) is expressed as a decimal. This way,
estimated slopes from both the AD and the IPD have a comparable interpretation
(Lambert et al., 2002). The regression coefficients from the interaction intervention –
mean covariate value from the IPD (model equations (3.5.1) and (3.5.2)) – where the
covariate indicates the presence or absence of a certain characteristic, and the slope
from the AD meta-regressions, where the covariate value is the proportion of
participants in a study with a certain characteristic, both estimate the change in
outcome for a one unit increase in the proportion (i.e. from 0 to 1, or the difference in
effect of the intervention in the presence and absence of the covariate). Therefore,
both the IPD and the AD, whether individually- or cluster-allocated, can contribute
to the estimation of a single regression coefficient, B , representing the between-
study associations.
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3.3.5 Application
As for previous publications in this field, because of the flexibility of the modelling
allowed, all models described below are fitted using Bayesian Markov chain Monte
Carlo (MCMC) methods, as implemented in the software WinBUGS (Spiegelhalter,
D. et al., 2003). Unless stated otherwise, for all models applied in this chapter, the
MCMC sampler was run for 10,000 iterations, discarded as ‘burn-in’, and further
5,000 iterations were done on which inferences are based. Chain convergence was
checked on all presented posterior sample summaries, including checking stability
across distinct sets of initial values. All unknown parameters require prior distributions
within a Bayesian paradigm, and are given prior distributions which are intended to be
vague throughout. See Appendix 2 for more details on Bayesian methods.
For each subsequent set of results, medians of the MCMC posterior sample are
presented and 95% credible intervals (CrI) of the posterior distribution as a Bayesian
measure of the uncertainty of estimated parameter. The models considered in sections
3.3.1 to 3.3.4 have been fit sequentially, “building up” to the full complexity of model
(3.5) to the outcome of interest, possession of a ‘functioning smoke alarm’. Initially, it
is compared the results of the pair-wise models without covariates for AD (all
evidence base), AD only (55% of the evidence base) and IPD (reduced to AD – 45%
of the evidence base). This is followed by the synthesis of IPD and of AD plus IPD,
including the IPD where available, ignoring covariates. It is then considered the binary
covariate on ‘number of parent status’ as a potential treatment effect modifier. This
covariate is binary (0 = two parent household (2P); 1 = single parent household (1P))
for each individual in the IPD and a percentage (mean) when referring to the
proportion of 1P in a study for the AD studies. Initially, two meta-regression models
are specified, using summary evidence (i.e. the entire evidence base reduced to AD).
Given the relatively small number of trials available, the model has been specified
separating the variability regarding interaction effects. This is followed by a model
with overall interaction coefficients. The latter models are slight modifications of
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model (3.5) in which within- and between-study associations are merged into an
overall parameter.
3.3.5.1 Analysis of models without covariates
Table 3.2 shows the results of meta-analytic models applied to the functioning smoke-
alarm outcome without considering any covariates. The 3 columns of results relate to
the application of model (3.1) to different sets of evidence.
Table 3.2 - Parameter estimates from fitting the pair-wise meta-analytic model to AD
without covariates to the functioning smoke alarm outcome.
The synthesis of all available evidence in AD (i.e. 20 studies) using a REs model,
returns an intervention effect which favours the treatment (OR 2.4, 95% CrI 1.51 –
Interpretation
Median of
MCMC
posterior
sample
95 per cent
credible interval
Median of
MCMC
posterior
sample
95 per cent
credible interval
Median of
MCMC
posterior
sample
95 per cent
credible interval
Log odds ratios for
intervention effect
d 0.884 0.414 to 1.387 0.862 0.063 to 1.685 0.926 0.169 to 1.859
Between-study
variance   τ
2 0.708 0.285 to 1.893 0.919 0.267 to 3.936 0.926 0.18 to 4.677
Odds ratios for
intervention effect e
d 2.420 1.513 to 4.004 2.368 1.065 to 5.391 2.524 1.184 to 6.420
Deviance
Information
criteria
DIC
Notes:
Model (3.1) - 20 studies
included
Model (3.1) - 11 studies
included
Model (3.1) - 9 studies
included
Random effects MA of AD
Random effects MA of AD
only
Random effects MA of IPD
reduced to AD
i) available IPD was reduced to AD, and this was combined with the existing AD.
235.97 122.41 115.28
Parameter
Function of parameter
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4.0). Between-study heterogeneity, , is taken into account and estimated as 0.7
(95% CrI 0.29 – 1.89), revealing a fair amount of variability across studies. Similar
point estimates are obtained when splitting the study sample in the group for which
evidence at aggregate level is available and the group for which evidence at the
individual level (reduced to AD) is available. It is noted that for these models,
uncertainty of estimated parameters is found to be higher, most certainly a
consequence of the smaller number of studies included.
Table 3.3 refers to the case of meta-analyzing IPD studies only (i.e. 9 studies) and of
synthesizing the entire evidence base whether in aggregate or in individual level
format (i.e. 20 studies). If evidence at the individual level is the only format of
evidence available, the statistical combination of these could be implemented by using
model (3.2). These consider an extension to this model in order to consider the fact
that 2 of the studies are cluster-allocated and 7 are individually-allocated (Table 3.3
column 1 of results). This model estimates almost equivalent results, compared to the
ones obtained when applying model (3.1) to the same set of studies reduced to AD.
In Table 3.3 column 2, results of applying model (3.3) to the evidence base are shown.
This model considers the simultaneous synthesis of AD and IPD. It is interesting to
note the resemblance of estimated parameter posterior distributions of applying model
(3.1) and model (3.3), to all studies (i.e. 20) – results columns 1 of Table 3.2 and
results column 2 of Table 3.3. These similarities were expected and small differences
can be observed. These differences can be justified by: (i) the use of different
approaches in the cluster adjustment as adjustments were made prior to the modelling
in the AD model and both outside (for AD) and within (for IPD) modelling in the IPD
+ AD model; (ii) the slight influence of the prior distributions; and by (iii) simulation
error.
2ˆ
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Table 3.3 - Parameter estimates from fitting the pair-wise meta-analytic models to IPD and
to AD and IPD without covariates to the functioning smoke alarm outcome.
3.3.5.2 Analysis of models considering a binary covariate
It is well documented that children suffering socio-economic disadvantages are at
higher risk of unintentional injury at home than the more fortunate (Edwards et al.,
2006). In fact, parents in lower income households and/or those in lower social grade
households are less likely to have taken certain preventive actions (Kendrick et al.,
2007, Reimers & Laflamme, 2005, Haynes et al., 2003). Literature is also available
which has explored the relationship between maternal age and child injury risk
(Reading et al., 1999, Scholer et al., 1999). The majority of these studies found that
children are at greater risk of injury in families where the mother is younger or in
single parent families (O'Connor et al., 2000). Information on the risk factor related to
Interpretation
Median of
MCMC
posterior sample
95 per cent
credible interval
Median of
MCMC
posterior sample
95 per cent
credible interval
Log odds ratios for
intervention effect
d 0.920 0.084 to 1.867 0.850 0.311 to 1.408
Between-study
variance   τ
2 1.070 0.231 to 4.948 0.823 0.3 to 2.458
Odds ratios for
intervention effect e
d 2.510 1.088 to 6.472 2.339 1.364 to 4.087
Deviance
Information
criteria
DIC
Parameter
2939.13 3099.71
Notes:
i) Results shown relate to an extension to model (3.2) which takes into consideration the fact that in some studies
participants were cluster-allocated and in some others individually-allocated.
Model (3.2)i) - 9 studies included Model (3.3) - 20 studies included
Random effects MA of IPD
only
Random effects MA of AD and
IPD
Function of parameter
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the number of parents in the household (i.e. two or single parent families) is
considered in the next section.
In nine of the 20 studies, information was available for the binary covariate related to
whether the family was composed of a single parent or two parents and hence whether
the uptake of smoke alarms was different for these two participating subgroups. Meta-
regression models described consider treatment x covariate interaction terms which
result in non-linear intervention effects. In addition to this, potential baseline covariate
imbalances between study-arms and across studies may contribute to differences
between the log-OR of the intervention effect estimates between models which
consider and do not consider the covariate of interest.
Applying model (3.4) to the set of 9 studies, all at aggregate level, and considering the
overall study covariate proportion, the OR for intervention effect in 2Ps is 2.5 (95%
CrI 0.93 – 8.56) and 1Ps is 0.4 (95% CrI 0.01 – 19.59) – results reported in Table 3.4.
Though for both subgroups, CrI include 1, the results suggest that the intervention may
be more effective for one subgroup than for the other. A treatment x covariate
interaction (β) of -1.9 (95% CrI -5.94 – 1.73) indicates that 1Ps do not benefit from
strategies aimed at increasing safety equipment ownership as those investigated in the
current case study. The point estimate for the between-study variance parameter is
reasonably large (approximately 1.4) and that the 95% CrI is quite wide (0.29 to 8.76)
reflecting the uncertainty in its estimation.
If, instead of considering all evidence formats with information on the covariate, the
focus is on the evidence in IPD format, reducing it to AD (i.e. 7 studies), and using the
overall covariate proportion for each of the studies, the same conclusions can be
obtained. Nevertheless, a slight increase in uncertainty is observed in all estimates,
particularly in the treatment interaction term, β, and in the between-study variance.
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Table 3.4 - Parameter estimates from fitting the pair-wise meta-regression model to AD with
a binary covariate (single parent status) to the functioning smoke alarm outcome.
It is worth highlighting that estimated treatment x covariate associations through the
use of model (3.4) for AD may not reflect the true relationship at the individual level –
these associations may have occurred purely by chance, due to the presence of
confounding factors, or ecological bias (Berlin et al., 2002). Therefore, all the meta-
regression results described above have to take these factors into consideration.
Interpretation
Median of
MCMC
posterior sample
95 per cent
credible interval
Median of
MCMC
posterior sample
95 per cent
credible interval
Log odds ratios for
intervention effect
d 0.926 -0.069 to 2.147 1.049 -0.309 to 2.619
Regression coefficient for
treatment interaction with
single-parent status
  β -1.853 -5.941 to 1.725 -2.014 -7.783 to 3.864
Between-study variance   τ 2 1.433 0.287 to 8.76 1.925 0.354 to 15.591
Odds ratios for intervention
effect e
d 2.525 0.933 to 8.563 2.854 0734 to 13.724
Ratio of the odds ratios for
single-parent vs two-
parent households
e β 0.157 0.003 to 5.611 0.133 <0.001 to 47.6661
Odds ratio for intervention
effect in single-parent
households
e d+β 0.395 0.007 to 19.59 0.383 0.001 to 162.74
Deviance Information
criteria
DIC 104.844 90.334
Model (3.4) - 9 studies included Model (3.4) - 7 studies included
Random effects MR of AD,
including a binary covariate
Random effects MR of IPD
reduced to AD, including a
binary covariate
Parameter
Function of parameter
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Single parent status information was available in 7 out of the 9 studies in IPD format.
The results of estimating treatment interactions terms, separating the between- and the
within-study associations are shown in Table 3.5.
Table 3.5 - Parameter estimates from fitting pair-wise meta-regression models to IPD and to
AD plus IPD with covariate ‘single parent status’ to the functioning smoke alarm outcome
data considering exchangeable treatment interactions and modelling separately within and
between study associations.
Interpretation
Median of
MCMC
posterior sample
95 per cent
credible interval
Median of
MCMC
posterior sample
95 per cent
credible interval
Regression coefficient for
within study association
with single-parent (vs two
parent families)
  β W 0.035 -0.483 to 0.556 0.054 -0.508 to 0.585
Regression coefficient for
between study association
with single-parent (vs two
parent families)
  β B -1.957 -7.881 to 3.238 -1.918 -5.951 to 1.611
Difference between
regression coefficient for
within and between study
associations with single-
parent (vs two parent
families)
  β diff -1.985 -7.937 to 3.247 -1.999 -6.032 to 1.616
Deviance Information
criteria
DIC 2436.89 2451.52
Notes:
i) This model is a short version of model (3.5) which considers only the 2 initial parts of this model, i.e. the ones relating to the
synthesis of IPD.
Model (3.5) i) - 7 studies included Model (3.5) - 9 studies included
Random effects MA of IPD
only
Random effects MA of AD and
IPD
Parameter
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The first set of results refers to using IPD only and a shorter version of model (3.5).
The second column of results refers to the direct use of model (3.5) with IPD included
where possible (7 studies) in addition to AD (2 studies), and interactions are assumed
to be exchangeable. To assess whether ecological bias exists, the difference between
the association terms is estimated, diff ’s. The CrIs of the difference between within-
and between-study association estimates do include 0. Hence, there is little evidence to
suggest systematic differences between the covariate treatment interactions estimated
by the within-study and between-study variation. In the subsequent analysis presented,
these two sets of coefficients are replaced with a single one combining the between
and within study association information.
The meta-regression of IPD only and of AD + IPD, without separating within- and
between-study association effects is shown in Table 3.6. In both synthesis models,
results favour the intervention in the two-parent households (OR 2.7, 95% CrI 0.84 –
11.05 and OR 2.5, 95% CrI 0.87 – 8.27, respectively), nonetheless this effect is
somewhat ‘weak’ as CrIs include 1. The treatment x covariate interaction estimate, ˆ ,
is approximately 0, suggesting an almost null impact. This indicates a similar
intervention effect between both subgroups, as ORs for the IPD only model and for
AD + IPD are approximately 2.7 (95% CrI 0.8 – 11.64) and 2.5 (95% CrI 0.88 – 8.67).
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Table 3.6 - Parameter estimates from fitting the pair-wise model to IPD and to AD plus IPD
with information on the covariate ‘single parent status’ to the binary functioning smoke
alarm outcome data considering exchangeable and independent treatment interactions, not
separating between- and within-study interactions.
The following section considers the fact that control and intervention groups differ in
different studies. This extends and restructures evidence in order to have not only pair-
wise comparisons (A vs. B) but a whole set of comparisons among the relevant set of
interventions using direct and indirect evidence.
Interpretation
Median of
MCMC
posterior sample
95 per cent
credible interval
Median of
MCMC
posterior sample
95 per cent
credible interval
Log odds ratios for
intervention effect
d 0.992 -0.177 to 2.404 0.922 -0.136 to 2.112
Regression coefficient for
treatment interaction with
single-parent status
  β -0.001 -0.519 to 0.521 -0.018 -0.529 to 0.495
Between-study variance   τ 2 1.695 0.335 to 11.33 1.422 0.299 to 7.702
Odds ratios for intervention
effect e
d 2.697 0.838 to 11.045 2.515 0.873 to 8.269
Ratio of the odds ratios for
single-parent vs two-
parent households
e β 0.999 0.595 to 1.684 0.983 0.589 to 1.641
Odds ratio for intervention
effect in single-parent
households
e d+β 2.696 0.799 to 11.64 2.473 0.884 to 8.666
Notes:
i) This model is a short version of model (3.5), considering only the 2 initial parts of this model relating to the synthesis of IPD.
ii) Models were simplified by aggregating in a single term both within and between study associations.
Model (3.5) i) and ii)- 7 studies
included
Model (3.5) ii) - 9 studies
included
Random effects MA of IPD
only
Random effects MA of AD and
IPD
Function of parameter
Parameter
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3.4 Methods for estimating a pooled treatment effect – indirect and
mixed treatment comparisons
This section reviews existing MTC methodology, which I extend in future sections.
First, two simple hypothetical cases will be used to exemplify an indirect treatment
comparison and a MTC. Figure 3.1a shows a network formed by pair-wise
comparisons between the three interventions – A, B and C. Direct head-to-head
evidence is available for comparisons of A vs. C and B vs. C. There is no direct
evidence between A and B (no solid line connects these two treatments). Treatments
A and B are indirectly linked through C, which is the common comparator in this
diagram. An indirect comparison estimate of A and B can be derived using evidence
from A vs. C and B vs. C trials. On the log-OR scale, an estimate of A vs. B
comparison, dAB, can be derived from existing evidence (Ades, A. E. et al., 2006b):
dAB = dCB - dCA.
Figure 3.1b represents the case when four interventions, A, B, C and D, are of
interest. Not only is direct evidence available for the comparisons C vs. A and C vs.
B, but also for A vs. B and A vs. D. Given the network of existing direct evidence,
indirect estimates can be derived for C vs. A, C vs. B, A vs. B and B vs. D, using the
same rationale as before. Except for some cases (i.e. B vs. D and C vs. D), Figure
3.1b shows that both types of evidence (i.e. direct and indirect) are available for most
pair-wise comparisons. When analysing data in this way, as for standard meta-
analysis, a decision needs to be made as to whether each trial is assumed to provide
an estimate of exactly the same quantity (fixed effect) or if the studies included in the
meta-analysis provide estimates that are realisations from a common distribution of
possible, exchangeable (random effect) outcomes . Such an approach generalises to
networks of any complexity; see elsewhere for further details (Caldwell et al., 2005,
Lu, G. & Ades, 2004).
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Figure 3.1 – Diagrams of evidence structures: (a) indirect comparison of intervention A and
B given studies on the comparisons of CA and CB, and (b) network of studies reflecting
MTCs of CA, CB, AB and AD trials.
Section 3.4.1 below outlines a standard REs MTC model for a binary outcome
(Ades, A. E. et al., 2006b) which is expanded upon in future sections – FEs
approaches are not pursued here, but could be attained with straightforward
simplifications of the model. Once again, all models described below are fitted using
Bayesian MCMC methods and all unknown parameters requiring prior distributions
are given priors which are intended to be vague throughout.
C
A B
(a)
C
A B
(b)
D
dCA
dCB
dAB dAB = dCB – dCA
C A B
dCA
dCB
dAB
dCA = dCB – dAB
dAD
C A B D
dCB = dCA – dAB
dAB = dCB – dCA
dBD = dAD – dAB
dCD = dCA – dAD
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3.4.1 Synthesizing aggregate data only
Following the approach used by Ades et al. (2006b) a REs MTC model for binary
outcome data, using only AD, can be written as:
 jkjkjk npBinr ,~
 




 


bk
bkCBAb
p
jbkjb
jb
jk
afterallyalphabeticif
if,....,,
logit


   22 ,~,~  AbAkbkjbk ddNdN 
(3.6)
where rjk, denotes the number of observed events, and jkn the total number of
individuals in the kth treatment arm of the jth trial. The underlying probabilities of an
event for each arm in each trial are represented by
jkp . The quantity jb represents
the log-odds of an event for treatment b in study j, and dbk is the log-OR for treatment
k relative to the study-specific baseline treatment b. Each
jbk , the log-OR for
treatment k relative to treatment b in trial j, is assumed to be Normally distributed
with mean dbk and variance 2 . Prior distributions need to be specified for jb and d
  610,0~ N and for    2,0~ Unif . Note that dAA = 0.
This synthesis model requires modifications in order to incorporate trials with 3 or
more arms, as the model must take into account the correlation structure between
arms of the same trials. These alterations rely on the use of the multivariate normal
distribution for the intervention effects (see elsewhere for details of implementation
(Lu, G. & Ades, 2004)).
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3.4.2 Synthesizing individual participant-level data only
A REs model for MTC using IPD only can be written as:
 ijkijk pBernoulliY ~
 




 


bk
bkCBAb
p
jbkjb
jb
ijk
afterallyalphabeticif
if,....,,
logit


   22 ,~,~  AbAkbkjbk ddNdN 
(3.7)
For each study, the binary response of the ith participant, in the kth treatment arm of
the jth study, Yijk (i.e. 1 = event, 0 = no event), is assumed to follow a Bernoulli
distribution with the probability of the event of interest occurring of pijk . As above, a
standard logistic regression is fitted to each participant i of the jth trial, with
jb ,
representing the log-odds for the control group (baseline b) in study j. The
jbk ,
derived from the treatment group indicator for each participant i, is the log-OR for
treatment k relative to the study-specific (j) baseline treatment b. Prior distributions
need to be specified for
jb , d and  , as specified in model (3.6). A similar
modification to allow for studies with more than 2 arms, akin to that in section 3.4.1,
is straightforward and can also be applied to all subsequent models described.
Applications of the IPD MTC model as in (3.7) have not been encountered.
3.4.3 Synthesizing individual and aggregate level data
Similar to the pair-wise case discussed in Section 3.3.3, an IPD only network meta-
analysis would rely on the availability of IPD datasets for all studies. Since the
availability of IPD for all studies is fairly unlikely, one may have to statistically
synthesise evidence in IPD and AD simultaneously. The model described below can
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be viewed as an integration of the previous two models, (3.6) and (3.7), with all
notation conventions remaining the same. Similarly to model (3.3) and (3.5), the
following model is described in 4 interrelated parts. Thus, a REs MTC model for the
combination of IPD and AD for binary outcomes, allowing for different allocation
procedures, can be written as:
(3.8) Part I – Model for individually allocated IPD studies
 ijkijk pBernoulliY ~
 




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

bk
bkCBAb
p
jbk
IPD
jb
IPD
jb
ijk
afterallyalphabeticif
if,...,,
logit


 610,0~ NIPDjb
(3.8.1)
For i = 1, 2, ... , number of participants in the jth individually allocated IPD study; j =1, 2, . . . ,
number of individually allocated IPD studies; and k = 1, 2, … , number of treatments for which
participants were allocated to.
Part II - Model for cluster allocated IPD studies
 imjkimjk pBernoulliY ~
 




 


bk
bkCBAb
p
jbk
IPDc
mjb
IPDc
mjb
imjk
afterallyalphabeticif
if,...,,
logit
.
.


 2. .,~ jjIPDcmjb cN 
(3.8.2)
For i = 1, 2, ... , number of participants in the mth cluster of the jth cluster-allocated IPD study; m = 1,
2, . . . , number of clusters in the jth study; j = (number of individually allocated IPD studies +
1),…,(number of individually allocated IPD studies + number of cluster allocated IPD studies) ; and k
= 1, 2, … , number of treatments for which participants were allocated to.
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While equation (3.8.1) is used for individually allocated IPD studies, equation (3.8.2)
allows for clustering effects within studies. In equation (3.8.2) a separate
unconstrained control group odds for each cluster is estimated on the logit scale
within each study, IPDcmjb
. , assuming that these are exchangeable within each study,
with mean θj and variance 2. jc - both these parameters requiring the specification of
(vague) prior distributions (  610,0N and  10,0Unif , respectively). Cluster effects
between studies are assumed to be independent.
Part III - Model for both cluster and individually allocated AD studies
 jkjkjk npBinr ,~
 




 


bk
bkCBAb
p
jbk
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jb
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jb
jk
afterallyalphabeticif
if,....,,
logit


(3.8.3)
For j = (number of individually allocated IPD studies + number of cluster allocated IPD studies +
1)... (total number of studies).
Equation (3.8.3) combines both individually- and cluster-allocated studies in AD
since pre-model data adjustments were made to appropriately inflate the treatment
effect variances for the effects of clustering in the cluster-allocated trials. This
inflation may be made by estimating the ICC, as previously demonstrated in related
literature (Donner & Klar, 2002). A prior distribution needs to be specified for ADjb
  610,0~ N .
Part IV: Combination of estimates of the intervention effect
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   22 ,~,~  AbAkbkjbk ddNdN  (3.8.4)
For k = 1 . . . , total number of treatments.
Equation (3.8.4) specifies a RE to be placed across all treatment effect estimates
from the IPD and AD, sjb ' , imposing the exchangeability property. In this way,
synthesis across both types of data is achieved since equations (3.8.1), (3.8.2), and
(3.8.3) “share” parameters. Prior distributions need to be specified for d   610,0~ N
and σ   2,0~ Unif . It is notable that for an analysis such as this, which does not
consider participant level covariates, no loss of information is expected when using
AD compared to IPD. As for model 3.3, model 3.8 is expected to provide the same
results as the synthesis of AD and may seem over-elaborated. Nonetheless, this is no
longer the case when information on covariates is included, as it is shown in the next
section.
3.4.4 Mixed treatment comparisons models: including covariates
The inclusion of study-level covariates may explain some of the between-study
heterogeneity and reduce inconsistency in the network (Cooper, Nicola J. et al., 2009).
Of course, treatment effect associations may be explored using AD and average study
level covariates. Meta-regression techniques can be translated into the MTC situation
in quite a straightforward way, although the disadvantages previously highlighted still
persist (Dias et al., 2011a, Nixon, R. M. et al., 2007, Jansen, 2006). Cooper et al.
(2009), consider three different assumptions that can be made about treatment x
covariate interactions, namely: (i) they are independent for every treatment in the
network; (ii) they are the same for all treatments in the network; and (iii) they are
assumed exchangeable for all treatments in the network. Option (i) is the least
stringent but requires more data; option (ii) makes the strongest assumption, while
option (iii) is a ‘half-way-house’ between the first two, where interactions can be
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different across treatments but they borrow strength from one another. When data
availability is expected to be limited - as it is in the motivating example - option (iii)
may be most appealing and is pursued below.
The following MTC model is described in parts and extends model (3.8) for the
combination of IPD and AD, considering (a) individual level covariate values for the
IPD, (b) study-level covariate information for AD, (c) exchangeable treatment x
covariate interactions, and (d) the partitioning of the variability regarding the
interactions (extending the framework used by Riley and Steyerberg (2010) to the
MTC setting). Alternative assumptions could be accommodated with relatively
straightforward modifications to the model specification.
(3.9) Part I - Model for individually allocated IPD studies including covariates
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(3.9.1)
For i =1, 2, ... , number of participants in the individually allocated jth IPD study; and j =1, 2, . . . ,
number of individually allocated IPD studies
Part II - Model for cluster allocated IPD studies including covariates
 imjkimjk pBernoulliY ~ (3.9.2)
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For i =1, 2, ... , number of participants in the mth cluster of the jth cluster allocated IPD study; m = 1,
2, . . . , number of clusters in the jth study; and j = (number of individually allocated IPD studies +
1),…,(number of individually allocated IPD studies + number of cluster allocated IPD studies).
There are three extra terms in (3.9.1) and (3.9.2) compared to (3.8.1) and (3.8.2),
namely: (i) a study-specific individual level covariate regression term, ijj x0 (or
imjj x0 for cluster-allocated studies), where j0 is the main covariate effect and xij
(ximj) refers to the value for the binary covariate in the ith participant (in the mth
cluster) of the jth study; (ii) an interaction term to account for the within-study
interaction,  jijWbk xx  (or  jimjWbk xx  for cluster-allocated studies), where
within-study relationship is modelled by centring xij (ximj) about the mean covariate
value, jx , in each study and Wbk is assumed different for each (active) treatment vs.
control comparator but exchangeable throughout all IPD studies (i.e.
 2,~ WB
W
Ab
W
Ak
W
bk N   , needing a prior distribution to be specified for WB
  2,0~ Unif ; and (iii) an interaction term to model the between-study relationship,
j
B
bk x , by interacting with the mean covariate value, which, like
W
bk ,
B
bk is also
assumed different but exchangeable. While within-study relationships may only be
estimated through IPD and are captured by Wbk , indicating variations in an
individual’s event risk for a change in xij (ximj), the between-study relationships may
be estimated by both IPD and AD and are captured by Bbk , denoting the variations in
underlying mean event risk for a change in jx (the mean covariate value for the jth
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study). The difference between these two terms represents an estimate of the
ecological bias (Riley, Richard D. & Steyerberg, 2010). In (3.9.2) both θj and jc.
require the specification of vague prior distributions   610,0~ N .
Part III - Model for both cluster and individually allocated AD studies including
covariates
 jkjkjk npBinr ,~
 




 


bk
bkCBAb
X
p
j
B
bkjbk
AD
jb
AD
jb
jk
afterallyalphabeticif
if,...,,
logit


(3.9.3)
j = (number of individually allocated IPD studies + number of cluster allocated IPD studies + 1), . . .
, (total number of studies)
As in model (3.6), the likelihood contribution, rjk, is described in the usual way. One
additional term is included, j
B
bk X , which represents a study-level specific
covariate regression term for treatment k relative to the study-specific baseline
treatment b for each j trial. This term is equivalent to the exchangeable interaction
term estimated in the two IPD statistical models above, which model the between-
study relationship, jBbk x . Once again, a vague prior distribution is specified for
AD
jb   610,0~ N .
Part IV - Combination of estimates of intervention effect including covariates
 2,~  jBbkAbAkjbk XddN 
 2,~ BB
B
Ab
B
Ak
B
bk N  
(3.9.4)
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k = 1 . . . , total number of treatments
In equation (3.9.4), the study-specific individual level covariate regression terms,
sj '0 , are given vague prior distributions   610,0~ N . Exchangeability of Bbk is
declared, with prior distributions needing to be specified for BB   2,0~ Unif . If
independent treatment interactions are desired across the network, it would simply
require defining Wbk and
B
bk as following Normality with mean 0 and large variance.
Extension to multiple regression coefficients is straightforward. Note:
0,, WAA
B
AAAAd  .
3.4.5 Application
Evidence presented in Table 3.1 is structured in order to consider the different
controls and treatments received by the various groups across studies. The resulting
evidence network is presented in Figure 3.2. An MTC analysis of this data, ignoring
the IPD, has been published elsewhere (Cooper, N. et al., 2012).
Notice that there are as many comparisons with (1) UC strategy as between non-UC
interventions. Out of the 10 direct comparisons expressed by the network, 6 are
informed by at least 1 study available in IPD format (continuous line). Figure 3.2 also
indicates (dashed line) the network structure of evidence with information on the
covariate of interest - household parent status (i.e. two or single parent household).
Due to missing data issues, a smaller network is obtained (i.e. only 6 interventions are
included in the comparison) when including studies which have information on this
covariate, as there is no covariate information available for studies assessing
intervention (7) E + FE + F + HI (i.e. the intervention of ‘highest intensity’). The
implications of these data restrictions/limitations are considered in section 3.5 and in
the discussion section.
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Figure 3.2 - Network diagram for the functioning smoke alarm outcome with information on the number and format of evidence available for each
treatment comparison (continuous line) and on the number and format of evidence available for single parent status (dashed line).
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As for the pair-wise models in section 3.3, the MTC models are fitted sequentially,
‘building up’ to the full complexity of model (3.9). Initially, the results of the MTC
models for IPD, with AD plus IPD, including the IPD where available, ignoring
covariates, are compared. The binary covariate ‘single parent status’ is then
considered again, as a potential effect modifier. Firstly, a model is specified with
exchangeable interaction coefficients separating the estimated treatment x covariate
interaction effects from the within- and between-study variation. This is followed by
a model with overall exchangeable interaction coefficients and comparisons between
(overall) exchangeable and independent interaction effects. These latter models are
slight modifications of model (3.9) in which within- and between-study associations
are merged into an overall parameter.
Once again, unless stated otherwise, for all models presented in this section, the same
model setting as before is used (i.e. 10,000 ‘burn-in’ iterations, followed by 5,000
iterations, on which inferences are based). The WinBUGS code used for model (3.9)
of the synthesis of AD plus IPD, including the binary covariate and separating
within- and between-study associations, is provided in Appendix 3, with specific
prior distributions used for this example.
3.4.5.1 Analysis of example without covariates
Table 3.7 shows parameter estimates obtained for the novel approaches, without
covariates. The first column of results relates to the analysis which combines the nine
IPD studies using model (3.7) – akin to doing an IPD synthesis excluding studies for
which IPD could not be obtained. In the second results column, and through the use
of model (3.8), all 20 studies are synthesised, using IPD where available (nine
studies) and AD where not (11 studies).
When only IPD is considered, a smaller evidence network (i.e. with six rather than
seven interventions) is evaluated with intervention E + HI being excluded as there
are no IPD studies including this treatment strategy.
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Table 3.7 - Parameter estimates from fitting different MTC synthesis models without
including covariates to the functioning smoke alarm outcome data
Carrying out the synthesis of only IPD through the use of model (3.7), results are
found to be similar to the synthesis of the same studies using model (3.6), when all
trial evidence is reduced to AD (results shown in Appendix 4 - Table A4). The same
Interpretation
Median of
MCMC
posterior sample
95 per cent
credible interval
Median of
MCMC
posterior sample
95 per cent
credible interval
Parameter
E -0.297 -2.045 to 1.425 -0.130 -1.116 to 0.82
E + FE 2.036 -1.074 to 5.338 1.125 -0.05 to 2.427
E + FE + HI 1.130 -0.86 to 3.391 0.956 0.033 to 2.177
E + FE + F 0.930 -0.843 to 2.651 0.962 -0.235 to 2.171
E + HI --- ii) --- ii) 1.169 -0.407 to 3.167
E + FE + F + HI 1.165 -1.732 to 3.886 1.938 0.827 to 3.158
Between-study
variance
  τ 2 1.677 0.347 to 3.812 0.651 0.151 to 2.362
E 0.743 0.129 to 4.158 0.878 0.328 to 2.271
E + FE 7.664 0.342 to 208.15 3.080 0.952 to 11.33
E + FE + HI 3.096 0.423 to 29.69 2.601 1.033 to 8.823
E + FE + F 2.534 0.431 to 14.17 2.618 0.791 to 8.768
E + HI --- ii) --- ii) 3.220 0.666 to 23.743
E + FE + F + HI 3.205 0.177 to 48.7 6.944 2.286 to 23.52
Deviance
Information
criteria iii)
DIC
Odds ratios for
intervention
effects (vs usual
care) - e d 's i)
Function of parameter
i) E - education; E + FE - education plus low cost / free equipment; E + FE + HI - education plus low cost / free equipment plus home
inspection; E + FE + F - education plus low cost / free equipment plus fitting; E + HI - education plus home inspection; E + FE + F + HI -
education plus low cost / free equipment plus fitting + home inspection.
Notes:
2937.67 3059.49
ii) IPD evidence not available for this treatment comparison.
iii) Although presented models are not comparable, the DIC statistic is shown for completeness.
Log odds ratios for
intervention
effects (vs usual
care) - d's i)
Random effects MTC of IPD
Random effects MTC of AD
and IPD
Model (3.7) - 9 studies included Model (3.8) - 20 studies included
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is true for the results of synthesising all 20 studies at AD when compared to results
when using synthesis model (3.8) (results not shown but published elsewhere
(Cooper, N. et al., 2012)). This is to be expected, as there is no extra information in
the IPD when overall mean effects are of interest (i.e. covariates are not considered).
The most likely reasons why these two pairs of results do not agree exactly relates to
how cluster adjustment is dealt with in the AD and IPD and potentially the slight
influence of the prior distributions.
Larger differences are apparent between the use of all 20 studies (i.e. IPD + AD) and
only the nine for which IPD is available. When synthesising the full set of evidence,
the most ‘intense’ intervention – E + FE + F + HI – stands out, with an OR of 6.9
(95% CrI 2.29 – 23.52). When considering only evidence from the 9 IPD studies, the
intervention E +FE is estimated as being the most effective compared to standard
care, although this carries high uncertainty (OR 7.7 (95% CrI 0.34 – 208.15)).
3.4.5.2 Analysis of models including a binary covariate
Unfortunately, only 2 of the 11 studies for which only AD was available provided an
estimate of the percentage of included subjects from 1Ps. Additionally, no parent
status information was available for two of the nine studies for which IPD was
available (see Table 3.1). The impact on the network diagram of the forced omission
of 11 of the studies is indicated by the dashed lines in Figure 3.2. Compared to the
network for all 20 studies (solid lines in Figure 3.2), this shows that even though six
out of the initial seven interventions are still included, they have ‘weaker links’ in
terms of the amount of evidence informing each of the comparisons.
The results of estimating treatment interactions terms separating the between- and the
within-study associations are shown in Table 3.8. These results refer to the direct
implementation of model (3.9) where IPD is included where possible (seven studies)
and AD where not (two studies) and interactions are assumed to be exchangeable.
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Table 3.8 - Parameter estimates from fitting a MTC model of AD and IPD with covariate
‘single parent status’ to the functioning smoke alarm outcome data, considering exchangeable
treatment interactions and modelling separately within and between associations.
Interpretation Parameter
Median of
MCMC
posterior sample
95 per cent credible
interval
E -0.018 -0.779 to 0.704
E + FE 0.363 -0.856 to 3.235
E + FE + HI 0.366 -0.663 to 2.48
E + FE + F -0.023 -0.664 to 0.604
E + HI 0.143 -1.855 to 2.934
E 2.667 -1.67 to 6.059
E + FE 2.603 -2.426 to 6.957
E + FE + HI 2.688 -2.374 to 7.114
E + FE + F 2.521 -2.387 to 6.97
E + HI 2.761 -2.146 to 7.167
E 2.671 -1.692 to 6.186
E + FE 1.997 -3.514 to 6.683
E + FE + HI 2.151 -3.093 to 6.83
E + FE + F 2.553 -2.423 to 7.002
E + HI 2.462 -2.954 to 7.268
Deviance Information
criteria
DIC 2452.65
* Model includes information on covariate related to household having one or two parents - treatment
interactions are assumed exchangeable and are split in within- and between-study associations.
Regression coefficients
for between study
association with single
parent status (vs two
parent families)i) - β B 's
Regression coefficients
for within study
association with single
parent (vs two parent
families)i) - β W's
i) E - education; E + FE - education plus low cost / free equipment; E + FE + HI - education plus low
cost / free equipment plus home inspection; E + FE + F - education plus low cost / free equipment plus
fitting; E + HI - education plus home inspection; E + FE + F + HI - education plus low cost / free
equipment plus fitting + home inspection.
Random effects MTC of AD and IPD with covariate *
Model (3.9) - 9 studies included
Difference between
regression coefficients for
within and between study
associations with single
parent (vs two parent
families)i) - β diff 's
Notes:
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To assess the existence of ecological bias, the difference between the association terms
is estimated, diff ’s. The CrIs of the difference between within- and between-study
association estimates for household parent status include 0. Therefore, there is little
evidence to suggest the presence of systematic differences between the covariate
treatment interactions estimated by the within-study and between-study variation. In
all subsequent analyses presented, these two sets of coefficients are replaced with a
single one, combining the between- and within-study information.
The results of four different RE approaches to the analysis of the available evidence
are presented in Figure 3.3. “MTC AD RE – exchangeable” refers to the analysis
where all nine studies are fitted using AD (and all covariates are study-level) and the
treatment x covariate interactions are assumed to be exchangeable; “MTC AD RE –
independent” refers to a similar analysis, but with each treatment x covariate
interaction assumed to be independent. “MTC AD + IPD RE – exchangeable”
considers seven IPD and two AD studies. Finally, “MTC AD+IPD RE – independent”
is similar to the previous one, only with independent interaction terms.
While the main treatment effects (the d’s) are reasonably consistent across all four
models, the point estimates and the uncertainty in the interaction terms (the β’s) are
considerably different. Uncertainty was much reduced when IPD information is
available and used as such. Where it is not, estimates are shrunk towards the estimates
where IPD is available in the model where interactions are assumed to be
exchangeable. Interestingly, this resulted in all interaction effects being close to 0 for
the exchangeable interactions model, including IPD where available. This contrasts
with parameter estimates from the independent interaction model, using all evidence in
the AD format, which are particularly large in magnitude and very uncertain.
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Figure 3.3 - Parameter estimates from fitting the MTC of AD and the MTC of AD plus IPD
models with information on covariate ‘single parent status’ to the functioning smoke alarm
outcome data, considering exchangeable and independent treatment interactions, not
separating between- and within-study interactions.
(Notes: * - comparable DIC statistics; ** - comparable DIC statistics)
On the basis of the DIC statistic (see Appendix 2 for details on this measure of model
goodness of fit), all models including the covariate provide a ‘better’ fit to the data
than the models where it is not included (e.g. “MTC AD+IPD RE – exchangeable”:
Log scale (relative to UC)
-8 -6 -4 -2 0 2 4 6 8 10
E+HI, 
E+FE+F, 
E+FE+HI, 
E+FE, 
E, 
E+HI, d
E+FE+F, d
E+FE+HI, d
E+FE, d
E, d
MTC AD RE - exchangeable (DIC = 105.24*)
MTC AD RE - independent (DIC = 105.28*)
MTC AD+IPD RE - exchangeable (DIC = 2451.77**)
MTC AD+IPD RE - independent (DIC = 2451.99**)
Posterior median, 95% CrI
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DIC = 2451.77; “MTC AD+IPD RE – no covariate”: DIC = 2468.53). This indicates
that a proportion of the existent heterogeneity/inconsistency in the synthesis is being
explained when incorporating a relevant covariate (Cooper, Nicola J. et al., 2009).
From all models considered in Figure 3.3, the ones with lowest DIC statistics are the
ones which consider exchangeable treatment x covariate associations (i.e. “MTC AD
RE – exchangeable” and “MTC AD+IPD RE – exchangeable” with DIC = 105.6 and
DIC = 2451.9, respectively).
3.5 Challenges for the synthesis of (little) evidence of different
formats: extending developed synthesis models
The novel methods described in section 3.4 extend the standard (pair-wise) meta-
analysis by providing important information to decision makers on the optimal
intervention strategy for a given purpose. The inclusion of covariates in the
synthesis modelling provides a way of allowing for systematic variability between
trials within pair-wise contrasts to be explained. This way, different participant
subgroups may attain different intervention effects than would have been indicated
by overall comparison with trials as a whole. To further evaluate the role of subgroup
differences on the treatment effect, a baseline covariate effect assessment (i.e. the
effect for a participant belonging to a particular subgroup – single or two parent
families – under no intervention conditions) would facilitate a better understanding
of how intervention relative benefits varied according to certain characteristics of
participants. Policy decision makers could then consider the absolute magnitude of
benefits while taking into account possible heterogeneity within the population of
interest.
One additional complication is that information on the covariate(s) of interest can
often be missing or incomplete in the dataset. In the case study there is missing
covariate information at three levels, that is: (i) in the IPD where covariate
information is available only for a percentage of subjects (i.e. not collected or
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presented for some individuals in the dataset); and/or (ii) in the IPD where complete
absence of information on the covariate is observed (i.e. not collected or presented
for all individuals in the dataset) ; and/or (iii) in the AD where for some studies the
mean (percentage) of individuals with the characteristic(s) of interest is missing.
The following section will present an extension of the MTC synthesis model (3.9),
which takes into consideration both the incorporation of the baseline covariate effect
and a multiple imputation procedure of the missing covariate values at AD and IPD
through MCMC, and assuming these are ‘missing at random’21 – see further detail in
Appendix 2.
3.5.1 Extensions to mixed treatment comparisons models including
covariate(s): the synthesis of aggregate and individual level data
The following MTC model differs from model (3.9) in that: (i) it does not partition
variability regarding interactions; (ii) it considers the issue of covariate missing
values by imputing them using the posterior predictive distribution of the parameter
to which it refers; and (iii) it estimates and incorporates the covariate baseline effect.
Shorter versions of this model for AD and for IPD only can be easily derived and
will not be described. A full specification of the synthesis model for AD and IPD
used is:
(3.10) Part I - Model for individually allocated IPD studies including covariates
 ijkijk pBernoulliY ~
(3.10.1)
21 The missing-at-random assumption (sometimes called the ignorability assumption) considers that
the probability that an observation is missing may depend on the observed values but not the missing
values, as sufficient data has already been collected.
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For i =1, 2, ... , number of participants in the individually allocated jth IPD study; and j =1, 2, . . . ,
number of individually allocated IPD studies
Part II - Model for cluster allocated IPD studies including covariates
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 2. .,~ jjIPDcmjb cN   xpBernoulliximj .~
(3.10.2)
For i =1, 2, ... , number of participants in the mth cluster of the jth cluster allocated IPD study; m = 1,
2, . . . , number of clusters in the jth study; and j = (number of individually allocated IPD studies +
1),…,(number of individually allocated IPD studies + number of cluster allocated IPD studies).
Compared to equations (3.9.1) and (3.9.2), the changes applied to (3.10.1) and
(3.10.2) are the following: (i) the individual level covariate regression term,
ijx0
(or
imjx0 for cluster-allocated studies), becomes non-study specific and represents
the baseline effect of the subgroups of interest, xij (ximj); (ii) the split in within- and
between-study variability is not considered, that is, these are merged into a single
parameter,
bk ; and (iii) a distributional assumption is imposed on the covariate
values, indicating that xij (ximj) are Bernoulli distributed with event probability p.x,
common across all IPD studies. By imposing this (prior) distributional assumption
over the covariate values, these model sections consider existing covariate evidence
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and uses this information to multiple impute the missing covariate information
through the MCMC procedure.
Part III - Model for both cluster and individually allocated AD studies including
covariates
 jkjkjk npBinr ,~
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(3.10.3)
j = (number of individually allocated IPD studies + number of cluster allocated IPD studies + 1), . . .
, (total number of studies)
Part IV - Combination of estimates of intervention effect including covariates
 2,~  jbkAbAkjbk XddN 
 2,~ BAbAkbk N  
 1,0~. Unifxpa  1,0~. Unifxpb  xpbxpaBetaxp .,.~.
(3.10.4)
k = 1 . . . , total number of treatments
As for model (3.9), the likelihood of the contribution of both cluster- and
individually-allocated AD studies, rjk, is described in the usual way in part three of
the model. Subgroup baseline effect, represented by the
0 term, is considered
common to both IPD and AD and it requires a (vague) prior distribution to be
specified   610,0~ N . The study-level covariate information, Xj, follows a Beta
distribution with parameters pa.x and pb.x, both Uniformly distributed   1,0~ Unif .
The same distributional assumption is imposed on p.x so that parameter sharing
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exists throughout the different model parts, linking IPD and AD information and
enabling the estimation of common predicted covariate distribution. Extension to
multiple regression coefficients is straightforward. Note: 0, AAAAd  .
3.5.2 Application
In the findings from the analysis reported in section 3.4.5.2, missing data are dealt
with in a simple and straightforward way, that is, by discarding studies (with
evidence at summary- and individual level) with the totality of the covariate
information absent. Also, for the IPD for which covariate information is missing for
some of the trial participants, these individuals are discarded, that is, a complete case
analysis is performed. The impact on the evidence network of the ‘forced’ omissions
of these studies is large, as not only did certain comparisons become “weaker” in
terms of the amount of evidence informing them, but also the network included only
6 out of the 7 initial interventions. Many disadvantages are expected from using this
type of approach to missing data, from which the one mainly highlighted here is the
introduction of an element of ambiguity into the statistical analysis undertaken22.
As reported in Table 3.1, information on the covariate relating to single parent status
is absent in 55% of the trials23. This represents a significantly high proportion of
missing information; nonetheless, 7 trials had information on this covariate at the
individual level which means an imputation procedure over this covariate is expected
to be robust.
22 A complete case analysis is considered unbiased provided that the missingness mechanism is
independent of the outcome. In particular, complete case analysis is still unbiased if missingness in
baseline covariates is dependent on the baseline covariates themselves (i.e. missing not at random).
The problem with complete case analysis here is therefore more that it is inefficient, rather than being
biased (Rubin, Donald B., 2004, Rubin, D. B., 1976).
23 That is from the 20 available studies, 2 out of the 11 AD and 7 out of the 9 available IPD trials have
information on the households’ single parent status.
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Table 3.9 shows the results from fitting the 3 different synthesis models (i.e. of all
evidence at summary level, of IPD alone and of both AD and IPD) including the
covariate on single parent status. These results include the imputation of covariate
values, increasing the available evidence base to a new level. Log-ORs (the sd 'ˆ ) and
ORs (the sed 'ˆ ) for each intervention (relative to the ‘baseline’ intervention) are
provided for each model. This is complemented by the results of the single parent
subgroup baseline effect, 0ˆ , and the treatment x covariate interaction terms, s'ˆ .
Between-study heterogeneity is also illustrated through 2 .
The imputation analysis performed over the covariate ‘missings’ allowed for each
model evidence base to be comparable. This implies that the full set of “relevant”
studies (i.e. 20) is now used for the AD and for the AD + IPD models (Table 3.9 –
first and third column of results, respectively) and 9 IPD studies for the synthesis of
IPD only analysis (Table 3.9 – second column of results).
With information on nine IPD studies, the synthesis model of the mixture of AD and
IPD estimates a treatment effect on the log scale of 1.7 (95% CrI 0.33 – 3.13) for the
most “intense” intervention (i.e. (7) E + FE + F HI). Similar conclusions in terms of
the most effective intervention can be drawn from synthesizing all evidence at
summary level, although in this case, CrIs include zero (log-OR 1.6, 95% CrI -0.19
– 3.19). The inclusion of IPD studies impacts upon the main treatment effect
estimates compared to the AD model, upwardly inflating the between-study variance
estimate and its uncertainty. Estimated baseline subgroup effect is shown to be very
different and with opposite signs across models, once more flagging up the
‘weaknesses’ of the AD model estimates compared to the ones obtained by using the
AD + IPD model.
With respect to interaction estimates, uncertainty is much reduced when IPD is
available, resulting in some associations effects to be close to 0 (i.e. for (2) E and for
(5) E + FE + F). Again, this shows that potential ecological bias is being accounted
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for when IPD is included in the synthesis as it facilitates an appropriate estimation of
treatment x covariate interactions.
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Table 3.9 - Parameter estimates from fitting the MTC model of AD, IPD only and AD and
IPD with covariate ‘single parent status’ to the functioning smoke alarm outcome data;
considering exchangeable treatment interactions, estimating subgroup baseline effects and
imputing missing covariate values.
Median of
MCMC
posterior
sample
95 per cent
credible
interval
Median of
MCMC
posterior
sample
95 per cent
credible
interval
Median of
MCMC
posterior
sample
95 per cent
credible
interval
E -1.082 -3.004 to 0.884 -0.334 -2.141 to 1.41 -0.188 -1.218 to 0.819
E + FE 0.875 -0.521 to 2.413 1.988 -1.155 to 5.349 1.028 -0.261 to 2.412
E + FE + HI 0.515 -0.617 to 1.993 0.971 -1.044 to 3.277 0.681 -0.344 to 1.87
E + FE + F 0.504 -0.981 to 2.169 0.932 -0.826 to 2.771 0.935 -0.263 to 2.13
E + HI 0.835 -0.995 to 2.989 --- iii) --- iii) 1.149 -0.649 to 3.298
E + FE + F + HI 1.561 -0.189 to 3.188 1.019 -1.877 to 4.161 1.732 0.326 to 3.13
Regression
coefficient ii)
  β 0 single parent 1.063 -1.159 to 3.445 -0.346 -0.664 to -0.029 -0.313 -0.63 to 0.002
E 1.597 -1.449 to 4.43 0.080 -0.534 to 0.659 0.089 -0.504 to 0.652
E + FE 1.079 -2.46 to 4.546 0.509 -1.3 to 3.579 0.310 -1.223 to 2.332
E + FE + HI 1.481 -2.065 to 5.039 1.121 -0.072 to 3.126 0.881 -0.159 to 2.592
E + FE + F 1.071 -2.844 to 4.677 0.102 -0.519 to 0.716 0.071 -0.537 to 0.666
E + HI 1.375 -2.22 to 5.116 --- iii) --- iii) 0.401 -1.265 to 2.859
E + FE + F + HI 1.231 -2.398 to 4.993 0.404 -1.993 to 3.429 0.394 -1.548 to 3.048
Between-study
variance τ
2 0.474 0.017 to 2.041 1.663 0.316 to 3.817 0.654 0.14 to 2.333
Function of parameter
E 0.339 0.05 to 2.421 0.716 0.118 to 4.094 0.828 0.296 to 2.268
E + FE 2.399 0.594 to 11.171 7.298 0.315 to 210.4 2.797 0.77 to 11.156
E + FE + HI 1.673 0.54 to 7.335 2.642 0.352 to 26.49 1.975 0.709 to 6.491
E + FE + F 1.656 0.375 to 8.749 2.539 0.438 to 15.97 2.547 0.768 to 8.417
E + HI 2.305 0.37 to 19.863 --- iii) --- iii) 3.155 0.523 to 27.064
E + FE + F + HI 4.765 0.828 to 24.246 2.772 0.153 to 64.11 5.651 1.385 to 22.869
i) E - education; E + FE - education plus low cost / free equipment; E + FE + HI - education plus low cost / free equipment plus home inspection; E + FE + F -
education plus low cost / free equipment plus fitting; E + HI - education plus home inspection; E + FE + F + HI - education plus low cost / free equipment
plus fitting + home inspection.
20 studies included 9 studies included Model (3.10) - 20 studies
included
Random effects MTC of
AD with imputation
Random effects MTC of
IPD with imputation
Random effects MTC of
AD and IPD with
imputation
iii) IPD evidence not available for this treatment comparison.
ii) Covariate term for single parent status (baseline subgroup effect)
Interpretation
Parameter
Log odds ratios
for intervention
effects (vs usual
care) - d's i)
(Overall)
Regression
coefficients for
intervention
interactions (vs
usual care) - β's i)
Odds ratios for
intervention
effects (vs usual
care) - e d 's i)
Notes:
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3.6 Discussion
Findings summary
This chapter contributes to the synthesis of evidence methods literature by describing
and applying a series of meta-analytic models, including novel MTC models that
allow IPD and both AD and IPD to be included while considering a participant level
covariate and making different assumptions about the covariate effects (Cooper,
Nicola J. et al., 2009). Modelling of cluster allocation effects (Sutton, A. J. et al.,
2008), distinct covariate effects based on between- and within-study variability
(since the former is susceptible to ecological biases (Riley, Richard D. & Steyerberg,
2010)), and the multiple imputation of missing covariate information were also
considered.
The motivating example showed that the use of evidence at the individual level,
whether or not in the combination with summary evidence, provided more precise
estimates and estimates of greater accuracy of the treatment x covariate interaction
effects, when compared to those estimated through AD only. Additionally, different
assumptions about the covariate interactions were tested. In this example, assuming
interaction ‘exchangeability’ provided the ‘best’ fit to the data compared to assuming
common or independent regression slopes.
The motivating example – assessing the effectiveness of interventions to increase the
uptake of functioning smoke alarms in households – showed that more ‘intense’
interventions are more effective than those which are less so, with the one providing
education plus low cost/free equipment plus fitting plus home inspection having the
highest level of effectiveness from the set.
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Evidence synthesis in Health Technology and Public Health programmes
appraisal
Estimating the effectiveness of alternative health care interventions is at the heart of
not only clinical but also economic evaluations. The NICE for England and Wales
uses economic analyses to recommend health care technologies for use in the NHS.
As stated in Chapter 2, the guide to methods for HTA published by the NICE (2008)
acknowledges that the construction of ‘…an analytical framework to synthesise the
available evidence in order to estimate clinical and cost effectiveness…’ should be
performed and recommends that ‘… all relevant evidence must be identified, quality
assessed and pooled using explicit criteria and justifiable and reproducible methods’
(page 27). Meta-analyses techniques are often used to summarize evidence on
clinical effectiveness in the NICE technology appraisals, and to subsequently inform
related economic analyses. The use of indirect and MTC methodologies in informing
decision-making is also becoming more common.
The notion of what should be considered to be relevant evidence in HTA and PH is
yet to be unequivocally determined. Consequently, issues surrounding the use of IPD
compared to AD also remain unclear. Resistance from authors/researchers to release
IPD data, the costs related to time and computational burdens compared to analysis
of AD only, and the delay in producing the evidence for decision making all work
against the routine collection and use of IPD. The benefits of obtaining IPD over and
above the existing AD should be taken into account, since clear benefits, such as
more accurate estimation of subgroup effects, as demonstrated here, make a strong
case for using IPD in synthesis models whenever possible. However, IPD may not
always be available for all studies; hence the methods developed here. It is believed
that these are an improvement on existing alternatives identified by a recent review
of the literature (Riley, R. D. et al., 2007).
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Strengths and limitations
This chapter did not explore issues related to sub-optimum data quality, such as the
use of non-randomised studies in the synthesis (although bias adjustment proposals
have been published (Turner, R. M. et al., 2009, Welton et al., 2009, Spiegelhalter,
David J. & Best, 2003)) or adjusting for arm imbalances in the covariate of interest
(although approaches recently developed for pair-wise meta-analysis could be
applied to the MTC models developed here (Turner, R. M. et al., 2009)).
The evidence base with respect to the covariate of interest on single parent status was
enhanced through an imputation procedure. Using all the available evidence enabled
establishing comparisons between results from models with and without covariate
information. The multiple imputation procedure assumed a ‘missingness’ mechanism
of ‘missing at random’. Nonetheless, no sensitivity analysis was performed to verify
the validity of obtained estimates, despite the advice in some of the literature
(Carpenter et al., 2007).
For heterogeneity to be realistic, restrictions were imposed in the main analysis
through the use of ‘not so vague’ priors, which may constrain the interpretation of
results. Nonetheless, sensitivity analyses have been conducted over these prior
distributions for between-study variances, which showed that results were not
sensitive to the choice of distribution parameterization.
The MTC synthesis modelling could have explored other potential extensions. These
could come from examining other differential effects by child and family factors (i.e.
more subgroup analysis), from including and exploring the effect of study quality in
the analysis, and from the assessment of possible network inconsistencies between
direct and indirect evidence. A further worthwhile extension would be to develop a
generalized linear modelling framework to extend the proposed approach to other
types of outcome measures (e.g. categorical, continuous) building on recent work
(Dias et al., 2011b).
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Conclusions
Using IPD from all studies is desirable. Nonetheless, this will not be possible in the
majority of instances and thus it is believed that the models presented have a
valuable role in the evaluation of interventions, particularly where there is
inconsistency in the network and/or the treatment subgroup effects are of interest.
This chapter brings into question the often publicised view that IPD syntheses are the
‘gold standard’ if only a fraction of the available studies can be included; i.e. it is
argued that it is better not to exclude any studies from the analysis, irrespective of the
format in which they are available.
Models herein described were applied to a particular PH example. Nevertheless,
they are potentially of use in other health care contexts, including HTA assessments
of drugs and devices where IPD may be available for a particular product, but not for
competitor products. In the following chapter, the cost effectiveness of the PH
programmes evaluated is assessed. This is performed by using the outputs of the
synthesis models described in this chapter as decision model inputs, with further
discussion of the impact of using evidence at the individual level in comparison with
using only AD.
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CHAPTER 4
4. ECONOMIC EVALUATION OF SMOKE ALARM PROGRAMS
FOR PREVENTING FIRE-RELATED INJURIES OF PRE-SCHOOL
CHILDREN IN THE HOME
4.1 Defining the context: Economic Evaluation of Public Health
interventions
Chapter 3 developed a series of novel evidence synthesis methods based on the
format of evidence available (AD and IPD). The estimates derived from these new
methods can be used to simultaneously evaluate the effectiveness of several
interventions. The aim of the current chapter is to use derived synthesis estimates
based on AD in order to explore the cost effectiveness of PH programmes
(encompassing seven competing strategies) to increase the uptake of functioning fire
alarm equipment and to reduce fire related injuries in children younger than five
years of age. The next chapter (Chapter 5) will consider the use of IPD for cost
effectiveness modelling. The current and following chapters are, therefore, inter-
related in the sense that, in turn, they explore the impact on model based cost
effectiveness estimates of two alternative methods to estimate the effectiveness
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parameters in a decision model; either through the synthesis of AD or by combining
AD and IPD. In doing so, both chapters build on synthesis of the evidence of
effectiveness presented and discussed in Chapter 3.
As highlighted in Chapter 1, economic evaluation compares the costs and
consequences of alternative courses of action. Resource allocation decisions based on
this tool aim to maximise health gains from the available resources – resources which
are finite within the public sector. While this instrument has been widely used in the
past two decades to support decision making in the health care setting, it has only
been in recent years that an increase has occurred in the awareness of its advantages,
and, consequently, an increase in its use, for PH. Reasons for this relate to the fact
that issues affecting the evaluation of the effectiveness of PH interventions also
affect their economic evaluation. These issues include, for example, the general lack
of data on the interventions and general poor quality where it does exist, lack of
randomised data on interventions (or data from which the effect of interventions may
be appropriately isolated), and issues of bias and confounding.
Given that the use of cost effectiveness in the assessment of PH policies is still in its
infancy, many still consider effectiveness to be the only (or the principal) relevant
factor in the implementation of a policy. To inform effectiveness, a review of the
literature is commonly undertaken, the results of which may require aggregation (i.e.
combination of quantitative evidence from multiple sources) in order to attain a
legitimate understanding of the effects of these multifaceted programmes. To
undertake this aggregation, the data (usually from RCTs) needs to be sufficiently
homogenous, or heterogeneity needs explicit consideration. When data carries some
degree of heterogeneity (for example, due to differences in population
characteristics, settings, or differences in the design and conduct of trials), it is of
interest to explore how the treatment effect changes across patient subgroups.
However, it is not sufficient to examine the effectiveness of a PH programme (and
the impact of heterogeneity) – the analysis of the effectiveness of public policies
should also be cross-referenced with data on their costs (Drummond et al., 2005).
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The Canadian National Centre for Healthy Public Policy has laid out the principles
for assessing PH policies (Morestin et al., 2010) and recognises the need for
evaluating costs alongside effects. It highlights many methodological challenges
specific to PH, some of which are: (i) the attribution of effects (both intended and
unintended) of the policy on the targeted population and problem; (ii) the costs and
consequences which should be analysed, considering the feasibility of the
programme; and (iii) the acceptability of the policy by the relevant stakeholders,
which often involves subjective judgements, beliefs, values and interests of the actors
concerned. In addition, a recent study by Weatherly et al. (2009) identifies further
challenges regarding outcomes valuation and in considering equity (i.e. of obtaining
an equilibrium between an efficient and an equitable allocation of resources). The
authors recognise that empirical literature offers very limited insight on how to
appropriately respond to all these factors.
In the UK, there has been increasing awareness on the need to assess PH
programmes, and on the need to develop methods specific to this area. As an
example, guidance on the methods for conducting systematic reviews in PH has
recently been released from the Centre for Reviews and Dissemination (CRD, 2009)
and from the Cochrane Collaboration (Armstrong et al., 2007)) . Also, the NHS
Health Development Agency (Kelly et al., 2005) and the NICE (NICE, 2009) has
released guidance for the economic appraisal of PH interventions. In these, a general
framework is presented highlighting the mechanisms that should be applied in the
economic evaluation of PH interventions. These include, for instance, guidance on
identifying, reviewing, extracting, synthesising and presenting evidence, as well as
guidance on possible modelling approaches, perspectives and the identification and
selection of model inputs.
This chapter develops a cost effectiveness model of the PH strategies described and
evaluated in Chapter 3. Section 4.2 briefly summarises existing economic literature
on the prevention of fire related accidents in the home. Section 4.3 presents the
methodology used to perform the proposed economic evaluation and includes, for
example, the decision model structure and a description of the evidence used to
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populate it. This is followed by a discussion of the cost effectiveness results at
population and subgroup levels in section 4.4. Finally, section 4.5 discusses the
findings, highlights possible policy implications and flags up scope for further work.
4.2 Review of the existing economic evidence in accident prevention
This section focuses on the economics of injury prevention programmes. In particular,
it highlights relevant economic literature concerning interventions aimed at reducing
fire-related injuries.
The purpose of this review is to illustrate: (i) the types of accident prevention
programmes that have been economically assessed previously; (ii) how these
programmes were evaluated; (iii) the economic model framework used; (iii) the data
inputs informing them; (iv) the main modelling assumptions implemented; (v) the
viewpoint of the analysis; (vi) and the sensitivity analysis put into practice. Studies
were identified through searches on the Medline, Embase, Cinahl, Assia, Psychinfo
and Web of Science databases, from the inception of the database until December
2009. The inclusion criteria included full economic evaluation (cost effectiveness)
studies, examining interventions that could be included in injury prevention briefings
or implemented by centres for the primary and secondary prevention of thermal
injuries in children aged 0-19 years and their families – the participants of interest. The
outcome measure assessed was the possession and use of home fire alarm safety
equipment. From the more than 400 studies and/or abstracts identified, three were
found to be relevant (Pitt et al., 2009, Ginnelly et al., 2005b, Haddix et al., 2001),
revealing that little economic evidence is available in the literature on this subject. A
discussion of these three studies follows.
Both Haddix et al. (2001) and Ginnelly et al. (2005b) carried out economic
evaluations of smoke alarm give-away schemes using decision modelling. The first
study evaluated a give-away scheme implemented in the USA, while the latter was a
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UK scheme. These were not aimed specifically at children. Using a societal and/or
health care system perspective, these studies gave some insights into the key trade-offs
between resources and outcomes within such programmes. In the study by Ginnelly et
al. (2005b) the scheme was not found to be cost effective, while in the Haddix et al.
(2001) evaluation it was considered an ‘…economically beneficial program for
preventing fatal and non-fatal residential fire related injuries…’. Probabilistic
sensitivity analysis was implemented in the former, whereas in the latter univariate
and multivariate deterministic analyses were performed.
Pitt et al. (2009) used the Ginnelly et al. (2005b) study as a starting point and
implemented a cost utility analysis of the lifetime costs and effectiveness of relevant
home safety interventions with particular emphasis on programmes that provided
smoke alarms. The aim of this study was to evaluate interventions that reduced
unintentional injuries in children under 15 years of age. Using a public sector
perspective and a Markov-state transition model, the authors evaluated the provision
and installation of free smoke alarms vs. ‘no intervention’. The intervention was found
to be cost effective and three model parameters were highlighted as result drivers: the
intervention uptake level (i.e. intervention effectiveness); the prevalence of smoke
alarms in households of the targeted population; and the functional decay rate of the
equipment. This study failed to compare all relevant options by not exploring, for
instance, alternative programmes such as: free supply of the home safety device vs.
free supply and installation; free device supply vs. tailored device supply and advice;
or different amounts of safety education and information alongside the safety device-
based programme components. Pitt et al. (2009) was used as basis for the NICE PH
guidance on the prevention of unintentional injuries among under-15s in the home
(NICE, 2010).
The small number of existing studies, together with the issues highlighted above (e.g.
interventions evaluated and target population), justifies the development of a new
economic evaluation in this chapter.
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4.3 Methods
The decision problem and the structure of the decision models used to evaluate the
cost effectiveness of smoke alarm programmes aimed at reducing household fires
involving children up to the age of five are presented next. The principles for model
design set out by Philips et al. (2006) were used.
4.3.1 The decision problem
The study population includes UK households with pre-school children (unit of
analysis). The aim of the interventions assessed here is to reduce injuries, whether
minor, moderate or disabling, and deaths in children, as a consequence of a fire
accident in the home. The strategies evaluated are those described in Chapter 3. Only
households with a single child are considered, and it is assumed that the intervention is
offered when they are born.
4.3.2 Decision model structure
In modelling the decision problem described above there was a general awareness that,
in many aspects of the evaluation, data was going to be sparse or inexistent. As stated
by Weatherly and colleagues (2009), this is usually the case when modelling PH type
interventions compared to health technologies, like pharmaceuticals, for which greater
and higher quality evidence may be available.
While the developed model is mainly focused on possible reductions of household
fires and fire-related injuries in children under five, the lifetime costs and benefits of
each of the strategies are considered. The model’s time horizon was set to one hundred
years, by which time the majority of individuals will have died. The model used a
cycle length of one year, which was considered an appropriate reflection of potential
transitions between model states.
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The model structure is depicted in Figure 4.1. The model is split into three parts. Parts
one and two model the process up to 5 years, while part three focuses on the
evaluation of long term consequences and costs. Each part is described in turn in the
next subsections.
Part 1 – Intervention model
Part one is labelled as the intervention model (Figure 4.1 - part 1) and it models the
number of households accepting the intervention or not, the uptake of smoke alarms in
a family that has accepted the intervention and the likelihood of having functioning
equipment. The interventions modelled are expected to act on the rate of uptake of the
safety equipment.
Part 2 – Five year Markov structure
Part two of the model uses a Markov structure to evaluate the occurrence of events
until children are aged five, in households with and without functioning smoke alarm
equipment (labelled as a 5 year Markov structure). Households with functioning
equipment can then see reduction in the risk of a household fire. The state transition
diagram for part 2 is shown in Figure 4.1 - part 2. This part considers conditions
labelled ‘well’, ‘disabled’ and ‘death’, entailing six model states, namely:
(S1) (Household with) functioning smoke alarm (and child ‘well’);
(S2) (Household with) no functioning smoke alarm (and child ‘well’);
(S3) (Household with) functioning smoke alarm and (child) disability;
(S4) (Household with) no functioning smoke alarm and (child) disability;
(S5) (Child) death due to fatal fire injury; and
(S6) (Child) death due to other causes.
The progress between model states is conditional on the occurrence of fires in the
household, and on the consequences for the child (fire-related injuries). The health
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consequences include six event types: (a) no injury; (b) minor injury; (c) moderate
injury; (d) severe injury; as well as fatal injuries and probability for all cause
mortality, namely (e) fatal fire injury; and (f) all cause mortality.
From states S1 and S2 the child can move to any of the other model states. Once in
the ‘disabled’ condition (S3 and S4), the child can either transit to one of the absorbing
states or stay in one of the ‘disabled’ states, without the possibility of transiting to S1
or S2. The model also considers the possibility of the safety equipment ceasing to
function and, in the case of it failing to function, that it is repaired. This is achieved
with the introduction of a decay/repair factor, which establishes the transition rates,
from ‘functioning’ to ‘non-functioning’ equipment and vice-versa (e.g. S1 to S2).
A severe fire-related injury was defined as one requiring an inpatient stay greater than
five days of treatment in an intensive care unit. It was assumed that any child suffering
a severe injury (particularly burns) would suffer some form of disability and would
carry that impairment for the rest of its life. A child experiencing these events would
therefore suffer a decrement in (health related) quality of life and would be subject to
additional health costs for the rest of its lifetime. In the event of a minor fire-related
injury, a child is assumed not to have any significant decrease in their quality of life or
any additional ongoing health costs and in theory this type of injury might occur more
than once. Like for minor injuries, moderate injuries also involve a utility decrement
(higher than for a minor injury), however this is restricted to that event/cycle and does
not imply a lifetime disability.
Figure 4.1 - Decision analytical model structure, part 1: model for households receiving interventions; part 2: Markov state transition model for
pre-school children aged 1 to 5; and part 3: Markov state transition model for rest of life (5 years onwards).
Part 1 - Decision tree (Intervention allocation) Part 2 - 5 year Markov structure Part 3 - 95 years→ lifetime Markov structure
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Part 3 – Lifetime Markov structure
The final part of the decision model, that is, model part three, labelled as lifetime
Markov structure, is a simple Markov process which is used to model the
progression of the child for the next 95 years (i.e. the remainder of their lives) – Figure
4.1 - part 3. An individual who is ‘well’ or ‘disabled’ at the age of five stays in this
state until death – enabling the incorporation of the lifetime impact of a disabling fire-
related injury in the evaluation.
Explicit assumptions imposed by using this model structure are highlighted in the next
section and discussed in section 4.5.
4.3.3 Decision analytic model assumptions/simplifications
As with any model, simplifications and assumptions are required. In this work it was
assumed:
i) The probability of a household accepting an intervention was the same across
interventions, owing to a lack of information on the uptake of the different
programmes;
ii) Lack of evidence on the benefits and detriments of interventions where multiple
children are involved, the decision model only considers households with a single
child. This may be a conservative assumption, as on one hand multiple children
could benefit from the same equipment, on the other it would increase the probability
of at least one of them being injured in a home fire;
iii) The model ignores potential (positive or negative) spill over effects on sibling(s)
and/or parent(s). For instance, parents could benefit from their own actions in
installing and maintaining the safety equipment in the home;
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iv) The probability of a future fire-related injury is assumed not to be dependent on
past accidents, and remains constant throughout the relevant model time frame (i.e. 5
years for part 2 of the model). This assumption is common to most Markov models
and implies that a household’s awareness of the risk of accident remains the same,
irrespective of whether a previous event occurred;
v) The model only allows for one fire-related accident and injury in any one year.
4.3.4 Model implementation
As described in Chapter 3, effectiveness evidence was synthesised within a Bayesian
framework. The synthesis results were used in the decision model using 5,000
posterior samples (extracted from the Convergence Diagnostic and Output Analysis
WinBUGS output (CODA)). Evidence to inform other model parameters was
identified from the literature and is described in the next section. Measures of
uncertainty related to each of the model input parameters were sought in the literature
and used to define probability distributions to represent parameter related uncertainty
in the decision model. The model is probabilistic and 5,000 samples were run in the
probabilistic sensitivity analysis – the number of simulations performed in the decision
model was conditional to the amount of MCMC simulations in the synthesis analysis.
The decision model was implemented in software package R version 2.11.0
(Copyright © 2010 The R Foundation for Statistical Computing) and decision model R
code is supplied in Appendix 5.
4.3.5 Identifying, combining and analysing existing relevant evidence
Public health methods guidance states that all ‘relevant’ evidence should be
considered. Ideally, systematic reviews of the literature should be conducted, but this
is not necessary for all types of information in economic modelling (NICE, 2009).
Non-exhaustive reviews are commonly put into practice for model parameters other
than relative effectiveness (Anderson, 2010).
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A non-exhaustive literature search was performed in order to identify evidence to
populate model parameters other than effectiveness. Although a variety of sources of
evidence were identified and used, for a large number of parameters evidence was
scarce. In the following subsections, a summary of the key literature sources are
described, starting with the effectiveness evidence and followed by evidence to
populate parameters for each model part.
When a measure of uncertainty was available, a distribution was defined and used
probabilistically in the model. For a significant proportion of the parameters, however,
no data existed and an informed estimate was made after consultation with the
collaborating team (Denise Kendrick, Alex J. Sutton and Nicola J. Cooper).
Table A6 (in Appendix 6) presents a complete list of model parameters and data
sources. This table also shows the parameter estimates and distributional assumptions
used in the model.
4.3.5.1 Relative effectiveness
A description of how effectiveness evidence was identified and used to populate the
cost effectiveness model follows.
Methods of synthesis with and without covariates
Evidence at aggregate level and methods of synthesis have been described in Chapter
3 (sections 3.3 and 3.4). This chapter uses evidence at the summary level (20 studies)
to inform the effectiveness model parameter – a common approach in many analyses.
It is important to appropriately provide the link between what is provided by the
clinical effectiveness synthesis modelling and how the output of that synthesis is used
to inform cost effectiveness model input parameters. This work considered: (i) the use
of predictive treatment effect distributions; and (ii) the importance of modelling
baseline effects and how these are incorporated in the synthesis outcome.
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With respect to i), when (a) treatment effect heterogeneity results from unavoidable
variation in implementation; or when (b) the intervention is aimed at individuals in
groups of potentially heterogeneous effect sizes – as is often the case with PH
interventions, estimated treatment effects will not reflect the efficacy of
implementing the programmes in the future. In order to overcome this issue, Ades
and colleagues (2005) recommend that modellers consider using the predictive
distribution of a future treatment effect, or assume that the future implementation
will result in a distribution of treatment effects. The posterior predictive distributions
are used to model our knowledge of possible values the probability of the outcome of
interest could take in the control group and in each of the treatment groups.
With respect to ii), in order to obtain an unbiased and statistically efficient treatment
comparison, it is optimal to account for baseline factors that influence the outcome.
There is, in fact, some credibility attached to demonstrating that effects adjusted for
baseline do not alter the conclusion derived from the unadjusted analysis (Pocock et
al., 2002). In using the output of the synthesis to inform the cost effectiveness model,
it is beneficial to consider these baseline effects. Such effect adjustment may be
estimated by adding the (log scale) treatment effects to the baseline to obtain the
absolute efficacy of each of the treatments, on the assumption of a certain probability
of ‘success’ (i.e. the uptake of safety equipment) of the common comparator (say,
treatment A). To estimate the baseline for this common comparator, the usual
approach is to conduct a separate synthesis of the evidence on this treatment alone.
To consider these components in the models developed in Chapter 3, it is necessary
to extend them. Algebraic descriptions of the modelling extensions which consider
these two issues are given below. For synthesis models which do not consider
covariate effects (models 3.6, 3.7 and 3.8 described in Chapter 3):
  mAAp.treatlogit
  Akfor.p.treatlogit k  kpreddmA
(4.1)
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 2,~ AANmA   2,~. Akk dNpredd
k = 1 . . . , total number of interventions
The absolute log odds of ‘success’ (i.e. uptake of ‘functioning’ smoke alarm
equipment in the household) of intervention A, mA, is based on a separate model.
This parameter is assumed to be Normally distributed, with mean A and variance
2
A . The probability of ‘success’ for intervention k (where k ≠ A) was calculated by
adding the predictive distribution of each relative treatment effect, d.predk, to the
predictive distribution of the baseline probability of ‘success’ (i.e. probability of
safety equipment uptake), mA.
With respect to the synthesis modelling with covariate information (models 3.9 and
3.10 in Chapter 3):
    mA 1A0A p.treatlogitp.treatlogit
 
 
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..p.treatlogit
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0k 





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predpreddmA
preddmA

 2,~ AANmA   2,~. Akk dNpredd
 60 10,0~ N  2,~. Bbkk Npred 
k = 1 . . . , total number of interventions
(4.2)
Compared to 4.1, in extension 4.2 the probabilities of ‘success’ for each strategy k
(where k ≠ A) are calculated as before, but now differs between subgroups. The
probability of ‘success’ in subgroup = 0 (e.g. subgroup of 2Ps), p.treat0k, is
compounded by the ‘common comparator’ baseline effect and the treatment effect
predictive distribution. The probability of ‘success’ in subgroup = 1 (e.g. subgroup of
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1Ps), p.treat1k, is formed by the two previous components and augmented by the
subgroup baseline score, 0 , and the predicted distribution of the covariate effect,
kpred. .
The following sections summarises the overall population results – using extension 4.1
– and the subgroup results with imputation of covariate information – using extension
4.2.
Results for the synthesis of aggregate data without covariates
The results presented here relate to the MTC model which synthesises AD. The
network of evidence, its structure, and the results for these models have been described
in Chapter 3. Here the focus is on those estimates from the MTC that represent key
input parameters in the decision model, that is, the absolute probability of ‘success’ of
each intervention. These results are shown in Table 4.1. This table of results presents
medians and 95% CrIs of the MCMC posterior samples. Results show that, except
for usual care and interventions supplying only education, most interventions have a
rate of success in excess of 80% (median estimate).
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Table 4.1 – ORs and absolute probabilities of success estimates for each intervention result of
fitting MTC model for AD without including covariates to the functioning smoke alarm
outcome data.
Results for the synthesis of aggregate data with covariates
The reader is here reminded of the policy rationale behind performing subgroup CEA.
As intervention effects may change across population subgroups, different decisions
may be performed for each of these subgroups with respect to the cost effectiveness of
particular interventions. The rationale is to enable the derivation of subgroup specific
estimates – estimates that work as vehicles to obtain subgroup cost effectiveness
outcomes to support decision making.
Median of
MCMC
posterior sample
95 per cent
credible interval
Parameter
(2) E 0.876 0.34 to 2.234
(3) E + FE 3.130 0.916 to 11.28
(4) E + FE + HI 2.598 1.023 to 8.618
(5) E + FE + F 2.646 0.792 to 9.057
(6) E + HI 3.232 0.674 to 24.15
(7) E + FE + F + HI 6.934 2.255 to 23.93
(1) UC 0.695 0.647 to 0.74
(2) E 0.671 0.207 to 0.942
(3) E + FE 0.876 0.459 to 0.986
(4) E + FE + HI 0.852 0.448 to 0.983
(5) E + FE + F 0.859 0.4 to 0.982
(6) E + HI 0.880 0.413 to 0.991
(7) E + FE + F + HI 0.941 0.651 to 0.993
Note: (1) UC - usual care; (2) E - education; (3) E + FE - education plus low cost / free
equipment; (4) E + FE + HI - education plus low cost / free equipment plus home inspection;
(5) E + FE + F - education plus low cost / free equipment plus fitting; (6) E + HI - education
plus home inspection; (7) E + FE + F + HI - education plus low cost / free equipment plus
fitting + home inspection.
Random effects MTC of AD -
network of 20 studies
Absolute
probability of
success of
interventions
Odds ratios
for
intervention
effects (vs
usual care)
Probability
Interpretation
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This subsection revisits analyses by fitting alternative synthesis models which use
covariate information. The first model (model (a)) includes as a covariate the number
of parents in the household (i.e. one parent household (1P) vs. two-parent household
(2P)); the second (model (b)) considers only their employment status as covariate (i.e.
employed parents (2U) vs. at least one parent unemployed (1U)); and the third (model
(c)) includes both variables. For each model, medians and 95% CrIs of the posterior
samples are shown.
Table 4.2 presents OR estimates for each intervention and the absolute probabilities of
‘success’ derived using models (a) and (b). As in the unadjusted analysis, when
considering subgroups, results indicate that (7) E+FE+F+HI is the strategy with the
highest probability of ‘success’ in the uptake of ‘functioning’ smoke alarms in the
household.
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Table 4.2 Relative intervention effect estimates and absolute probabilities of success
estimates for each intervention, result of fitting MTC models for AD including: (a) a
covariate relating to the number of parents (i.e. 1P vs. 2P) in the household; and (b) a
covariate parents’ employment status (i.e. 2U vs. 1U), to the functioning smoke alarm
outcome data.
Model (c) uses information on both covariates, enabling the estimation of covariate
effects for four population subgroups: two employed parents (2EP), employed single
parent families (1EP), two parent families with at least one parent unemployed (2UP),
and unemployed single parent families (1UP). Results are shown in Table 4.3. Again,
Median of
MCMC
posterior
sample
95 per cent
credible
interval
Median of
MCMC
posterior
sample
95 per cent
credible
interval
Function of parameter Function of parameter
(2) E 0.339 0.05 to 2.421 (2) E 0.268 0.021 to 2.692
(3) E + FE 2.399 0.594 to 11.17 (3) E + FE 1.114 0.082 to 16.77
(4) E + FE + HI 1.673 0.54 to 7.335 (4) E + FE + HI 0.849 0.163 to 5.46
(5) E + FE + F 1.656 0.375 to 8.749 (5) E + FE + F 1.054 0.055 to 22.84
(6) E + HI 2.305 0.37 to 19.86 (6) E + HI 1.595 0.121 to 34.53
(7) E + FE + F + HI 4.765 0.828 to 24.25 (7) E + FE + F + HI 2.652 0.235 to 36.72
(1) UC 0.714 0.565 to 0.813 (1) UC 0.803 0.421 to 0.956
(2) E 0.446 0.066 to 0.926 (2) E 0.525 0.036 to 0.955
(3) E + FE 0.857 0.402 to 0.983 (3) E + FE 0.814 0.149 to 0.993
(4) E + FE + HI 0.799 0.378 to 0.978 (4) E + FE + HI 0.768 0.192 to 0.984
(5) E + FE + F 0.798 0.295 to 0.977 (5) E + FE + F 0.813 0.105 to 0.993
(6) E + HI 0.848 0.354 to 0.989 (6) E + HI 0.861 0.199 to 0.997
(7) E + FE + F + HI 0.923 0.509 to 0.992 (7) E + FE + F + HI 0.915 0.307 to 0.995
(1) UC 0.714 0.565 to 0.813 (1) UC 0.803 0.421 to 0.956
(2) E 0.925 0.256 to 0.998 (2) E 0.833 0.046 to 0.999
(3) E + FE 0.981 0.432 to 1 (3) E + FE 0.954 0.17 to 1
(4) E + FE + HI 0.982 0.455 to 1 (4) E + FE + HI 0.966 0.233 to 1
(5) E + FE + F 0.973 0.274 to 1 (5) E + FE + F 0.917 0.081 to 0.999
(6) E + HI 0.986 0.475 to 1 (6) E + HI 0.968 0.2 to 1
(7) E + FE + F + HI 0.992 0.615 to 1 (7) E + FE + F + HI 0.979 0.232 to 1
Absolute
probability of
success of
interventions
for single
parent
families (1P)
Odds ratios
for
intervention
effects (vs
usual care)
Absolute
probability of
success of
interventions
for families
with at least
one parent
unemployed
(1E)
Absolute
probability of
success of
interventions
for two
parent
families (2P)
Absolute
probability of
success of
interventions
for families
with
employed
parents (2E)
Interpretation
Probability
Odds ratios
for
intervention
effects (vs
usual care)
Random effects MTC of AD including covariate information - network of 20 studies with imputation
a) Including covariate relating to number of parents in
the household
b) Including covariate relating to parents employment
status in the household
Probability
Interpretation
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results show that, in each of these subgroups, the probability of ‘success’ is higher for
intervention (7) E + FE + F + HI.
Table 4.3 – Absolute probabilities of success estimates for each intervention result of fitting
MTC model for AD including covariates ‘single parent status’ and ‘parents’ employment
status’ to the functioning smoke alarm outcome data.
4.3.5.2 Evidence used in model part 1 – the intervention model
Table 4.4 lists and describes the model parameters used in the intervention model, and
provides references for the sources from which information was extracted. Table 4.4 is
a subsection of Table A6 presented in Appendix 6, which shows the complete list of
parameters used in the analysis.
Median of
MCMC
posterior
sample
95 per cent
credible
interval
Median of
MCMC
posterior
sample
95 per cent
credible
interval
(1) UC 0.600 0.097 to 0.967 (1) UC 0.600 0.097 to 0.967
(2) E 0.125 0.002 to 0.939 (2) E 0.905 0.004 to 1
(3) E + FE 0.615 0.025 to 0.993 (3) E + FE 0.992 0.074 to 1
(4) E + FE + HI 0.528 0.034 to 0.98 (4) E + FE + HI 0.994 0.074 to 1
(5) E + FE + F 0.474 0.01 to 0.988 (5) E + FE + F 0.978 0.024 to 1
(6) E + HI 0.717 0.038 to 0.997 (6) E + HI 0.994 0.085 to 1
(7) E + FE + F + HI 0.753 0.024 to 0.995 (7) E + FE + F + HI 0.995 0.074 to 1
(1) UC 0.600 0.097 to 0.967 (1) UC 0.600 0.097 to 0.967
(2) E 0.957 0.002 to 1 (2) E 0.678 0 to 1
(3) E + FE 0.992 0.01 to 1 (3) E + FE 0.938 0 to 1
(4) E + FE + HI 0.991 0.01 to 1 (4) E + FE + HI 0.957 0 to 1
(5) E + FE + F 0.987 0.007 to 1 (5) E + FE + F 0.830 0 to 1
(6) E + HI 0.996 0.024 to 1 (6) E + HI 0.966 0.001 to 1
(7) E + FE + F + HI 0.997 0.018 to 1 (7) E + FE + F + HI 0.967 0 to 1
Interpretation
Probability
Absolute
probability of
success of
interventions
for two
employed
parent
families
(2EP)
Random effects MTC of AD including information for both covariates - network of 20 studies with imputation
Interpretation
Absolute
probability of
success of
interventions
for families
with two
parents and
at least one
parent
unemployed
(2UP)
Absolute
probability of
success of
interventions
for
unemployed
single parent
families
(1UP)
Probability
Absolute
probability of
success of
interventions
for employed
single parent
families
(1EP)
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The first parameters listed are the absolute probabilities of ‘success’ of each
intervention in increasing the uptake of ‘functioning’ smoke alarms in a household.
The sources of evidence for this model parameter are the results from the MTC models
shown in the previous section (4.3.5.1). Lack of evidence forces an assumption to be
made on families’ level of acceptance of the interventions. This assumption was based
on the expert knowledge of one (thesis) external advisor (Denise Kendrick) and
assumed that a 90% acceptance level, constant across alternatives. The baseline
probability of a household owning a ‘functioning smoke alarm’ and the incidence of
fires in a household where there is a functioning smoke alarm were derived from
official governmental statistics.
Table 4.4 - List of model input parameters used within part 1 (intervention) of the decision
model for functioning smoke alarms. Parameter descriptions and sources of evidence used to
inform the parameter are shown.
Model
input
parameter
Parameter description Source(s) of evidenceinforming the parameter
Parameter type: Probabilities
p_MTCfunc Absolute probability of a functioning smoke alarm specific
to each intervention
From MTC, as described in
section 4.3.5.1
p_accept Probability accept intervention (assumed same for all
interventions)
Assumption
pop_fsa Probability a household having a functioning smoke alarm Survey of English Housing 2004/5
(Government, 2006) - Table 5.2
Parameter type: Resource cost
Interventions Costs
c_hsi Cost of home safety inspection based on cost of LA home
care worker for 40 minutes of their time including travel
PSSRU 2008 (Curtis, 2008)
c_alarmg Cost of smoke alarm giveaway (with ten-year sealed
battery)
Personal communication Jane
Zdanowska
c_educ Cost of providing education programme per household
accepting intervention - based on cost of home care worker
for 20 minutes of their time including travel
DiGuiseppi et al. (1999) – updated
to 2009 prices
c_fixed Fixed cost of an intervention scheme (e.g. set-up,
administration, etc). Composite value derived from cost
analysis of DiGuiseppi et al. (1999)
c_acc Additional cost incurred for each household that accept
intervention (composite value)
c_install Cost of having the smoke alarm installed
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A fixed cost for each intervention of approximately £55,000 was obtained from the
cost analysis implemented by DiGuiseppi and colleagues (1999). This fixed cost
involved a variety of items such as intervention set-up (e.g. pilot test, distribution, staff
training and reminders) and administration (e.g. programme coordination, brochures
and photocopying). The study by DiGiuseppi et al. (1999) also provided estimates of
the cost of installing a fire alarm, providing education to parents and the cost of
parents accepting the intervention. The Personal Social Services Research Unit
(PSSRU) 2008 report (Curtis, 2008) was used to obtain an estimate (based on
assumptions) of the cost of performing a home inspection. Personal communication
with field trialists was used to obtain an estimate of the cost of a smoke alarm within a
giveaway programme. Where possible, cost data was inflated to 2009 prices (Curtis,
2009).
A vector of the general population mean utility values for the (non-injured) population
were obtained from Kind et al. (1999). This study provided UK population norms and
uncertainty estimates by age group, which were used across the entire decision model.
4.3.5.3 Evidence used in model part 2 – the 5 year Markov structure
The sources of evidence used to inform part two of the decision model are provided
below, according to the type of model parameter being informed.
Event rates
The Survey of English Housing (Government, 2006) was used to obtain information
on smoke alarm battery testing, important in determining the repair rate and the decay
level of the equipment. Official reports also provided data on the likelihood of there
being no injuries or fatalities following a fire (Government, 2007). The likelihood of
Parameter type: Utility parameters per cycle
u_pop General background mean utilities for non-injured
population
UK Population Norms (Kind et al.,
1999)
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children incurring a fire-related injury, disaggregated by type of injury, was obtained
from personal communication with an NHS Burns service specialist (Ken Dunn). This
estimate was informed by a study developed by the Manchester burns unit in
collaboration with the International Burn Injury Database (available at
www.ibidb.org). Fire and rescue services’ probabilities of attending a household fire
were obtained from official sources (Government, 2006), as well as the likelihood of
intensive treatment being involved. All-cause mortality estimates for the UK
population were extracted from the Office for National Statistics (ONS) website – see
Table 4.5 for detailed estimates used.
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Table 4.5 - All cause mortality.
Costs
Health care costs
Emergency ambulance and paramedic unit costs were obtained from official national
estimates (Curtis, 2008), charged per minute and multiplied by the expected number
of minutes these units take to arrive at the accident scene (only applied to severe
Year All cause probability
of death
Year All cause probability
of death
Year All cause probability
of death
0 0.004881 34 0.000837 68 0.015637
1 0.000371 35 0.000906 69 0.017008
2 0.0002155 36 0.0009105 70 0.018694
3 0.0001635 37 0.000981 71 0.0206325
4 0.000129 38 0.0010745 72 0.0230315
5 0.0001165 39 0.0011525 73 0.0256835
6 0.000102 40 0.001245 74 0.028487
7 0.000089 41 0.001345 75 0.0318565
8 0.0001075 42 0.0014625 76 0.0357665
9 0.000098 43 0.001584 77 0.03985
10 0.0000965 44 0.001693 78 0.044449
11 0.0001045 45 0.001894 79 0.050377
12 0.0001095 46 0.0020245 80 0.055856
13 0.0001385 47 0.0022465 81 0.0625195
14 0.0001465 48 0.0024795 82 0.0697915
15 0.000189 49 0.002651 83 0.0778325
16 0.0002535 50 0.003029 84 0.087146
17 0.0003615 51 0.003282 85 0.096125
18 0.000401 52 0.003505 86 0.106745
19 0.0004225 53 0.003948 87 0.1128245
20 0.0004475 54 0.00434 88 0.125178
21 0.000441 55 0.004743 89 0.135927
22 0.000455 56 0.0051635 90 0.1540795
23 0.0004525 57 0.005472 91 0.1751405
24 0.0004785 58 0.0059335 92 0.191869
25 0.000488 59 0.006512 93 0.2098855
26 0.0005445 60 0.007054 94 0.225663
27 0.0005335 61 0.008026 95 0.248501
28 0.000574 62 0.008787 96 0.2689845
29 0.000598 63 0.009764 97 0.2897915
30 0.000643 64 0.0107225 98 0.308781
31 0.000664 65 0.011695 99 0.324315
32 0.0007345 66 0.0127985 100 0.3522955
33 0.000794 67 0.0140685
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events, i.e. severe fire-related child injuries). Average costs (and standard errors) of
fire-related events were obtained from personal communication with a NHS Burn
service specialist in Manchester (Ken Dunn), based on a non-published study carried
out by this burns unit on a patient level costing system. Deaths resulting from fires
incurred a cost of around £185 (updated to 2009 prices), which include both coroners
and autopsy fees (Ginnelly et al., 2005b). The cost of a yearly precautionary check-up
of the safety equipment was put at an average of £62 (2008/9 NHS Reference Costs
Guidance, 2010). Mean incurred NHS costs of disabilities per year was reported in the
Long Term Health and Healthcare outcomes of Accidental Injury study (HALO)
(Nicholl et al., 2009).
Out of pocket / private costs
The total cost of property damage caused by a fire was derived from the British Crime
Survey 2002/3 (Government, 2004b). The cost of a battery for a smoke alarm for one
year was obtained from web-based safety equipment providers.
Law Enforcement and Rescue Services Costs
The costs of law enforcement and rescue services were also taken into consideration.
Police presence at the fire scene where severe injuries occurred was assigned the same
cost as that assumed by Ginnelly et al. (2005b) updated to 2009 prices. Fire rescue
services were costed at approximately £3,000, with the value obtained from official
governmental statistics (Government, 2004a). Both of these are assumed fixed.
Utilities
Utility values were assigned to all the model states. Utility data (decrements) were
drawn from Sanchez and colleagues (2008) to inform each of the non-fatal fire-related
events (i.e. minor, moderate and severe injuries). Along with many other elements,
this study assessed EQ-5D information collected prospectively from burn victims,
categorizing them in terms of the severity / degree of burns. Evidence extracted from
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this source was deemed fixed in the decision model. A reduction in an individual’s
quality of life following an event leading to disability was obtained from the HALO
report (Nicholl et al., 2009). This study investigated long term health effects and
health-related quality of life of patients who had sustained serious injuries from fire-
related accidents. A sustained yearly mean reduction of 0.1 in EQ-5D score for
patients suffering a permanent injury was estimated, from a population norm of 0.8 for
patients monitored for up to 11 years after an accident. Using the method of moments
and through a Beta distribution, this information was probabilistically modelled.
The following table (Table 4.6) compiles the information described above for part two
of the decision model.
Table 4.6 – List of model input parameters used within part 2 (5 year Markov structure) of
the decision model for functioning smoke alarms. Parameter descriptions and sources of
evidence used to inform the parameter are shown.
Model
input
parameter
Parameter description Source(s) of evidenceinforming the
parameter
Parameter type: Probabilities
p_checkup Probability have a precautionary checkup following a fire Fire Statistics 2007
(Government, 2007) - Table 8
p_fire.func Probability of a fire where functioning smoke alarms
present
Fire Statistics 2007
(Government, 2007) - Table 2.4
p_fire.nonfunc Probability of a fire where non-functioning smoke alarms
present
p_fire.noSA Probability of a fire where no smoke alarms present or
unspecified
p_fatalSA Probability of a fatality following a fire where functioning
smoke alarm present
p_fatalnSA Probability of a fatality following a fire where non-
functioning or no smoke alarm
p.1yrbattery Probability own a smoke alarm with battery life of 1 year Survey of English Housing
2004/5 (Government, 2006) -
Table 5.3
p.test1yr Probability test smoke alarm at least once a year Survey of English Housing
2004/5 (Government, 2006) -
Fig 5.1
p.testless1yr Probability test smoke alarm less than once a year
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p_noinjury
Probability of incurring ‘no injuries’ following a house fire
(given functioning smoke alarm/ non-functioning or no
smoke alarm)
Survey of English Housing
2004/5 (Government, 2006) –
Table 3.7; Fire statistics 2007
(Government, 2007) - Table 2.4
p_FRSattend Probability of inside household fire being attended by the
Fire and Rescue Service
Survey of English Housing
2004/5 (Government, 2006) -
Table 3.4
p_ITU The additional proportion of burn unit costs incurred in
ITU
Assumption based on analysis
in Hemington-Gorse et al.
(2009)
p_minor Probability a child aged 0-4 incurs a minor injury following
a house fire Ken Dunn (personal
communication)p_moderate Probability a child aged 0-4 incurs a moderate injury
following a house fire
p_severe Probability a children aged 0-4 incurs a severe injury
following a house fire
p_allcause Probability of all cause mortality for a UK citizen from 0 to
100 years old (for use in each decision model cycle)
(ONS, 2010b)
Parameter type: Resource cost
Health Care Costs
c_minPU Cost per minute of a Paramedic Unit PSSRU 2008 (Curtis, 2008) -
updated to 2009 pricesc_minEA Cost per minute of a Emergency Ambulance
mn.minor Mean cost (and standard error) of a minor injury
Ken Dunn (Personal
communication)mn.moderate Mean cost (and standard error) of a moderate injury
mn.severe Mean cost (and standard error) of a severe injury
c_fatal Cost of a fatality following a household fire (updated to
2008/9 prices) – includes coroners and autopsy costs
Ginnelly et al. (2005b) -
updated to 2009 prices
c_dispyr Mean incurred NHS costs of disability per year
HALO study (Nicholl et al.,
2009) and personal
communication with Jon
Nicholl
c_checkup Cost of precautionary check-up of safety equipment NHS reference costs 2008/9
(2008/9 NHS Reference Costs
Guidance, 2010) - code VB11Z
Out of Pocket / Private Costs
c_battery Cost of smoke alarm 1 year battery to individual www.safelincs.co.uk – 2009
price
c_property Total cost of damage caused by the fire British Crime Survey: Fires in
the Home 2002/3 (Government,
2004b) - updated to 2009 prices
Law Enforcement and Rescue Services Costs
c_police Cost of police attending – assumed only to attend where
severe injuries
Ginnelly et al. (2005b) -
updated to 2009 prices
c_FRSresponse Cost of Fire and rescue Service attending a fire Economic Cost of Fire 2004
(Government, 2004a) - Table
3.6 - updated to 2009 prices
Parameter type: Utility parameters per cycle
u_min Deficit in utilities for minor injury (DRG 460 + 459)
Sanchez et al. (2008)
u_mod Deficit in utilities for moderate injury (DRG 458 + 457)
u_sev Deficit in utilities for severe injury (DRG 472)
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4.3.5.4 Evidence used in model part 3 – the lifetime Markov structure
In the final part of the decision model, few parameterizations were needed to reflect
the lifetime Markov structure. The sources of evidence used to inform these
parameters are the same as the ones described for parts 1 and 2 of the decision model
and are referred to in Table 4.7.
Table 4.7 – List of model input parameters used within the decision model for functioning
smoke alarms. Sources of evidence used to inform the parameter and parametric assumption
used to model parameter uncertainty is also shown.
4.3.6 Base case and scenario analysis
4.3.6.1 Base case analysis
A key element of any economic evaluation is the definition of the ‘perspective’ from
which the analysis is considered. Economic evaluations of health interventions
commonly take a health service perspective. Nonetheless, given the inherent
u_deficit Deficit in utilities following a disability HALO study (Nicholl et al.,
2009) and personal
communication with Jon Nicholl
u_pop As in Table 4.4
Model
input
parameter
Parameter description Source(s) of evidenceinforming the parameter
Parameter type: Probabilities
p_allcause As in Table 4.5
Parameter type: Resource cost
c_dispyr As in Table 4.5
Parameter type: Utility parameters per cycle
u_deficit As in Table 4.5
u_pop As in Table 4.4
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complexity of PH interventions, their costs and effects will often be borne outside of
the health care system, due to its impact on the welfare of the whole of society, not
just on the individuals or organisations directly involved. A wider perspective, such as
public sector or societal, allows for the capture of the impact of the interventions
across sectors, such as health or education.
The base case analysis of the current study follows the NICE PH reference case
recommendations (NICE, 2009), from the public sector perspective. This includes
health care, law enforcement and rescue services related costs.
Table 4.8 presents a summary of the base case characteristics used in the current
evaluation, adapted from Table 6.1 in “Methods for the development of the NICE PH
guidance” (NICE, 2009).
Table 4.8 - Summary of the base case
Element of assessment Base case
Type of economic evaluation Cost-effectiveness analysis
Perspective on costs Public sector, including the NHS and PSS
Perspective on outcomes All health effects on individuals
Evidence on outcomes
Simultaneous synthesis of evidence of multiple
interventions
Measure of health effects QALYs
Main source of data for
measurement of health-
related quality of life (HRQL)
Reported directly by patients (HALO report (Nicholl
et al., 2009))
Source of preference data
for valuation of changes in
HRQL
Representative sample of the public (UK Population
Norms (Kind et al., 1999))
Discount rate
An annual rate of 3.5% was used on both costs and
health effects
Equity weighting
An additional QALY has the same weight, regardless
of the characteristics of the individuals who gain the
health benefit
Size of the cohort simulated 100,000
Time horizon
100 years - until population all dead in order to
account for all outcomes
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4.3.6.2 Further analyses
Four alternative analyses were conducted, consisting of: a quasi-societal viewpoint
including not only health care and public sector costs but also out of pocket costs – not
including indirect or intangible costs (scenario 2); and NHS and Personal Social
Services (PSS) viewpoint including only health care related costs (scenario 3). In
order to explore the impact of fixed intervention costs, an extra scenario was
considered in which these were excluded (scenario 4). This latter scenario is a
simplification of the base case scenario. The impact of varying the time horizon was
also evaluated by implementing a scenario that considered only the short term effects
(i.e. the initial five years) of the programmes (scenario 1). For further details on the
types of costs that were included in each of the scenarios, please consult Table 4.9
below.
Table 4.9 – List of scenarios considered in current analysis (each one assessed as a specific
scenario, includes base case) showing how these are interconnected and their inherent
hierarchical structure.
Item
Base case
(Public
sector)
Scenario 1:
Public sector
viewpoint with
short-term
effects
Scenario 2:
Quasi-societal
viewpoint
Scenario 3:
NHS and PSS
viewpoint
Scenario 4: NHS
and PSS viewpoint
with no
implementation
costs
Interventions costs
Health care costs
Out of pocket /
private costs
Law Enforcement
and Rescue Services
Costs
Time horizon of 100
years
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4.4 Cost effectiveness results
The cost effectiveness results of the decision model described in the previous section
are presented in this section. This section is split into two subsections: section 4.4.1
where overall population results (no subgroups) are shown, and section 4.4.2 where
subgroup cost effectiveness results are discussed. The latter considers results by family
type (2P and 1P) and by family employment status (i.e. 2U and 1U).
The methods guidance for health technology appraisal (NICE, 2008) states that the
£20,000 to £30,000 threshold values should be considered when evaluating the cost
effectiveness of health technologies. Although these values are occasionally used
throughout to support the interpretation of the results shown next, it is important to
note that a predefined threshold does not exist outside of the health sector. Section 4.5
comes back to this subject.
4.4.1 Overall population results (no covariates)
The base case results are shown in Table 4.10. The mean change in benefits and costs
relative to intervention (1) UC and for a cohort size of 10,000 individuals, as well as
ICERs for each of the programmes, are presented. The estimated incremental changes,
in both QALYs and costs, relative to (1) UC are found to be considerably small when
considering a cohort size of 10,000 households. The estimated ICER for the strategy
involving the delivery of education and free (or sponsored) equipment, (3) E+FE, is
approximately £33,000/QALY gained. Only two interventions are on the efficiency
frontier ((3) E + FE and (7) E + FE + F + HI), while the remaining 4 interventions
are either dominated or extendedly dominated (having higher costs or ICERs than
more effective interventions, respectively). Figure 4.2a is a graphic representation of
the incremental expected outcomes (in the x-axis effect gains and in the y-axis cost
differences).
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Table 4.10 – Results of the base case scenario for all interventions (for when effectiveness AD
were synthesised and used to populate the decision model)
QALYs Costs (£s)
(1) UC ---- ---- ---
(2) E 0.253 10.25 Extended dominated
(3) E + FE 0.558 18.44 33,045
(4) E + FE + HI 0.551 39.96 Dominated
(5) E + FE + F 0.548 37.55 Dominated
(6) E + HI 0.330 31.91 Dominated
(7) E + FE + F + HI 0.591 59.15 1,244,477
Mean Δ (relative to (1) UC) for 
cohort size of 10,000
ICER (£s)Intervention
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Figure 4.2 – (a) Cost effectiveness plane and (b) acceptability curves for the functioning
smoke alarms decision model.
Figure 4.2b shows a graphical illustration of the probability of the alternative
interventions being cost effective. It depicts the typical ‘ogive’ shape of the Cost
Effectiveness Acceptability Curves (CEACs), a characteristic observed when the joint
density of costs and effects is contained in the first quadrant (positive incremental
costs and effects). If threshold values of £20,000 and £30,000 are used, the usual care
((1) UC) intervention has the highest probability of being cost effective (0.906 and
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0.579, respectively). Nonetheless, for threshold values of approximately £34,000
cost/QALY and above, programmes including education and free / low-cost
equipment are considered most cost effective.
The intervention which yields the highest health benefits (most effective intervention)
is the one with the “highest intensity”, that is, intervention (7) which includes,
education, free / low-cost equipment and its installation as well as home safety
inspections. This result is consistent with what was found in Chapter 3 (section 3.5.2)
and in section 4.3.5.1 of this chapter. Nevertheless, a decision maker would need to be
willing to pay £1.2m per additional QALY (Table 4.10) to fund this programme.
As explained by Fenwick and colleagues (2001), it should be noted that an alternative
with the highest probability of being cost effective for a particular threshold value may
not be the one yielding the highest NBs. In Figure 4.3 the probabilities of being cost
effective are shown for the interventions that attained the highest expected NB (Cost
Effectiveness Acceptability Frontier (CEAF)).
Figure 4.3 – Cost effectiveness acceptability frontier for the functioning smoke alarms
decision model.
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Figure 4.3 highlights that for threshold values between £0 and £100,000 threshold
ratios, only two interventions should be considered, and that uncertainty is the highest
(i.e. probability = 0.5) close to the ICER for intervention (3) E + FE. Beyond that,
decision uncertainty falls with the increase in threshold values.
4.4.2 Subgroup cost effectiveness analysis results
It is important to assess the cost effectiveness of interventions by population subgroup,
as an intervention may be cost effective for one subgroup of the population and not for
another. Thus, there may be population health gains from stratifying decisions based
on subgroup membership. The current subsection shows results from exploring: (i) the
number of parents in the household (i.e. 1P or 2P) – section 4.4.2.1; (ii) parent(s)’
employment status (i.e. 2U or 1U) – section 4.4.2.2; and (iii) both these factors –
section 4.4.2.3.
4.4.2.1 Subgroups analyses: number of parents in the household (two vs. single)
For both subgroups, decisions to adopt or reject interventions are found to be identical
to the ones made above for the overall population (results not shown). Interestingly,
for 1Ps, the programme including only education (i.e. (2) E) achieves a considerable
probability of being cost effective (i.e. of around 0.2) at approximately £30,000 per
QALY gained. This implies higher decision uncertainty at around this threshold
value.
4.4.2.2 Subgroups analyses: household employment status (employed vs. at least one parent
unemployed)
When considering the subgroup of 2U, for a £30,000 threshold ratio, the probability of
being cost effective is higher for (1) UC (of approximately 0.67). For the other
subgroup, not only interventions (3) E + FE and (7) E + FE + F + HI are dominant
over other alternatives, but also strategy (4) E + FE + HI is. Estimated ICERs for
these two latter interventions are extremely large, in excess of £2m per QALY gained
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(Table 4.11a). Again, although extended dominated by other alternatives, intervention
(2) E has around 20% probability of being cost effective at approximately £32,000
threshold value – see Table 4.11b for further details.
Table 4.11 - ICERs and probabilistic sensitivity analysis results for each intervention for the
base case scenario and for the subgroup of (a) 2Us and of (b) 1Us.
4.4.2.3 Subgroups analyses: number of parents in the household and their employment
status
Results shown in this subsection (Table 4.12) reveal that, at around £30,000 per
QALY gained, (1) UC is the best strategy for all subgroups. If the threshold is
£35,000 per QALY gained, then (3) E + FE becomes the best strategy for subgroups
labelled in Table 4.12 as (b) and (c), and marginally (d). Usual care ((1) UC) remains
(1) UC (2) E (3) E + FE (4) E + FE +
HI
(5) E + FE +
F
(6) E + HI (7) E + FE +
F + HI
---
Extended
dominated 35,965 Dominated Dominated Dominated 786,894
20,000 0.914 0.011 0.075 0.000 0.000 0.000 0.000
30,000 0.674 0.038 0.288 0.000 0.000 0.000 0.000
50,000 0.185 0.054 0.758 0.001 0.002 0.000 0.000Pr
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(1) UC (2) E (3) E + FE (4) E + FE +
HI
(5) E + FE +
F
(6) E + HI (7) E + FE +
F + HI
---
Extended
dominated 32,149 2,048,905 Dominated Dominated 2,628,186
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the best for subgroup labelled as (a). All ‘active’ interventions have a low probability
of being cost effective at £30,000 per additional QALY.
Table 4.12 - Cost effectiveness results for the functioning smoke alarms decision model for
four subgroups (a) two employed parent household (2EP); (b) employed single parent
household (1EP); (c) two parent household with at least one unemployed (2UP); and (d)
unemployed single parent household (1UP).
(1) UC (2) E (3) E + FE (4) E + FE +
HI
(5) E + FE +
F
(6) E + HI (7) E + FE +
F + HI
--- Extended
dominated
40,721 Dominated Dominated Dominated 1,027,227
20,000 0.933 0.005 0.062 0.000 0.000 0.000 0.000
30,000 0.753 0.019 0.228 0.000 0.000 0.000 0.000
50,000 0.353 0.023 0.622 0.001 0.001 0.000 0.000
--- Extended
dominated
32,055 3,989,355 Dominated Dominated 5,747,717
20,000 0.858 0.051 0.091 0.000 0.000 0.000 0.000
30,000 0.505 0.151 0.344 0.000 0.000 0.000 0.000
50,000 0.124 0.073 0.802 0.000 0.001 0.000 0.000
--- Extended
dominated
33,961 Dominated Dominated Dominated 1,849,602
20,000 0.856 0.065 0.079 0.000 0.000 0.000 0.000
30,000 0.526 0.191 0.283 0.000 0.000 0.000 0.000
50,000 0.180 0.101 0.717 0.001 0.002 0.000 0.000
--- Extended
dominated
35,013 1,642,801 Dominated Dominated 3,227,412
20,000 0.874 0.050 0.076 0.000 0.000 0.000 0.000
30,000 0.554 0.154 0.292 0.000 0.000 0.000 0.000
50,000 0.199 0.115 0.680 0.003 0.004 0.000 0.000Pr
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4.4.3 Results of analysis under alternative scenarios
A series of alternative scenarios were run to contrast with the base case results, as
defined in section 4.3.6.2. Following a full incremental analysis, estimated ICERs for
each of the scenarios are shown in Table 4.13. It can be observed that results for the
scenarios considering NHS and PSS viewpoint are identical to the ones obtained for
the reference case where no subgroups are considered, that is, estimated ICER for
intervention (3) E + FE is approximately £33,000 per QALY gained. This result
indicates that, if the NICE threshold acceptance range recommendations were to be
used, and decisions were to be made by a health sector decision maker, none of the
‘active’ alternatives would be funded.
Table 4.13 – Cost effectiveness results of the 4 scenarios for all interventions and all
participant households and for when AD on effectiveness was synthesised and used to
populate the decision model, all the rest remaining constant.
Adopting the NHS and PSS perspective but excluding the upfront cost of
implementing the interventions (i.e. assuming that these costs are assured by another
sector or sectors of society), implies many changes in results when compared to other
alternative scenarios. The set of dominated or extended dominated programmes is now
completed by (1) UC, (4) E + FE + HI and (6) E + HI. The fact that (1) UC becomes
Scenario 1: Public sector
viewpoint considering
short-term effects (5
years simulation process)
Scenario 2: Quasi-
societal viewpoint
Scenario 3: NHS
and PSS viewpoint
Scenario 4: NHS and
PSS viewpoint,
excuding
implementation costs
(1) UC --- --- --- Dominated
(2) E Extended dominated Dominated Extended dominated ---
(3) E + FE 70,020 659,482 32,752 1,255
(4) E + FE + HI Dominated Dominated Dominated Extended dominated
(5) E + FE + F Dominated Dominated Dominated 789
(6) E + HI Dominated Dominated Dominated Extended dominated
(7) E + FE + F + HI 2,380,430 1,037,609 1,254,939 1,480
ICER (£s) - Full incremental analysis
Intervention
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dominated implies that intervention (2) E is the comparison starting point, as this
programme shows both lower costs and benefits across non-dominated alternatives.
The magnitudes of the estimated ICERs are found to be low, not going over £2,000
per QALY gained. The programme with the lowest estimated ICER was the one which
included education, supply of free or low cost equipment and its installation (i.e. (5) E
+ FE + F).
4.5 Discussion
Summary of findings
Assessing the effectiveness of alternative strategies is important in a health care
system operating under fixed budget constraints, where decisions on the use of the
technologies must be based on cost effectiveness. This study evaluated the cost
effectiveness of alternative interventions to increase the household uptake of
‘functional’ smoke alarms and, consequently, reduce the number of home fire-related
injuries in pre-school children.
The results of the analyses of the evidence of effectiveness presented in Chapter 3
indicate that more complex interventions (which include multiple components such as
education, equipment and its fitting and inspection) have higher probability of
increasing the possession of functioning smoke alarms than those less multifaceted. In
this chapter it is shown that these are associated with higher costs and in order for
them to be adopted, decision makers need to be ‘willing to pay’ or displace large
amounts of funds. Strategies which provide education and free or sponsored
equipment to families can be adopted at a lower willingness to pay value. Results are
consistent with previous trial-based model results (Ginnelly et al., 2005b), and
marginally similar to the decision model results obtained in the NICE PH guidance on
the prevention of unintentional injuries among under-15s in the home (NICE, 2010).
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Study strengths, limitations and further work
This study considers a number of methodological improvements over other modelling
approaches previously undertaken in this area (Pitt et al., 2009, Ginnelly et al., 2005b,
Haddix et al., 2001). For instance, in the current study: (i) multiple interventions were
compared in both effect and cost dimensions – which, to the author’s knowledge, is
the first time that this has been done within a PH study; (ii) different scenarios with
respect to the perspective of the analysis were implemented; and (iii) subgroup
analysis, that, as discussed in the next paragraphs, considered two potential
heterogeneous factors and explored the cost effectiveness for different population
subsets.
Nevertheless, the framework presented carries some clear limitations and/or strong
assumptions. These are briefly described in section 4.3.3. It is worth highlighting that,
due to lack of evidence, the conclusions of the current study is limited to the
population of UK homes with only one child under 5. The generalisation of the study
findings to other populations, such as considering all UK homes (including the ones
with multiple children), or even to all members of the household (i.e. to both parents
and children), should not be performed without appropriately accounting for this in the
bulk of the evidence used to populate the decision model.
Common to both effectiveness and economic assessments of injury prevention
schemes is the lack of evidence regarding both their effects and costs. Generally, it is
difficult to understand how best to design and deliver these interventions in order to
efficiently increase home safety. Without this knowledge, policymakers are
uninformed on how to reduce fire-related injuries and tackle potential inequalities in
child injury rates (Dowswell & Towner, 2002).
Randomised controlled trials are usually highest in rank in the quality of evidence
hierarchy, and are often considered the best design to evaluate the (not always
straightforward) link between cause and effect. Nevertheless, these studies do carry
certain limitations for the evaluation of PH interventions (Drummond et al., 2005). For
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instance, RCTs are limited in their action, mainly owing to internal validity and ethical
considerations. In fact, they tend to produce biased effect estimates (over-inflating) of
the policy’s efficacy (NICE, 2009). Other types of study designs, like observational
studies, are also deemed to provide good quality evidence, conditional on how well
potential sources of bias are taken into account.
In the assessment performed in this chapter, the evidence base on effectiveness was
sparse, as many of the comparisons within the network contained only a small number
of trials (Chapter 3). This led to high uncertainty in some estimates which, in turn, was
propagated throughout the decision model, affecting the estimates of costs and
QALYs. Additional studies may be required to augment the evidence base and
reduce uncertainty over decisions on the cost effectiveness of alternative strategies in
this area of PH. Moreover, there were numerous decision model input parameters for
which limited data existed. This was addressed by ensuring that for all these
parameters the source of evidence was reliable and preferably of official
(governmental) origin.
The differences across interventions in terms of estimated mean costs and benefits
were found to be considerably small. This fact may raise several issues, such as
decision makers considering all strategies to be fairly equal, or even that the
transaction costs of implementing more complex interventions not outweigh their
benefits.
The complexity of PH interventions is also linked to the existence of heterogeneity
within a targeted population. Variability in study populations, interventions and
settings, and variations in study designs and outcomes, are all considered sources of
heterogeneity. In the assessment of PH programmes, relevant sources of heterogeneity
should be identified and explored explicitly (e.g. through subgroup analysis). Analysts
and policy makers are often interested in examining variation among, for example,
different social, ethnic, demographic and educational groups (Rychetnik et al., 2002).
The current study has considered the analysis of subgroups and estimated subgroup
specific cost effectiveness information. This evidence may allow decision makers to
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consider the absolute magnitude of benefits and costs while taking into account
possible heterogeneity within the population of interest.
The NICE PH methods guidance (2009) encourages the use of the cost per QALY as
an economic outcome measure – as in Pitt et al. (2009) report, the current study used
this framework. However, the guidance raises the point that the QALY measure may
not be sufficient to capture the complex impact and context of some PH programmes,
in particular programmes involving social support, education, and guidance to
individuals. To address this other measures such as life years gained, cases averted or
a more disease-specific outcome, are recommended in alternative..
The usual NICE ICERs acceptance region recommendations do not exist outside the
health sector, making it difficult to judge whether the benefits accruing to the non-
health sectors are cost effective (NICE, 2009). Therefore, decisions on whether to
recommend interventions should not be based on cost effectiveness alone but also on
equity. Generally, the relevant economic literature discussed in section 4.2 used a £0
– £50,000 or a £20,000 – £30,000 threshold range to evaluate programmes’ cost
effectiveness. In the analysis presented in this chapter, although the interpretation of
results was supported by the same general ranges, these were made taking this fact
into account.
Parents are usually the target population of the preventative upstream interventions
assessed here. It is the parents’ responsibility to supply a safe environment and
safeguard the health of their children, in light of their vulnerability and lack of risk
awareness in early years. Interventions aim to change parents’ awareness, attitudes and
behaviours across various safety issues. One structural limitation of the model
developed in this study is that it ignores potential spill-over effects towards parents,
who could also benefit from installing and maintaining ‘functioning’ safety equipment
in their homes. Another limitation is the fact that other possible model states may
exist in real life that are not considered by the current model. For example, the model
could have examined varying degrees of disability or even a possible return to the
‘well’ state after a severe injury following a fire-related injury in the household.
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Concluding remarks
In this chapter important findings were made about the cost effectiveness of
interventions in promoting the uptake of functional smoke alarms and consequently, in
reducing child injuries at home. However, there continues to be insufficient evidence
to inform and support PH policy/decision making. This state of affairs can be changed,
but it will require strong direction to ensure the priorities for economic evaluation
evidence become organised and coordinated at local, regional and national levels.
Most of the evidence used to inform model parameters was available at summary
level. It would be useful to understand the extent to which the availability of
individual level evidence for at least some of the model parameters, would impact on
final outcomes- particularly, when subgroup analysis is at stake. This issue will be
explored in Chapter 5.
154
CHAPTER 5
5. USING AGGREGATE- AND INDIVIDUAL-PARTICIPANT
LEVEL DATA FOR COST EFFECTIVENESS MODELLING
5.1 Background
The literature review carried out in Chapter 2 acknowledged that it is not uncommon
to have access to IPD, possibly alongside study AD, to inform cost effectiveness
decision analytic models. However, in this situation, methods of analyses were
lacking. Motivated by the need to consider all ‘relevant’ evidence, Chapter 3
developed new synthesis methodology for when IPD, or when both AD and IPD, are
available.
One of the recommendations made in Chapter 3 was to include, whenever possible,
evidence at the individual level in the MTC analysis. Using a real life example,
Chapter 3 illustrated that the inclusion of IPD enables the estimation of intervention
effects at the subgroup level with greater accuracy and precision, compared to the use
of summary evidence only. Ignoring available IPD may, therefore, compromise the
validity of estimates, leading to erroneous interpretations of the underlying treatment x
covariate associations and, consequently, of the true subgroup effects.
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Using the same case study (presented in Chapter 1), this chapter aims to expand on
Chapter 3 in evaluating the impact of using IPD, from relative effectiveness to cost
effectiveness. The chapter begins by providing the framework of the analysis in
Section 5.2, followed by a discussion in section 5.3, of the effectiveness and cost
effectiveness results from using AD + IPD in the absence of subgroups. Section 5.4
extends this analysis and presents results when considering mutually exclusive
subgroups. Finally, section 5.5 discusses the chapter’s findings and how they fit within
the current methods literature, highlighting limitations and scope for further work.
5.2 Framework of analyses
The CEA presented in Chapter 4 evaluated the use of alternative strategies that
promoted the uptake of ‘functioning’ smoke alarm equipment in order to reduce child
fire-related injuries in the home. Evidence on a multitude of parameters was collated
in a decision model aiming at describing the short, medium and long term effects of
preventing the consequences of fires in households. In the analyses presented in
Chapter 4, effectiveness evidence for the alternative interventions was derived using
AD from the existing evidence base. Here, the same evidence base on relative
effectiveness is used but now considers IPD where available (given that IPD was made
available for a proportion of all studies, the ‘IPD model’ contained a mixture of AD +
IPD).
Use of effectiveness evidence generated using AD + IPD
The specific methods used in the synthesis (of AD and of IPD) were presented in
detail in Chapter 3. The reader is reminded that relative effectiveness evidence was
further transformed for inclusion in the decision model. In particular, extensions to
the synthesis modelling were made to consider the use of predictive treatment effect
distributions (Ades, A. E. et al., 2005) and the modelling of baseline effects (Pocock
et al., 2002). Details on these extensions are provided in section 4.3.5.1 of Chapter 4,
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where although they are presented within an AD context, these can be easily
generalised to the use of IPD context. Methods will not be further reported here,
though results are shown for each intervention, the probabilities of household uptake
of a ‘functioning’ smoke alarm, estimated through the use of AD and AD + IPD.
Information is provided through medians and 95% CrIs of the MCMC posterior
samples.
Cost effectiveness
To facilitate comparisons between the effect of AD and AD + IPD in cost
effectiveness, input data and model structure for parameters other than effectiveness
remain unchanged (reported in Chapter 4). Any differences in cost effectiveness
results are, therefore, a direct consequence of differences between the effectiveness
input information. To evaluate the impact on cost effectiveness of using IPD rather
than AD, ICERs and probabilities of being cost effective will be compared.
On the one hand, if effectiveness estimates are similar whether using AD or AD +
IPD, when informing the decision model, no effect on cost effectiveness estimates is
expected. If effectiveness estimates are not similar whether using AD or AD + IPD, it
is difficult to predict the effects of those differences on cost effectiveness outcomes,
which will depend mainly on the reasons behind those differences and their direction.
A gain in precision24 from using IPD may reduce decision uncertainty (e.g. when two
interventions are at stake, one will have a higher probability of being cost effective and
the other a lower probability). In contrast, it is not straightforward to infer the effects
of gains in accuracy (i.e. bias25 reduction) from IPD compared to AD on cost
effectiveness.
24 In general statistical terms, precision is defined to be the reciprocal of the variance, i.e. precision =
1 / variance.
25 By bias it is meant that an inaccurate estimation of the association of interest is obtained. In the
context above, bias =   0ˆ E .
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Subgroup effectiveness and cost effectiveness
Chapter 3 illustrated that when no covariates are taken into account, effectiveness
results from using AD and AD + IPD should be equivalent, given the outcome
assessed is binary26. However, AD and study level covariate information were shown
to provide an incomplete and/or inaccurate understanding of the true nature of the
association between the intervention effect and particular participant characteristics,
generating imprecise and/or biased estimates. Ecological fallacy bias (Berlin et al.,
2002, Lambert et al., 2002, Piantadosi et al., 1988) and/or confounding (Bland, 2000)
are the main reasons for this inaccuracy, as discussed in Chapter 3.
The above mentioned issues mean that, when subgroup CEA is performed, the use of
IPD, rather than AD, may affect cost effectiveness. The impact of using AD may be
reflected, for instance, through obtaining imprecise and/or biased cost effectiveness
estimates, resulting in wrong recommendations and/or decisions being made for all or
specific groups of the population. By improving precision and/or reducing bias, IPD
may facilitate approval/rejection decisions and, consequently, allow for efficiency
increments in the maximisation of health gains.
As in previous chapters, the case study is used to explore the following alternative
subgroup scenarios: (i) the number of parents in the household (i.e. ‘single’ or ‘two
parent’ family); (ii) parent(s)’ employment status (i.e. 2U or 1U); and (iii) both of
these factors.
The following sections discuss the effectiveness and cost effectiveness results from
using information for the mixture of AD + IPD, and compare these to using AD
alone. Results are initially shown for the overall population, followed by results of
the analyses considering population subgroups.
26 As discussed in Chapter 2 and 3, summary data of binary outcomes are considered ‘sufficient
statistics’, and there is no loss of information when using them (Fisher, 1922).
158
5.3 Results in the absence of subgroups
5.3.1 Effectiveness
Results in Table 5.1 show the probability of ‘functioning’ smoke alarm uptake for
each intervention, when no covariates are considered. As expected, results are very
similar between the AD and AD + IPD models. Any small differences may be a
consequence of the MCMC iterative procedure (i.e. simulation error) or a consequence
of different approaches being used with respect to cluster adjustment (i.e. ad-hoc in the
AD case and built-in in the IPD case).
Intervention (7) E + FE +F + HI has the highest probability of uptake of
(‘functioning’) smoke alarms. Except for interventions (1) UC and (2) E, both models
estimate probabilities of ‘functioning’ smoke alarm uptake in excess of 80%.
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Table 5.1 - Absolute probabilities of ‘success’ estimates (i.e. uptake of ‘functioning’ safety
equipment in the household) for each intervention result of fitting different MTC models
(AD and AD plus IPD) without including covariates, to the functioning smoke alarm
outcome data.
5.3.2 Cost effectiveness
This section discusses the impact of using AD + IPD effectiveness evidence to
populate the decision model, compared to using AD only. Table 5.2 depicts the results
of the two alternative analyses, by reporting expected benefits and costs, ICERs and
the probability of each treatment being cost effective. Given that relative effectiveness
does not differ between these two analyses (section 5.3.1), cost effectiveness results
are not affected. In both scenarios, intervention (1) UC has the highest probability of
being cost effective with approximately 0.9 and 0.6 at £20,000 and £30,000 threshold
values, respectively. At a threshold value of approximately £35,000 and above per
QALY gained, programmes including education and free / low-cost equipment ((3) E
+ FE) are most cost effective for the population. Despite the high effectiveness of
intervention 7, its costs preclude recommendation at conventional threshold levels.
Median of
MCMC
posterior sample
95 per cent
credible interval
Median of
MCMC
posterior sample
95 per cent
credible interval
(1) UC 0.695 0.647 to 0.74 0.686 0.412 to 0.869
(2) E 0.671 0.207 to 0.942 0.655 0.155 to 0.951
(3) E + FE 0.876 0.459 to 0.986 0.868 0.382 to 0.987
(4) E + FE + HI 0.852 0.448 to 0.983 0.849 0.382 to 0.986
(5) E + FE + F 0.859 0.4 to 0.982 0.853 0.327 to 0.985
(6) E + HI 0.880 0.413 to 0.991 0.876 0.347 to 0.993
(7) E + FE + F + HI 0.941 0.651 to 0.993 0.938 0.575 to 0.994
** (1) UC - usual care; (2) E - education; (3) E + FE - education plus low cost / free equipment; (4) E + FE + HI - education plus low cost /
free equipment plus home inspection; (5) E + FE + F - education plus low cost / free equipment plus fitting; (6) E + HI - education plus
home inspection; (7) E + FE + F + HI - education plus low cost / free equipment plus fitting + home inspection.
Random effects MTC of AD -
network of 20 studies
Absolute
probability of
success of
interventions
**
Notes:
* Nine of the 20 studies had individual level data available
Random effects MTC of AD
and IPD - network of 20
studies*
Probability
Interpretation
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Table 5.2 – Cost effectiveness results for all interventions and for when AD and AD plus IPD
on effectiveness was synthesised and used to populate the decision model. Both analyses use
base case characteristics and, in both, evidence informing all other economic model
parameters remained the same.
AD effectiveness evidence used
Intervention Expected
Costs
Expected
QALYs
ICER
(£/QALY)
NMB (£)
Probability
cost
effective
NMB (£)
Probability
cost
effective
NMB (£)
Probability
cost
effective
(1) UC 981,747 54.46134 --- 107,480 0.906 652,093 0.579 1,741,320 0.108
(2) E 981,748 54.46137 Extendeddominated
107,479 0.014 652,093 0.062 1,741,320 0.074
(3) E + FE 981,749 54.46140 33,045 107,479 0.080 652,093 0.359 1,741,321 0.818
(4) E + FE + HI 981,751 54.46140 Dominated 107,477 0.000 652,091 0.000 1,741,319 0.000
(5) E + FE + F 981,751 54.46140 Dominated 107,477 0.000 652,091 0.000 1,741,319 0.000
(6) E + HI 981,750 54.46138 Dominated 107,477 0.000 652,091 0.000 1,741,318 0.000
(7) E + FE + F
+ HI
981,753 54.46140 1,244,477 107,475 0.000 652,089 0.000 1,741,317 0.000
AD + IPD effectiveness evidence used
(1) UC 972,862 54.46162 --- 125,691 0.914 670,291 0.605 1,759,490 0.114
(2) E 972,863 54.46164 Extended
dominated
125,691 0.011 670,290 0.060 1,759,490 0.074
(3) E + FE 972,864 54.46167 33,752 125,690 0.076 670,291 0.335 1,759,491 0.811
(4) E + FE + HI 972,866 54.46167 Dominated 125,688 0.000 670,288 0.000 1,759,489 0.000
(5) E + FE + F 972,866 54.46167 Dominated 125,689 0.000 670,289 0.000 1,759,489 0.001
(6) E + HI 972,865 54.46165 Dominated 125,689 0.000 670,289 0.000 1,759,488 0.000
(7) E + FE + F
+ HI
972,868 54.46167 1,107,554 125,686 0.000 670,287 0.000 1,759,487 0.000
£50,000 per QALY
Cost effectiveness threshold at
£20,000 per QALY £30,000 per QALY
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5.4 Results in the presence of mutually exclusive subgroups
5.4.1 Subgroup analyses: number of parents in the household (two vs single)
5.4.1.1 Effectiveness
In this subsection the probabilities of smoke alarm uptake estimates for each
intervention are presented for instances when a binary covariate on the number of
parents in the household is included in the modelling. Results are depicted graphically
in Figure 5.1.
In general, point estimates are lower when using AD within the 2P subgroup,
compared to using AD + IPD. The reverse is observed in the 1P subgroup. The use of
IPD is reflected by having narrower 95% CrI in the 2P subgroup, when compared to
the use of AD only. In the 1P subgroup the gain in accuracy when using IPD is more
evident, with large shifts in the point estimates when compared to using AD only. The
largest point estimate difference between these two models is found in the 1P
subgroup and for intervention (2) E: when using AD, the ‘functioning’ smoke alarm
uptake probability is estimated to be approximately 0.93; when using AD + IPD it is
estimated to be 0.63.
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Figure 5.1 – Absolute probabilities of ‘success’ estimates (i.e. uptake of ‘functioning’ safety equipment in the household) for two parent families
(2P) and single parent families (1P) from fitting the MTC model for AD (i.e. MTC AD RE) and for AD plus IPD (i.e. MTC AD+IPD RE).
Note: (1) UC - usual care; (2) E - education; (3) E + FE - education plus low cost / free equipment; (4) E + FE + HI - education plus low cost / free equipment plus home inspection; (5) E + FE + F -
education plus low cost / free equipment plus fitting; (6) E + HI - education plus home inspection; (7) E + FE + F + HI - education plus low cost / free equipment plus fitting + home inspection.
Absolute probability of success
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5.4.1.2 Cost effectiveness
Results in Table 5.3 relate to the subgroups analysis of two and single parent
families. For the 2P subgroup, decisions to adopt or reject interventions are similar
using AD and AD + IPD, which, in turn, are similar to those discussed above for the
overall population. With respect to 1Ps, results are slightly different when
effectiveness AD and AD + IPD are used. If AD is used, the intervention including
only education (i.e. (2) E) achieves approximately 20% probability of being cost
effective at approximately £30,000 per additional QALY, while combining AD +
IPD, this probability is no more than 8% – the reader is reminded that the largest
difference between effectiveness point estimates (i.e. smoke alarm uptake
probabilities) from AD and AD + IPD was found for this intervention (see Figure
5.1). Despite this, in both situations, interventions (2), (4), (5) and (6) are dominated
or extended dominated by other programmes and approval decisions are not altered
between AD and AD + IPD if a £30,000 threshold value is used. However, when
using AD, approval decisions are altered if the decision maker is willing to ‘pay’ (or
displace) approximately £32,000 per additional QALY (i.e. intervention (3) E + FE
is cost effective). This is indicative of higher decision uncertainty around this
particular threshold value, which is not observed when IPD is used.
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Table 5.3 - Cost effectiveness results for all interventions, for the 2P and 1P subgroups and
for when AD and AD plus IPD effectiveness evidence was synthesised and used to populate
the decision model.
(1) UC (2) E (3) E + FE (4) E + FE+ HI
(5) E + FE
+ F (6) E + HI
(7) E + FE
+ F + HI
AD effectiveness evidence used
---
Extended
dominated
33,806 Dominated Dominated Dominated 1,443,376
20,000 0.920 0.004 0.076 0.000 0.000 0.000 0.000
30,000 0.629 0.031 0.339 0.000 0.000 0.000 0.000
50,000 0.140 0.034 0.825 0.000 0.000 0.000 0.000
AD + IPD effectiveness evidence used
---
Extended
dominated
33,078 Dominated Dominated Dominated 1,414,877
20,000 0.897 0.011 0.092 0.000 0.000 0.000 0.000
30,000 0.592 0.064 0.344 0.000 0.000 0.000 0.000
50,000 0.110 0.075 0.813 0.000 0.001 0.000 0.000
(1) UC (2) E (3) E + FE (4) E + FE
+ HI
(5) E + FE
+ F
(6) E + HI (7) E + FE
+ F + HI
AD effectiveness evidence used
---
Extended
dominated
30,877
Extended
dominated
Dominated Dominated 2,507,302
20,000 0.843 0.066 0.091 0.000 0.000 0.000 0.000
30,000 0.455 0.193 0.352 0.000 0.000 0.000 0.000
50,000 0.066 0.116 0.817 0.001 0.000 0.000 0.000
AD + IPD effectiveness evidence used
---
Extended
dominated
33,583
Extended
dominated
Dominated Dominated 1,272,082
20,000 0.903 0.013 0.084 0.000 0.000 0.000 0.000
30,000 0.591 0.077 0.332 0.000 0.000 0.000 0.000
50,000 0.129 0.089 0.779 0.001 0.002 0.000 0.000
* where λ is the threshold ratio
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5.4.2 Subgroup analyses: household employment status (employed vs at least
one parent unemployed)
5.4.2.1 Effectiveness
Absolute probabilities of ‘functioning’ smoke alarms uptake for each subgroup
relating to household employment status are shown in Table 5.4.
Table 5.4 – Absolute probabilities of ‘success’ estimates (i.e. uptake of ‘functioning’ safety
equipment in the household) from fitting the MTC model for AD and for AD plus IPD
including covariate ‘single parent status’ to the functioning smoke alarm outcome data.
Median of
MCMC
posterior sample
95 per cent
credible interval
Median of
MCMC
posterior sample
95 per cent
credible interval
(1) UC 0.803 0.421 to 0.956 0.802 0.405 to 0.945
(2) E 0.525 0.036 to 0.955 0.759 0.193 to 0.977
(3) E + FE 0.814 0.149 to 0.993 0.910 0.405 to 0.993
(4) E + FE + HI 0.768 0.192 to 0.984 0.890 0.355 to 0.991
(5) E + FE + F 0.813 0.105 to 0.993 0.902 0.402 to 0.993
(6) E + HI 0.861 0.199 to 0.997 0.926 0.429 to 0.996
(7) E + FE + F + HI 0.915 0.307 to 0.995 0.961 0.627 to 0.997
(1) UC 0.803 0.421 to 0.956 0.802 0.405 to 0.945
(2) E 0.833 0.046 to 0.999 0.718 0.139 to 0.977
(3) E + FE 0.954 0.17 to 1 0.895 0.34 to 0.994
(4) E + FE + HI 0.966 0.233 to 1 0.873 0.265 to 0.992
(5) E + FE + F 0.917 0.081 to 0.999 0.874 0.275 to 0.992
(6) E + HI 0.968 0.2 to 1 0.910 0.329 to 0.996
(7) E + FE + F + HI 0.979 0.232 to 1 0.952 0.505 to 0.997
Random effects MTC of AD -
network of 20 studies
Random effects MTC of AD
and IPD - network of 20
studies*
Interpretation
Probability
Absolute
probability of
success of
interventions for
families with
employed
parents (2E) **
Absolute
probability of
success of
interventions for
families with at
least one parent
unemployed
(1E) **
Notes:
* Nine of the 20 studies had individual level data available
** (1) UC - usual care; (2) E - education; (3) E + FE - education plus low cost / free equipment; (4) E + FE + HI - education plus low cost /
free equipment plus home inspection; (5) E + FE + F - education plus low cost / free equipment plus fitting; (6) E + HI - education plus
home inspection; (7) E + FE + F + HI - education plus low cost / free equipment plus fitting + home inspection.
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The use of IPD in the MTC modelling implies a gain in precision, translated as having
a narrower 95% CrI of the uptake probability posterior samples, when compared to the
use of AD. This is verified for both subgroups. The largest point estimate difference
from using AD and AD + IPD is found for intervention (2) E – this is true for both
subgroups. Generally, differences between estimates of AD and AD + IPD are larger
in 2Us, than in the 1Us.
5.4.2.2 Cost effectiveness
Table 5.5 shows the subgroup cost effectiveness results for ‘employed’ and ‘at least
one unemployed parent’ subgroups. The use of AD leads to more marked difference
between subgroups, whereas the use of IPD brings some consistency to the results in
the sense that expected ICERs and the probabilities of being cost effective are similar
for both subgroups for each intervention.
167
Table 5.5 – Cost effectiveness results for all interventions, for the 2U and 1P subgroups and
for when AD and AD plus IPD effectiveness evidence was used.
(1) UC (2) E (3) E + FE (4) E + FE
+ HI
(5) E + FE
+ F
(6) E + HI (7) E + FE
+ F + HI
AD effectiveness evidence used
---
Extended
dominated
35,965 Dominated Dominated Dominated 786,894
20,000 0.914 0.011 0.075 0.000 0.000 0.000 0.000
30,000 0.674 0.038 0.288 0.000 0.000 0.000 0.000
50,000 0.185 0.054 0.758 0.001 0.002 0.000 0.000
AD + IPD effectiveness evidence used
---
Extended
dominated
32,480 Dominated Dominated Dominated 1,308,633
20,000 0.904 0.014 0.082 0.000 0.000 0.000 0.000
30,000 0.555 0.096 0.349 0.000 0.000 0.000 0.000
50,000 0.108 0.080 0.812 0.000 0.000 0.000 0.000
Employed Parent' Households
Interventions
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(1) UC (2) E (3) E + FE (4) E + FE
+ HI
(5) E + FE
+ F
(6) E + HI (7) E + FE
+ F + HI
AD effectiveness evidence used
---
Extended
dominated
32,149 2,048,905 Dominated Dominated 2,628,186
20,000 0.861 0.048 0.091 0.000 0.000 0.000 0.000
30,000 0.498 0.162 0.340 0.000 0.000 0.000 0.000
50,000 0.104 0.108 0.786 0.001 0.000 0.000 0.000
AD + IPD effectiveness evidence used
---
Extended
dominated
33,194 Dominated Dominated Dominated 1,272,219
20,000 0.892 0.025 0.083 0.000 0.000 0.000 0.000
30,000 0.574 0.086 0.340 0.000 0.000 0.000 0.000
50,000 0.121 0.084 0.794 0.000 0.000 0.000 0.000
At Least One Unemployed Parent' Households
Interventions
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Notes:
* where λ is the threshold ratio
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5.4.3 Subgroup analyses: number of parents in the household and their
employment status
5.4.3.1 Effectiveness
Table 5.6 shows the probability of ‘success’ of the interventions for four subgroups.
For subgroup ‘two employed parents family’ (2EP), the ‘functioning’ smoke alarm
uptake for all interventions estimated when using AD is lower than the one estimated
from AD + IPD. In general, it is also the case for this subgroup that differences
between probability point estimates obtained from using AD and AD + IPD are larger
across interventions. These differences are generally smaller in the subgroup of
unemployed single parents (1UP). Again, the intervention for which the largest
difference in point estimates between using AD and AD + IPD is found for is the one
which provides only education, (2) E.
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Table 5.6 - Absolute probabilities of ‘success’ estimates (i.e. uptake of ‘functioning’ safety
equipment in the household) from fitting the MTC model for AD and for AD plus IPD
including covariates ‘single parent status’ and ‘parents’ employment status’ to the functioning
smoke alarm outcome data.
Median of
MCMC
posterior sample
95 per cent
credible interval
Median of
MCMC
posterior sample
95 per cent
credible interval
(1) UC 0.600 0.097 to 0.967 0.602 0.162 to 0.948
(2) E 0.125 0.002 to 0.939 0.606 0.065 to 0.976
(3) E + FE 0.615 0.025 to 0.993 0.832 0.155 to 0.993
(4) E + FE + HI 0.528 0.034 to 0.98 0.764 0.129 to 0.989
(5) E + FE + F 0.474 0.01 to 0.988 0.822 0.165 to 0.992
(6) E + HI 0.717 0.038 to 0.997 0.868 0.157 to 0.996
(7) E + FE + F + HI 0.753 0.024 to 0.995 0.917 0.281 to 0.997
(1) UC 0.600 0.097 to 0.967 0.602 0.162 to 0.948
(2) E 0.957 0.002 to 1 0.551 0.03 to 0.981
(3) E + FE 0.992 0.01 to 1 0.839 0.106 to 0.997
(4) E + FE + HI 0.991 0.01 to 1 0.870 0.139 to 0.998
(5) E + FE + F 0.987 0.007 to 1 0.788 0.085 to 0.994
(6) E + HI 0.996 0.024 to 1 0.892 0.13 to 0.998
(7) E + FE + F + HI 0.997 0.018 to 1 0.927 0.201 to 0.999
(1) UC 0.600 0.097 to 0.967 0.602 0.162 to 0.948
(2) E 0.905 0.004 to 1 0.541 0.039 to 0.973
(3) E + FE 0.992 0.074 to 1 0.807 0.122 to 0.993
(4) E + FE + HI 0.994 0.074 to 1 0.731 0.097 to 0.989
(5) E + FE + F 0.978 0.024 to 1 0.780 0.109 to 0.991
(6) E + HI 0.994 0.085 to 1 0.844 0.115 to 0.996
(7) E + FE + F + HI 0.995 0.074 to 1 0.899 0.205 to 0.997
(1) UC 0.600 0.097 to 0.967 0.602 0.162 to 0.948
(2) E 0.678 0 to 1 0.504 0.023 to 0.98
(3) E + FE 0.938 0 to 1 0.831 0.092 to 0.997
(4) E + FE + HI 0.957 0 to 1 0.858 0.108 to 0.998
(5) E + FE + F 0.830 0 to 1 0.754 0.061 to 0.994
(6) E + HI 0.966 0.001 to 1 0.884 0.1 to 0.998
(7) E + FE + F + HI 0.967 0 to 1 0.919 0.173 to 0.999
Random effects MTC of AD -
network of 20 studies
Random effects MTC of AD and
IPD - network of 20 studies *
Interpretation
Probability
Absolute
probability of
success of
interventions for
two employed
parent families
(2EP) **
Absolute
probability of
success of
interventions for
employed single
parent families
(1EP) **
Absolute
probability of
success of
interventions for
families with two
parents and at
least one parent
unemployed
(2UP) **
Absolute
probability of
success of
interventions for
unemployed
single parent
families (1UP)
**
Notes:
* For nine of the 20 studies individual level data was available
** (1) UC - usual care; (2) E - education; (3) E + FE - education plus low cost / free equipment; (4) E + FE + HI - education plus low cost / free
equipment plus home inspection; (5) E + FE + F - education plus low cost / free equipment plus fitting; (6) E + HI - education plus home
inspection; (7) E + FE + F + HI - education plus low cost / free equipment plus fitting + home inspection.
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5.4.3.2 Cost effectiveness
Cost effectiveness results for the four subgroups are shown in Table 5.7. The use of
IPD rather than just AD, contributes to the consistency of cost effectiveness results
across subgroups. When considering the subgroup of 2EPs, a shift in the expected
ICER estimate for intervention (3) E +FE is observed when using AD – that is, an
estimated mean ICER of approximately £41,000 compared to £35,500 per QALY
gained when IPD is used. This shift implies that, for instance, using a £30,000
threshold value, the estimated probability of intervention (1) UC being cost effective is
0.75 when using AD, but 0.64 when using AD + IPD.
If a threshold value of £30,000 is used, approval / rejection decisions are the same for
each subset of the population – (1) UC is the intervention recommended. This is valid
when using AD + IPD. When using AD, and for a threshold value of £33,000 per
QALY gained, intervention (3) E + FE would be recommended for use in the 1EP
subgroup. If AD + IPD is used, intervention (3) E + FE is not considered cost
effective at that particular threshold value, indicating that cost effectiveness decisions
may alter depending on the level of disaggregation of the evidence informing model
inputs and the ability to appropriately capture the true underlying effects and
associations.
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Table 5.7 – Cost effectiveness results for all interventions, for 4 subgroups of families: (a) 2 employed (2EP); (b) employed single (1EP); (c) 2
with at least one unemployed (2UP); and (d) unemployed single parents (1UP). Results are shown for when using AD and AD plus IPD to populate
the decision model.
(1) UC (2) E (3) E +
FE
(4) E +
FE + HI
(5) E +
FE + F
(6) E +
HI
(7) E +
FE + F + (1) UC (2) E
(3) E +
FE
(4) E +
FE + HI
(5) E +
FE + F
(6) E +
HI
(7) E +
FE + F +
--- Extended
dominated
40,721 Dominated Dominated Dominated 1,027,227 --- Extended
dominated
35,538 Dominated Dominated Dominated 1,058,776
20,000 0.933 0.005 0.062 0.000 0.000 0.000 0.000 20,000 0.909 0.018 0.072 0.000 0.000 0.000 0.000
30,000 0.753 0.019 0.228 0.000 0.000 0.000 0.000 30,000 0.636 0.076 0.288 0.000 0.000 0.000 0.000
50,000 0.353 0.023 0.622 0.001 0.001 0.000 0.000 50,000 0.197 0.074 0.726 0.000 0.002 0.000 0.000
--- Extended
dominated
32,055 3,989,355 Dominated Dominated 5,747,717 --- Extended
dominated
35,937 Dominated Dominated Dominated 1,021,409
20,000 0.858 0.051 0.091 0.000 0.000 0.000 0.000 20,000 0.912 0.017 0.072 0.000 0.000 0.000 0.000
30,000 0.505 0.151 0.344 0.000 0.000 0.000 0.000 30,000 0.644 0.072 0.284 0.000 0.000 0.000 0.000
50,000 0.124 0.073 0.802 0.000 0.001 0.000 0.000 50,000 0.203 0.074 0.720 0.001 0.002 0.000 0.000
--- Extended
dominated
33,961 Dominated Dominated Dominated 1,849,602 --- Extended
dominated
35,839 Extended
dominated
Dominated Dominated 989,129
20,000 0.856 0.065 0.079 0.000 0.000 0.000 0.000 20,000 0.912 0.019 0.069 0.000 0.000 0.000 0.000
30,000 0.526 0.191 0.283 0.000 0.000 0.000 0.000 30,000 0.640 0.077 0.283 0.000 0.000 0.000 0.000
50,000 0.180 0.101 0.717 0.001 0.002 0.000 0.000 50,000 0.198 0.084 0.712 0.002 0.003 0.000 0.000
--- Extended
dominated
35,013 1,642,801 Dominated Dominated 3,227,412 --- Extended
dominated
36,186 Extended
dominated
Dominated Dominated 946,311
20,000 0.874 0.050 0.076 0.000 0.000 0.000 0.000 20,000 0.905 0.018 0.076 0.000 0.000 0.000 0.000
30,000 0.554 0.154 0.292 0.000 0.000 0.000 0.000 30,000 0.645 0.070 0.285 0.000 0.000 0.000 0.000
50,000 0.199 0.115 0.680 0.003 0.004 0.000 0.000 50,000 0.214 0.089 0.691 0.003 0.003 0.000 0.000
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(d) Unemployed Single Parent Household (1UP) (d) Unemployed Single Parent Household (1UP)
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(c) Two Parent Household with at Least One Unemployed (2UP) (c) Two Parent Household with at Least One Unemployed (2UP)
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(b) Employed Single Parent Household (1EP) (b) Employed Single Parent Household (1EP)
(a) Two Employed Parent' Households (2EP) (a) Two Employed Parent' Households (2EP)
ICER (£s) ICER (£s)
AD effectiveness evidence used AD + IPD effectiveness evidence used
Interventions Interventions
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5.5 Discussion
Summary of findings
In a binary outcome setting, the use of IPD is particularly useful in guiding decision
making for particular population subgroups. In comparison with the use of evidence in
summary format, the ability to appropriately estimate treatment x covariate associations
means an accurate and/or more precise judgement of an intervention’s cost effectiveness
for a particular subgroup of the population. Thus, access and use of IPD is important in
providing an appropriate answer to one of the key questions of any appraisal; that is,
from the available evidence, for which subset of the targeted population is the
programme considered cost effective?
The case study results revealed that all active interventions were not cost effective at
population level using a £30,000 threshold value. This result was consistent using AD
and AD + IPD. Results supported the idea that, if only effectiveness AD was used,
uncertainty about the intervention to approve for particular subgroups was higher.
Similar conclusions to the population average were obtained in the subgroup analyses.
Nonetheless, the fact that the case study conclusions pointed to the same decision for
each population subgroup does not imply that in other case studies, or in other
circumstances, the decision would be the same for all subgroups27.
Study strengths, limitations and further work
The main contribution of the current chapter was to illustrate and discuss the expected
benefits from integrating the results of a novel MTC model for the simultaneous
27 As emphasised in Chapter 4, the reader is reminded of the inexistence of a predefined threshold
outside the health sector. As the case study results shown in this chapter were obtained using a public
sector viewpoint, it implies that approval decisions are not straightforward.
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synthesis of IPD and AD within a decision model. The main tools for the analysis
developed here were the novel synthesis models discussed in Chapter 3 and the decision
analytic model described in Chapter 4.
As discussed in Chapter 3, the novel evidence synthesis models enhance the use of
evidence to the individual level, in a binary outcome setting. By comparison with the
use of AD only, advantages from the IPD approach were discussed. Nonetheless, these
synthesis models could be extended to consider other types of outcome measures. For
instance, if the MTC outcome was of continuous or time to event nature, it would be
interesting to assess the impact on cost effectiveness results when using AD and IPD
due to, for example, the existence of nonlinearities, among other potential issues.
Another issue that may be considered a limitation, relates to the fact that, in the
comparisons between 1 (overall population), 2 or 4 subgroups, it was assumed that the
analyst had, in turn, access to: (i) no information on any covariate of interest; (ii)
information on one covariate; or (iii) information on two covariates simultaneously.
This implies that different synthesis models, with different specifications, were used to
obtain relative effectiveness estimates.
The findings from this chapter show the importance of using all relevant evidence when
informing a specific decision problem, in particular the role of accessing and using
evidence at the individual level. Nonetheless, analysts / modellers are aware that the
quality of the evidence used is a major factor in enabling decision makers to reach
appropriate judgements on the cost effectiveness of alternative interventions, even if
available at the individual level. The quality of the evidence and its adequacy for the
problem at hand, are also determinants in supplying support for the decision making
process.
What is the value of acquiring individual level data?
Individual participant data are regarded as the optimal vehicle for an appropriate
estimation of cost effectiveness outcomes and quantification of uncertainty through
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decision modelling. Formal modelling and assessment of baseline risks of particular
events, of intervention effects and of treatment x covariate associations, with attendant
uncertainty, are some of the fundamental advantages of using this data format. It is
argued that, when wanting to reduce decision uncertainty in a specific decision problem,
funding bodies should consider exploration of all existing evidence, in particular IPD,
before directing additional funds to sponsor new trials aimed at resolving (some of) the
uncertainty.
Nevertheless, there is a series of obstacles in obtaining and using evidence at the
individual level. These obstacles stem mainly from the difficulty in acquiring evidence
at this level from the various possible sources (e.g. pharmaceutical companies, trial
funding bodies), but also from the (time and computational) burden of exploring and
analysing it. The question for which there is no clear or direct answer is whether these
IPD ‘barriers’ outweigh its advantages, some of which are highlighted in the current
exercise.
Individual level data are unquestionably valuable. Quantifying the expected costs of
uncertainty when using AD or IPD is an important issue as it may inform decision
makers on the added value of this supplementary level of evidence. It is here flagged up
the need to explore this issue further.
Concluding remarks
This chapter showed how IPD and AD may affect cost effectiveness and allocation
decisions. Although the use of IPD may be challenging, higher accuracy and/or
precision are achieved when analysing subgroup effectiveness. Consequently, cost
effectiveness estimates derived using IPD will lead, in principle, to better decisions.
The quantification of decision uncertainty may inform decision makers on the additional
benefits provided by IPD. It is expected that it will improve the estimation of the upper
bound value of conducting further research. This topic will be subject to extensive
discussion in the following chapter.
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CHAPTER 6
6. THE VALUE OF FURTHER RESEARCH: THE ADDED VALUE
OF INDIVIDUAL-PARTICIPANT LEVEL DATA
6.1 Introduction
6.1.1 Background
In health care, decisions are inevitably made under uncertainty. In the presence of
uncertainty, a decision maker should not only consider (i) the suitability of the
provision of health care (given the available information), but also (ii) whether it is
worthwhile to fund supplementary research (to decrease existing decision uncertainty).
Chapter 5 argued the possible advantages of using evidence at the individual level
(rather than at the aggregate level) when assessing cost effectiveness, thus directly
informing question i) and laying the foundation for informing question ii) above.
Using an example from the PH field, Chapter 5 showed that the use of effectiveness
evidence at the aggregate level provided only partial and/or incorrect insight into the
true relationship between the relative effects of interventions and particular patient
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characteristics28. Subgroup cost effectiveness estimates obtained when including
evidence as IPD were more accurate (i.e. less biased) and/or more precise.
In estimating the value of conducting further research [item ii) listed above],
characterising and quantifying decision uncertainty and its consequences are key
components. One of the main reasons for the existence of decision uncertainty is that
decisions are based on sampled data, so that true model parameter values cannot be
known with certainty29. Whilst a particular health technology may be (on average) cost
effective, our confidence in this assessment may be low. Moreover, it may also be
important to explore heterogeneity between patients (e.g. through defining subgroups
of the targeted population). In fact, population average based judgements may disguise
sources of heterogeneity that should be reflected in decision making. When conducting
subgroup analyses, quantifying uncertainty for each population strata can and should
be performed (NICE, 2008, Sculpher, M., 2008). Not only is the possibility of making
different decisions for different subsets of the population important, but also
determining the value of performing further research in each subset is. As highlighted
previously, for the class of models used in this thesis, it is in situations like this that
the role of (and the benefits from) using IPD, compared with AD, becomes more
evident, i.e. quantifying uncertainty in subgroups is generally most accurately attained
when this type of evidence is available.
There has been an increase in awareness of the need to deal with subgroups and
heterogeneity in health care decision making. Defining appropriate and meaningful
subgroups is complex in itself. Sculpher (2008) highlights several potential forms of
subgroups and heterogeneity, pointing the reader in the direction of correctly
identifying subgroups and the advantages of reflecting these in decision making. This
paper was the basis for the NICE methods guidance on subgroup analysis (NICE,
28 It is important to remind the reader that, in this example, binary outcome measures were synthesised
across studies using a MTC.
29 As highlighted in the introductory chapter, structural uncertainty is also another key element for
decision uncertainty.
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2008). Coyle et al. (2003) outline a more quantitative approach, defining population
NBs in the presence of subgroups. Taking into account equity considerations, the
authors allow for different decisions between subgroups and also identify optimal
criteria in access to health care technologies, leading to the maximisation of efficiency
gains, though decision uncertainty was not explored to inform the need for further
research.
In the limit, the existence of heterogeneity implies that decisions may be made at the
individual level. This was discussed by Basu (2009), who put forward the idea of
performing individual level effectiveness assessments (individualized comparative
effectiveness research, i-CER). The i-CER replaces the usual average treatment effect
estimation for the entire target population (or subgroup) by assessing the effect of the
treatment at the individual level. Basu and Meltzer (2007) outlined a method to
quantify the potential gains of providing decision making at the individual level. Their
framework proposes the estimation of the expected value of individualised care
(EVIC) to show what society is willing to pay in order that individually efficient
decisions may be made (Basu & Meltzer, 2010).
More recently, Basu (2011) demonstrated how individual preferences can be estimated
to facilitate the estimation of the EVIC. It was shown that market failures such as the
presence of asymmetric, imperfect and/or incomplete information [between the person
(patient) and the insurer] may generate inefficiencies in the society owed to moral
hazard effects (Pauly & Blavin, 2008). In this paper Basu presented a new modelling
approach, which allowed for both within- and between-treatment heterogeneity in
outcomes. This novel econometric approach facilitates the estimation of marginal
benefit curves, derived from both observed and unobserved patient characteristics,
aimed at representing individual treatment effects heterogeneity. This methodological
development contributed to the understanding of the value of considering
heterogeneity in CEA, although it has not formally addressed the issue of uncertainty
associated with decisions based on other than the average.
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Espinoza et al. [unpublished, (2011)] advocated that whilst a higher number of
subgroups may generate more population net health, the transaction costs associated
may not compensate these at the margin. The framework developed, combined the
work of Coyle (2003) and Basu and Meltzer (2010, 2007), generalising this framework
and defining in practice how to conduct CEA in the presence of subgroups. Espinoza
et al. (2011) extended Coyle’s (2003) work by addressing the potential benefits of
characterizing heterogeneity not only in terms of increased individual benefits based
on current information, but also in estimating the value of conducting further research.
The authors generalised the concept of expected value of perfect information (EVPI)
adopted by Claxton and others (1996) in order to consider mutually exclusive
population subgroups. They extended Basu and Meltzer’s (2010, 2007) work by
acknowledging that a continuum exists from decisions made at the mean-, at the
subgroup- and at the individual level, the latter with all existing heterogeneity
explained and in absence of (decision) uncertainty. It also provided support for the
understanding of EVIC by highlighting the concept of the value of heterogeneity
(VoH), separating it into static and dynamic values – concepts that will be discussed
later in this chapter.
6.1.2 Aims and objectives
This chapter uses Basu and Meltzer’s (2010, 2007) and Espinoza and colleagues’
(2011) framework to explore issues around the potential benefits of accessing data at
the individual level. While Espinoza and colleagues’ paper conceptually highlighted
the potential sources of heterogeneity and the choices to effect an appropriate selection
of subgroup specifications for the analysis, it provided few insights on the particular
type of data needed to perform such tasks30 (i.e AD and/or IPD). Therefore, this
chapter seeks to assess the added value of having access to IPD, compared to using
AD only, in appropriately performing subgroup value of information analysis. This
chapter begins by examining the situation of having access to relevant evidence at
30 In fact, Espinoza and colleagues’ (2011) paper demonstrated their conceptual framework by
implementing it in an already existing trial base economic model.
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summary level and/or at individual level without considering subgroups. The objective
is not to prospectively identify optimal research designs using these two evidence
types (i.e. with optimal sample size and patient allocation procedure, correct follow-up
periods and endpoints (Briggs, A. H. et al., 2006)), but to provide sufficient evidence
to support the use of particular intervention(s).
The framework developed in this chapter aims to be as generic as possible in
understanding the implications of considering IPD. These implications are illustrated
through the use of a case study, as explored in previous chapters. The effectiveness of
different programmes, intended to increase the uptake of functioning fire alarm
equipment in households (binary outcome, 1 – the presence of functioning smoke
alarm equipment, 0 – no functioning equipment), was explored in Chapter 3. It was
extended in Chapter 4 with a cost effectiveness assessment of the different relevant
alternatives. Assessments were made with the purpose of verifying the advantages of
having access and using all relevant evidence, in particular, of using IPD (Chapter 5).
The current chapter assesses the added value of acquiring IPD in providing
information for further research on fire alarm program awareness.
In the case study used in this chapter – as in Chapters 3, 4 and 5 – the use of IPD only
(i.e. ignoring the existence of AD) implies a smaller evidence network and,
consequently, a smaller number of alternative interventions to be evaluated. As a
result, comparisons here are only made between results from using the evidence at AD
and AD + IPD, with IPD only analysis excluded. Therefore, in this chapter and in the
context of the motivating example, the use of the expressions ‘IPD’ and ‘AD + IPD’
may be considered exchangeable.
This chapter also seeks to provide an assessment of the value in considering
heterogeneity in decisions made on the basis of existing and additional information. In
this respect, the case study makes use of two binary covariates: number of parents in
the family (0 = 2P; 1 = 1P) and their employment status (0 = 2U; 1 = 1U). With the
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use of these two covariates, two (and two different specifications31) or four subgroups
are defined. To fully understand the value of considering IPD in the presence of
subgroups, four scenarios are considered: (i) no subgroups (AD) vs. no subgroups
(IPD) ; (ii) no subgroups (AD) vs. all subgroups (IPD); (iii) some subgroups (AD) vs.
all subgroups (IPD); and (iv) all subgroups (AD) vs. all subgroups (IPD). Scenario (i)
proposes providing an answer to the expected benefits from considering IPD
compared to AD when making population average decisions. Scenarios (ii), (iii) and
(iv) propose to assess the gains in disentangling existing heterogeneity at different
levels of population strata. Thus, the maximum possible NBs gained from considering
IPD (i.e. IPD with all subgroups) are compared with different AD disaggregation
levels (i.e. AD with no, some and all considered population subgroups).
As mentioned in Chapters 3, 4 and 5, different synthesis models are used to analyse
different subgroup specifications (i.e. in previous chapters, different synthesis models
were considered where: no covariate information is available; is available for just one
binary covariate; or is available for two covariates). The main reason for this approach
was to observe the consequences of a gradual increase in the availability of evidence
(i.e. from AD to IPD) and of information on covariates (i.e. from total absence of
information on covariates to availability of information on two covariates). This
approach continues to be used throughout the current chapter32.
This chapter starts by describing the main concepts of value of information analysis –
section 6.2, comprising an assessment of how available evidence may shape the
31 A specification is a subgroup definition based on an available particular level of data disaggregation.
For instance, a certain population of interest may be split in 2 mutually exclusive subgroups on the basis
of whether or not patients are diabetic (specification 1), on whether or not they are hypertense
(specification 2) or any other disaggregation based on patients characteristics. As explained by
Espinoza and colleagues (2011), the difficulty lies in obtaining information on subgroups and, more
importantly, in how to select between alternative specifications.
32 Nonetheless, a single synthesis model including the 2 covariates could be used to perform all the
analyses in this chapter. That is, the results of a 2 binary covariates synthesis model (i.e. providing
results for 4 population subgroups) could be used as a starting point to obtain results for when wanting
to assess the scenarios of ‘no subgroups’ or ‘2 subgroups’. This exercise, named ‘backward estimation’,
is explored in the Appendix 7.
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quantification of the value of additional research. This is followed by an application
that considers evidence at the summary-level and also the mixture of summary and
IPD. Section 6.3 extends the methodology to the subgroup setting, exemplifying,
through the case study, situations where two and four subgroups are defined. The final
section summarizes the main chapter findings and discusses several issues including
further research topics.
6.2 Value of additional research in the absence of subgroups
Given the presence of uncertainty surrounding the expected NBs associated with the
use of alternative technologies, decision recommendations based on current
information may change if these uncertainties are resolved. The joint probability that a
decision based on existing information will be wrong and the consequences of making
a wrong decision can be assessed and quantified (Claxton, K. et al., 2002). The
methodologies used to enable this quantification are shown next. Definitions and
descriptions of the methods are introduced first (section 6.2.1), followed by issues
relating to available evidence and the value of further research (section 6.2.2). The
results obtained through the motivating example will be given (section 6.2.3).
6.2.1 Definitions and methods
In a decision model with a vector of unknown parameters θ, with a choice to be made
between a vector of mutually exclusive interventions  Yy ,...,2,1 , the best possible
decision is the one that yields the highest expected NB33, that is, under current
information (Ades, A. et al., 2004, Claxton, K., 1999, Stinnett & Mullahy, 1998) the
optimal strategy is the one that:
33 The cost effectiveness of an alternative y can be expressed in terms of NMB (NMBy = Qy • λ - Cy,
where Cy represents the costs and Qy the consequences for alternative y).
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  ,max yNBEy (6.1)
Because true values of θ are unknown, under perfect information the NB attained is
the average of the maximum NBs over the joint distribution of θ:
  ,max yNBE y (6.2)
The EVPI is the difference between the estimated payoffs of having perfect
information from those obtained under current information, and represents the
expected opportunity loss of uncertainty surrounding decisions (Claxton, K., 1999),
that is:
     ,max,maxEVPI yNBEyNBE yy  (6.3)
The above expression refers to decisions made for one individual. At the patient
population level the EVPI reflects potential benefits of current and future patients from
additional information. This requires an assessment of the period (T) over which
information that may be acquired in the near future would be useful for the current
decision problem and the incidence over this time period (It). The population EVPI
(PEVPI), discounted at rate α, may be estimated as (Philips et al., 2008):
  

T
t
tI
t 1
EVPIPEVPI

(6.4)
6.2.2 Available evidence and the value of further research
Although in many instances, access to IPD is preferred, decision analysis does not
consider evidence as unsatisfactory if data is available only at summary level.
Nonetheless, the type of evidence available may influence one’s certainty about the
adoption decision. The current subsection focuses on the important question of the
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impact the type of evidence may have on the estimation of the need for further
research34.
Assuming the general case of a statistical synthesis model parameterized by θ and
evaluating the probability distributions of observed data (i.e. evidence or likelihood),
 xp , and pooled statistic ˆ which serves as an estimator of θ, based on any
observed data xi (i=1, …, m studies). It is assumed that the data follows some
unknown distribution and, by constructing an estimator which reflects it, it is closer to
the underlying true value, θ (whose posterior predictive distribution is then used to
populate a decision model input parameter). The analyst can have access to these m
studies at a summary level, an AD evidence base. Alternatively, it is possible to
envisage a situation in which one has access to IPD from each of these m studies, an
IPD evidence base. With access to a mixture of AD and IPD (only a proportion of
studies are available at the individual level), the aim may be to enumerate possible
benefits the synthesis of IPD may bring to the correct estimation of decision model
input parameters, considering expected consequences over the EVPI estimation when
compared to the synthesis of AD only.
In the absence of subgroups and with binary outcomes, estimated EVPI is not expected
to differ when using AD or IPD to describe the evidence base, since AD is a sufficient
statistic35 (as is the case in this chapter’s motivating example36). In contrast,
34 A further relevant question (not addressed within the current work) may be to explore design issues
regarding the additional evidence. This relates to a prospective assessment of the sampling and could be
implemented using of the expected value of sampling information (EVSI) framework. The idea here is
that resolving uncertainty completely can only be achieved by using infinitely large samples. Thus, to
explore plausible designs of further research, it is sensible to calculate the EVSI, setting it alongside the
costs of obtaining the sample. As defined by Claxton and Posnett (1996), the EVSI is “…the difference
between the reduction in the expected loss due to sample information and the costs of obtaining the
sample…and represents the societal return to proposed research”. In practical terms, EVSI often
informs the optimal sample size for a future study.
35 Summary data of binary outcomes are considered ‘sufficient statistics’ as there is no loss of
information in comparison to IPD (as discussed in Chapter 2 – section 2.2).
36 In the case study, if no subgroups are being considered, EVPI estimates should be equivalent for
when using AD and for when using the same evidence set partially at IPD format. Marginal differences
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differences in EVPI are to be expected when synthesising continuous outcomes.
Interpretations of such differences should be carried out with caution. These do not
reflect the value of acquiring further evidence or the value of acquiring IPD rather than
AD. In this case, AD and IPD represent the same evidence base, where the IPD is one
realisation of all possible datasets described by the AD37. Hence, using IPD generates
more efficient estimates38 of EVPI than using AD.
Three ways can be envisaged in which access to IPD, rather than AD, can influence
results (in the absence of subgroups). The following scenarios are intended to be as
generic as possible.
between these may however occur, caused by external factors (e.g. due to the cluster adjustment
procedure in the synthesis that is done ad-hoc in the AD case and built-in in the IPD case, or due to
simulation error – although we acknowledge that the latter can be resolved (Oakley et al., 2010)).
37 This can be easily illustrated with a brief example: let’s consider that the researcher has access to the
following AD – four individuals are sampled from the targeted population (n = 4) in which two have
had the event of interest (r = 2) and two of them have a relevant characteristic represented by the
covariate (cov). Despite the researcher not having access to the IPD which generated the AD
information, the IPD can only be one of the following: a) all individuals that had the event do not have
the characteristic of interest (IPD 1 in the table below); b) all individuals that had the event have the
characteristic of interest (IPD 2 in the table below); and c) half the individuals that had the event also
have the characteristic of interest (IPD 3 in the table below).
The IPD that was reduced to generate the AD can only be one of the 3 cases described above; that is, it
is one realisation from a range of possible datasets from the AD. The figure above represents the
evidence generated on a hypothetical parameter of interest (in this case the probability of observing an
event in the subgroup of patients with the covariate), generated from each possible IPD dataset and from
the AD. Estimates from AD are expected to consider the possibility of evidence being from any of the
IPD sets. Thus, AD estimates are shown as less precise.
38 With IPD we expect to obtain an unbiased statistic with sufficiently smaller variance (efficient
statistic) when compared to using AD. As defined in chapter 5, by bias it is meant that an inaccurate
estimation of the association of interest is obtained.
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Scenario 1.1: If, by comparison with the use of AD evidence base, the use of IPD
involves an increase in parameter(s) precision (efficiency), obtained distribution of
relative treatment effects will have lower or equal variance, i.e.    IPDAD VarVar  ˆˆ  –
Figure 6.1a. Therefore, across a range of possible threshold values, EVPI values are
expected to decrease due to the precision gained on this particular decision model
parameter, all other model parameters constant – Figure 6.1b.
Figure 6.1 - Representation of (a) an increase in estimates precision when IPD is considered;
and (b) the possible consequences over the EVPI when using AD and IPD in these
circumstances (scenario 1.1).
Scenario 1.2: If, by comparison with the use of an AD evidence base, the use of IPD
may involve a reduction or elimination of bias in estimates, which may imply a shift in
the distribution of effects (for simplicity it is here assumed an impact on the scale
parameter, and not on the shape and/or dispersion parameters) – Figure 6.2a depicts a
hypothetical situation where the estimates derived from AD are biased upwards, i.e.
   IPDAD EE  ˆˆ  . This may be translated in shifts in the mean ICER and
consequently shifts in EVPI curves as depicted in Figure 6.2b – assuming constant
information for all other model parameters.
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Figure 6.2 - Representation of (a) a decrease (removal) of bias in obtained estimates when
IPD is considered; and (b) the possible consequences over the EVPI when using AD and IPD
in these circumstances (scenario 1.2).
Whilst in scenario 1.1 it can be predicted that EVPI is lower when using IPD, in the
current scenario it cannot.
Scenario 1.3: This situation entails both an increase in precision and a reduction in
bias from using IPD relatively to AD. The following graphical representation
illustrates this scenario and interpretations can be inferred from the two previous
examples – Figure 6.3. In this scenario it cannot be predicted how the availability of
IPD will affect the EVPI estimates.
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Figure 6.3 - Representation of (a) an increase in precision and a decrease (removal) of bias in
obtained estimates when IPD is considered; and (b) the possible consequences over the EVPI
when using AD and IPD in these circumstances (scenario 1.3).
In the following subsection comparisons will be made between using AD and AD +
IPD to inform the case study decision model.
6.2.3 Application: value of additional research in the context of having access to
individual participant level data
The analyses carried out in this subsection are made under the PH perspective. A 10
years expected lifetime of the programmes39 and an annual effective population (i.e.
expected number of new households with dependent/s under 5 years old per year in the
UK) of 31,000 households (ONS, 2010a) were considered adequate for the value of
information analysis calculations.
Figure 6.4 summarizes the main cost effectiveness results when AD is used to inform
the smoke alarms decision model. In this analysis, no subgroups are taken into account
(i.e. it is assumed that no covariate information is available) and relate to population
39 The choice of the programme lifetime is linked to the fact that most alarms installed today have a life
span of about 8-10 years. After this time the entire unit should be replaced, as recommended by the
National Fire Protection Association (NFPA).
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average decisions – see Chapter 4, section 4.4 for additional details. Usual care,
identified as (1) in the figure, has the highest expected NBs and is also associated with
the highest probability of being cost effective at a £30,000 threshold ratio, though this
might not always be the case (Fenwick et al., 2004).
Figure 6.4 – Cost effectiveness results for the smoke alarms decision model: NMBs estimates
at £30,000 threshold ratio versus the probability of the intervention(s) being cost effective.
Results shown are for when AD only was used to inform the effectiveness decision model
parameters and when no subgroups are considered.
Note: (1) UC – usual care; (2) E - education; (3) E + FE - education plus low cost / free equipment; (4) E +
FE + HI - education plus low cost / free equipment plus home inspection; (5) E + FE + F - education plus
low cost / free equipment plus fitting; (6) E + HI - education plus home inspection; (7) E + FE + F + HI -
education plus low cost / free equipment plus fitting + home inspection.
As highlighted in Chapter 5, since the outcome variable analysed in the MTC model is
binary, population average (cost) effectiveness results obtained using AD and AD +
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IPD are expected to be similar40 in the absence of covariates (no subgroups). These
similarities were expected. In Table 6.1 a more detailed view of the cost effectiveness
results when AD + IPD effectiveness evidence is used to inform the decision model,
all other evidence informing the model remaining constant.
Table 6.1 – Expected cost effectiveness of functioning smoke alarms interventions per
participant for when using AD plus IPD effectiveness evidence to inform the economic model.
The figures presented in the above table are at the participant level. Estimates of the
NMBs obtained are of approximately £28.7 and £29.4 billions, when using AD and
AD + IPD, respectively41. In Figure 6.5 estimates obtained with current information
are represented at the lower end of the bar. The upper end represents the population
NBs attained with perfect information. The population EVPI is the difference between
the NBs with perfect information and with current information. As expected, the
population EVPI estimates are almost equivalent – approximately £5,420 and £5,450
40 Although estimates from both scenarios should be equivalent, small differences were found and are
discussed above and in Chapter 5.
41 Again, population EVPI estimates from using AD and AD + IPD should be equivalent. Nonetheless,
marginal differences exist. Reasons for these differences are discussed above and in Chapter 5.
Intervention ICER
(£/QALY)
NMB (£) Probability
cost effective
NMB (£) Probability
cost effective
(1) UC --- 125,691.2 0.914 670,290.8 0.605
(2) E Extended
dominated
125,690.7 0.011 670,290.5 0.060
(3) E + FE 33,752 125,690.5 0.076 670,290.6 0.335
(4) E + FE + HI Dominated 125,688.3 0.000 670,288.4 0.000
(5) E + FE + F Dominated 125,688.5 0.000 670,288.6 0.000
(6) E + HI Dominated 125,688.7 0.000 670,288.5 0.000
(7) E + FE + F + HI 1,107,554 125,686.4 0.000 670,286.6 0.000
£20,000 per QALY £30,000 per QALY
Cost effectiveness threshold at
190
when using AD and when using AD + IPD, respectively. For a threshold value of
£30,000, estimated population EVPI is approximately £45,000 – results are not shown.
Additionally, and for both situations (AD and AD + IPD), population EVPI estimate
reaches its maximum value at approximately £33,000, when the threshold equals the
ICER of the intervention which involves providing education and free or sponsored
smoke alarm equipment (i.e. (3) E + FE) – see Chapter 4 for additional details.
Figure 6.5 – Population expected NMBs at a threshold value of £20,000 per QALY (2009
values) derived from the cost effectiveness decision model for functioning smoke alarms.
Results are shown for the use of AD and AD plus IPD effectiveness evidence.
The next section explores the implications of performing similar analysis in the
context of considering population stratifications.
NBs with perfect information
NBs with current information
NBs with perfect information
NBs with current information
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6.3 Value of additional research in the presence of mutually
exclusive subgroups
This section restates and rephrases the two important questions (referred to in the
introduction of this chapter) that are part of the health technologies appraisal process,
but now are made with subgroup considerations. Namely: i*) with existing
information, is the technology considered cost effective for all population strata –
approval of the health care intervention for which population?; and ii*) is there
justification for requesting further information for all population strata – and if not, is
further research warranted for making decisions regarding the use of the intervention
in specific subgroups of the population?
This section extends the previous one to accommodate considerations regarding the
presence of subgroups, considering also the concept of value of heterogeneity. Again,
definitions and descriptions of the methods are introduced first (section 6.3.1),
followed by issues relating to available evidence in considering subgroups (section
6.3.2). Finally, the results of these analyses are presented considering the example
(section 6.3.3).
6.3.1 Definitions and methods
Espinoza et al. (2011) show that when the decision maker is interested in subgroup
specific results, the maximum expected NBs for each subgroup k (out of a total of K
mutually exclusive subgroups), under current information can be calculated as
(analogous to equation (6.1)):
 kky yNBE k  ,max (6.5)
With respect to the situation with perfect information, the expected value of the
decision for subgroup k is:
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 kky yNBE k  ,max (6.6)
The expected opportunity cost of uncertainty for subgroup k can be expressed as:
   kkykky yNBEyNBE kk   ,max,maxEVPIk  (6.7)
The EVPI considering subgroups (EVPIK) is simply the weighted average across
subgroups considering the proportion of patients in each subgroup (wk). If, for
instance, two subgroups are considered (i.e.  2,1k ), with w1 and w2 representing the
proportion of each subgroup in the population (where   1and1,0  
K
k kk ww ),
EVPIK is:
     
     1 2
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
  
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    

(6.8)
The population EVPI (PEVPIK) considering subgroups is given by:
  

K
t
,
KK 1
EVPIPEVPI
k
T
t
tk
k I

(6.9)
where the time period for which the information on interventions is pertinent to the kth
subgroup is represented by Tk and where Ik,t represents the incidence over period t.
Espinoza et al. (2011) coined the concept of value of heterogeneity, which indicates
the merit of resolving existing heterogeneity in a subgroup setting. That is, the value of
making different decisions in different subgroups with current information and the
value of resolving parameter uncertainty conditional on a particular level of
heterogeneity. A brief description of the issues surrounding this concept is provided
here, with the aid of a schematic representation. Figure 6.6 shows the value of
heterogeneity using hypothetical examples – it compares the maximum NBs obtained
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with current and perfect information when the population is analysed as a whole and
when it is split into two, three, ..., k subgroups to the limit of explaining all existing
heterogeneity and maximizing potential benefits by performing decisions at the
individual level42 (right hand side of the figure). This diagram reflects the idea of the
existence of a continuum amongst decisions for each of these population
stratifications. Additionally, it provides grounds for the two dimensions of the VoH:
the static and the dynamic values43.
If equal gains are observed with current information when subgroups are considered or
not (gains A in Figure 6.6), the static VoH is equal to zero. If, when considering two
subgroups, the NMBs obtained with current information are higher than the ones
obtained for the average population (i.e. C > A), the static VoH is positive. Again
when considering two subgroups, if the estimated NMB with perfect information is
greater than the gains obtained for the population average (i.e. the quantity represented
by B), the dynamic VoH is positive. If the specification used to define the subgroups
facilitates the split of the targeted population and results in NMB distributions that do
not overlap, little decision uncertainty is expected and it may imply a situation like the
one illustrated with EVPIA > EVPIB2.
42 In this conceptual diagram it is assumed that, when performing decisions at the individual level (I -
individualised care), the total characterization of the heterogeneity is accomplished. This implies the
absence of decision uncertainty and that the decision maker has all information possible to efficiently
allocate resources given the complete knowledge of the individual characteristics that determine
heterogeneity (including the counterfactual). Additionally, it is assumed that transaction costs
associated with obtaining/exploring more granular subgroup specifications exist, but are neglectable.
That is, the costs of analysing/exploring available data in order to obtain an optimal level of
disaggregation is considered small and outweighed by the benefits of considering those subgroups
specifications. See section 6.4 for further discussion on these issues.
43 As described by Espinoza et al. (2011), when the decision maker wants to consider the value of
exploring further the available data (i.e. current information) with a view to explore issues of
heterogeneity, this is called the static value of heterogeneity, since this activity does not involve further
data collection. On the other hand, the dynamic value of heterogeneity represents the absolute value of
collecting further information when considering a particular level of subgroup disaggregation.
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Figure 6.6 – Two forms of VoH: (i) the static value (represented by gain A and representing
the NMB obtained with existing information for the average population, equivalent to the
gains obtained when considering 2 subgroups); and (ii) the dynamic value (represented by the
vertical distance B, where EVPIB1 > EVPIA). The x-axis reflects the number of subgroups and
the y-axis the NMBs. Reproduced from Espinoza et al. (2011) and Claxton (2011), with
permission from the authors.
The following section will discuss issues relating to available evidence when
quantifying the expected cost of uncertainty in a subgroup framework.
6.3.2 Available evidence and the value of further research in the presence of
subgroups
Returning to the general scenarios discussed in section 6.2.2, and taking into account
the need to consider the presence of subgroups, the use of IPD, compared to the use of
AD only, may correct for bias and/or increase precision in relation to population
average estimates. This section will analyse the impact of these effects now in the
presence of subgroup effects. Scenarios 2.1 to 2.3 (listed below) will consider
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potential gains in precision. Given the multiplicity of directions in which the means of
the treatment effect distributions (relating to each subgroup) may shift, and the
unpredictable effects on the total (weighted average) EVPI estimation, the impact of
bias is not presented here as it becomes essentially an empirical question. Following
the rationale described in section 6.1.2, three situations may be considered in any type
of clinical outcome setting (i.e. discrete or continuous): no subgroups (AD) vs. all
subgroups (IPD) – scenario 2.1; some subgroups (AD) vs. all subgroups (IPD) –
scenario 2.2; and all subgroups (AD) vs. all subgroups (IPD) – scenario 2.3. These are
subject to discussion below.
Scenario 2.1: The use of IPD may facilitate the use of formal modelling of treatment x
covariate associations44, which, in particular circumstances, may not be attainable
when using AD. In this scenario, the case is considered where EVPI for subgroups can
be only estimated when IPD is available, allowing the appropriate quantification of
uncertainty in subgroup related effect estimates. A possible graphical representation
may be found in Figure 6.7a, where a distribution of effects for the overall population
was obtained from both evidence formats. In this case, as with scenario 1.1, the EVPI
is expected to be higher or equal with AD than with IPD (empty circle on or above full
circle in Figure 6.7b – a reminder that IPD is being considered only to increase the
precision of the estimates). Given that IPD has the ability to disentangle existing
heterogeneity when stratifying, an estimate of EVPI for two subgroups is only
obtained when using IPD. With two subgroups, different adoption decisions may be
made for each subgroup, which implies distinct NMB distributions for each.
Consequently, the EVPI is here expected to be lower when compared to the overall
population (i.e. IPD2k
IPD
1k EVPIEVPI   , with k number of subgroups – as represented in
Figure 6.7b). If the two subgroup specification does not facilitate the characterization
of uncertainty and, consequently, NMB distributions overlap, higher decision
44 While this is the most frequently encountered form of subgroup analysis (i.e. on treatment effect) it is
not the only one, and indeed not the most important one in CEA. Modelling heterogeneity in baseline
risk is by far the most used in cost effectiveness modelling.
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uncertainty may be expected, implying IPD2k
IPD
1k EVPIEVPI   – a situation which is not
represented graphically. As the use of IPD allows the characterization of
heterogeneity, in extending this from two to K subgroups, to (I) individualised care,
the situation illustrated in Figure 6.7b may be obtained.
Figure 6.7 – Representation of (a) considering existing heterogeneity in the identification of 2
subgroups and possible impact in the distribution of subgroup effects when IPD is considered
and the inability of performing this analysis when using AD; and (b) the possible consequences
over the EVPI when using AD and IPD in these circumstances (scenario 2.1).
Scenario 2.2: If AD allow the estimation of q subgroup effects (through, for instance,
meta-regression analysis), and the use of IPD facilitates resolving existing
heterogeneity for q and l subgroups (where q < l < k, with k representing all possible
subgroups), a situation as represented in Figure 6.8a may be obtained.
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Figure 6.8 - Representation of (a) considering existing heterogeneity in the identification of 4
subgroups and possible impact in the distribution of subgroup effects when IPD is considered
and the inability of performing this analysis when using AD, although possible for 2
subgroups; and (b) the possible consequences over the EVPI when using AD and IPD in these
circumstances (scenario 2.2).
This diagram reinforces the idea that, if the interest is in performing analysis on l
number of subgroups, this may be restricted by the type of evidence available (e.g.
AD). If IPD is available, it may meet the necessary conditions to perform the analysis,
with the additional potential benefit of obtaining estimates with greater precision (for q
and l subgroup effect estimates) in comparison with the distribution of effects derived
from AD. Replicating this scenario in real world decisions, where these are made on a
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continuum, EVPI is expected to be lower or equal when IPD are available and used in
the model compared to estimated EVPI when AD is used – Figure 6.8b.
Scenario 2.3: Assuming that AD also enables estimation of all required subgroup
effects, a situation as represented in Figure 6.9a may exist. Less precision is expected
in interaction estimates derived from AD when compared to IPD. This fact is
translated in a higher capacity of IPD to explore heterogeneity (and reduce the level of
uncertainty within each subgroup) – Figure 6.9b.
Figure 6.9 – Representation of (a) considering existing heterogeneity in the identification of 4
subgroups and possible impact in the distribution of subgroup effects when AD and IPD are
considered; and (b) the possible consequences over the EVPI when using AD and IPD in these
circumstances (scenario 2.3).
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In the next subsection the motivating example results of using both AD and IPD (i.e.
AD + IPD) to estimate the expected cost of uncertainty are shown.
6.3.3 Application: value of additional research in the presence of subgroups and
in the context of having access to individual participant level data
The following analyses consider three alternative subgroup specifications separately,
i.e. when considering the number of parents in the household and/or the parents’
employment status. By using the formulations expressed in equations (6.7) to (6.9)
(and Appendix 7), NB and EVPI estimates are obtained when using AD only and
when using the mixture of AD and IPD to inform key effectiveness parameters. The
alternative specifications analysed comprise:
a) the average population (no subgroups) – addressed in section 6.2.3;
b) two subgroups (k = 2) specification 1, defined by the number of parents in the family.
The proportion of patients in each of the two subgroups is estimated from the
available trial evidence (results across trials are averaged) and will be used further as
the weights, wk – in regards to the number of parents in the household, 71.0% of
which are 2Ps and 29.0% 1Ps.
c) two subgroups (k = 2) specification 2, defined by the parents’ employment status. In
the samples of the trials used to evaluate effectiveness, 45.7% are 2Us and 54.3%
have at least one parent unemployed in the family (defining wk);
d) when the analyst/modeller has simultaneous access to information on the two binary
covariates (i.e. number of parents in the household and their employment status), these
can be used jointly to define four subgroups (k = 4). For each of the four subgroups
the following weights (wk) are used: two employed parents (2EP), 38.0%; two parents,
at least one of them unemployed (2UP), 33.0%; single parent employed (1EP), 7.7%;
and single unemployed parent (1UP), 21.3%.
Permutations of these four alternatives represent situations such as the ones described
by scenarios 2.1 to 2.3 in section 6.3.2. For instance, comparisons of AD in a) with
AD + IPD in b) or c) are those considered in scenario 2.1.
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6.3.3.1 Further research: for which population?
Figure 6.10 shows the estimated population NBs for a £20,000 threshold for each of
the specifications a) to d) above. In this figure the situation in which covariate
information is not considered is reiterated for completeness (i.e. Figure 6.10a repeats
the graphical representation of Figure 6.5). In each graphical representation of Figure
6.10, the lower ends of the bars represent the NMB estimates obtained with current
information. The upper ends of the bars represent the NMBs attained with perfect
information. The population EVPI is the difference between the upper ends and the
lower ends of the bars. The graphs considering subgroups (i.e. b) to d) above), have
different shading for each population subgroup and each bar section corresponds to the
contribution of a particular subgroup towards the total weighted population EVPI.
At a £20,000 threshold value, the same decision is being made when the population is
split (i.e. rejection of any of the ‘active’ alternatives – see Chapter 4 and Chapter 5 for
additional detail). In Figure 6.10 it is observed that the estimated (weighted)
population EVPI is marginally higher when it is split into two subgroups than when it
is considered as a whole – no subgroups (PEVPIk=2 > PEVPIk=1, with k representing
the number of subgroups – e.g. PEVPIk=2 = £6,938 > £5,456 = PEVPIk=1 for single
parent status when using AD + IPD) 45. This is true when using AD and AD + IPD to
inform the decision model. However, and as expected, as the number of subgroups
increases, population EVPI decreases (PEVPIk=2 > PEVPIk=4, e.g. PEVPIk=2 = £6,938
> £5,417 = PEVPIk=4 for four subgroups when using AD + IPD). This is true when
using AD + IPD to inform the decision model, but not verified when AD is used.
With current information, higher benefits are obtained when considering two
subgroups compared with considering the average population, implying a positive
static VoH.
45 Nonetheless, as different synthesis models are being used across the different subgroup scenarios, it
is believed that care must be taken in interpreting these differences – see Appendix 7 and 8 for further
details.
201
A potentially more appropriate analysis would employ both covariates simultaneously.
When four subgroups are being considered and AD + IPD is being used, population
EVPI estimates are observed to be marginally lower than when using AD estimates
(i.e. IPDAD4
AD
4 PEVPIPEVPI

  kk ). This is consistent with the fact that using IPD
resolves some of the existing decision uncertainty, lowering the EVPI.
Figure 6.10 - Population expected NMBs at a threshold value of £20,000 per QALY (2009
values) derived from the cost effectiveness decision model for functioning smoke alarms.
Results are shown for the use of AD and AD plus IPD for when decisions are made for (a) the
average population (repeated from above for completeness); (b) 2 subgroups, specification 1 –
single parent status specification; (c) 2 subgroups, specification 2 – parent’s employment
status specification; and (d) 4 subgroups.
(c) (d)
(a)
NBs with perfect information
NBs with perfect information
NBs with perfect information
NBs with current information
(b)
Population EVPI (weighted
average of each subgroup
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In graphs (b) to (d) of Figure 6.10, it can be observed that the shading areas within
each of the bars, which represent the contribution of each of the subgroups, are of
different sizes. This implies that different subgroups contribute differently to the (total
weighted) population EVPI. Moreover, for the same subgroup, this estimated
contribution is different if IPD is being considered or if it is not. To understand how
this EVPI was estimated, it is of interest to disentangle this value in the individual
subgroup expected values – Table 6.2. In Figure 6.10b (and corresponding 4th and 5th
columns in Table 6.2), the effects of considering IPD are observed, with the
contribution of each individual subgroup to the total EVPI estimate for the “single
parent” subgroup specification differing when using AD and when using AD + IPD.
While the use of AD indicates a small imbalance between the contributions of these
subgroups (i.e. £2,668 and £3,576 for single and two parent families, respectively), the
use of AD + IPD points to a stronger imbalance between these two groups of
participants, with the 2Ps subgroup having an estimated value of further research of
£5,337.
The EVPI estimates obtained when considering four subgroups – represented in Figure
6.10d and the last four columns of Table 6.2 – are of £6,591 for AD and £5,417 for
AD + IPD. For AD + IPD, for instance, the subgroup for which the expected cost of
uncertainty is higher is the 2EP subgroup, contributing £2,135 to the total of £5,417.
The same is not true if AD estimates are used. In this case the 2UP subgroup is the one
that would require a larger amount of investment (£2,402 to the total of £6,591). At the
other extreme, the subgroup for which the estimated value of additional research is
lower is 1EP with £427 and £480 for AD + IPD and AD, respectively.
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Table 6.2 – Population EVPI at a threshold value of £20,000 per QALY (2009 values) derived
from the cost effectiveness decision model for functioning smoke alarms. Results are shown
for the use of AD and AD plus IPD for when decisions are made for: 1 subgroup (the entire
targeted population); 2 subgroups – single parent status specification; 2 subgroups – parent’s
employment status specification; and 4 subgroups.
6.3.3.2 Further research: optimal number of subgroups?
The following exercise is intended to understand the optimal number of subgroups to
be defined for intervention(s) approval and subsequent further research development.
Underlying this problem are two main issues that need addressing: (a) if no further
research is undertaken, how many subgroups should be defined? (akin to asking which
specification maximizes the static VoH); and (b) if further research is undertaken, how
many subgroups should be defined? (akin to having dynamic VoH).
In the case study, the NB estimates with current and with perfect information are fairly
similar. Given this, only the perfect information case is represented graphically
(Figure 6.11). Thus, a direct answer to question (b) above will be provided, whereas an
answer to issue (a) will be provided indirectly. Figure 6.11 depicts the (individual
level) NMBs obtained with perfect information for different subgroup specifications
(i.e. situations a) to d) described above) and for when AD and AD + IPD estimates are
used to inform the modelling. The reader is reminded that in the current assessment,
the choice of the number of subgroups is limited to the definition of a maximum of
four subgroups.
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If four subgroups are considered, similar NMB gains are obtained, as in the two
subgroup specifications (i.e. ‘number of parents in the family’ or ‘parents’
employment status’). With perfect information, it can be said that no apparent
substantial additional gains are obtained if more than two subgroups are taken into
account – answering question (b) above. If no further research is undertaken, that is,
judgements are made with existing current information, the same conclusion can be
derived – answering question (a) above46.
Figure 6.11 – Expected (individual level) NMBs with perfect information (for £20,000
threshold values and 2009 values) for the cost effectiveness decision model for functioning
smoke alarms. Results are shown for the use of AD and AD plus IPD effectiveness evidence to
inform the decision model when heterogeneity is considered. That is, no subgroups, weighted
average for 2 subgroups (2 specifications – number of parents in the family and their
employment status) and the weighted average for the 4 subgroups are considered.
46 Interpretations are assuming neglectable transactions costs or that these do not outweigh the above
mentioned gains. If transactions costs are found to be relevant, decisions on performing further research
and on the selection of the optimal number of subgroups must be made by taking into account both
estimated gains and costs.
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It can be observed that under perfect information, higher NMBs are attained if two
subgroups are considered and employment specification used (approximately £119k).
This is obtained when AD is used and, in fact, in the four situations reflected in the
figure, there is the only one where NMB estimates for AD are found to be higher than
for AD + IPD. Reasons underlying this phenomenon are related to: (i) the fact that
different synthesis models are analysing different subgroup specifications, as
described in section 6.1.2 and in Appendices 7 and 8; (ii) confounding factors and/or
ecological bias affecting the AD estimates; and (iii) due to simulation error.
6.4 Discussion
This chapter examines the advantages of having access to evidence at the individual
participant level when quantifying decision uncertainty with the purpose of estimating
an upper boundary for the value of additional research. The rationale behind this is
that parameter uncertainty is translated into decision uncertainty. However, different
formats of the same evidence set (i.e. AD and IPD) may provide different
distributional ‘scenarios’ about the same set of parameters. These will provide
different estimations of existing decision uncertainty, which can be quantified in
expected costs. Additionally, and making use of the expected NB approach, this
chapter considers this framework in the context of subgroup analysis, reshaping the
question of the value of acquiring additional research to: for which population stratum
is it valuable to conduct this additional research?
One of the most important recent contributions in the field of heterogeneity and
subgroup analysis in health care has been made by Basu and Meltzer (2007). These
authors formalised the concept of EVIC, attaching it to the gain from improved
decision making from understanding heterogeneity. Espinoza et al. (2011) extended
the understanding of heterogeneity by considering its static and dynamic value – a
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crucial distinction when questions about performing further research are at stake – and
by considering the idea of the existence of a continuum amongst decisions when
stratifying the targeted population. This chapter adds to these existing frameworks by
assessing the advantages and disadvantages of using AD and IPD in appropriately
disentangling existing heterogeneity. Starting by exploring the impact of these
evidence types on the estimation of the need for further research, this chapter extends
previous work developed in this area by highlighting the capabilities of available
evidence in quantifying the value of further research in the presence of mutually
exclusive subgroups. Additionally, and considering the existence of population
subgroups, the framework discussed in this chapter allows the investigation of whether
requesting further information for particular population strata is justified, and,
moreover, how those judgements depend on the type of evidence (i.e. AD and/or IPD)
being used in the analysis. It is argued that, conceptually, the use of an evidence set
containing IPD is translated in a more appropriate characterisation of decision
uncertainty compared to using AD only. It is pointed out that this is true when making
decisions for the whole population and when splitting the population into subgroups.
Chapters 2, 3 and 5 highlighted the fact that exploring heterogeneity is problematic
when AD only is available: analyses may be underpowered, the control for
confounding may be limited and biased interpretations of the treatment x covariate
associations may result. In addition, subgroup analyses can only be performed for
those studies that publish equivalent subgroup information. For the majority of the
studies, covariates are defined or stratified differently. The issues with using AD for
this effect can be tackled when IPD is available for synthesis. This chapter highlights
the advantages of using IPD to explore heterogeneity in CEA, compared to the use of
AD only. Two main features of using IPD rather than AD were explored: gains in
precision; and reduction/elimination of bias in decision model input parameter
estimates. The effects of these over the estimation of the expected cost of uncertainty
are discussed at length and compared and contrasted against the effects of using AD
only.
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In this chapter a motivating example is analysed where data stratification is
conditioned by data availability on covariates. Like in previous chapters, the rationale
behind each subgroup scenario analysed assumes that the covariate information
available is the one used in the analysis (e.g. in the population average scenario, no
subgroups are considered because it is assumed that information on covariates was
non-existent). Moreover, it is not the purpose of this chapter to seek to determine
suitable grounds for the stratification applied to the case study. In particular, no equity
considerations are placed on the subgroup formation – as demonstrated by Coyle et al.
(2003), imposing equity constraints regarding subgroup identification could provide
the opportunity to assess if the costs incurred in inflicting these constraints would be
worthwhile. These issues will be considered for future research.
In the motivating example used in this chapter, comparisons made across subgroup
scenarios and between NMB estimates with current and perfect information obtained
using AD and IPD (i.e. AD + IPD) have been performed with caution. This is because
different synthesis models are used to analyse different subgroup specifications. The
approach taken may have limited the comparisons’ interpretability and is highlighted
as the main factor contributing to some unpredictable results obtained for particular
subgroup specifications (i.e. for the analysis considering the subgroup of 2U and of
1U). Nonetheless, an alternative approach is proposed which, as a starting point,
considers the synthesis model results of two binary covariates (i.e. providing results
for four population subgroups). This approach is described in Appendix 7 and is
explored with a brief illustrative example. The application to the chapters’ case study
is presented in Appendix 8.
Throughout this chapter, EVPI estimates obtained by using AD and IPD have been
compared and contrasted depending on a number of factors, the most important being
the number of subgroups considered. However, it is highlighted that care must be
taken in interpreting the differences between EVPI estimates coming from these two
different data structures. To view this EVPI difference in terms of the value of
acquiring additional evidence or of acquiring IPD rather than AD to resolve existing
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decision uncertainty is incorrect, and the temptation to do so may be considered a
limitation of the framework and of the analysis presented.
Important elements that need to be considered in the framework discussed in this
chapter are the transaction costs related to exploring available evidence, understanding
information about existing heterogeneity and also the costs attached to implementing
treatment decisions for each subgroup. These, as highlighted by Espinoza et al.
(2011), are expected to increase with the number of population subgroups being
considered. In the framework discussed throughout this chapter, and in the case study
used, transaction costs are assumed negligible or not outweighing the gains.
The availability of IPD may add an extra layer of complexity to the transaction costs
equation, as the task of obtaining and exploring the IPD is in itself a burden. In
addition to the costs of obtaining the IPD, to fully understand heterogeneity, new
research may be needed in order to attempt to resolve it. Nonetheless, a single IPD (or
even multiple) is not an ‘unlimited’ source of evidence. As more and more
stratifications of the dataset(s) are performed (and hence, expected population health
gains potentially increased), subgroup sample size decreases (smaller amounts of
evidence available) and subgroup-specific uncertainty is expected to increase. Thus,
the saturation of a particular dataset may be achieved at different stratification levels.
All these (transaction) costs should be factored in when assessing the impact of using
IPD when quantifying subgroup level decision uncertainty. These are not under
consideration in the framework presented in this chapter.
The current work could be extended by evaluating the expected value of perfect
information for parameters47 (EVPPI). Such analysis focuses on prioritising the
parameters for which further research would be most valuable (Briggs, A. H. et al.,
2006). It would be interesting to understand how the EVPPI estimates would vary for
the key effectiveness parameters, depending on the evidence format used (i.e. AD and
47 Similar to EVPI, the EVPPI represents the value of reducing uncertainty surrounding a particular
parameter or group of parameters in the decision model (Briggs, A. H. et al., 2006).
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IPD), and comparing these with the EVPI estimate obtained in the analysis performed
in this chapter (due to model input parameter correlation, it is expected that EVPI
estimates obtained and the sum of EVPPI estimates will be similar but not equivalent).
This issue will be considered in future research.
The framework developed in this chapter clearly forces the position of the standard
economic analysis of health technologies currently being performed to a non-optimal
choice for a number of reasons. In the first instance, obtaining the usual mean cost
effectiveness estimates may not take into account underlying population
heterogeneous factors. Regarding subgroup CEA may offer better decisions with
respect to the optimisation of (limited) available health resources and maximize
population health. Secondly, considering subgroups in the analysis also enables the
understanding of which subgroup(s) justify investment of additional funds in order to
increase certainty about approval recommendations. Finally, these two issues may
only be attainable if the type and characteristics of the evidence used in the analysis
are adequate to perform such tasks. The use of IPD rather than AD may influence not
only the extent to which an appropriate understanding of heterogeneity is attained, but,
more importantly, it may shape approval decisions for particular population subgroups
and judgements in future research.
Overall, this chapter describes and explores some key issues relating to heterogeneity
and subgroup analysis within the value of information setting and in the context of
using IPD. The discussion of the results from a motivating example supplies insights
over the added value of having access to IPD, in particular in the synthesis of evidence
context.
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CHAPTER 7
7. DISCUSSION
The overall purpose of this thesis was to contribute to the methodological debate on
the use of evidence, particularly, the use of IPD and AD, for cost effectiveness
decision analytic modelling in health care economic evaluation. In response to the
objectives and research targets initially presented in Chapter 1, this chapter
summarizes the contents, main findings, and contributions to knowledge of this thesis,
as well as identifying future research possibilities.
7.1 Summary of the main thesis findings
Chapter 2 summarised the methodological and analytical issues in the use and
synthesis of evidence for cost effectiveness modelling. The current state of the art in
this field was presented, alongside a discussion of the challenges that
analysts/modellers may face when dealing with evidence from a variety of sources to
inform a range of model inputs. Through the development of a taxonomy, this chapter
offered guidance on the appropriate synthesis methodologies to use for a given model
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parameter. It also identified areas where further methodological and applied
contributions are needed.
This review indicated that most evidence synthesis methods development in recent
years has been carried out with respect to optimizing the use and synthesis of clinical
evidence, often used to inform effectiveness decision model parameters. While for
other, not less important, model parameters (such as the ones explicitly considered in
this chapter: disease natural progression; cost/resource use; and health utility data),
methodological advances have been fairly limited. This unbalanced rate of methods
development across parameter types is intrinsically related to their characteristics, and
the characteristics of the data that often informs them.
Chapter 2 was devoted to pursuing the first research target of this thesis, that is, to
review the literature with respect to methods and applications on the use of evidence
for the economic modelling of health care programmes, setting the scene for the four
subsequent chapters.
When populating a decision model and, in particular, when populating effectiveness
model input parameters, it is often the case that IPD may only be available for a
proportion of the relevant studies which constitute the evidence base. Chapter 3
explored the methods for the synthesis of binary effectiveness evidence. This
exploration included recent modelling frameworks which allowed both IPD and AD to
be jointly modelled in the estimation of effect(s) of intervention(s). Given the apparent
non-existence of synthesis methodology for multiple interventions’ comparison
considering IPD, Chapter 3 described and discussed developed novel modelling
approaches to not only model IPD on its own, but also in conjunction with summary-
level data. The development of novel synthesis models tackled some of the
methodological literature gaps identified in Chapter 2.
The methods developed in Chapter 3 also considered extensions to allow covariate
information at both participant- and study-level to be included, raising important
methodological issues with respect to the estimation of covariate effects. Through the
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use of IPD, whether or not in combination with summary evidence, estimates of the
covariate effects obtained were more precise and of greater accuracy, when compared
to those estimated through AD only. In addition, assumptions about the covariate
effect were tested. The MTC model, assuming different but exchangeable treatment x
covariate interactions, was shown to provide the ‘best’ fit in the situation where
scarcity of data is evident, compared to modelling without considering exchangeability
of regression slopes.
Furthermore, the synthesis of evidence at the individual level allowed estimating
distinct covariate effects based on between- and within-study variability. Extending
the developed synthesis methods to consider these interactions provided a formal
approach for assessing the presence and impact of aggregation/ecological fallacy bias.
The issue of having limited availability of covariate information at both participant-
and study-level was explored and was dealt with by making use of the multiple
imputation features available through the MCMC simulation in order to impute the
missing covariate information. By not discarding evidence for which no covariate
information was available, comparisons between models with and without covariate
effect estimation were enabled.
Chapter 3 methodological findings were supported by the use of a motivating example
within the PH accident prevention scheme. The assessment of the effectiveness of
interventions aiming to increase the uptake of functioning smoke alarms in households
with pre-school children showed that more ‘intense’ interventions were identified as
more effective than less ‘intensive’ ones, with the programme providing education,
low cost or sponsored equipment, equipment fitting and inspection having the highest
level of effectiveness from the set.
Chapter 3 provided an answer to one of the stipulated research targets which aimed to
use all relevant evidence by exploring and enhancing the use of IPD to best
(simultaneously) evaluate the effectiveness of multiple intervention options.
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Chapter 4 showed how the issues identified in Chapter 2 and addressed in Chapter 3
were also relevant for CEA. This is an applied addition to the thesis, which showed the
impact on the cost effectiveness outcomes of using AD only. The chapter provided the
decision modelling grounds for the remainder of the thesis, as the question of whether
interventions to promote the uptake of functioning smoke alarms are cost effective is
raised, and if proved to be so, are worthy of public investment. Economic evaluation is
introduced as a tool to inform decision-making in this regard and a brief review of
existing economic evidence on this subject is provided. To the author’s knowledge,
this was one of the first times a MTC framework was used to evaluate the
effectiveness of PH programmes. It was also one of the first times a simultaneous
assessment over the cost effectiveness of seven programmes was made towards the
final outcome of reducing the occurrence of household fires and related child injuries.
Despite the fact that the decision model developed in Chapter 4 was informed by
summary-level effectiveness evidence only, important findings were made about the
cost effectiveness of the interventions at the population and at the subgroup-level. In
the base case scenario (i.e. using the public sector viewpoint), it was shown that, if a
£30,000 threshold ratio were to be used, the same decision would be provided whether
for the population average or for subgroups, that is, rejection of all ‘active’
interventions. Additionally, scenarios were incorporated in this chapter, which
evaluated different (analysis) viewpoints and timeframes. These scenarios showed that
taking an NHS and PSS perspective led to similar mean ICER estimates for dominant
interventions and, consequently, came to the same decision as for the base case (i.e.
public sector viewpoint).
Chapter 5 extended the case study cost effectiveness assessment performed in Chapter
4 to the evaluation of the impact of using different formats of evidence. Chapter 5
looked at one of the goals from the second research objective set out in Chapter 1, that
is, the assessment of the added value of having access and using IPD for cost
effectiveness decision making, by exploring approval decisions for the average
population and population subgroups. The simultaneous use of IPD and AD was
found to be particularly useful in clarifying decision making for subgroups, when
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compared to the use of AD only. This followed from the ability of the synthesis
models used to model IPD in appropriately estimating treatment x covariate
associations which enhanced the possibility of performing more accurate judgements
over interventions’ cost effectiveness. In general, when subgroup evaluations were
made, decision uncertainty was found to be higher for a particular threshold range,
when using aggregate effectiveness evidence only, compared to using IPD. Subgroup
cost effectiveness estimates derived from using IPD, lead, in principle, to better
decisions, and thus, to better use of limited health resources, when considering
population heterogeneity.
As in the previous chapters, Chapter 6 again highlights the advantages of having
access to evidence at the individual level, compared to having access and using AD
only. This chapter discusses the advantages of using IPD in the estimation and
quantification of decision uncertainty. This is done with the purpose of estimating an
upper boundary for the value of additional research, providing an answer to the
objective set out in Chapter 1 of wanting to perform judgements over the feasibility of
funding additional research at the population level and at different population strata.
A series of conceptual scenarios were presented, where the use of IPD, compared to
AD, were assumed to lead to an increase in precision, reduction/elimination of bias, or
both. The expected effects of these factors on the estimation of the expected loss of the
expected opportunity loss were discussed. The conceptual scenarios presented
considered the absence and the presence of population subgroups. The important issue
that different decisions may be recommended for different subsets of the population,
and that these may well maximize population health in a more efficient way than
population average judgements, was discussed. Additionally, issues surrounding the
estimation of the value of further research in each of these population subsets were
considered. The framework proposed in this chapter showed that the use of an
evidence set containing IPD may be translated in a more accurate estimation of
decision uncertainty for subgroups of the population compared to using AD only.
Generally, IPD generates more robust estimates of the (total weighted) population
EVPI than the use of AD only, particularly when exploring population heterogeneity.
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Overall, this chapter described and explored some key issues relating to heterogeneity
and subgroup analysis within the value of information setting and in the context of
having access and using IPD.
7.2 What could have been done differently?
Taxonomy characteristics
The taxonomy considers three dimensions – number and format of data sources and
number of parameters to inform; though these may not capture all possible scenarios,
potentially limiting its guidance role in some circumstances. The taxonomy could
have been developed to include other (not less important) dimensions or sub-
dimensions, such as taking into account covariate information within each taxonomy
section.
Evidence informing cost effectiveness decision modelling
A systematic review process is at the basis of the effectiveness evidence base used to
inform the cost effectiveness modelling. The same kind of methodical process was not
put into practice to obtain evidence to populate other decision model parameters. This
procedure is not considered necessary for all types of information in economic
modelling, as highlighted in the NICE PH methods guidance (2009). Nonetheless,
engaging in a more exhaustive search process would potentially provide additional
short- and long-term evidence, particularly with respect to costs and consequences for
cost effectiveness modelling.
Subgroup analysis and exploring heterogeneity
The systematic reviews (Wynn et al., 2010, Kendrick et al., 2007) which identified the
studies of the motivating example used in this thesis explored the association of the
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risk of injury with six explanatory factors (i.e. child age, gender, ethnic group, single
parent status, residing in rented accommodation and employment status). However,
only two of these factors were chosen for analysis in this thesis (i.e. single parent
family status and employment status), because these two covariates were the ones for
which more information was available – that is, the choice was data driven. No aims
were set to determine what were and were not suitable grounds for the covariates
included in the modelling and, consequently, for the stratifications applied to the case
study. It would have been interesting to explore this issue further, irrespective of the
data limitations identified.
7.3 Recommendations for accessing and analysing individual-level
evidence
One theme running through this thesis has been the advantages of having access and
analysing IPD. In fact, in cost effectiveness analyses multiple sources of evidence are
often used for which, in most cases, only the AD evidence is available. However, the
challenge imposed is to understand when it is worth obtaining individual patient data –
i.e. to IPD or not to IPD? Should it be when the ‘relevant’ information (e.g. on adverse
effects, population groups) is not reported in related published papers? Or, regardless,
when purely wanting to increase precision and/or reduce bias in the exploration of
individual level characteristics and how these affect approval decisions? Should a
threshold be set for the amount of evidence needed (and its disaggregation level) to
appropriately address a decision problem at hand?
Analysts / modellers should consider which methodological factors are expected to
influence results in their particular problem setting. Additionally, in deciding whether
to obtain the IPD, one should equate the burden in terms of time and resources needed
in the analysis, as well as the constraints in terms of expertise required to conduct
these analyses.
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This thesis claims that, in most circumstances, there are advantages in having access
and analysing IPD. It showed that IPD has clear value over summary data for both
synthesis and decision modelling aspects of the analysis. A key advantage is that
individual level data provides a wealth of data that facilitates the specification and
evaluation of cost effectiveness for particular population subgroups. I believe these
benefits are important in achieving consensus in approval decisions by
multidisciplinary decision makers.
7.4 Recommendations for future research
The taxonomy developed in Chapter 2 focused mainly on clinical effectiveness
evidence, discussing also the application of the taxonomy to other key input
parameters in any economic model (i.e. disease natural history, resource use/costs, and
preferences). It is encouraged (i) a fuller application of the taxonomy to all model
parameters in future modelling; (ii) the continued exploration of the adequacy of the
taxonomy dimensions to the individual characteristics of other decision model
parameters; and (iii) the maintenance of the characteristics, contents and dimensions of
the taxonomy, to continue viewing it as a tool designed to help health economics
modellers to adequately address the research problems faced.
As highlighted throughout this thesis, there is a set of advantages in considering
evidence at the individual level, when compared to the use of AD only. These
advantages are derived mainly from the additional flexibility provided by this
evidence format to explore and answer clinical and economic research questions.
Nonetheless, there is a series of obstacles relating to IPD, from the difficulty in having
access to this sort of data to the burden of having to explore and model large datasets.
However, and before engaging in trying to access or explore IPD, it would be
interesting to investigate the idea of a mechanism or framework that would allow the
quantification of the benefits of considering IPD beforehand. For instance, quantifying
the gains that would be obtained if IPD enabled the appropriate selection of relevant
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covariates and subgroup formation (adequately explore existing heterogeneity) and the
extent to which it would correct existing covariate effect biases.
A series of meta-analytic models, including novel MTC models, were developed and
implemented in Chapter 3. These allowed the synthesis modelling of IPD and of AD
and IPD simultaneously in a binary outcome setting. The use of a motivating example
within the PH setting allowed the application of the novel synthesis models to real
world data – and to a great extent, these developments were driven by the challenges
presented to me by this particular example. Although the novel methods are
generalisable to other situations (of the same characteristics as the motivating
example), it would be interesting to apply these to other case studies or to simulated
data – although it is acknowledged that many considerations are needed when
designing and generating simulated data (Burton et al., 2006).
It would be interesting to extend the developed modelling work to explicitly appreciate
the type and quality of the study information being synthesised – following up on bias
adjustment proposals already existing in the current literature (Turner, R. M. et al.,
2009, Welton et al., 2009, Spiegelhalter, David J. & Best, 2003). This thesis
acknowledges that the inclusion of study-level covariates in the synthesis modelling
may explain some of the between-study heterogeneity and reduce inconsistency in the
network – reinforcing some of the recent work published in this area (Cooper, Nicola
J. et al., 2009). Nonetheless, and following up on the recent work by Dias and
colleagues (Dias et al., 2010b), it would be interesting to extend this work to explicitly
evaluate consistency across the evidence base, considering that a proportion of this
evidence may be available at the individual level. Last but not least, a natural
extension of the synthesis modelling developed could be to consider a generalized
linear modelling framework, broadening the approach to other types of outcome
measures (e.g. categorical, continuous, time to event).
A keystone of any economic evaluation is the perspective employed by the analysis.
This dictates the range of costs and consequences included in the evaluation. Different
perspectives foster different outcomes, which may result in different resource
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allocation decisions. This thesis follows the NICE recommendations (2009) for the
evaluation of PH interventions by using a public sector perspective as base case. Using
this broader perspective, it enables the identification and inclusion of the majority of
the consequences. This analysis allows the exploration of the impact of taking a
narrower perspective, such as the usual health services viewpoint, which may be
required by a decision maker. The development of consistent methods for the
measurement and valuation of the broader inter-sectoral consequences of PH
interventions is a topic for further research.
Finally, alternative approaches to subgroup analysis have been proposed in the recent
literature which could have been followed in this thesis. For instance, the framework
introduced by Basu and Meltzer (Basu & Meltzer, 2007), cited in Chapter 6, could
have been applied to analyse the IPD with a view to quantifying residual unexplained
heterogeneity and the EVIC. This would have allowed the estimation of the value that
society is willing to pay so that individually efficient decisions are made, optimizing
the resource allocation process.
7.5 Conclusions
This thesis explored the use of evidence, and in particular, the use of IPD in all the
different stages of an economic evaluation: the synthesis of the evidence, cost
effectiveness and analysis of subgroups, and value of further research. Although the
author would like to see the use of IPD to be made compulsory (or, at least strongly
recommended) in certain HTA assessments, it may be too early to make such
recommendations. It is hoped that the research conducted throughout this thesis
provides guidance for a better use of available evidence, bridges some of the existing
gaps in the methods literature and stimulates the broader use of IPD in the conduct of
more and better economic evaluations of health care and/or PH interventions.
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APPENDICES
Appendix 1
Relevant issues in decision analytic modelling for health care
Defining the decision problem
A clear identification of the question to be addressed in the analysis must be made.
This includes defining the target population or population subgroup(s) and the relevant
options subject to comparison. The location and setting in which the alternative
interventions are being delivered should also be detailed.
Structuring the decision model
After specifying the problem at hand the structure of the model can be outlined,
conditional to predefined boundaries. These boundaries may be based in the
availability of data, or translated in limiting the modelling to possible consequences of
the options under evaluation – parsimony rules apply. The nature of the interventions
under assessment and their potential consequences will be key elements in shaping the
model.
Perspectives, time horizon and discounting
The viewpoint assumed in an analysis is an important factor as economic outcomes
may vary largely depending on what perspective is specified. The possible set of
perspectives includes broader views, as the societal ones, to narrower ones, such as the
patient. As set out by the NICE methods guidance (NICE, 2008), technology
appraisals in the UK should consider only costs incurred by the NHS and PSS budgets
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in their base case analysis. Nonetheless, evaluations of PH interventions may consider
effects on sector budgets other than health (NICE, 2009).
Technologies, programmes or services comparative assessment is usually made at a
specific point in time. The timing of costs and consequences related to these
programmes must be considered even if they occur in the future. Thus, these should be
long term enough in order to consider all of the main health and economic
consequences (Drummond et al., 2005).
It is instinctive to think that future costs and benefits should be reduced or
‘discounted’ to reflect the fact that they should not have the same weight in decision-
making as those incurred in the present. The time preference concept underlies this
idea; that is, there is a preference for having the resources now rather than in the
future, with the advantage of benefiting from them in the meantime. It is important to
highlight that, in recent years, much has been debated and written about considering
equal or differential discount rates for health outcomes and costs (Claxton, K. et al.,
2011, Gravelle et al., 2007, Claxton, K. et al., 2006, Gravelle & Smith, 2001). The
current discount rate recommendation from the NICE is that both costs and effects
should be discounted at the rate of 3.5% (NICE, 2008). The NICE official guidance on
discounting is being used in this thesis.
Identifying and synthesising evidence
When an adequate structure of the model has been established and the discounting
mechanism, perspective and time horizon of the analysis decided on, the task of
identifying available relevant evidence to populate it starts. This procedure should
make use of the general principles of evidence-based medicine set out by Sackett et al.
(1996). Guidelines exist for systematic identification and quality assessment of
effectiveness evidence (CRD, 2009). With respect to other decision model parameters
(e.g. resource use and utilities), modest contributions to the literature have been made
(these are highlighted and discussed throughout the thesis). When a set of sources are
available to inform a specific decision model parameter, evidence synthesis plays an
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important role and is currently seen as a requirement for decision modelling. (Sutton,
A. J. & Abrams, 2001, Sutton, A. J. et al., 2000a).
Evaluating variabilities, uncertainties and heterogeneities
As uncertainty surrounds model estimates, any decision based on cost effectiveness
will also be uncertain (NICE, 2008). Models and uncertainty go hand in hand:
uncertainty looms not only in the input evidence that informs them but also in their
selection and quality assurance. When quantifying uncertainty, it is important to
distinguish between patient variation within a cohort and uncertainty in knowledge.
Variability or “first-order” uncertainty refers to between-individual diversity in the
population to which the policy is applicable, reflecting “chance” (Stinnett & Paltiel,
1997). Not being a source of uncertainty, heterogeneity relates to the differences
between patients that can be explained, e.g. differences between sub-groups of patients
(Briggs, A. H. et al., 2006). Uncertainty can arise from parameters (Spiegelhalter,
David J. & Best, 2003, Briggs, A. H., 2000). Parameter uncertainty, or “second-order”
uncertainty, usually refers to the uncertainty surrounding an expected value, i.e. the
fact that there is never certainty as to the expected costs and effects when the treatment
is provided for a particular population (Briggs, A. H. et al., 2006). Consequently, it is
reducible with more evidence. Uncertainty may also arise from the structure used in
the decision model. Structural uncertainty reflects the assumptions imposed by the
modelling framework and has received relatively little attention in the literature (Bojke
et al., 2009, Philips et al., 2006).
In cost effectiveness, uncertainty in its outcomes is an opportunity for a technology (or
technologies) to be funded such that population health is not maximised. This raises an
opportunity cost to uncertainty in terms of health forgone. The evaluation of
uncertainty in decision models is often called probabilistic sensitivity analysis (PSA)
or probabilistic modelling. The ground of probabilistic modelling is to reveal the
uncertainty in the input parameters and illustrate its consequences on the outputs of
interest (Briggs, A. H. et al., 2006). However, the mathematical relationship between
inputs is often too complex to return the exact distribution of the estimator for the cost
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effectiveness measure. In that case, Monte Carlo simulation procedures are often used
to quantify uncertainty over the expected outcome measures. Using the joint
distribution of costs and effects and through the use of Bayesian decision theory it is
possible to address questions on whether current available evidence is considered
sufficient to support the choice of a specific intervention and whether additional
research is valuable.
Assessing the value of additional research
Decision uncertainty may address the question of whether additional research is
required or should be undertaken. Probabilistic modelling outputs can be used as a
vehicle to quantify the cost of making a wrong decision or delaying it. This entails
patients’ forgone health gains and the waste of available resources. The difference
between obtained net gains and those that could have been attained by reimbursing the
optimal technology (or set of technologies) represents the opportunity cost of
uncertainty, the EVPI (Claxton, K. P. & Sculpher, 2006, Ginnelly et al., 2005a).
Carrying out further research is meaningful if this estimated quantity surpasses the
costs of conducting such research. Where estimated EVPI signifies that undertaking
additional research is potentially worthwhile, further questions may be of interest with
respect to the type of research that is more valuable. Decisions are also required as to
the optimal design of the additional research. Value of information methods may be
extended to account for patient allocation, trial quality, and trial design issues
(Claxton, K. & Thompson, 2001).
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Appendix 2
Bayesian methods
The Bayesian approach to statistics (Lee, 1997) is well established in the literature
and is used in a number of areas of health care research, including data synthesis
(Sutton, A. J. & Abrams, 2001, Sutton, A. J. et al., 2000a) and the economic
evaluation of heath care technologies (Ades, A. E. et al., 2006b, Spiegelhalter, David
J. & Best, 2003, O'Hagan et al., 2001, Spiegelhalter, D. J. et al., 2000, 1999). Within
the evidence synthesis framework, Bayesian methodology has made solid progress,
being used extensively over the last decade (Sutton, A. J. & Abrams, 2001, Sutton, A.
J. et al., 2000a). In fact, economic evaluation research has benefited from these
advances, with the implementation of Bayesian decision analysis as an explicit
working platform and, particularly, with the increased use and requirement for
probabilistic analysis (NICE, 2008, Claxton, K. et al., 2005).
Bayesian methods can be considered an alternative to the classical (frequentist)
approach to statistical inference. It is a more appealing and intuitive framework, since
both the data and model parameters are considered as random quantities. The key
feature is the likelihood function, that defines how reasonable are the data given values
of those model parameters. The increased use of Bayesian methods is also linked to
advances in computational methods, allowing for a more efficient computation in
combining non-conjugate probability distributions. A key difference between the two
approaches is that Bayesian methods allow the model to incorporate external
information alongside available data – prior distributions. When very little or no
information is accessible, subjective, non-informative or ‘vague’ beliefs are set as
priors.
In Bayesian theory, the joint prior probability density function for all model
parameters,  p , is combined with the study data, y, in the form of a likelihood
function,  yL  , to obtain the joint posterior probability density function,  yp  .
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This is entitled Bayes’ Theorem (Lee, 1997), that is,       pyLyp  . The
following subsections will describe Bayesian simulation techniques and their
characteristics.
MCMC simulation and WinBUGS software
Simulation based methods, like MCMC, have been broadly used (Carlin & Louis,
2009, Gelman, 2004, Carlin & Louis, 2000, Gilks et al., 1998). One of these methods,
Gibbs sampling, has received significant attention in the last few years, with the
algorithm being used to generate a sequence of samples from the joint probability
distribution of two or more random variables.
WinBUGS, an interactive Windows version of the BUGS (Bayesian inference Using
Gibbs Sampling) software, performs Bayesian analysis of complex statistical models
using Gibbs sampling. Using simulation, inferences need to consider the initial transient
behaviour of the chain(s) and the consequent need for visual or numerical assessment of
convergence. The initial set of iterations must be discarded, as these are not independent
(i.e. ‘burn-in’ period). For each inferential procedure, a series of random samples are
obtained from parameters’ joint posterior distributions. To make sure that these come
from a stationary distribution, this thesis generally considers an initial set of 10,000
iterations of the MCMC sampler as ‘burn-in’ and a subsequent set of 5,000 iterations for
inferential purposes.
MCMC simulation and multiple imputation
In Bayesian inference, MCMC is one of the primary methods for generating multiple
imputations in nontrivial problems (Schafer, 1997). When imputing missing
information, MCMC generates independent draws of the missing data from its
predictive distribution. Multiple imputation through MCMC techniques is attractive
for exploratory or multi-purpose analyses involving a large number of estimands.
Rather than using a small number of imputed data sets (as frequentist approaches do),
MCMC makes it possible to take an independent draw from the imputation dataset
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within each iteration. One advantage of this is that the posterior standard errors of
regression coefficients already summarize the uncertainty about the process for the
missing data and also the uncertainty about the coefficients themselves. The
disadvantage is that the imputations will be much slower and care in checking
convergence is needed. Thus, although WinBUGS modelling is attractive owing to its
practicality, careful checking of convergence and sensitivity to prior distributions and
initial values is needed when using its imputation features.
Model selection and criticism
As with any inferential technique used to explore the complexities of real world data,
comparison of alternative model formulations is important in identifying those which
appear to adequately portray data information. In the classical modelling framework,
model comparison is usually performed through the use of two quantities, a measure of
model fit and of its complexity. As an increase in model complexity (i.e. an increase in
the number of free model parameters) is attended by an improvement in model fit (in
general defined by a deviance statistic), a trade-off situation arises, as described in the
early work of Akaike (1973).
The DIC (Deviance information criterion (Spiegelhalter, D. J. et al., 2002)) is a
generalization of the AIC (Akaike information criterion (Akaike, 1973)) and the BIC
(Bayesian information criterion (Schwarz, G., 1978)) and is considered a useful criteria
for Bayesian model comparison. The DIC can be considered a Bayesian measure of fit
or adequacy, penalized by additional model complexity. The DIC statistic,
DpDDIC  , comprises a classical estimate of model fit, posterior expectation
   DED  , where  D is the deviance   yL log2 , plus the effective number
of parameters,  ˆDDpD  , where  ˆD is the likelihood at the posterior expectation
of a stochastic node,  . The larger is D , the worse the fit; the larger is Dp , the better
the model will fit the data.
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Advantages and disadvantages of the Bayesian approach to meta-analysis
Some authors have assessed the adoption of a Bayesian approach to meta-analytic
modelling (Sutton, A. J. & Abrams, 2001, Sutton, A. J. et al., 2000a, Su & Po, 1996).
The majority of the advantages of a Bayesian approach highlighted next constitute the
reasons for opting for this methodological approach and these may be depicted
throughout this thesis.
Adopting a Bayesian approach: (a) enables evidence from a variety of sources,
regarding a specific problem, to be taken into account within a coherent modelling
framework; (b) may consider prior beliefs to be included in the modelling in the form of
prior distributions – not considered in this thesis as all priors are intended to be vague;
(c) considers parameter uncertainty jointly by automatically accounting for it in the
analysis; (d) allows probability statements to be made directly regarding quantities of
interest – this is particularly useful if wanting to rank a series of interventions with
respect to the probability of being best; and (e) leads naturally into a decision theory
framework which may also consider costs and utilities regarding health care / public
health decisions.
Nevertheless, as for any modelling or simulation exercise, there are disadvantages.
Some of these are: (a) using non-informative priors may place impartiality and
objectivity further away; (b) different (vague) prior distributions may be considered in
the same modelling framework which may generate varying results (this means that,
when using a Bayesian framework, sensitivity to the specification of the prior
distributions is important); and (c) the modelling may be computationally complex and
intense to implement, and therefore time consuming to perform.
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Appendix 3
WinBUGS codes used to combine the two data formats, AD and IPD, including a
binary patient covariate.
This code relates to model (3.9) described above and is designed to be as generic as
possible and easy for the user to modify to adapt to specific applications. For example,
if no data exist in one or more of the sections, the corresponding section of code can
simply be deleted from the model.
Six datasets/ data-files are required to fit the complete model: two containing
constants, one which indexes study treatments and specifies study baseline treatments,
two for IPD and one for the AD. It should be noted again that for the clustered
allocated AD adjustments should be done prior defining WinBUGS data model. All
data should be loaded before the model is compiled.
Due to size and agreements of use, the original data sets are not included in their
entirety, but a couple of lines of data are supplied for each study/data combination for
illustration purposes.
model {
### Part 1: Model for non-clustered IPD trial data ###
for(i in 1:n.non.cluster.subjects) {
# Likelihood for non-clustered IPD data
outcome[i] ~ dbern(p[i])
# Model for non-clustered IPD data
logit(p[i]) <- mu[study[i]] + delta[index[i]] * (1 - equals(treat[i], baseline[i])) +
beta_cov[study[i]] * cov[i] + beta.w[index[i]] * (cov[i] - meancov[i]) *
(1-equals(treat[i],baseline[i]))) +
beta.b[index[i]] * (1-equals(treat[i], baseline[i])) * meancov[i]
}
# Vague priors for non-clustered IPD
for(j in 1:n.ipd.non.cluster.trials) {
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beta_cov[j]~dnorm(0, 1.0E-6)
mu[j]~dnorm(0, 1.0E-6)
}
### Part 2: Model for IPD cluster trial data ###
for(i in 1:n.cluster.subjects) {
# Likelihood for cluster IPD data
c.outcome[i] ~ dbern(c.p[i])
# Model for cluster IPD data
logit(c.p[i]) <- c.mu[c.study[i], c.cluster[i]] +
delta[c.index[i] + n.non.cluster.arms] * (1 - equals(c.treat[i], c.baseline[i])) +
c.beta_cov[c.study[i]] * c.cov[i] +
beta.w[c.index[i] + n.non.cluster.arms] * (c.cov[i] - c.meancov[i]) *
(1-equals(c.treat[i], c.baseline[i])) +
beta.b[c.index[i] + n.non.cluster.arms] * (1 - equals(c.treat[i], c.baseline[i])) *
c.meancov[i]
}
# Vague priors for cluster IPD
for(i in 1:n.ipd.cluster.trials) {
c.beta_cov[i]~dnorm(0, 1.0E-6)
# Random-effects for clusters in IPD
for(j in 1:n.cluster.max) {
c.mu[i, j] ~ dnorm(mu.mean[i], inv.tau.sq.mu[i])
}
mu.mean[i] ~ dnorm(0, 1.0E-6)
inv.tau.sq.mu[i] <- 1 / (sigma.mu[i] * sigma.mu[i])
sigma.mu[i] ~ dunif(0,2)
tau.sq.mu[i] <- sigma.mu[i] * sigma.mu[i]
}
for(i in 1:(n.non.cluster.arms + n.cluster.arms)) {
md[i] <- d[treat1[i]] - d[baseline1[i]]
# Random-effects IPD trial-specific LORs
delta[i] ~ dnorm(md[i], prec)
beta.w[i] <- bw[treat1[i]] - bw[baseline1[i]]
beta.b[i] <- bb[treat1[i]] - bb[baseline1[i]]
}
# Part 3: Model for non-cluster and cluster aggregate data #
for(i in 1:n.agg.arms) {
# Binomial likelihood for AD data
outcome.ad[i] ~ dbin(pa[i], n[i])
# Model for AD data
logit(pa[i]) <- mu.ad[a.study[i]] + delta[i + n.non.cluster.arms + n.cluster.arms] *
(1 - equals(a.treat[i], a.base[i]))
delta[i + n.non.cluster.arms + n.cluster.arms] ~ dnorm(md.ad[i], prec)
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md.ad[i] <- d[a.treat[i]] - d[a.base[i]] + (bb[a.treat[i]] - bb[a.base[i]]) * a.cov[i]
}
# Vague priors for AD trial baselines
for(j in 1:n.agg.trials) {
mu.ad[j] ~ dnorm(0, 1.0E-6)
}
### Part 4: Model for combining all treatment effect estimates ###
# Vague priors for basic parameters
bw[1] <- 0
bb[1] <- 0
d[1] <- 0
for (k in 2:max.treat) {
bw[k] ~ dnorm(m.betaw,prec.betaw)
bb[k] ~ dnorm(m.betab, prec.betab)
d[k] ~ dnorm(0, 1.0E-6)
}
# Vague priors for random-effects
m.betaw ~ dnorm(0, 1.0E-6)
tau.betaw ~ dunif(0,2)
tau.sq.betaw <- (tau.betaw * tau.betaw)
prec.betaw <- 1 / (tau.sq.betaw)
m.betab ~ dnorm(0, 1.0E-6)
tau.betab ~ dunif(0,2)
tau.sq.betab <- (tau.betab * tau.betab)
prec.betab <- 1 / (tau.sq.betab)
tau ~ dunif(0,2)
tau.sq <- tau * tau
prec <- 1 / (tau.sq)
### Dataset 1: Constants to define for IPD###
# Number of participants in all IPD individually allocated studies #
list(n.non.cluster.subjects = 2702,
# Number of IPD individually allocated studies #
n.ipd.non.cluster.trials = 6,
# Number of IPD individually allocated study arms #
n.non.cluster.arms = 12,
# Number of participants in all IPD cluster allocated studies #
n.cluster.subjects = 537,
# Number of IPD cluster allocated studies #
n.ipd.cluster.trials = 1,
# Number of IPD cluster allocated study arms #
n.cluster.arms = 2,
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# Maximum number of clusters in any of the IPD cluster allocated studies #
n.cluster.max = 37,
# Number of interventions being assessed #
max.treat = 6)
### Dataset 2: Constants to define for AD###
# Number of AD studies #
list(n.agg.trials = 2,
# Number of AD study arms #
n.agg.arms = 4)
### Dataset 3: Indexing study treatments and specifying baseline treatments ###
treat[] baseline1[]
1 1
3 1
1 1
4 1
2 2
5 2
... ...
... ...
... ...
END
# treat1 = treatment group codification (coded 1 to n number of treatments – each line of
# this dataset contains information for a treatment arm, therefore every 2 lines contains the
# treatment codification for a 2-arm study), baseline1 = baseline treatment codification
### Dataset 4: Individually allocated IPD studies ###
study[] treat[] outcome[] baseline[] cov[] meancov[] index[]
1 1 0 1 0 0 – 1 1
1 1 0 1 1 0 – 1 1
... ... ... ... ... ... ...
... ... ... ... ... ... ...
... ... ... ... ... ... ...
END
# study = study number, treat = treatment arm (coded 0,1),
# outcome = outcome (coded 0,1), baseline = baseline treatment code,
# cov = binary covariate of interest (coded 0,1),
# meancov = binary covariate study average (proportion of individuals with characteristic,
# 0 to 1), index = treatment arm code.
### Dataset 5: Cluster allocated IPD studies ###
c.study[] c.treat[] c.outcome[] c.baseline[] c.cov[] c.meancov[] c.index[] c.cluster[]
1 0 0 1 1 0 – 1 1 1
1 0 0 1 0 0 – 1 1 1
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... ... ... ... ... ... ... ...
... ... ... ... ... ... ... ...
... ... ... ... ... ... ... ...
END
# c.study = study number, c.treat = treatment arm (coded 0,1),
# c.outcome = outcome (coded 0,1), c.baseline = baseline treatment code,
# c.cov = binary covariate of interest (coded 0,1),
# c.meancov = binary covariate study average (proportion of individuals with characteristic,
# 0 to 1), c.index = treatment arm code, c.cluster = cluster number
### Dataset 6: Individually and cluster allocated AD studies ###
a.study[] a.treat[] outcome.ad[
]
n[] a.base[] a.cov[]
1 1 50 100 1 0.99
1 2 100 200 1 0.98
... ... ... ... ... ...
... ... ... ... ... ...
... ... ... ... ... ...
END
# a.study = study number, a.treat = treatment arm code (coded 1 to n number of
# treatments), outcome.ad = number of events, n = number of participants,
# a.base = baseline treatment code, a.cov = treatment arm aggregate value expressed as a
decimal
### Initial values, either need specifying or generating for the below scalars, vectors and
matrices ###
list(delta = c(0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0),
d = c(NA,0,0,0,0, 0),
bw = c(NA,0,0,0,0, 0),
bb = c(NA,0,0,0,0, 0),
mu = c(0,0,0,0,0, 0),
beta_cov = c(0,0,0,0,0, 0),
mu.mean = c(0),
sigma.mu = c(1),
c.beta_cov = c(0),
tau = 1,
mu.ad = c(0,0),
m.betaw = 0,
tau.betaw = 1,
m.betab = 0,
tau.betab = 1,
mA = 0,
c.mu = structure(.Data=c(0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0,
0,0,0,0,0, 0,0), .Dim = c(1,37))
# This matrix will have dimension n.ipd.cluster.trials x n.cluster.max
)
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Appendix 4
Table A4 - Parameter estimates from fitting the MTC synthesis model to IPD reduced to AD to the
functioning smoke alarm outcome data without including covariates.
Interpretation
Median of
MCMC
posterior sample
95 per cent
credible interval
Parameter
E -0.302 -2.064 to 1.357
E + FE 2.037 -1.081 to 5.351
E + FE + HI 1.147 -0.795 to 3.432
E + FE + F 0.925 -0.846 to 2.675
E + HI --- ii) --- ii)
E + FE + F + HI 1.150 -1.734 to 3.9
Between-study
variance   τ
2 1.657 0.341 to 3.824
E 0.739 0.127 to 3.884
E + FE 7.666 0.339 to 210.72
E + FE + HI 3.148 0.452 to 30.94
E + FE + F 2.522 0.429 to 14.52
E + HI --- ii) --- ii)
E + FE + F + HI 3.159 0.177 to 49.39
Deviance
Information
criteria
DIC 116.07
i) E - education; E + FE - education plus low cost / free equipment; E + FE + HI - education
plus low cost / free equipment plus home inspection; E + FE + F - education plus low cost /
free equipment plus fitting; E + HI - education plus home inspection; E + FE + F + HI -
education plus low cost / free equipment plus fitting + home inspection.
Notes:
ii) IPD evidence not available for this treatment comparison.
Model (3.6) - 9 studies included
Random effects MTC of IPD
reduced to AD
Log odds ratios for
intervention
effects (vs usual
care) - d's i)
Function of parameter
Odds ratios for
intervention
effects (vs usual
care) - e d 's i)
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Appendix 5
Decision model R code for the economic evaluation of functioning smoke alarm
programs.
The following code relates to modelling for the average population and under the
public sector perspective, and intends to illustrate how the modelling was performed.
Two datasets / data-files are required to run the economic model: one relates to all
cause mortality (as showed in Table 4.5) and the other one, the CODA, with the
effectiveness estimates of the different interventions.
#P=Preventative Strategy
#1=Usual Care (includes usual safety education)
#2=Education
#3=Education + low cost/free equipment (10yr sealed battery unit)
#4=Education + low cost/free equipment (10yr sealed battery unit) + home inspection
#5=Education + low cost/free equipment (10yr sealed battery unit) + fitting
#6=Education + home inspection
#7=Education + low cost/free equipment (10yr sealed battery unit) + fitting + home inspection
#S=Health state
#1=functioning fire alarm
#2=non-functioning fire alarm
#3=functioning fire alarm /disability
#4=non-functioning fire alarm /disability
#5=death fatal injury
#6=death other causes
#N=Number of households
#C=Cycle
#T=Total number of years
#pi_[C, S, P]
#lambda[C, S(t), S(t-1), P]
#-----------------------------------------------------------------#
##### DATA 1: constants and vectors definition ######
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#-----------------------------------------------------------------#
## PARAMETER TYPE: OTHER
# Size of the cohort simulation going through the model
N <- 100000
# Number of prevention strategies being evaluated
P <- 7
# Number of cycles in part 2 of the model
C <-5
# Number of cycles in the whole decision model (model timeframe)
T <- 100
# Number of health states in the model
S <- 6
# Number of ceiling ratio values (from 0 to £200,000)
K <- 101
# Total number of households in the UK
n_hh <- 22539000
# Discount rate for utilities
disc_u <- 0.035
# Discount rate for costs
disc_c <- 0.035
# Number of minutes of Paramedic Unit - assumed only attend where severe injuries (SE assumption)
mnPU <- 49.5
precPU <- 0.038
sdPU <- 1/sqrt(precPU)
# Number of minutes of Emergency Ambulance - assumed only attend where moderate injuries (SE
assumption)
mnEA <- 38.6
precEA <- 0.038
sdEA <- 1/sqrt(precEA)
## PARAMETER TYPE: PROBABILITIES
# Probability have precautionary check-up following a fire
r_checkup <- 5658
n_checkup <- 12935
# Probability of a fire where functioning smoke alarms present
r_fire_func <- 22771
# Probability of a fire where non-functioning smoke alarms present
r_fire_nonfunc <- 7052
# Probability of a fire where no smoke alarms present or unspecified
r_fire_noSA <- 22883
r_nonfunc_noSA <- r_fire_nonfunc + r_fire_noSA
r_total_fires <- r_fire_func + r_fire_nonfunc + r_fire_noSA
r_fire_nfunc<-r_fire_nonfunc + r_fire_noSA
# Probability of a fatality following a fire where functioning smoke alarm present
r_fatalSA <- 109
# Probability of a fatality following a fire where non-functioning or no smoke alarm
r_fatalnSA <- 232
# Probability of owning a smoke alarm with battery life of 1 year
r_1yrbattery <- 11888
n_1yrbattery <- 15850
# Probability test smoke alarm at least once a year
r_1yrtest <- 15616
n_test <- 18372
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# Probability test smoke alarm less than once a year
r_testless1yr <- 367
# We assume no decay if part of giveaway scheme as given 10 year sealed unit smoke alarm
# Probability of incurring 'no injuries' following a house fire (given functioning smoke alarm/ non-
functioning or no smoke alarm)
r_noinjury <- c(47967, 47967)
#Calculated from r_total.fires * 0.91 = prob of no injury
# Probability of inside household fire being attended by the Fire and Rescue Service
r_FRSattend <- 9
n_fires <- 272
# The additional proportion of burn unit costs incurred in ITU
#p_ITU <- 0.4
p_ITUa <- 9.2
p_ITUb <- 13.8
# Probability a child aged 0-4 incurs a moderate injury following a house fire
r_moderate <- 3
# Probability a child aged 0-4 incurs a minor injury following a house fire
r_minor <- 7
# Total number of children aged 0-4 which incured in an injury following a house fire
n_burnsinjury <- 19
# Probability accept intervention (assumed same for all interventions)
#p_accept <- 0.9
p_accepta <- 0.7
p_acceptb <- 0.077778
# Probability a household having a functioning smoke alarm
r_fsa <- 14709
n_sa <- 18386
# Probability of having a standard 1 year smoke alarm battery
p_battery <- 0.75
p_batterya <- 3.25
p_batteryb <- 1.083333
# Probability of having a 10 year long life lithium smoke alarm battery
#p_battery10y <- 0.06
#p_battery10ya <- 14.98
#p_battery10yb <- 234.686667
##
## PARAMETER TYPE: RESOURCE COST
##
#INTERVENTIONS COSTS
# Cost of home safety inspection based on cost of LA home care worker for 40 minutes of their time
including travel
c_hsi <- 12
# Cost of providing education programme per household accepting intervention - based on cost of home
care worker
# for 20 minutes of their time including travel
c_educ <- 6
# Fixed cost of an intervention scheme (e.g. set-up, administration, etc).
c_fixed <- 54977
# Additional cost incurred for each household that accept intervention (composite value)
c_acc <- 0.49
# Cost of smoke alarm giveaway (with ten-year sealed battery)
c_alarmg <- 4.41
# Cost of having the smoke alarm installed
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c_install <- 10.66
#HEALTH CARE COSTS
# Cost per minute of a Paramedic Unit
c_minPU <- 7.21
# Cost per minute of a Emergency Ambulance
c_minEA <- 7.11
# Mean cost (and standard error) of a minor injury
mn_minor <- 1087
se_minor <- 209
var_minor <- se_minor * se_minor
mn_minorsq<- mn_minor * mn_minor
sigmasq_minor<- log(1+ var_minor / mn_minorsq)
mu_minor<- log(mn_minor) - 0.5 * sigmasq_minor
# Mean cost (and standard error) of a moderate injury
mn_moderate <- 2573
se_moderate <- 1415
var_mod<- se_moderate * se_moderate
mn_modsq<- mn_moderate * mn_moderate
sigmasq_mod<- log(1 + var_mod / mn_modsq)
mu_mod<- log(mn_moderate) - 0.5 * sigmasq_mod
# Mean cost (and standard error) of a severe injury
mn_severe <- 58519
se_severe <- 32019
var_sev<- se_severe * se_severe
mn_sevsq<- mn_severe * mn_severe
sigmasq_sev<- log(1 + var_sev / mn_sevsq)
mu_sev<-log(mn_severe) - 0.5 * sigmasq_sev
# Cost of a fatality following a household fire (updated to 2008/9 prices) - includes coroners and
autopsy costs
c_fatal <- 185.16
# Cost of a disability per year
#c_dispyr <- 342
c_dispyra <- 16
c_dispyrb <- 0.046784
# cost of precautionary check-up NHS reference costs 2008/9 code VB11Z
mu_c_checkup <-62
#Calculate cost of precautionary check-up standard error from interquartile range
qrt1_c_checkup <- 45
qrt3_c_checkup <- 74
se_c_checkup<-((qrt3_c_checkup - qrt1_c_checkup) / (2 * 0.6745))
##
##OTHER COSTS
##
#OUT OF POCKET / PRIVATE COSTS
#Cost to individual - assume would buy standard unit
#c_alarmind <- c(0,4.41,0,0,0,4.41,0)
#Smoke alarm cost
c_sa <- 0
# http://www.safelincs.co.uk/Ionisation-Smoke-Alarms/ # Cost of smoke alarm if falls on individual
# Smoke alarm battery cost
c_battery <- 0 # 1 year battery
#c_battery10y <- 8.89 # 10 year long life lithium batteries
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#c_battery10ya <- 16
#c_battery10yb <- 1.799775
#c_sa <- 0
#c_battery <- 0
#c_battery.std <- 0 #Use when including private costs
#c_property <- 980 # Use when including private costs
#c_propertya <- 16
#c_propertyb <- 0.016327
##
#LAW ENFORCEMENT AND RESCUE SERVICES COSTS
# Cost of police attending - assumed only to attend where severs injuries
c_police <- 156.67
# Cost of Fire and rescue Service attending a fire
c_FRSresponse <- 3051
## PARAMETER TYPE: UTILITY PARAMATERS PER CYCLE
# Deficit in utilities for minor injury (DRG 460 + 459)
u_min <- 0.0487
# Deficit in utilities for moderate injury (DRG 458 + 457)
u_mod <- 0.069
# Deficit in utilities for severe injury (DRG 472)
u_sev <- 0.107
# Deficit in utilities following a disability
#u_deficit <- 0.1
u_deficita <- 14.3
u_deficitb <- 128.7
#-------------------------------------------------------------------#
##### DATA 2: Mortality and population utilities ######
#-------------------------------------------------------------------#
mortutil_data<-read.table('…', header=T, sep="\t", quote="\"", dec=".",
fill=T,na.strings=c(""),as.is=1:3)
#-------------------------------------------------------------------#
##### DATA 3: Probability intervention is effective ####
#-------------------------------------------------------------------#
p_MTCfunc_pred_temp<-read.table('…', header=F, sep="\t", quote="\"", dec=".",
fill=T,na.strings=c(""),as.is=1:1)
sims <- seq(1,5000,1)
ProbMatrix<- matrix(data = NA, nrow = 5000, ncol = 7, dimnames = list(sims,
c("preff1","preff2","preff3","preff4","preff5","preff6","preff7")))
for (i in 1:5000) {
for (k in 1:7) {
ProbMatrix[i,1] <- p_MTCfunc_pred_temp[i, 2]
ProbMatrix[i,2] <- p_MTCfunc_pred_temp[i + 5000, 2]
ProbMatrix[i,3] <- p_MTCfunc_pred_temp[i + 10000, 2]
ProbMatrix[i,4] <- p_MTCfunc_pred_temp[i + 15000, 2]
ProbMatrix[i,5] <- p_MTCfunc_pred_temp[i + 20000, 2]
ProbMatrix[i,6] <- p_MTCfunc_pred_temp[i + 25000, 2]
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ProbMatrix[i,7] <- p_MTCfunc_pred_temp[i + 30000, 2]
}
}
#-------------------------------------------------------------------#
#-------------------------------------------------------------------#
###### DECISION MODEL FOR SMOKE ALARMS ##
#-------------------------------------------------------------------#
#-------------------------------------------------------------------#
Nsim <- 5000
u_pop = array(NA, dim=c(Nsim,T), dimnames=list(seq(1,Nsim,1),seq(1,T,1)))
pi_ = array(NA, dim=c(T,S,P),
dimnames=list(seq(1,T,1),c("fsa","nfsa","fsad","nfsad","dfi","doc"),seq(1,P,1)))
CHECK = array(NA, dim=c(T,P), dimnames=list(seq(1,T,1),seq(1,7,1)))
ct_ = array(NA, dim=c(T,P), dimnames=list(seq(1,T,1),seq(1,7,1)))
ut_ = array(NA, dim=c(T,P), dimnames=list(seq(1,T,1),seq(1,7,1)))
decay = array(NA, dim=c(P), dimnames=list(seq(1,P,1)))
p_fsa = array(NA, dim=c(4,P), dimnames=list(seq(1,4,1),seq(1,P,1)))
o1 = array(NA, dim=c(C,4,P),
dimnames=list(c("cycle1","cycle2","cycle3","cycle4","cycle5"),seq(1,4,1),seq(1,P,1)))
o2 <- o1; o3 <- o1; o4 <- o1; o5 <- o1; o6 <- o1; o7 <- o1; o8 <- o1; o9 <- o1; o10 <- o1; o11 <- o1; o12
<- o1; o13 <- o1; o14 <- o1; o15 <- o1; o16 <- o1
TOT = array(NA, dim=c(C,4,P),
dimnames=list(c("cycle1","cycle2","cycle3","cycle4","cycle5"),seq(1,4,1),seq(1,P,1)))
lambda = array(NA, dim=c(T,S,S,P),
dimnames=list(seq(1,T,1),c("fsa","nfsa","fsad","nfsad","dfi","doc"),c("fsa","nfsa","fsad","nfsad","dfi","
doc"),seq(1,P,1)))
TOTAL = array(NA, dim=c(T,S,P),
dimnames=list(seq(1,T,1),c("fsa","nfsa","fsad","nfsad","dfi","doc"),seq(1,P,1)))
c_equip = array(NA, dim=c(P,4), dimnames=list(seq(1,P,1),seq(1,4,1)))
c_fire = array(NA, dim=c(4), dimnames=list(seq(1,4,1)))
c_o1 = array(NA, dim=c(C,P,4),
dimnames=list(c("cycle1","cycle2","cycle3","cycle4","cycle5"),seq(1,P,1),seq(1,4,1)))
c_o2 <- c_o1; c_o3 <- c_o1; c_o4 <- c_o1; c_o5 <- c_o1; c_o6 <- c_o1; c_o7 <- c_o1; c_o8 <- c_o1;
c_o9 <- c_o1; c_o10 <- c_o1;
c_o11 <- c_o1; c_o12 <- c_o1; c_o13 <- c_o1; c_o14 <- c_o1; c_o15 <- c_o1; c_o16 <- c_o1
cost = array(NA, dim=c(T,S,P),
dimnames=list(seq(1,T,1),c("fsa","nfsa","fsad","nfsad","dfi","doc"),seq(1,P,1)))
TotC = array(NA, dim=c(P), dimnames=list(seq(1,P,1)))
mean_C = array(NA, dim=c(P), dimnames=list(seq(1,P,1)))
TotU = array(NA, dim=c(P), dimnames=list(seq(1,P,1)))
mean_U = array(NA, dim=c(P), dimnames=list(seq(1,P,1)))
u = array(NA, dim=c(T,S,P),
dimnames=list(seq(1,T,1),c("fsa","nfsa","fsad","nfsad","dfi","doc"),seq(1,P,1)))
u_o1 = array(NA, dim=c(C,P,4),
dimnames=list(c("cycle1","cycle2","cycle3","cycle4","cycle5"),seq(1,P,1),seq(1,4,1)))
u_o2 <- u_o1; u_o3 <- u_o1; u_o4 <- u_o1; u_o5 <- u_o1; u_o6 <- u_o1; u_o7 <- u_o1; u_o8 <- u_o1;
u_o9 <- u_o1; u_o10 <- u_o1;
u_o11 <- u_o1; u_o12 <- u_o1; u_o13 <- u_o1; u_o14 <- u_o1; u_o15 <- u_o1; u_o16 <- u_o1
Rc = array(NA, dim=c(K), dimnames=list(seq(1,K,1)))
ProbMatrix <- cbind(ProbMatrix, "p_accept"=rbeta(Nsim, p_accepta, p_acceptb))
ProbMatrix <- cbind(ProbMatrix, "pop_fsa1"=rbeta(Nsim, r_fsa+1, n_sa-r_fsa+1))
ProbMatrix <- cbind(ProbMatrix, "p_fire1"=rbeta(Nsim, r_fire_func+1, n_hh-r_fire_func+1))
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ProbMatrix <- cbind(ProbMatrix, "p_fire2"=rbeta(Nsim, r_nonfunc_noSA+1, n_hh-
r_nonfunc_noSA+1))
ProbMatrix <- cbind(ProbMatrix, "p_fire3"=rbeta(Nsim, r_fire_func+1, n_hh-r_fire_func+1))
ProbMatrix <- cbind(ProbMatrix, "p_fire4"=rbeta(Nsim, r_nonfunc_noSA+1, n_hh-
r_nonfunc_noSA+1))
ProbMatrix <- cbind(ProbMatrix, "p_1yrtest"=rbeta(Nsim, r_1yrtest+1, n_test-r_1yrtest+1))
ProbMatrix <- cbind(ProbMatrix, "p_testless1yr"=rbeta(Nsim, r_testless1yr+1, n_test-r_testless1yr+1))
ProbMatrix <- cbind(ProbMatrix, "p_1yrbattery"=rbeta(Nsim, r_1yrbattery+1, n_1yrbattery-
r_1yrbattery+1))
ProbMatrix <- cbind(ProbMatrix, "p_noinjury"=rbeta(Nsim, r_noinjury+1, r_total_fires-r_noinjury+1))
#Assuming probability of injury the same regardless of functioning or non-functioning SA
ProbMatrix <- cbind(ProbMatrix, "p_injury1"=1-ProbMatrix[,"p_noinjury"])
ProbMatrix <- cbind(ProbMatrix, "p_injury2"=1-ProbMatrix[,"p_noinjury"])
ProbMatrix <- cbind(ProbMatrix, "p_injury3"=1-ProbMatrix[,"p_noinjury"])
ProbMatrix <- cbind(ProbMatrix, "p_injury4"=1-ProbMatrix[,"p_noinjury"])
ProbMatrix <- cbind(ProbMatrix, "p_fatal1"=rbeta(Nsim, r_fatalSA+1, r_fire_func-r_fatalSA+1))
ProbMatrix <- cbind(ProbMatrix, "p_fatal3"=ProbMatrix[,"p_fatal1"])
ProbMatrix <- cbind(ProbMatrix, "p_fatal2"=rbeta(Nsim, r_fatalnSA+1, r_fire_nfunc-r_fatalnSA+1))
ProbMatrix <- cbind(ProbMatrix, "p_fatal4"=ProbMatrix[,"p_fatal2"])
ProbMatrix <- cbind(ProbMatrix, "p_minor"=rbeta(Nsim, r_minor+1, n_burnsinjury-r_minor+2))
ProbMatrix <- cbind(ProbMatrix, "p_moderate"=rbeta(Nsim, r_moderate + (1-
ProbMatrix[,"p_minor"]), n_burnsinjury - r_moderate + (1-ProbMatrix[,"p_minor"])))
ProbMatrix <- cbind(ProbMatrix, "p_severe"= 1 - ProbMatrix[,"p_minor"] -
ProbMatrix[,"p_moderate"])
ProbMatrix <- cbind(ProbMatrix, "p_ITU"= rbeta(Nsim, p_ITUa, p_ITUb))
ProbMatrix <- cbind(ProbMatrix, "p_FRSattend"= rbeta(Nsim, r_FRSattend+1, n_fires-
r_FRSattend+1))
ProbMatrix <- cbind(ProbMatrix, "p_checkup"= rbeta(Nsim, r_checkup+1, n_checkup-r_checkup+1))
ProbMatrix <- cbind(ProbMatrix, "p_battery"= rbeta(Nsim, p_batterya, p_batteryb))
#ProbMatrix <- cbind(ProbMatrix, "p_battery10y"= rbeta(Nsim, p_battery10ya, p_battery10yb))
ProbMatrix <- cbind(ProbMatrix, "c_educ"=rep(c_educ,5000))
ProbMatrix <- cbind(ProbMatrix, "c_fixed"=rep(c_fixed,5000))
ProbMatrix <- cbind(ProbMatrix, "c_alarmg"=rep(c_alarmg,5000))
#ProbMatrix <- cbind(ProbMatrix, "c_alarmind"=ProbMatrix[,"c_alarmg"])
ProbMatrix <- cbind(ProbMatrix, "c_sa"=rep(c_sa,5000))
ProbMatrix <- cbind(ProbMatrix, "c_hsi"=rep(c_hsi,5000))
ProbMatrix <- cbind(ProbMatrix, "c_install"=rep(c_install,5000))
ProbMatrix <- cbind(ProbMatrix, "c_acc"=rep(c_acc,5000))
ProbMatrix <- cbind(ProbMatrix, "c_battery"=rep(c_battery,5000))
#ProbMatrix <- cbind(ProbMatrix, "c_battery10y"=rgamma(Nsim, c_battery10ya, c_battery10yb))
ProbMatrix <- cbind(ProbMatrix, "c_interv1"=rep(0,5000))
ProbMatrix <- cbind(ProbMatrix, "c_interv2"=ProbMatrix[,"c_educ"])
ProbMatrix <- cbind(ProbMatrix, "c_interv3"=ProbMatrix[,"c_educ"] + ProbMatrix[,"c_alarmg"])
ProbMatrix <- cbind(ProbMatrix, "c_interv4"=ProbMatrix[,"c_educ"] + ProbMatrix[,"c_alarmg"] +
ProbMatrix[,"c_hsi"])
ProbMatrix <- cbind(ProbMatrix, "c_interv5"=ProbMatrix[,"c_educ"] + ProbMatrix[,"c_alarmg"] +
ProbMatrix[,"c_install"])
ProbMatrix <- cbind(ProbMatrix, "c_interv6"=ProbMatrix[,"c_educ"] + ProbMatrix[,"c_hsi"])
ProbMatrix <- cbind(ProbMatrix, "c_interv7"=ProbMatrix[,"c_educ"] + ProbMatrix[,"c_alarmg"] +
ProbMatrix[,"c_hsi"] + ProbMatrix[,"c_install"])
ProbMatrix <- cbind(ProbMatrix, "PU_mins"=rnorm(Nsim, mnPU, sdPU))
ProbMatrix <- cbind(ProbMatrix, "EA_mins"=rnorm(Nsim, mnEA, sdEA))
ProbMatrix <- cbind(ProbMatrix, "c_min"=rlnorm(Nsim, mu_minor, sqrt(sigmasq_minor)))
ProbMatrix <- cbind(ProbMatrix, "c_minor"=ProbMatrix[,"c_min"] + ProbMatrix[,"p_ITU"] *
ProbMatrix[,"c_min"])
ProbMatrix <- cbind(ProbMatrix, "c_mod"=rlnorm(Nsim, mu_mod, sqrt(sigmasq_mod)))
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ProbMatrix <- cbind(ProbMatrix, "c_moderate"=ProbMatrix[,"c_mod"] + ProbMatrix[,"p_ITU"] *
ProbMatrix[,"c_mod"] + c_minEA * ProbMatrix[,"EA_mins"])
ProbMatrix <- cbind(ProbMatrix, "c_sev"=rlnorm(Nsim, mu_sev, sqrt(sigmasq_sev)))
ProbMatrix <- cbind(ProbMatrix, "c_severe"=ProbMatrix[,"c_sev"] + ProbMatrix[,"p_ITU"] *
ProbMatrix[,"c_sev"] + c_minPU * ProbMatrix[,"PU_mins"] + c_police)
ProbMatrix <- cbind(ProbMatrix, "c_dispyr"=rgamma(Nsim, c_dispyra, c_dispyrb))
ProbMatrix <- cbind(ProbMatrix, "c_checkup"=rnorm(1,mu_c_checkup,se_c_checkup))
ProbMatrix <- cbind(ProbMatrix, "c_noinjury"=ProbMatrix[,"p_checkup"] *
ProbMatrix[,"c_checkup"])
ProbMatrix <- cbind(ProbMatrix, "u_deficit"=rbeta(Nsim, u_deficita, u_deficitb))
ProbMatrix <- cbind(ProbMatrix, "c_property"=rep(0,5000))
for(l in 1:T) {
u_pop[,l] <-rnorm(Nsim,mortutil_data[l,"mnu_pop"], mortutil_data[l,"u_pop.se"])
ProbMatrix <- cbind(ProbMatrix, u_pop[,l])
colnames(ProbMatrix)[ncol(ProbMatrix)] <- paste("u_pop",l,sep="")
}
#PART 1 - Intervention model
#(separating the cohort into the different Markov health states)
CEmodelSA <- function(i,CEmodeldata= ProbMatrix) {
# i=1 ; CEmodeldata= ProbMatrix
input <- CEmodeldata[i,]
#input <- CEmodeldata
n1 <- NULL
n2 <- NULL
n3 <- NULL
n4 <- NULL
c_n1 <- NULL
c_n2 <- NULL
c_n3 <- NULL
c_n4 <- NULL
n1[1] <- N * input["pop_fsa1"] #Standard care
n2[1] <- 0
n3[1] <- 0
n4[1] <- N * (1 - input["pop_fsa1"])
#To choose between absolute effects (T[p]=p_MTCfunc[p]) or predictive distribution of the absolute
effects #(T_pred[p]=p_MTCfunc_pred[p])
for (p in 2:P) {
n1[p]<- N * input["pop_fsa1"]
n2[p]<- N * (1 - input["pop_fsa1"]) * input["p_accept"] * input[paste("preff",p, sep="")]
n3[p]<- N * (1 - input["pop_fsa1"]) * input["p_accept"] * (1 - input[paste("preff",p, sep="")])
n4[p]<- N * (1 - input["pop_fsa1"]) * (1 - input["p_accept"])
}
for (p in 1:P) {
pi_[1,1,p]<- n1[p] + n2[p]
pi_[1,2,p]<- n3[p] + n4[p]
pi_[1,3,p]<- 0
pi_[1,4,p]<- 0
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pi_[1,5,p]<- 0
pi_[1,6,p]<- 0
CHECK[1,p]<- pi_[1,1,p] + pi_[1,2,p] + pi_[1,3,p] + pi_[1,4,p] + pi_[1,5,p] + pi_[1,6,p]
c_n1[p]<- n1[p] * 0
c_n2[p]<- n2[p] * (input[paste("c_interv",p, sep="")] + input["c_acc"])
c_n3[p]<- n3[p] * (input[paste("c_interv",p, sep="")] + input["c_acc"])
c_n4[p]<- n4[p]
ct_[1,p]<- c_n1[p] + c_n2[p] + c_n3[p] + c_n4[p] + input["c_fixed"]
ut_[1,p]<- input["u_pop1"] * N
}
#PART TWO - MARKOV MODEL (5 year period)
decay[1] <- (1 - input["p_1yrtest"] - 0.5 * input["p_testless1yr"]) * input["p_1yrbattery"]
decay[2] <- decay[1]
decay[3] <- 0
decay[4] <- 0
decay[5] <- 0
decay[6] <- decay[1]
decay[7] <- 0
for(p in 1:P) {
#This part of the code allows to set different decays for different interventions
#e.g. wired, 1 yr battery, 10 yr battery, etc.
p_fsa[1,p]<- input["pop_fsa1"] * (1 - decay[p])
#'Decay' is proportion of smoke alarms no longer functional after 12 months
p_fsa[2,p]<- 0
#Probability go from not functioning to functioning included in the decay variable
p_fsa[3,p]<- p_fsa[1,p]
p_fsa[4,p]<- 0
}
for(p in 1:P) {
for(c in 2:C) {
for(k in 1:4) {
#1=functional, 2=non-functional, 3=functional / disability, 4=non-functional / disability
o1[c,k,p]<- (1 - input[paste("p_fire",k, sep="")]) * mortutil_data[c,"p_allcause"]
o2[c,k,p]<- (1 - input[paste("p_fire",k, sep="")]) * (1 - mortutil_data[c,"p_allcause"]) *
p_fsa[k,p]
o3[c,k,p]<- (1 - input[paste("p_fire",k, sep="")]) * (1 - mortutil_data[c,"p_allcause"]) * (1 –
p_fsa[k,p])
o4[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] *
input[paste("p_fatal",k, sep="")]
o5[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_minor"] * (1 –
mortutil_data[c,"p_allcause"]) * p_fsa[k,p]
o6[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_minor"] * (1 –
mortutil_data[c,"p_allcause"]) * (1 - p_fsa[k,p])
o7[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_minor"] *
mortutil_data[c,"p_allcause"]
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o8[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_moderate"] * (1 –
mortutil_data[c,"p_allcause"]) * p_fsa[k,p]
o9[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_moderate"] * (1 –
mortutil_data[c,"p_allcause"] ) * (1 - p_fsa[k,p])
o10[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_moderate"] *
mortutil_data[c,"p_allcause"]
o11[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_severe"] * (1 –
mortutil_data[c,"p_allcause"]) * p_fsa[k,p]
o12[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_severe"] * (1 –
mortutil_data[c,"p_allcause"]) * (1 - p_fsa[k,p])
o13[c,k,p]<- input[paste("p_fire",k, sep="")] * input[paste("p_injury",k, sep="")] * (1 –
input[paste("p_fatal",k, sep="")]) * input["p_severe"] *
mortutil_data[c,"p_allcause"]
o14[c,k,p]<- input[paste("p_fire",k, sep="")] * (1 - input[paste("p_injury",k, sep="")]) *
mortutil_data[c,"p_allcause"]
o15[c,k,p]<- input[paste("p_fire",k, sep="")] * (1 - input[paste("p_injury",k, sep="")]) * (1 –
mortutil_data[c,"p_allcause"]) * p_fsa[k,p]
o16[c,k,p]<- input[paste("p_fire",k, sep="")] * (1 - input[paste("p_injury",k, sep="")]) *
(1 - mortutil_data[c,"p_allcause"]) * (1 - p_fsa[k,p])
TOT[c,k,p]<-o1[c,k,p]+o2[c,k,p]+o3[c,k,p]+o4[c,k,p]+o5[c,k,p]+o6[c,k,p]+o7[c,k,p]+
o8[c,k,p]+o9[c,k,p]+o10[c,k,p]+o11[c,k,p]+o12[c,k,p]+o13[c,k,p]+o14[c,k,p]+o15[c,k,p]+o16[c,k,p]
}
}
}
#Transition probabilities
for (p in 1:P){
for(c in 2:C){
#From 'functioning' state
lambda[c,1,1,p]<-o2[c,1,p]+o5[c,1,p]+o8[c,1,p]+o15[c,1,p]
lambda[c,1,2,p]<-o3[c,1,p]+o6[c,1,p]+o9[c,1,p]+o16[c,1,p]
lambda[c,1,3,p]<-o11[c,1,p]
lambda[c,1,4,p]<-o12[c,1,p]
lambda[c,1,5,p]<-o4[c,1,p]
lambda[c,1,6,p]<-o1[c,1,p]+o7[c,1,p]+o10[c,1,p]+o13[c,1,p]+o14[c,1,p]
TOTAL[c,1,p]<-
lambda[c,1,1,p]+lambda[c,1,2,p]+lambda[c,1,3,p]+lambda[c,1,4,p]+lambda[c,1,5,p]+lambda[c,1,6,p]
#From 'non-functioning' state
lambda[c,2,1,p]<-o2[c,2,p]+o5[c,2,p]+o8[c,2,p]+o15[c,2,p]
lambda[c,2,2,p]<-o3[c,2,p]+o6[c,2,p]+o9[c,2,p]+o16[c,2,p]
lambda[c,2,3,p]<-o11[c,2,p]
lambda[c,2,4,p]<-o12[c,2,p]
lambda[c,2,5,p]<-o4[c,2,p]
lambda[c,2,6,p]<-o1[c,2,p]+o7[c,2,p]+o10[c,2,p]+o13[c,2,p]+o14[c,2,p]
TOTAL[c,2,p]<-
lambda[c,2,1,p]+lambda[c,2,2,p]+lambda[c,2,3,p]+lambda[c,2,4,p]+lambda[c,2,5,p]+lambda[c,2,6,p]
#From 'functioning / disability' state
lambda[c,3,1,p]<-0
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lambda[c,3,2,p]<-0
lambda[c,3,3,p]<-o2[c,3,p]+o5[c,3,p]+o8[c,3,p]+o15[c,3,p] + o11[c,3,p]
lambda[c,3,4,p]<-o3[c,3,p]+o6[c,3,p]+o9[c,3,p]+o16[c,3,p] + o12[c,3,p]
lambda[c,3,5,p]<-o4[c,3,p]
lambda[c,3,6,p]<-o1[c,3,p]+o7[c,3,p]+o10[c,3,p]+o13[c,3,p]+o14[c,3,p]
TOTAL[c,3,p]<-
lambda[c,3,1,p]+lambda[c,3,2,p]+lambda[c,3,3,p]+lambda[c,3,4,p]+lambda[c,3,5,p]+lambda[c,3,6,p]
#From 'non-functioning' state
lambda[c,4,1,p]<-0
lambda[c,4,2,p]<-0
lambda[c,4,3,p]<- o2[c,4,p]+o5[c,4,p]+o8[c,4,p]+o15[c,4,p] + o11[c,4,p]
lambda[c,4,4,p]<-o3[c,4,p]+o6[c,4,p]+o9[c,4,p]+o16[c,4,p] + o12[c,4,p]
lambda[c,4,5,p]<-o4[c,4,p]
lambda[c,4,6,p]<-o1[c,4,p]+o7[c,4,p]+o10[c,4,p]+o13[c,4,p]+o14[c,4,p]
TOTAL[c,4,p]<-
lambda[c,4,1,p]+lambda[c,4,2,p]+lambda[c,4,3,p]+lambda[c,4,4,p]+lambda[c,4,5,p]+lambda[c,4,6,p]
#From 'fatal' state
lambda[c,5,1,p]<-0
lambda[c,5,2,p]<-0
lambda[c,5,3,p]<-0
lambda[c,5,4,p]<-0
lambda[c,5,5,p]<-1
lambda[c,5,6,p]<-0
TOTAL[c,5,p]<-
lambda[c,5,1,p]+lambda[c,5,2,p]+lambda[c,5,3,p]+lambda[c,5,4,p]+lambda[c,5,5,p]+lambda[c,5,6,p]
#From 'all cause' state
lambda[c,6,1,p]<-0
lambda[c,6,2,p]<-0
lambda[c,6,3,p]<-0
lambda[c,6,4,p]<-0
lambda[c,6,5,p]<-0
lambda[c,6,6,p]<-1
TOTAL[c,6,p]<-
lambda[c,6,1,p]+lambda[c,6,2,p]+lambda[c,6,3,p]+lambda[c,6,4,p]+lambda[c,6,5,p]+lambda[c,6,6,p]
}
}
#Number of individuals (households) in each state at time t>1
for (p in 1:P) {
for(c in 2:C) {
for (s in 1:S) {
pi_[c,s,p]<- pi_[(c - 1),,p] %*% lambda[c,,s,p]
}
CHECK[c,p]<-pi_[c,1,p] + pi_[c,2,p] + pi_[c,3,p] + pi_[c,4,p] + pi_[c,5,p] + pi_[c,6,p]
}
}
#
#PART THREE - MARKOV MODEL (T-5 year period)
#
for (p in 1:P) {
for(c in (C+1):T) {
lambda[c,1,1,p]<-1 - mortutil_data[c,"p_allcause"]
lambda[c,1,2,p]<-0
lambda[c,1,3,p]<-0
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lambda[c,1,4,p]<-0
lambda[c,1,5,p]<-0
lambda[c,1,6,p]<-mortutil_data[c,"p_allcause"]
TOTAL[c,1,p]<-
lambda[c,1,1,p]+lambda[c,1,2,p]+lambda[c,1,3,p]+lambda[c,1,4,p]+lambda[c,1,5,p]+lambda[c,1,6,p]
lambda[c,2,1,p]<-0
lambda[c,2,2,p]<-1 - mortutil_data[c,"p_allcause"]
lambda[c,2,3,p]<-0
lambda[c,2,4,p]<-0
lambda[c,2,5,p]<-0
lambda[c,2,6,p]<-mortutil_data[c,"p_allcause"]
TOTAL[c,2,p]<-
lambda[c,2,1,p]+lambda[c,2,2,p]+lambda[c,2,3,p]+lambda[c,2,4,p]+lambda[c,2,5,p]+lambda[c,2,6,p]
lambda[c,3,1,p]<-0
lambda[c,3,2,p]<-0
lambda[c,3,3,p]<-1 - mortutil_data[c,"p_allcause"]
lambda[c,3,4,p]<-0
lambda[c,3,5,p]<-0
lambda[c,3,6,p]<-mortutil_data[c,"p_allcause"]
TOTAL[c,3,p]<-
lambda[c,3,1,p]+lambda[c,3,2,p]+lambda[c,3,3,p]+lambda[c,3,4,p]+lambda[c,3,5,p]+lambda[c,3,6,p]
lambda[c,4,1,p]<-0
lambda[c,4,2,p]<-0
lambda[c,4,3,p]<-0
lambda[c,4,4,p]<-1 - mortutil_data[c,"p_allcause"]
lambda[c,4,5,p]<-0
lambda[c,4,6,p]<-mortutil_data[c,"p_allcause"]
TOTAL[c,4,p]<-
lambda[c,4,1,p]+lambda[c,4,2,p]+lambda[c,4,3,p]+lambda[c,4,4,p]+lambda[c,4,5,p]+lambda[c,4,6,p]
lambda[c,5,1,p]<-0
lambda[c,5,2,p]<-0
lambda[c,5,3,p]<-0
lambda[c,5,4,p]<-0
lambda[c,5,5,p]<-1
lambda[c,5,6,p]<-0
TOTAL[c,5,p]<-
lambda[c,5,1,p]+lambda[c,5,2,p]+lambda[c,5,3,p]+lambda[c,5,4,p]+lambda[c,5,5,p]+lambda[c,5,6,p]
lambda[c,6,1,p]<-0
lambda[c,6,2,p]<-0
lambda[c,6,3,p]<-0
lambda[c,6,4,p]<-0
lambda[c,6,5,p]<-0
lambda[c,6,6,p]<-1
TOTAL[c,6,p]<-
lambda[c,6,1,p]+lambda[c,6,2,p]+lambda[c,6,3,p]+lambda[c,6,4,p]+lambda[c,6,5,p]+lambda[c,6,6,p]
}
}
#Number of individuals (households) in each state at time >C
for (p in 1:P) {
for(c in (C+1):T) {
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for (s in 1:S) {
pi_[c,s,p]<- pi_[(c - 1),,p] %*% lambda[c,,s,p]
}
CHECK[c,p]<- pi_[c,1,p] + pi_[c,2,p] + pi_[c,3,p] + pi_[c,4,p] + pi_[c,5,p] + pi_[c,6,p]
}
}
###########################################
#-------- COSTS IN EACH STATE ------------#
###########################################
# Equipment costs of having functioning smoke alarm at end of each cycle
#Usual Care, intervention 2 and 6
for(k in 1:4) {
c_equip[1,k]<- input["c_battery"] * input["p_battery"] # + input["c_battery10y"] *
input["p_battery10y"]
c_equip[2,k]<- input["c_sa"] + input["c_battery"] * input["p_battery"]
#+ input["c_battery10y"] * input["p_battery10y"]
c_equip[6,k]<- input["c_sa"] + input["c_battery"] * input["p_battery"]
#+ input["c_battery10y"] * input["p_battery10y"]
}
# All other intervention groups
for (p in 3:5) {
c_equip[p, 1]<- input["c_battery"] * input["p_battery"]
#+ input["c_battery10y"] * input["p_battery10y"]
c_equip[p, 2]<- input["c_sa"] + input["c_battery"] * input["p_battery"]
#+ input["c_battery10y"] * input["p_battery10y"]
c_equip[p, 3]<- c_equip[p,1]
c_equip[p, 4]<- c_equip[p,2]
}
c_equip[7, 1]<- input["c_battery"] * input["p_battery"]
#+ input["c_battery10y"] * input["p_battery10y"]
c_equip[7, 2]<- input["c_sa"] + input["c_battery"] * input["p_battery"]
#+ input["c_battery10y"] * input["p_battery10y"]
c_equip[7, 3]<- c_equip[p,1]
c_equip[7, 4]<- c_equip[p,2]
# Cost of having a fire at the household
for (k in 1:4) {
c_fire[k]<- input["p_FRSattend"] * c_FRSresponse + input["c_property"]
}
#Cost of taking each pathway through the model for functional, non-functional functional/disability
and non-functional/disability
for (p in 1:P){
for (c in 2:C){
for(k in 1:2){ #1=functional, 2=non-functional
c_o1[c,p,k]<- 0
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c_o2[c,p,k]<- c_equip[p,k]
#If already have smoke alarm this is cost of maintenance (ie.g. battery)
# If not, cost of equipment (i.e. smoke alarm)
c_o3[c,p,k]<- 0
c_o4[c,p,k]<- (c_fire[k] + c_fatal)
c_o5[c,p,k]<- (c_fire[k] + input["c_minor"] + c_equip[p,k])
c_o6[c,p,k]<- (c_fire[k] + input["c_minor"])
c_o7[c,p,k]<- (c_fire[k] + input["c_minor"])
c_o8[c,p,k]<- (c_fire[k] + input["c_moderate"] + c_equip[p,k])
c_o9[c,p,k]<- (c_fire[k] + input["c_moderate"])
c_o10[c,p,k]<- (c_fire[k] + input["c_moderate"])
c_o11[c,p,k]<- (c_fire[k] + input["c_severe"] + c_equip[p,k])
c_o12[c,p,k]<- (c_fire[k] + input["c_severe"])
c_o13[c,p,k]<- (c_fire[k] + input["c_severe"])
c_o14[c,p,k]<- (c_fire[k] + input["c_noinjury"])
c_o15[c,p,k]<- (c_fire[k] + input["c_noinjury"] + c_equip[p,k])
c_o16[c,p,k]<- (c_fire[k] + input["c_noinjury"])
}
for(k in 3:4) { #3=functional / disability, 4=non-functional / disability
c_o1[c,p,k]<- 0
c_o2[c,p,k]<- (c_equip[p,k] + input["c_dispyr"])
#If already have smoke alarm this is cost of maintenance (ie.g. battery)
# If not, cost of equipment (i.e. smoke alarm)
#c_disability is annual cost associated with being disabled by fire
c_o3[c,p,k]<- (0 + input["c_dispyr"])
c_o4[c,p,k]<- (c_fire[k] + c_fatal)
c_o5[c,p,k]<- (c_fire[k] + input["c_minor"] + c_equip[p,k] +
input["c_dispyr"])
c_o6[c,p,k]<- (c_fire[k] + input["c_minor"] + input["c_dispyr"] )
c_o7[c,p,k]<- (c_fire[k] + input["c_minor"])
c_o8[c,p,k]<- (c_fire[k] + input["c_moderate"] + c_equip[p,k] +
input["c_dispyr"])
c_o9[c,p,k]<- (c_fire[k] + input["c_moderate"] + input["c_dispyr"])
c_o10[c,p,k]<- (c_fire[k] + input["c_moderate"])
c_o11[c,p,k]<- (c_fire[k] + input["c_severe"] + c_equip[p,k] +
input["c_dispyr"])
c_o12[c,p,k]<- (c_fire[k] + input["c_severe"] + input["c_dispyr"])
c_o13[c,p,k]<- (c_fire[k] + input["c_severe"])
c_o14[c,p,k]<- (c_fire[k] + input["c_noinjury"])
c_o15[c,p,k]<- (c_fire[k] + input["c_noinjury"] + c_equip[p,k] +
input["c_dispyr"])
c_o16[c,p,k]<- (c_fire[k] + input["c_noinjury"] + input["c_dispyr"])
}
# From 'functioning fire alarm state
cost[c,1,p]<-
c_o1[c,p,1]+c_o2[c,p,1]+c_o3[c,p,1]+c_o4[c,p,1]+c_o5[c,p,1]+c_o6[c,p,1]+c_o7[c,p,1]+c_o8[c,p,1]+c
_o9[c,p,1]+c_o10[c,p,1]+c_o11[c,p,1]+c_o12[c,p,1]+c_o13[c,p,1]+c_o14[c,p,1]+c_o15[c,p,1]+c_o16[c
,p,1]
#From 'non-functioning fire alarm’ state
cost[c,2,p]<-
c_o1[c,p,2]+c_o2[c,p,2]+c_o3[c,p,2]+c_o4[c,p,2]+c_o5[c,p,2]+c_o6[c,p,2]+c_o7[c,p,2]+c_o8[c,p,2]+c
_o9[c,p,2]+c_o10[c,p,2]+c_o11[c,p,2]+c_o12[c,p,2]+c_o13[c,p,2]+c_o14[c,p,2]+c_o15[c,p,2]+c_o16[c
,p,2]
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#From 'functioning fire alarm / disability' state
cost[c,3,p]<-
c_o1[c,p,3]+c_o2[c,p,3]+c_o3[c,p,3]+c_o4[c,p,3]+c_o5[c,p,3]+c_o6[c,p,3]+c_o7[c,p,3]+c_o8[c,p,3]+c
_o9[c,p,3]+c_o10[c,p,3]+c_o11[c,p,3]+c_o12[c,p,3]+c_o13[c,p,3]+c_o14[c,p,3]+c_o15[c,p,3]+c_o16[c
,p,3]
#From 'non-functioning fire alarm / disability' state
cost[c,4,p]<-
c_o1[c,p,4]+c_o2[c,p,4]+c_o3[c,p,4]+c_o4[c,p,4]+c_o5[c,p,4]+c_o6[c,p,4]+c_o7[c,p,4]+c_o8[c,p,4]+c
_o9[c,p,4]+c_o10[c,p,4]+c_o11[c,p,4]+c_o12[c,p,4]+c_o13[c,p,4]+c_o14[c,p,4]+c_o15[c,p,4]+c_o16[c
,p,4]
#From 'death fatal injury' state
cost[c,5,p]<-0
#From 'death all cause' state
cost[c,6,p]<-0
}
for (c in (C+1):T) { #Cost of disability per year for the disability health states
cost[c,1,p]<- 0
cost[c,2,p]<- 0
cost[c,3,p]<- input["c_dispyr"]
cost[c,4,p]<- input["c_dispyr"]
cost[c,5,p]<- 0
cost[c,6,p]<- 0
}
}
for (p in 1:P) {
u[1,1,p]<- input["u_pop1"]
u[1,2,p]<- input["u_pop1"]
u[1,3,p]<- input["u_pop1"]
u[1,4,p]<- input["u_pop1"]
u[1,5,p]<- 0
u[1,6,p]<- 0
#Utilities of taking each pathway through the model for functional, non-functional,
#functional/disability and non-functional/disability
for (c in 2:C) {
for(k in 1:2) { #1=functional, 2=non-functional
u_o1[c,p,k]<- 0
u_o2[c,p,k]<- input[paste("u_pop",c, sep="")]
u_o3[c,p,k]<- input[paste("u_pop",c, sep="")]
u_o4[c,p,k]<- 0
u_o5[c,p,k]<- (input[paste("u_pop",c, sep="")] - u_min)
u_o6[c,p,k]<- (input[paste("u_pop",c, sep="")] - u_min)
u_o7[c,p,k]<- 0
u_o8[c,p,k]<- (input[paste("u_pop",c, sep="")] - u_mod)
u_o9[c,p,k]<- (input[paste("u_pop",c, sep="")] - u_mod)
u_o10[c,p,k]<- 0
u_o11[c,p,k]<- (input[paste("u_pop",c, sep="")] - u_sev)
u_o12[c,p,k]<- (input[paste("u_pop",c, sep="")] - u_sev)
u_o13[c,p,k]<- 0
u_o14[c,p,k]<- 0
u_o15[c,p,k]<- input[paste("u_pop",c, sep="")]
u_o16[c,p,k]<- input[paste("u_pop",c, sep="")]
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}
for(k in 3:4) { #3=functional / disability, 4=non-functional / disability
u_o1[c,p,k]<- 0
u_o2[c,p,k]<- (input[paste("u_pop",c, sep="")] - input["u_deficit"])
u_o3[c,p,k]<- (input[paste("u_pop",c, sep="")] - input["u_deficit"])
u_o4[c,p,k]<- 0
u_o5[c,p,k]<- ((input[paste("u_pop",c, sep="")] - input["u_deficit"]) –
u_min)
u_o6[c,p,k]<- ((input[paste("u_pop",c, sep="")] - input["u_deficit"]) –
u_min)
u_o7[c,p,k]<- 0
u_o8[c,p,k]<- ((input[paste("u_pop",c, sep="")] - input["u_deficit"]) –
u_mod)
u_o9[c,p,k]<- ((input[paste("u_pop",c, sep="")] - input["u_deficit"]) –
u_mod)
u_o10[c,p,k]<- 0
u_o11[c,p,k]<- ((input[paste("u_pop",c, sep="")] - input["u_deficit"]) –
u_sev)
u_o12[c,p,k]<- ((input[paste("u_pop",c, sep="")] - input["u_deficit"]) –
u_sev)
u_o13[c,p,k]<- 0
u_o14[c,p,k]<- 0
u_o15[c,p,k]<- (input[paste("u_pop",c, sep="")] - input["u_deficit"])
u_o16[c,p,k]<- (input[paste("u_pop",c, sep="")] - input["u_deficit"])
}
# From 'functioning fire alarm' state
u[c,1,p]<-
u_o1[c,p,1]+u_o2[c,p,1]+u_o3[c,p,1]+u_o4[c,p,1]+u_o5[c,p,1]+u_o6[c,p,1]+u_o7[c,p,1]+u_o8[c,p,1]+
u_o9[c,p,1]+u_o10[c,p,1]+u_o11[c,p,1]+u_o12[c,p,1]+u_o13[c,p,1]+u_o14[c,p,1]+u_o15[c,p,1]+u_o16
[c,p,1]
#From 'non-functioning fire alarm' state
u[c,2,p]<-
u_o1[c,p,2]+u_o2[c,p,2]+u_o3[c,p,2]+u_o4[c,p,2]+u_o5[c,p,2]+u_o6[c,p,2]+u_o7[c,p,2]+u_o8[c,p,2]+
u_o9[c,p,2]+u_o10[c,p,2]+u_o11[c,p,2]+u_o12[c,p,2]+u_o13[c,p,2]+u_o14[c,p,2]+u_o15[c,p,2]+u_o16
[c,p,2]
#From 'functioning fire alarm / disability' state
u[c,3,p]<-
u_o1[c,p,3]+u_o2[c,p,3]+u_o3[c,p,3]+u_o4[c,p,3]+u_o5[c,p,3]+u_o6[c,p,3]+u_o7[c,p,3]+u_o8[c,p,3]+
u_o9[c,p,3]+u_o10[c,p,3]+u_o11[c,p,3]+u_o12[c,p,3]+u_o13[c,p,3]+u_o14[c,p,3]+u_o15[c,p,3]+u_o16
[c,p,3]
#From 'non-functioning fire alarm / disability' state
u[c,4,p]<-
u_o1[c,p,4]+u_o2[c,p,4]+u_o3[c,p,4]+u_o4[c,p,4]+u_o5[c,p,4]+u_o6[c,p,4]+u_o7[c,p,4]+u_o8[c,p,4]+
u_o9[c,p,4]+u_o10[c,p,4]+u_o11[c,p,4]+u_o12[c,p,4]+u_o13[c,p,4]+u_o14[c,p,4]+u_o15[c,p,4]+u_o16
[c,p,4]
#From 'death fatal injury' state
u[c,5,p]<-0
#From 'death all cause' state
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u[c,6,p]<-0
}
for (c in (C+1):T) {
u[c,1,p]<- input[paste("u_pop",c, sep="")]
u[c,2,p]<- input[paste("u_pop",c, sep="")]
u[c,3,p]<- input[paste("u_pop",c, sep="")] - input["u_deficit"]
u[c,4,p]<- input[paste("u_pop",c, sep="")] - input["u_deficit"]
u[c,5,p]<- 0
u[c,6,p]<- 0
}
}
#Costs in each cycle of model
for (p in 1:P) {
for(c in 2:T) {
ct_[c,p] <- pi_[c,,p] %*% cost[c,,p] / ((1 + disc_c)^(c - 1))
}
TotC[p] <- sum(ct_[,p])
mean_C[p] <- TotC[p] / N
}
#Utlities in each cycle of model
for (p in 1:P){
for(c in 2:T) {
ut_[c,p] <- pi_[c,,p] %*% u[c,,p] / ((1 + disc_u)^(c - 1))
}
TotU[p] <- sum(ut_[,p])
mean_U[p] <- TotU[p] / N
}
return(c(mean_C, mean_U))
}
Nsim1<-5000
system.time(CE_out <- sapply(1:Nsim1,CEmodelSA))
#Cost effectiveness
NB = array(NA, dim=c(P,K, Nsim1), dimnames=list(seq(1,P,1),seq(1,K,1), seq(1,Nsim1,1)))
######## CALCULATING NMBs (CEILING RATIOS FROM £0 TO £200,000 ############
for(i in 1:Nsim1) {
for(k in 1:K) {
Rc[k]<- (k - 1) * 2000
for (p in 1:P) {
NB[p,k,i]<- Rc[k] * CE_out[7+p,i] - CE_out[p,i]
}
}
}
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### CALCULATING THE PROBABILITY OF INTERVENTION IS COST EFFECTIVE ###
### CALCULATING THE INTERVENTION WITH HIGHEST NMB ##########
### CALCULATING THE INDIVIDUAL (HOUSEHOLD) EXPECTED VALUE OF PERFECT
INFORMATION ##########
aux = array(NA, dim=c(Nsim1,K), dimnames=list(seq(1,Nsim1,1),seq(1,K,1)))
pCE = array(NA, dim=c(P,K), dimnames=list(seq(1,P,1),seq(1,K,1)))
meanNB = array(NA, dim=c(K,P), dimnames=list(seq(1,K,1),seq(1,P,1)))
CI = array(NA, dim=c(K), dimnames=list(seq(1,K,1)))
PI = array(NA, dim=c(K), dimnames=list(seq(1,K,1)))
EVPI = array(NA, dim=c(K), dimnames=list(seq(1,K,1)))
for(k in 1:K) {
aux[,k] <- apply(NB[,k,],2, max, na.rm=T)
for (p in 1:P) {
pCE[p,k]<- sum(aux == NB[p,k,], na.rm=T)/Nsim1
meanNB[k,p]<- mean(NB[p,k,])
}
CI[] <- apply(meanNB[,],1,max)
PI[k] <- mean(aux[,k])
EVPI[k] <- PI[k] - CI[k]
}
########## CALCULATING POPULATION EVPI ##########
discEffpop<- matrix(data = NA, nrow = 10, ncol = 1)
popEVPI<- matrix(data = NA, nrow = 101, ncol = 1)
Effpop<- 31000
for(k in 1:10) {
discEffpop[k]<- Effpop /(1 + disc_c)^(k-1)
}
sumdiscEffpop<-sum(discEffpop)
for(k in 1:K) {
popEVPI[k]<- sumdiscEffpop * EVPI[k]
}
########## CALCULATING THE PCE FOR FRONTIER ###########
pCE_CEAF = array(NA, dim=c(K,P), dimnames=list(seq(1,K,1),seq(1,P,1)))
for(k in 1:K) {
if (CI[k] == meanNB[k,1]) pCE_CEAF[k,1]<- pCE[1,k] else pCE_CEAF[k,1]<- NA
if (CI[k] == meanNB[k,2]) pCE_CEAF[k,2]<- pCE[2,k] else pCE_CEAF[k,2]<- NA
if (CI[k] == meanNB[k,3]) pCE_CEAF[k,3]<- pCE[3,k] else pCE_CEAF[k,3]<- NA
if (CI[k] == meanNB[k,4]) pCE_CEAF[k,4]<- pCE[4,k] else pCE_CEAF[k,4]<- NA
if (CI[k] == meanNB[k,5]) pCE_CEAF[k,5]<- pCE[5,k] else pCE_CEAF[k,5]<- NA
if (CI[k] == meanNB[k,6]) pCE_CEAF[k,6]<- pCE[6,k] else pCE_CEAF[k,6]<- NA
if (CI[k] == meanNB[k,7]) pCE_CEAF[k,7]<- pCE[7,k] else pCE_CEAF[k,7]<- NA
}
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Appendix 6
Table A6 – List of model input parameters used within the decision model for smoke alarms. Sources of evidence used to inform the parameter and
parametric assumption used to model parameter uncertainty is also shown.
Model input
parameter Parameter description
Source(s) of evidence
informing the parameter
Distributional
assumption Estimates
Parameter type: Other
N Size of the cohort simulation going through the model --- Fixed 100,000
P Number of prevention strategies being evaluated Defined by the MTC analysis Fixed 7
C Number of cycles in part 2 of the model Fixed 5
T Number of cycles in the whole decision model (model timeframe) Fixed 100
S Number of health states in the model Fixed 6
K Number of ceiling ratio values λ (from 0 to £200,000)  Fixed 101 
n.hh Total number of households in the UK 2001 UK Census (Statistics, 2001) Fixed 22,539,000
disc.u Discount rate for utilities Treasury (NICE, 2008) Fixed 3.5%disc.c Discount rate for costs Fixed 3.5%
PU_mins Number of minutes of Paramedic Unit – assumed only attend wheresevere injuries (SE assumption) PSSRU 2008 (Curtis, 2008)
(updated to 2009 prices)
Normal E[PU] = 49.5Var[PU] = 26.32 (assumption)
EA_mins Number of minutes of Emergency Ambulance – assumed only attendwhere moderate injuries (SE assumption) Normal
E[EA] = 38.6
precEA = 26.32 (assumption)
Parameter type: Probabilities
p_MTCfunc Probability of a functioning smoke alarm specific to each intervention From MTC analysis
p_accept Probability accept intervention (assumed same for all interventions) Assumption Beta
p_accepta = 0.7
p_acceptb = 0.077778
based on E[p_accept] = 0.9 and
assuming se[p_accept] = 0.225 **
pop_fsa Probability a household having a functioning smoke alarm Survey of English Housing 2004/5(Government, 2006) -Table 5.2 Binomial
r_fsa=14,709
n_sa=18,386
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p_checkup Probability have a precautionary checkup following a fire Fire Statistics 2007 (Government,2007) - Table 8 Binomial
r_checkup = 5,658
n_checkup = 12,935
p_fire.func Probability of a fire where functioning smoke alarms present
Fire Statistics 2007 (Government,
2007) - Table 2.4
Binomial r_fire.func = 22,771n_hh = 22,539,000
p_fire.nonfunc Probability of a fire where non-functioning smoke alarms present Binomial r_fire.nonfunc = 7,052n_hh = 22,539,000
p_fire.noSA Probability of a fire where no smoke alarms present or unspecified Binomial r_fire.noSA = 22,883n_hh = 22,539,000
p_fatalSA Probability of a fatality following a fire where functioning smoke alarmpresent Binomial
r_fatalSA = 109
r_fire.func = 22,771
p_fatalnSA Probability of a fatality following a fire where non-functioning or nosmoke alarm Binomial
r_fatalnSA = 232
r_fire.nonfunc = 22,771
p.1yrbattery Probability own a smoke alarm with battery life of 1 year Survey of English Housing 2004/5(Government, 2006) - Table 5.3 Binomial
r.1yrbattery = 11,888
n.1yrbattery=15,850
p.test1yr Probability test smoke alarm at least once a year Survey of English Housing 2004/5
(Government, 2006) - Fig 5.1
Binomial r.1yrtest = 15,616n.test = 18,372
p.testless1yr Probability test smoke alarm less than once a year Binomial r.testless1yr = 367n.test = 18,372
p_noinjury Probability of incurring ‘no injuries’ following a house fire (givenfunctioning smoke alarm/ non-functioning or no smoke alarm)
Survey of English Housing 2004/5
(Government, 2006) – Table 3.7;
Fire statistics 2007 (Government,
2007) - Table 2.4
Binomial
r_noinjury = 47,967
n_total.fires= r_fire.func +
r_fire.nonfunc + r_fire.noSA
p_FRSattend Probability of inside household fire being attended by the Fire andRescue Service
Survey of English Housing 2004/5
(Government, 2006) - Table 3.4 Binomial
r_FRSattend = 9
n_fires = 272
p_ITU The additional proportion of burn unit costs incurred in ITU Assumption based on analysis inHemington-Gorse et al. (2009) Binomial
P_ITUa = 9.2
P_ITUb = 13.8
based on E[p_ITU] = 0.4 and
assuming se[p_ITU] = 0.1 **
p_minor Probability a child aged 0-4 incurs in a minor injury following a housefire
Ken Dunn (personal
communication)
Multinomial r_minor = 7n_burnsinjury = 19
p_moderate Probability a child aged 0-4 incurs in a moderate injury following ahouse fire Multinomial
r_moderate = 3
n_burnsinjur = 19
p_severe Probability a children aged 0-4 incurs in a severe injury following ahouse fire Multinomial
r_severe = 1 – r_moderate –
r_minor = 9;
n_burnsinjury = 19
p_allcause Probability of all cause mortality for a UK citizen from 0 to 100 years (ONS, 2010b) Please see Table 4.5
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old (for use in each decision model cycle)
Parameter type: Resource cost
Interventions Costs £
c_hsi Cost of home safety inspection based on cost of LA home care workerfor 40 minutes of their time including travel PSSRU 2008 (Curtis, 2008) Fixed 12
c_alarmg Cost of smoke alarm giveaway (with ten-year sealed battery) Personal communication JaneZdanowska Fixed 4.41
c_educ
Cost of providing education programme per household accepting
intervention - based on cost of home care worker for 20 minutes of
their time including travel
DiGuiseppi et al. (1999) – updated
to 2009 prices
Fixed 6
c_fixed
Fixed cost of an intervention scheme (e.g. set-up, administration, etc).
Composite value derived from cost analysis of
DiGuiseppi et al. (1999)
Fixed 54,997
c_acc Additional cost incurred for each household that accept intervention(composite value) Fixed 0.49
c_install Cost of having the smoke alarm installed Fixed 10.66
Health Care Costs £
c_minPU Cost per minute of a Paramedic Unit PSSRU 2008 (Curtis, 2008) -
updated to 2009 prices
Fixed 7.21
c_minEA Cost per minute of a Emergency Ambulance Fixed 7.11
mn.minor
se_minor Mean cost (and standard error) of a minor injury
Ken Dunn (Personal
communication)
Lognormal E[minor] = 1,087se[minor] = 209
mn.moderate
se_moderate Mean cost (and standard error) of a moderate injury Lognormal
E[moderate] = 2,573
se[moderate] = 1,415
mn.severe
se_severe Mean cost (and standard error) of a severe injury Lognormal
E[severe] = 58,519
se[severe] = 32,019
c_fatal Cost of a fatality following a household fire (updated to 2008/9 prices)– includes coroners and autopsy costs
Ginnelly et al. (2005b) - updated to
2009 prices Fixed 185.16
c_dispyr Mean incurred NHS costs of disability per year
HALO study (Nicholl et al., 2009)
and personal communication with
Jon Nicholl
Gamma
c_dispyra = 16
c_dispyrb = 0.046784
based on E[c_dispyr] = 342 and
assuming se[c_dispyr] = 85.5 **
c_checkup Cost of precautionary check-up of safety equipment
NHS reference costs 2008/9
(2008/9 NHS Reference Costs
Guidance, 2010) - code VB11Z
Normal
E[c_checkup] = 62
se[c_checkup] = 21.5 based on
interquantile range
Out of Pocket / Private Costs £
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c_battery Cost of smoke alarm 1 year battery to individual www.safelincs.co.uk – 2009 price Fixed 1.39
c_property Total cost of damage caused by the fire
British Crime Survey: Fires in the
Home 2002/3 (Government,
2004b) - updated to 2009 prices
Gamma
c_propertya = 16
c_propertyb = 0.016327
based on E[c_property] = 980 and
assuming se[c_property] = 245 **
Law Enforcement and Rescue Services Costs £
c_police Cost of police attending – assumed only to attend where severe injuries Ginnelly et al. (2005b) - updated to2009 prices Fixed 156.67
c_FRSresponse Cost of Fire and rescue Service attending a fire
Economic Cost of Fire 2004
(Government, 2004a) - Table 3.6 -
updated to 2009 prices
Fixed 3,051
Parameter type: Utility parameters per cycle
u_min Deficit in utilities for minor injury (DRG 460 + 459)
Sanchez et al. (2008)
Fixed 0.0487
u_mod Deficit in utilities for moderate injury (DRG 458 + 457) Fixed 0.069
u_sev Deficit in utilities for severe injury (DRG 472) Fixed 0.107
u_deficit Deficit in utilities following a disability
HALO study (Nicholl et al., 2009)
and personal communication with
Jon Nicholl
Beta
u_deficita = 14.3
u_deficitb = 128.7
based on E[u_deficit] = 0.1 and
assuming se[u_deficit] = 0.025 **
u_pop General background mean utilities for non-injured population UK Population Norms (Kind et al.,1999) Normal
Under 25yrs, mean=0.94 (se=0.0021)
25-34yrs, mean=0.93 (se=0.0026)
35-44yrs, mean=0.91 (se=0.0027)
45-54yrs, mean= 0.85 (se=0.0043)
55-64yrs, mean=0.80 (se=0.0045)
65-74yrs, mean=0.78 (se=0.0045)
>75yrs, mean=0.73 (se=0.0045)
** using the method of moments
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Appendix 7
Chapter 6 formalises the concept of value of additional research in the presence of
mutually exclusive subgroups and of IPD. In this context, NMB estimates under
current and perfect information may increase (or decrease) from 1 to k subgroups (k
representing the maximum number of possible subgroups, considering observable
and non-observable individual characteristics). The decision made in each subgroup
is dependent on determining whether the same decision is made across subgroups or
a different decision is made in at least one of the subgroups considered. However,
under current information, if the same decision is made for all subgroups, estimated
total expected NMBs are the same, irrespective of the number of subgroups
considered.
In practice, if considering q subgroups from an existing set of l subgroups (i.e. q < l <
k) an available set of NB estimates can be used for l to perform EVPI estimations
over q subgroups, from a total of k existing subgroups – what it is termed here
‘backward estimation’. For instance, in the case of modelling for 2 (l) subgroups and
wanting to derive the EVPI for the whole population (1 (q) subgroup), with ynlNB

representing a matrix of n samples, from probabilistic modelling, for y strategies, and
wl the proportion of each subgroup in the population, the following formula should
be applied:
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The weights are applied directly on the n · y samples of the NB. The result is a matrix
of weighted average NBs of same dimensions. On this matrix, the usual functions of
the maximum and arithmetic mean are applied to derive the perfect and current
information as in equation (6.3). The difference between this framework and the one
set out in equations (6.7) and (6.8) is that the weights are applied to the NB estimates
before applying the maximum and mean functions, rather than after they are applied .
If, for instance, NBs estimates for 4 (l) subgroups are available and one wants to
obtain estimates for a particular 2 (q) subgroups specification, initially equation
(6.10) could be applied to obtain the weighted averages for each of the 2 (q)
subgroups ( ynNB 1 and
ynNB 2 ), using weights
*
lw , before proceeding with the
formula described in equation (6.3).
Illustrative example
To illustrate the backward estimation procedure, an illustrative numerical example is
provided in Table A7.1. In this example a simple hypothetical decision problem
compares three interventions (i.e. Int 1, Int 2, and Int 3) and four (mutually
exclusive) subgroups representing different proportions of the total targeted patient
population (i.e. diabetic and hypertensive – 10%; not diabetic and not hypertensive –
45%; diabetic and not hypertensive – 15%; and not diabetic and hypertensive –
30%). For simplicity, only five iterations of a probabilistic sensitivity analysis (PSA)
are reported for each subgroup and intervention. The expected maximum NMBs are
calculated for each alternative (averages at the bottom of the table) and the maximum
expected NMBs are calculated at each iteration and for each subgroup. Under
current information, Int 3 is the optimal choice for all subgroups (i.e. the same
decision is made for each of the subgroups being considered). The total weighted
average NMB with current information is of £12.48 [(7.2 x 0.1) + (13.8 x 0.45) +
(14.6 x 0.15) + (11.2 x 0.3) = 12.48]. The total weighted average NMB with perfect
information is of £15.4 [(11.8 x 0.1) + (15.8 x 0.45) + (16.6 x 0.15) + (15.4 x 0.3) =
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15.4]. The EVPI considering the four subgroups is estimated to be £2.92 [15.4 –
12.48 = 2.92].
However, comparisons across each subgroup specification may be compromised if
estimates used in each of these subgroup analyses resulted from different synthesis
models. This approach was used in the chapter’s case study, making use of equations
6.5 to 6.7 as described in section 6.3.1.
Table A7.1 – Value of Heterogeneity: the four subgroup illustrative example.
The four subgroup specifications can be used to estimate the NMB estimates for the
population average, and for each of the two subgroup specifications. Table A7.2
follows on from Table A7.1, illustrating how the backwards estimating procedure
can be performed to estimate population average estimates from four subgroups.
Following equation (A7.1), each NMB estimate (of each PSA iteration, each
subgroup and each interaction from Table A7.1) is weighted by the subgroup
proportion of the total population. For instance, for subgroup 1 (i.e. the DH subgroup
Iteration
Int 1 Int 2 Int 3 Max Int 1 Int 2 Int 3 Max Int 1 Int 2 Int 3 Max Int 1 Int 2 Int 3 Max
1 13 2 1 13 10 6 10 10 7 12 17 17 18 15 15 18
2 5 10 1 10 6 19 19 19 12 4 12 12 1 13 4 13
3 9 9 7 9 8 14 4 14 18 9 12 18 11 1 3 11
4 0 4 18 18 3 12 17 17 0 14 17 17 5 12 19 19
5 4 2 9 9 7 2 19 19 19 9 15 19 16 9 15 16
Average 6.20 5.40 7.20 11.80 6.80 10.60 13.80 15.80 11.20 9.60 14.60 16.60 10.20 10.00 11.20 15.40
NMB with current information = 7.2 x 0.1 + 13.8 x 0.45 + 14.6 x 0.15 + 11.2 x 0.3 = 12.48
NMB with perfect information = 11.8 x 0.1 + 15.8 x 0.45 + 16.6 x 0.15 + 15.4 x 0.3 = 15.4
EVPIK = 15.4 - 12.48 = 2.92
Legend:
Subgroup 4 - 30% NDHSubgroup 1 - 10% DH Subgroup 2 - 45% NDNH Subgroup 3 - 15% DNH
DH - diabetic and hipertense; NDNH - not diabetic and not hipertense; DNH - diabetic and not hipertense; NDH - not
diabetic and hipertense
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which represents 10% of the population), iteration 1 and intervention 1, a weighted
NMB estimate of £1.3 is obtained (13 x 0.1 = 1.3). Once all the subgroup weighted
NMB estimates are obtained the weighted average population NMBs are simply the
sum of these. For instance, the population NMB for intervention 2 and iteration 3 is
calculated to be £8.85 (9 x 0.1 + 14 x 0.45 + 9 x 0.15 + 1 x 0.3 = 0.9 + 6.3 + 1.35 +
0.3 = 8.85). With current information, the optimal choice is Int 3 with an estimated
NMB of £12.48. With perfect information, an expected maximum NMB of £14.14 is
estimated. Thus, the EVPI estimate using the backward estimation procedure from 4
to 1 subgroup is £1.66 (14.14 – 12.48 = 1.66).
Table A7.2 – Value of Heterogeneity: backward estimation from four subgroups to
population average estimates.
As the same choice of intervention is being made for each population subgroup, the
same NMBs with current information are expected to be obtained whether the
population average or four subgroups are considered. As expected, the NMB
estimate with current information considering subgroups (from Table A7.1) is
Iteration
Int 1 Int 2 Int 3 Int 1 Int 2 Int 3 Int 1 Int 2 Int 3 Int 1 Int 2 Int 3 Int 1 Int 2 Int 3 Max
1 1.3 0.2 0.1 4.5 2.7 4.5 1.05 1.8 2.55 5.4 4.5 4.5 12.25 9.2 11.65 12.25
2 0.5 1 0.1 2.7 8.55 8.55 1.8 0.6 1.8 0.3 3.9 1.2 5.3 14.05 11.65 14.05
3 0.9 0.9 0.7 3.6 6.3 1.8 2.7 1.35 1.8 3.3 0.3 0.9 10.5 8.85 5.2 10.5
4 0 0.4 1.8 1.35 5.4 7.65 0 2.1 2.55 1.5 3.6 5.7 2.85 11.5 17.7 17.7
5 0.4 0.2 0.9 3.15 0.9 8.55 2.85 1.35 2.25 4.8 2.7 4.5 11.2 5.15 16.2 16.2
Average 0.62 0.54 0.72 3.06 4.77 6.21 1.68 1.44 2.19 3.06 3.00 3.36 8.42 9.75 12.48 14.14
e.g. Subgroup 1 - Intervention 1 - Iteration 1 = 13 x 0.1 = 1.3 ; Subgroup 4 - Intervention 3 - Iteration 5 = 15 x 0.3 = 4.5
e.g. Population - Intervention 2 - Iteration 3 = 9 x 0.1 + 14 x 0.45 + 9 x 0.15 + 1 x 0.3 = 8.85
NMB with current information = 12.48 (same as before)
NMB with perfect information = 14.14
EVPI using backward estimation (4 to 1 subgroups) = 14.14 - 12.48 = 1.66
Subgroup 1 - 10%
DH
Subgroup 2 - 45%
NDNH
Subgroup 3 - 15%
DNH
Subgroup 4 - 30%
NDH Population
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equivalent to the weighted average population NMB estimate with current
information from using the backward estimation procedure (Table A7.2), that is,
£12.48. With respect to the NMBs obtained with perfect information, these are
estimated to be higher when considering the four subgroups (i.e. £15.4 – Table A7.1)
compared to the (weighted average) population (i.e. £14.14 – Table A7.2).
Table A7.3 and A7.4 illustrate the backward estimation approach from four
subgroups to two subgroups (for specification 1 – diabetic and not diabetic
populations, and for specification 2 – hypertensive and not hypertensive populations,
respectively) and from two subgroups to the population average NMB estimates. The
first step is to calculate the proportions for each (nested) population (e.g. the
proportion of hypertensive individuals in the diabetic population is of 0.4 [i.e. 0.1 /
(0.1 + 0.15) = 0.4].
Again following equation (A7.1), each NMB estimate (of each PSA iteration, each
subgroup and each interaction from Table A7.1) is weighted by the subgroup
proportion of the population. For instance, for the subgroup Diab, iteration 1 and
intervention 1, a weighted NMB estimate of £9.4 is obtained (13 x 0.4 + 7 x 0.6 =
9.4). Once all the NMB estimates are obtained for each subgroup, the NMBs with
current and perfect information can be obtained (e.g. the NMBs with current and
perfect information for the Diab subgroup are £ 11.64 and £12.92, respectively).
With these values, equations 6.5 to 6.7 may be applied to obtain weighted population
average estimates. For the Diab / Not Diab specification, the NMBs obtained with
perfect information are £14.36 [(12.92 x 0.25) + (14.84 x 0.75) = 14.36] and the
EVPI is estimated to be £1.88 (14.36 – 12.48 = 1.88). Similar calculations can be
made for the Hyper / Not Hyper subgroup specification. For that subgroup,
estimated EVPI is £2.47 (14.95 – 12.48 = 2.47).
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Table A7.3 – Value of Heterogeneity: backward estimation from four to two subgroups
(specification 1) and from two subgroups to population estimates.
Iteration
Int 1 Int 2 Int 3 Max Int 1 Int 2 Int 3 Max Proportion diabetic = 0.1 + 0.15 = 0.25
1 9.4 8 10.6 10.6 13.2 9.6 12 13.2 Proportion not diabetic = 0.45 + 0.3 = 0.75
2 9.2 6.4 7.6 9.2 4 16.6 13 16.6 Proportion of hipertense in diabetic population = 0.1 / 0.25 = 0.4
3 14.4 9 10 14.4 9.2 8.8 3.6 9.2 Proportion of not hipertense in diabetic population = 0.15 / 0.25 = 0.6
4 0 10 17.4 17.4 3.8 12 17.8 17.8 Proportion of hipertense in not diabetic population = 0.3 / 0.75 = 0.4
5 13 6.2 12.6 13 10.6 4.8 17.4 17.4 Proportion of not hipertense in not diabetic population = 0.45 / 0.75 = 0.6
Average 9.20 7.92 11.64 12.92 8.16 10.36 12.76 14.84
e.g. Subgroup Diab - Intervention 1 - Iteration 1 = 13 x 0.4 + 7 x 0.6 = 9.4 ;
Subgroup Not Diab - Intervention 3 - Iteration 5 = 19 x 0.4 + 15 x 0.6 = 17.4
Subgroup Diab:
NMB with current information = 11.64
NMB with perfect information = 12.92
EVPIK using backward estimation (4 to 2 subgroups) = 12.92 - 11.64 = 1.28
Subgroup Not Diab:
NMB with current information = 12.76
NMB with perfect information = 14.84
EVPIK using backward estimation (4 to 2 subgroups) = 14.84 - 12.76 = 2.08
Population:
NMB with current information = 11.64 x 0.25 + 12.76 x 0.75 = 12.48 (same as before)
NMB with perfect information = 12.92 x 0.25 + 14.84 x 0.75 = 14.36
EVPIK using backward estimation (2 to 1 subgroup) = 14.36 - 12.48 = 1.88
Subgroup Diab Subgroup Not Diab
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Table A7.4 – Value of Heterogeneity: backward estimation from four to two subgroups
(specification 2) and from two subgroups to population estimates.
Iteration
Int 1 Int 2 Int 3 Max Int 1 Int 2 Int 3 Max Proportion hipertense = 0.1 + 0.3 = 0.4
1 16.8 11.8 11.5 16.8 9.25 7.5 11.8 11.8 Proportion not hipertense = 0.15 + 0.45 = 0.6
2 2 12.3 3.25 12.3 7.5 15.3 17.3 17.3 Proportion of diabetic in hipertense population = 0.1 / 0.4 = 0.25
3 10.5 3 4 10.5 10.5 12.8 6 12.8 Proportion of not diabetic in hipertense population = 0.3 / 0.4 = 0.75
4 3.75 10 18.8 18.8 2.25 12.5 17 17 Proportion of diabetic in not hipertense population = 0.15 / 0.6 = 0.25
5 13 7.25 13.5 13.5 10 3.75 18 18 Proportion of not diabetic in not hipertense population = 0.45 / 0.6 = 0.75
Average 9.20 8.85 10.20 14.35 7.90 10.35 14.00 15.35
e.g. Subgroup Hiper - Intervention 1 - Iteration 1 = 13 x 0.25 + 18 x 0.75 = 16.75 ;
Subgroup Not Hiper - Intervention 3 - Iteration 5 = 19 x 0.25 + 15 x 0.75 = 18
Subgroup Hiper
NMB with current information = 10.20
NMB with perfect information = 14.35
EVPIK using backward estimation (4 to 2 subgroups) = 14.35 - 10.20 = 4.15
Subgroup Not Hiper
NMB with current information = 14.00
NMB with perfect information = 15.35
EVPIK using backward estimation (4 to 2 subgroups) = 15.35 - 14.00 = 1.35
Population:
NMB with current information = 10.20 x 0.4 + 14.00 x 0.6 = 12.48 (same as before)
NMB with perfect information = 14.35 x 0.4 + 15.35 x 0.6 = 14.95
EVPIK using backward estimation (2 to 1 subgroup) = 14.95 - 12.48 = 2.47
Subgroup Hiper Subgroup Not Hiper
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Appendix 8
Case study results using the ‘backward estimation’
Throughout the chapter, results are characterized by using different synthesis models,
depending on whether no covariate information was available, whether this was
available for just one binary covariate or whether it was available for both covariates.
Using the NBs estimates for 4 subgroups (i.e. considering the 2 covariates), equation
(A7.1) in addition to (6.7) to (6.9) may be applied to derive EVPI estimates for the
population (1 subgroup) and for the 2 subgroup specifications. As the same decision
is made for all four subgroups, estimated NBs under current information should be
the same when considering for 4, 2 or 1 subgroup. However, differences are expected
in the NBs estimated under perfect information.
Table A8.1 and A8.2 show the NBs results when using the output of synthesis model
with AD and with AD + IPD, respectively. It can be observed that in either case
estimated NBs obtained under current information are the same irrespective of the
number of subgroups or specifications considered. Under current information, the
NBs obtained from using AD + IPD are higher than those obtained from using AD
only, indicating that, using only the latter evidence format, the population net gains
may be underestimated. With respect to the population EVPI results, the expected
cost of uncertainty increases with the number of subgroups. This phenomenon is
observed for both threshold ratios used and for both scenarios with and without the
use of IPD. Moreover, except for the 1 subgroup estimates, population EVPI
estimates are higher when considering AD only compared to when considering AD +
IPD. These results are consistent with the conceptual idea reflected throughout the
chapter, that using IPD translates into a reduction of the expected cost of uncertainty.
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Table A8.1 – Expected (individual level) NMBs under current information and for
population EVPI (2009 values) of the cost effectiveness decision model for functioning
smoke alarms, for a threshold value of £20,000 and of £30,000. Results are shown for the
use of AD only and when heterogeneity is considered, that is, no subgroups, weighted
average for 2 subgroups (2 specifications – number of parents in the family and their
employment status) and the weighted average for the 4 subgroups are considered.
The fact that estimates obtained with AD are lower than with AD + IPD for one
subgroup is contra-intuitive. As discussed in section 6.2.2 of Chapter 6, one reason
for this phenomenon may be the fact that in the synthesis procedure, cluster
adjustment is performed within the synthesis model when modelling IPD, while for
AD these adjustments are made outside of the model. This implies that, for IPD
modelling, there is an additional layer of uncertainty relating to the design effect that
is not being considered when modelling AD only. See Chapter 3 for further details
on this issue. Another potential reason, albeit less probable, is that of simulation
error.
Threshold
value
4 subgroups
2 subgroups -
number
parents
2 subgroups -
employment
status
1 subgroup
£20,000 £111,939 £111,939 £111,939 £111,939
£30,000 £656,550 £656,550 £656,550 £656,550
£20,000 £6,478 £1,262 £1,790 £144
£30,000 £46,168 £24,407 £29,865 £13,255
Using AD effectiveness data
Population
EVPI
under
Current
Information
Net
monetary
benefits
(£)
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Table A8.2 – Expected (individual level) NMBs under current information and for
population EVPI (2009 values) of the cost effectiveness decision model for functioning
smoke alarms, for a threshold value of £20,000 and of £30,000. Results are shown for the
use of AD + IPD and when heterogeneity is considered, that is, no subgroups, weighted
average for 2 subgroups (2 specifications – number of parents in the family and their
employment status) and the weighted average for the 4 subgroups are considered.
Threshold
value
4 subgroups
2 subgroups -
number
parents
2 subgroups -
employment
status
1 subgroup
£20,000 £118,447 £118,447 £118,447 £118,447
£30,000 £663,061 £663,061 £663,061 £663,061
£20,000 £5,499 £957 £1,699 £155
£30,000 £42,235 £27,188 £29,429 £17,723
Net
monetary
benefits
(£)
under
Current
Information
Population
EVPI
Using AD+IPD effectiveness data
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LIST OF ABBREVIATIONS (IN ALPHABETIC ORDER)
1P Single parent or one parent household/family
1U At least one unemployed parent in household/family
1EP Employed single parent household/family
1UP Unemployed single parent household/family
2P Two parent household/family
2U Employed parent in household/family
2EP Two employed parents in household/family
2UP Two parent household/family with at least one parent
unemployed
AD Aggregate level data
AIC Akaike Information Criteria
BIC Bayesian Information Criteria
BUGS Bayesian inference Using Gibbs Sampling
CA Cluster Allocation of trial participants
CADTH Canadian Agency for Drugs and Technologies in Health
CBA Controlled Before and After trial
CBG-MEB Medicines Evaluation Board - Netherlands
CEA Cost Effectiveness Analysis
CEAC Cost Effectiveness Acceptability Curve
CEAF Cost Effectiveness Acceptability Frontier
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CODA Convergence Diagnostic and Output Analysis
CrI Credibility Interval
DIC Deviance Information Criteria
DH Diabetic and Hypertensive patients
DNH Diabetic and Non-Hypertensive patients
DoHA - HTA Department of Health and Ageing’s Health Technology
Assessment
DSU Decision Support Unit
E Education
E + FE Education plus Free Equipment
E + FE + HI Education plus Free Equipment plus Home Inspection
E + FE + F Education plus Free Equipment plus Fitting of equipment
E + HI Education plus Home Inspection
E + FE + F + HI Education plus Free Equipment plus Fitting of equipment
plus Home Inspection
EQ-5D EuroQol Five-Dimensional
EVIC Expected Value of Individualised Care
EVPI Expected Value of Perfect Information
EVPPI Expected Value of Perfect Information for parameters or
Partial Expected Value of Perfect Information
EVSI Expected Value of Sampling Information
FE Fixed-effect
FINOHTA Finnish Office for Health Technology Assessment
HALO The Long Term Health and Healthcare outcomes of
Accidental Injury study
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HIV/AIDS Human Immunodeficiency Virus / Acquired
ImmunoDeficiency Syndrome
HMO Health Maintenance Organisation
HTA Health Technology Assessment
HUI Health Utility Index
IA Individual Allocation of trial participants
ICC Intra Class Correlation Coefficient
ICD International Classification of Diseases
i-CER Individualized-Comparative Effectiveness Research
ICER Incremental Cost Effectiveness Ratio
INFARMED National Authority of Medicines and Health Products
IPD Individual participant level data
MCMC Markov Chain Monte Carlo
MPA Medical Products Agency - Sweden
MPES Multi Parameter Evidence Synthesis
MTC Mixed Treatment Comparison
NB Net Benefit
NDH Non-Diabetic and Hypertensive
NDNH Non-Diabetic and Non-Hypertensive
NHB Net Health Benefit
NHS National Health System
NMB Net Monetary Benefit
NICE National Institute for Health and Clinical Excellence
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NRT Non-Randomised Trial
ONS Office for National Statistics
OR Odds Ratio
PEVPI Population Expected Value of Perfect Information
PH Public Health
PSS Personal Social Services
PSSRU Personal Social Services Research Unit
QALY Quality Adjusted Life Year
QWB Quality of Well-Being
RCT Randomised Controlled Clinical Trials
RE Random-effect
RITA 3 Third Randomised Intervention Trial of unstable Angina
SBU Swedish Council on Health Technology Assessment
SF-6D Short Form Six-Dimensional
UC Usual Care
UK United Kingdom
USA United States of America
VoH Value of Heterogeneity
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